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lycosidases are essential in fundamental biological processes and are responsible 
for the degradation of most (oligo)saccharides, glycolipids and glycoproteins. 
Glycosidases are able to hydrolyze glycosidic linkages – acetal linkages that are very 
stable otherwise in physiological surroundings – with high efficiency.1 They are 
moreover often highly selective towards specific glycosidic linkages, in terms of the 
number (monosaccharide, oligosaccharide) and nature (configuration) of the 
carbohydrate moieties that make up these linkages. Malfunction of glycosidases is the 
cause of a variety of human inherited diseases referred to as lysosomal storage disorders 
(LSD).2-6 Fabry disease, for example, is caused by genetic deficiency of the lysosomal α-
galactosidase, αGal A7,8, and results in accumulation of the αGal A substrate, 
globotriaosylceramide, in several tissues.9,10 Malfunction of the lysosomal β-
galactosidase, GALC, in turn may cause Krabbe disease, which is characterized by the 
storage of psychosine in the brain.11-13 To study glycosidases in their physiological 
surroundings, activity-based protein profiling (ABPP) has come to the fore as a 
powerful technique in recent years.14-18 The research described in this Thesis entails the 
development and application of a set of activity-based probes (ABPs) for α-
galactosidases, β-galactosidases, α-mannosidases and β-mannosidases. Furthermore, 






1.1 Activity-based protein profiling 
 
Differentiation between functional and non-functional proteins in biological systems is 
a challenging objective. In the past decades, ABPP has emerged as a powerful strategy 
to obtain qualitative and quantitative information on active enzymes as present in 
complex proteomes.14-18 A requirement for the development of an ABP for ABPP 
experiments is the transient emergence of a covalent enzyme-substrate intermediate 
during the action of a given enzyme on its substrate. Mechanism-based covalent 
inhibitors can be developed based on this catalytic mechanism, and introduction of a 
reporter entity (a fluorophore, biotin or a bioorthogonal tag) onto an effective 
mechanism-based inhibitor may yield an effective ABP (Figure 1.1).  
Figure 1.1 Activity-based protein profiling (ABPP). A) Identification and quantification of the tagged 
enzymes. B) Determination of the inhibition potency by ABPs. MS: mass spectrometry. 
 
Biotin-containing ABPs can be used for qualitative ABPP as follows (Figure 1.1A). 
After incubation of a tissue culture or cell extract with a biotin-ABP and pull-down of 
all biotinylated proteins (both those that have reacted irreversibly with the ABP and 
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tagged enzymes are subjected to proteolysis (generally trypsin digestion) and the 
resulting oligopeptides are analysed by mass spectrometry. The thus obtained protein 
sequences are matched against protein sequence databases and in this way the ABP-
reactive enzymes are identified.19-23 Fluorescent ABPs can be used to obtain quantitative 
information on enzyme expression levels, provided that the identity of the modified 
enzymes is known. After incubation of a biological sample with a fluorescent ABP, 
denaturation of the protein contents and resolving the polypeptides by SDS-PAGE, 
ABP-modified proteins are detected and visualized by in-gel fluorescence scanning.23-27 
This reveals bands of the labelled proteins depending on the concentration of active 
enzyme, excluding precursor enzymes (zymogens) or malfunctioning enzymes.28-30 In 
this way, the level of active enzymes between different tissues can be analysed in a 
straightforward manner and the methodology can be applied in a diagnostic setting by 
linking enzyme activity levels with disease states. Fluorescent ABPs can moreover be 
used in competitive ABPP.31-34 For instance, a biological sample is incubated with a 
prospective inhibitor prior to incubation with the probe. After denaturation and 
resolving by SDS-PAGE, the inhibitor potency can be visualized by in-gel fluorescence 
scanning, in which inhibitor potency is directly related to the decrease in fluorescence 
intensity. Important advantages of competitive ABPP over other methodology is that 
information can be gleaned, next to inhibitor potency, also on inhibitor selectivity (in 
case the ABP used for ABPP readout has a broad enzyme specificity, and only one or a 
few of these targets are competed for) and cell permeability (for which purpose living 
cells are incubated with the prospective inhibitor prior to ABPP).35 
 
1.2 Classification of glycosidases 
 
Glycosidases, present in all kingdoms of life, are encoded by approximately 1% of the 
genome.36 This large variety of enzymes is able to hydrolyse a large selection of 
substrates with high efficiency. Classification of glycosidases according to the amino 
acid sequence similarities37 resulted into the Carbohydrate Active Enzyme (CAZy) 
database.38 Herein, 129 different families of glycosidase hydrolases (GHs) are classified 
to date. Although the substrate specificity of glycosidases in a specific family can be 
diverse, the catalytic mechanistic features are in general conserved within each GH 
family.39,40 These catalytic mechanisms can be classified as either inverting or retaining, 
based on the stereochemical outcome of the glycosidic bond (Figure 1.2).41 A pair of 
carboxylic acids is present in inverting glycosidases that act as general acid/base 




aglycon (Figure 1.2A). In retaining glycosidases, one carboxylic acid residue acts as a 
nucleophile and forms a covalent enzyme-substrate adduct while the other carboxylic 
acid acts as a general acid/base catalyst to protonate the expelled aglycon (Figure 1.2B). 
Subsequently, an incoming water molecule is deprotonated by this general acid/base 
catalyst and substitutes the anomeric carboxylate to release the enzyme.42-44 The 
covalent enzyme-substrate formation step in the itinerary of retaining glycosidases 
makes these GH families suitable for ABPP. 
Figure 1.2 General mechanism of inverting glycosidases (A) and retaining glycosidases (B). 
 
1.3 ABPs for retaining glycosidases 
 
(+)-Cyclophellitol (1), isolated from mushroom Phellinus sp. in 199045, adopts a 4H3 
conformation (Figure 1.3A) and thereby mimics the transition state conformation that 
emerges during retaining β-glucosidase-mediated hydrolysis of β-glucosidic linkages 
(Figure 1.3B). Cyclophellitol turned out to be a potent45, covalent and irreversible 
inhibitor of retaining β-glucosidases from various origin28,30,45, including the human 
lysosomal glucosylceramidase, GBA. Inspired by the mode of action of cyclophellitol30, 
cyclophellitol aziridine based probes (e.g. compound 2, Figure 1.3A) were synthesized 
and shown to be broad spectrum retaining β-glucosidase ABPs that could be used in 
both comparative and competitive ABPP experiments.23 The reaction itinerary of GH27 
α-galactosidases follow the same 4H3 transition state (Figure 1.3C)46, which allowed the 
development of a related, cyclophellitol-inspired, ABPP methodology.47 Thus α-
galactopyranose-configured cyclophellitol and the corresponding cyclophellitol 
aziridine were synthesized, after which the corresponding ABPs were developed from 
these and applied in ABPP experiments. Finally, α-glucopyranose-configured 
cyclophellitol and cyclophellitol aziridine based probes have been synthesized and 
applied to monitor GH31 α-glucosidase48 by again mimicking the substrate 4H3 
transition state conformation.49  
 

















































































































































































































































































Figure 1.3 A) Mechanism-based inhibition by cyclophellitol (1) of retaining β-glucosidases and the 
structure of cyclophellitol aziridine 2. Proposed mechanisms49 of β-glucosidases (B), GH27 α-
galactosidases46 (C), α-mannosidases50,51 (D) and β-mannosidases56-58 (E).  
 
These results raised the question whether cyclophellitol-based ABPs are also applicable 
for retaining exoglycosidases for which a 4H3 conformation is not part of the reaction 
itinerary. In the proposed reaction itinerary of GH38 α-mannosidases, for example, the 
substrate following protonation and expulsion of the aglycon, adopts a boat 
conformation (B2,5) in the transition state (Figure 1.3D).50,51 Interestingly, although α-
mannopyranose-configured cyclophellitol is expected to be in a 4H3 conformation, this 
compound has been shown in the past to be an effective jack bean α-mannosidase 
inhibitor.52,53 This suggests that retaining α-mannosidases, which are connected with 
various pathologies54,55, may be targeted by cyclophellitol aziridine based ABPs as well. 
The same holds true for retaining β-mannosidases (both from GH2 and GH113 
families), which process their substrate through a similar B2,5 transition state56-58 (Figure 
1.3E), and for which selective ABPs are not reported either. Such probes would be 
attractive to analyse β-mannosidosis, a lysosomal storage disorder that is caused by a 
deficiency of the retaining β-mannosidase, MANBA.59-61 
 
1.4 Reversible inhibitors based on transition state mimicry 
 
Several reversible, competitive glycosidase inhibitors have been developed and are 
employed for therapeutic applications.62 For example, the reversible α-glucosidase 
inhibitors acarbose (Glucobay, 3) and miglitol (Glyset, 4) are employed for clinical 
treatment of diabetes type II (Figure 1.4).63 Glycosidases enhance the reaction rate with 
an estimated 1017 fold compared to non-catalyzed hydrolysis of interglycosidic 
linkages.1 Therefore, the binding affinity of the substrate in transition state 
conformation with the enzyme is expected to be exceptionally strong (Kd < 10-22 M).63 
Based on this observation, transition state mimics are interesting motifs for the 
development of inhibitors. Zanamivir (Relenza, 5) and oseltamivir (Tamiflu, 6)49 
employ the transition state conformation and inhibit virus sialidases to treat influenza 
(Figure 1.4).64 
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Figure 1.4 Clinically used competitive glycosidases inhibitors. Acarbose (Glucobay, 3) and miglitol 
(Glyset, 4) for the treatment of diabetes type II. Zanamivir (Relenza, 5) and oseltamivir (Tamiflu, 6) 
for the treatment of influenza. 
 
Besides these examples of potent reversible inhibitors with an unsaturated structure (3, 
5 and 6), bicyclic structures can be employed to alter the conformation to emulate the 
transition state conformation (Figure 1.5). Nojiritetrazole 7, for example, adopts a 4H3 
conformation65 and is a potent retaining glucosidase inhibitor.66 Based on the 4H3 
conformation adopted by cyclophellitol (1), carba-cyclophellitol (8), in which the 
cyclophellitol epoxide-oxygen is substituted for carbon, is expected to be a potent 
reversible glucosidase inhibitor. Prior to the research described in this Thesis, the 
synthesis of two carba-cyclophellitols (8 and 9) has been reported but no data on their 
glycosidase-inhibitory properties has been given.67 In this Thesis, the synthesis of a 
library of carba-cyclophellitols based compounds and their inhibitory property towards 






Figure 1.5 Bicyclic structures that employ65 (7) or may employ67 (8 and 9) the 4H3 conformation to 
mimic the substrate conformation at the transition state of retaining glucosidases. 
 
1.5 Aim and outline of this thesis 
 
The research described in the first part of this Thesis aimed to develop and validate a 
set of selective ABPs for retaining α-galactosidases, β-galactosidases, α-mannosidases 
and β-mannosidases. The second part of the Thesis describes research efforts directed 
at the design of new competitive inhibitors for α-galactosidases, β-galactosidases, α-




In Chapter 2 α-galactosidase selective probes are developed and examined in biological 
settings to target lysosomal retaining α-galactosidases. Chapter 3 discusses the 
synthesis of a β-galactose-configured cyclophellitol aziridine and ABPs derived thereof. 
As part of the research described, the inverse-electron-demand Diels-Alder (IEDDA) 
ligation strategy was investigated, both in two-step labeling and as a means to derive at 
an appropriately functionalised one-step ABP. The strategy of cyclophellitol aziridine 
based probes is extended to α-mannosidases and β-mannosidases in Chapter 4 and 
Chapter 5, respectively. Interestingly, during the reaction itinerary of α-mannosidases 
and β-mannosidases in their processing of their substrates a B2,5 conformation emerges 
instead of the 4H3 conformation as in galactosidases or glucosidases. In both cases, 
however, mannosidase-configured cyclophellitol aziridine probes proved to be effective 
ABPs and thus the research described in Chapter 4 and 5 entails expansion of the ABP 
toolset by means of which retaining exoglycosidases can be monitored in complex 
biological samples. 
Chapter 6 describes the synthesis of a library of carba-cyclophellitols as potential 
inhibitors for α-galactosidases, β-galactosidases, α-glucosidases and β-glucosidases. The 
β-glucopyranose-configured carba-cyclophellitols are evaluated as inhibitors of the 
Thermotoga maritima TmGH1 retaining β-glucosidase, human lysosomal retaining β-
glucosidase GBA1 and human lysosomal α-glucosidase GAA as is described in Chapter 
7. Furthermore, NMR analysis, quantum mechanical analysis, DFT calculations and 
crystallography studies are performed to determine the conformation of the 
synthesised carba-cyclophellitols. Chapter 8 reports on the synthesis and evaluation of 
carba-cyclophellitol based inhibitors of galactosyltransferases and glucosyltransferases. 
Chapter 9 gives a summary of this Thesis and includes some future prospects, based on 
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he human lysosomal α-galactosidase A (αGal A, GLA, EC. 3.2.1.22) is responsible 
for the hydrolysis of terminal α-galactosides in glycosphingolipids, glycoproteins 
and oligosaccharides. Several mutations in the GLA gene2,3 have been reported which 
results in a deficiency of αGal A. As a consequence, accumulation of the 
globotriaosylceramide substrate in various tissues is observed4,5 and detected in plasma 
or urine samples.6 Affected patients are diagnosed with Fabry disease, which is an X-
linked recessive lysosomal storage disorder (LSD). Classically affected Fabry patients 
demonstrate symptoms such as corneal opacities, angiokeratomata, intolerance to heat, 
hypohidrosis, neuropathic pain and micro-albuminuria.7,8 Besides these diverse clinical 






α-N-acetylgalactosaminidase (α-NAGAL, EC 3.2.1.49) is a lysosomal retaining α-exo-
galactosidase closely related to αGal A. Both enzymes have 46% amino acid sequence 
identity, are within the CAZY GH27 family and are the same in 11 of the 13 active site 
residues.9 Compared to αGal A, α-NAGAL selectively cleaves terminal α-GalNAc 
residues from glycosphingolipids and is less efficient in processing galactose 
monosaccharides.10 Various mutations in the NAGA gene have been reported that 
cause a deficiency of α-NAGAL11,12, resulting into accumulation of glycoconjugates 
constituted with a terminal sialic-acid- or galactose-terminal saccharides.13 Patients of 
this rare lysosomal storage disorder, termed Schindler disease14, suffer from a large 
spectrum of symptoms such as seizures, autistic disorders and angiokeratoma.15 
However, these clinical observations are not completely understood in correlation with 
the genetic malfunction.16,17 
Glycosyl hydrolyses of the family GH27 process their substrates via a double 
displacement reaction mechanism (Figure 2.1A).18,19 Following protonation by the 
active site acid/base catalyst of the exocyclic oxygen of the scissile acetal linkage, the 
aglycon is displaced in a formal SN2 reaction by the catalytic nucleophile residue. In the 
next step, the deprotonated aspartic residue acts as a base and deprotonates a water 
molecule, after which the resulting hydroxide substitutes the anomeric carboxylate, 
thereby releasing galactose and reforming the enzyme active site. This mechanism, first 
proposed by Koshland18, results in retention of configuration at the anomeric carbon. 
 
Figure 2.1 A) Double displacement mechanism of retaining α-galactosidases. B) Proposed 
mechanism of α-galactopyranose-configured cyclophellitol aziridines as mechanism-based α-
galactosidase inhibitors. 
 
Based on this mechanism, which includes a covalent bonded enzyme-substrate adduct 
after nucleophillic attack at the anomeric center, a covalent binding inhibitor (Figure 
2.1B) of α-galactosidases has been synthesized20 and tested in vitro.21 This α-
galactopyranose-configured cyclophellitol aziridine bearing a fluorescent N-acyl 
substituent could be used in activity-based protein profiling (ABPP) of αGal A and α-
NAGAL activities. ABPP is a powerful technique to study active enzymes in various 
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complex systems, such as cell cultures and living organisms.22-24 A caveat in the α-
galactosidase-directed probes proved to be the hydrolytic lability of the N-acyl 
substituent, rendering their synthesis, purification and usage somewhat complicated. 
This chapter describes the synthesis and biological characterization of N-alkyl activity-
based probe (ABP) 3. Head-to-head comparison with previously described N-acyl ABP 
2 (Figure 2.2) reveals that, despite this caveat, N-acyl ABP 2 is more effective compared 
to its N-alkyl counterpart because it appeared to have better fluorescence properties. 
Following these observations, expansion of the α-galactosidase probe set was 
undertaken by the synthesis and biological evaluation of BodipyGreen and Cy5 
modified probes (4 and 5, respectively), results on which are presented in this chapter 
as well. 
 
Figure 2.2 Structures of α-galactopyranose-configured cyclophellitol aziridine (1) and the N-acylated 




2.2 Results and discussion 
 
2.2.1 N-alkyl Bodipy-probe TB340 (3). 
Cyclophellitol aziridine ABP 3 was synthesized following the strategy depicted in 
Scheme 2.1. Alkylation of the aziridine nitrogen of cyclophellitol aziridine 1 with 1-
azido-8-iodooctane25 in the presence of K2CO3 at elevated temperatures in DMF, gave 
azide 6. In the final stage Bodipy alkyne 726 was reacted in a Huisgen copper(I)-
catalyzed [2+3]-cycloaddition with azide 6, yielding 2.3 mg of TB340 (3) in 2% over 2 
steps. In comparison with N-acyl ABP 2 (7.4 mg, 2%)20 the efficiency of both synthetic 
strategies appears to be similar. However, N-acyl cyclophellitol aziridines are prone to 
hydrolysis during lyophilization and purification has to be performed via HPLC 
purification at neutral (H2O, MeCN) or basic conditions (25 mM to 50 mM NH4HCO3 
in H2O/MeCN). This is in contrast to the successful purification by standard silica gel 
chromatography of N-alkyl aziridine 6. Finally, opening of the aziridine moiety after 
concentration under reduced pressure or after lyophilization was not encountered. 
 
Scheme 2.1 Synthesis of N-alkyl Bodipy probe TB340 (3). 
Reagent and conditions: a) 1-azido-8-iodooctane25, K2CO3, DMF, 80 °C, 18 h, 24%; b) 726, 
CuSO4·5H2O, sodium ascorbate, DMF, rt, 18 h, 8%. 
 
In a next set of head-to-head comparison experiments, N-alkyl probe 3 and N-acyl 
probe 2 were examined in vitro against recombinant α-galactosidase (rGLA) and in situ 
against wild-type GLA fibroblasts. First, the inhibition potential of both probes was 
tested in vitro and in situ (Figure 2.3A). Both probes are very potent inhibitors with 
apparent IC50 values in the low nanomolar range in vitro and in situ. As depicted in 
Figure 2.3B and 2.3C, both probes are pH dependent and labeling of GLA was also 
effective in a slightly more basic medium. However, from a kinetic point of view, N-
acyl probe 2 is more efficient and labeling of rGLA was immediately detected at 4 °C in 
a time-course-dependent labeling. N-alkyl probe 3 in contrast labels significantly 
slower (Figure 2.3D). Additionally, the observed fluorescence output was lower for N-
alkyl probe 3 (Figure 2.3E). In a competition experiment by pre-incubation with known 
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selective α-galactosidase inhibitors cyclophellitol aziridine 820 and cyclophellitol 921, 
labeling of both probes was prevented (Figure 2.3F). Finally, hourly washing of the 
samples did not affect the labeling, which proves the covalent mode of binding of both 
probes (Figure 2.3G).  
 
Figure 2.3 A) The inhibition potential of ABPs 2 and 3 were determined in vitro (rGLA) and in situ 
(wild-type GLA fibroblast); B) In-gel labeling of rGLA at various pH values; C) Quantification of the 
fluorescent readout of ABP 2 and 3 (B) compared to 4-methylumbelliferone production from 4-
methylumbelliferyl-α-galactopyranoside at various pH values; D) Time and temperature depended 
labeling of 100 fmol rGLA with 100 fmol ABP at 48 °C (top) and 37 °C (bottom); E) The detection 
limit of ABP-emitted fluorescence was determined using rGLA (10 pmol) with varying concentrations 
of ABP; F) Competition assay using known selective inhibitor 820, 921, SDS with ABP 2 and 3 in rGLA 
(top) and in wild-type GLA fibroblast lysate (bottom); G) The samples were hourly extensive washed 


































































2.2.2 N-acyl BodipyGreen (TB220, 4) and Cy5 (TB474, 5).  
The synthesis of ABPs 4 and 5 is depicted in Scheme 2.2. The required BodipyGreen-
acid 11 was obtained after copper(I)-catalyzed click reaction of 8-azidooctanoic acid 
1027 with BodipyGreen 1526. Cy5 derivative 14 in turn was synthesized in two steps. 
First, Cy5-OSu ester 1228 was reacted with propargylamine to obtain compound 13. 
Subsequently coupling with 8-azidooctanoic acid 1027 in the presence of copper(II) 
sulfate pentahydrate and sodium ascorbate resulted in compound 14. In the final stage 
of the synthetic route, cyclophellitol aziridine 120 was coupled with 11 or 14 in the 
presence of 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) to obtain target 
compounds 4 and 5.  
 
Scheme 2.2 Synthesis of TB220 (4) and TB474 (5). 
Reagent and conditions: a) 1526, CuSO4·5H2O, sodium ascorbate, DMF, 80 °C, overnight, 94%; b) 
propargylamine, Et3N, CH2Cl2, rt, 2.5 h, 25%; c) 1027, CuSO4·5H2O, sodium ascorbate, DMF, 80 °C, 
overnight, 86%; d) 11 or 14, EEDQ, 0 °C, DMF, 18% (4 ), 5% (5). 
 
After having TB220 (4) and TB474 (5) in hand, the inhibitory potential towards 
recombinant GLA (rGLA) was first assessed. Various concentrations of the probes were 
pre-incubated for 30 min in rGLA, after which the residual enzyme activity was 
measured using the fluorogenic substrate, 4-methylumbelliferyl α-D-galactoside (4-mu 
α-gal), and residual enzyme activity towards this substrate in the presence of varying 
inhibitor concentrations was used to obtain IC50 values. Both TB220 (4) and TB474 (5) 
proved to inhibit rGLA in the nanomolar range (2.0 nM and 11.39 nM, respectively), 
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which corresponds to N-acyl aziridine 2 (2.0 nM21) for rGLA. In the next experiment 
0.5 equivalent of TB220 (4) was used to label 1.0 equivalent Fabrazyme (Figure 2.4A) 
and incubated for 1h. The residual α-galactosidase in the sample was either directly 
labeled with ABP 2 or the sample was first washed for 8h before addition of ABP 2. 
Labeling of GLA due to TB220 (4) was clearly visual in the green channel despite the 
washing protocol, demonstrating the covalent mode of labeling. In order to confirm the 
irreversible mode of binding of probe TB474 (5), the pre-incubation time of the probe 
and rGLA was varied. As depicted in Figure 2.4B, longer incubation time of the probe 
in rGLA increases the apparent inhibition potency, supporting the non-reversal mode 
of binding of this probe. Finally, effective fluorescent labeling of rGLA with TB474 (5) 
was demonstrated (Figure 2.4C).
 
 
Figure 2.4 A) Fabrazyme (GLA) was labeled with 2 or TB220 (4), washed for 0 or 8 hours and post-
labeled with TB220 (4) and 2, respectively; B) The inhibitory potential of TB474 (5) was determined 
towards GLA with various incubation times; C) In vitro labeling of rGLA at different protein 
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This chapter describes the synthesis of the N-alkylated version (3) of the N-acyl-
cyclophellitol aziridine 2 which proved to be a highly potent α-galactosidase inhibitor 
and ABP. From a synthetic perspective, efficiencies towards both compounds are 
comparable but N-acyl aziridine 2 is prone to hydrolysis during lyophilization and 
purification. The biological properties were examined in head-to-head experiments, 
demonstrating equal potency towards recombinant α-galactosidase. N-acyl probe 2, 
however, outcompetes N-alkyl probe 3 in labeling efficiency. Therefore, N-acylated 
probes are preferable for α-galactosidase detection in an activity-based protein profiling 
setting. In the second part of this chapter, BodipyGreen and Cy5 modified probes (4 
and 5, respectively) were synthesized and demonstrated to be covalent inhibitors of 
GLA in the low nanomolar range. Selective labeling of GLA was visualized by gel 





General: Chemicals were purchased from Acros, Sigma Aldrich, Biosolve, VWR, Fluka, Merck and 
Fisher Scientific and used as received unless stated otherwise. Dichloromethane (DCM), N,N-
dimethylformamide (DMF) and toluene were stored over flame-dried 4 Å molecular sieves before use. 
Traces of water from reagents were removed by co-evaporation with toluene in reactions that require 
anhydrous conditions. All reactions were performed under an argon atmosphere unless stated 
otherwise. TLC analysis was conducted using Merck aluminum sheets (Silica gel 60 F254) with 
detection by UV absorption (254 nm), by spraying with a solution of (NH4)6Mo7O24·4H2O (25 g/L)  
and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid, a solution of KMnO4 (20 g/L) and K2CO3 (10 
g/L) in water or ninhydrin (0.75 g/L), followed by charring at ∼150 ˚C. Column chromatography was 
performed using Screening Device b.v. Silica Gel (particle size of 40 – 63 μm, pore diameter of 60 Å) 
in the indicated solvents. For reversed-phase HPLC purifications an Agilent Technologies 1200 series 
instrument equipped with a semi-preparative column (Gemini C18, 250x10 mm, 5 μm particle size, 
Phenomenex) was used. LC/MS analysis was performed on a Surveyor HPLC system (Thermo 
Finnigan) equipped with a C18 column (Gemini, 4.6 mm x 50 mm, 5 μm particle size, Phenomenex), 
coupled to a LCQ Adventage Max (Thermo Finnigan) ion-trap spectrometer (ESI+). The applied 
buffers were H2O, MeCN and 1% aqueous TFA. 1H NMR and 13C NMR spectra were recorded on a 
Brüker AV-400 (400 and 101 MHz respectively) or a Bruker AV-850 (850 and 214 MHz respectively) 
spectrometer in the given solvent. Chemical shifts are given in ppm (δ) relative to the residual solvent 
peak as internal standard. Coupling constants are given in Hz. High-resolution mass spectrometry 
(HRMS) analysis was performed with a LTQ Orbitrap mass spectrometer (Thermo Finnigan), 
equipped with an electronspray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10 
A new generation of fluorescent ABPs to target retaining α-galactosidases 
21 
mL/min, capillary temperature 250 °C) with resolution R = 60000 at m/z 400 (mass range m/z = 150–
2000) and dioctyl phthalate (m/z = 391.28428) as a “lock mass”. The high-resolution mass 




Unprotected cyclophellitol aziridine 120 (87.6 mg, 0.50 mmol) was 
dissolved in DMF (4 mL). 1-Azido-8-iodooctane25 (224 mg, 0.80 
mmol) and K2CO3 (297 mg, 2.15 mmol) were added to the solution and the mixture was stirred at 80 
°C for 18 h. After the full conversion of the starting material, the resulting solution was concentrated 
under reduced pressure. Then the crude product was purified by silica gel column chromatography 
(3% MeOH in DCM -> 20% MeOH in DCM) resulting as a colorless oil 6 (40 mg, 0.121 mmol, 24%). 
TLC: Rf = 0.3 (10%, v/v, MeOH in DCM). LC/MS analysis: Rt: 5.47 min (linear gradient 10% → 50% B 
in 12.5 min), m/z 329.20 [M+H]+. 1H NMR (850 MHz, CD3OD): δ 4.02 (dd, J = 4.3, 8.5 Hz, 1H), 3.78 
(t, J = 1.7 Hz, 1H), 3.70 (ddd, J = 44, 8.5, 6.8 Hz, 2H), 3.33 (dd, J = 8.5, 1.7 Hz 1H), 3.27 (t, J = 4.0 Hz, 
2H), 2.38 – 2.34 (m, 1H), 2.20 – 2.16 (m, 1H), 1.94 (dd, J = 6.8, 4.3 Hz, 1H), 1.91 – 1.88 (m, 1H), 1.61 – 
1.57 (m, 4H), 1.55 (d, J = 6.8 Hz, 1H), 1.41 – 1.31 (m, 6H). 13C NMR (214 MHz, CD3OD): δ 74.9, 73.2, 
70.4, 63.4, 62.4, 52.5, 46.2, 44.9, 42.2, 30.6, 30.5, 30.2, 29.9, 28.4, 27.8. HRMS: calculated for [C-
15H28N4O4]+ 329.21833, found 329.21815. 
 
ABP 3 
Azide compound 6 (12.0 mg, 0.036 mmol) was dissolved 
in DMF (2 mL), Bodipy 726 (20.9 mg, 0.043 mmol), 
CuSO4 (1 M, 13 μL, 13 μmol) and sodium ascorbate (1 
M, 14 μL, 14 μmol) were added to the solution under 
argon atmosphere. After stirring at room temperature 
for 18 h, the resulting mixture was concentrated under 
reduced pressure. Then the crude product was purified 
by semi-preparative reversed HPLC (linear gradient: 52% -> 60% B in A, 12 min, solutions used A: 50 
mM NH4HCO3 in H2O, B: MeCN) and lyophilized resulting as a purple powder product 3 (2.3 mg, 2.8 
μmol, 8%). LC/MS analysis: Rt 6.83 min (linear gradient 10% → 90% B in 12.5 min), m/z 813.33 
[M+H]+. 1H NMR (850 MHz, CD3OD): δ 7.85 (d, J = 8.5 Hz, 4H), 7.70 (s, 1H), 7.44 (d, J = 7.44 Hz, 
2H), 6.97 (d, J = 7.7 Hz, 4H) 6.69 (d, J = 4.3 Hz, 2H), 4.33 (t, J = 6.8 Hz, 2H), 4.00 (dd, J = 8.5, 4.3 Hz, 
1H), 3.85 (s, 3H), 3.78 – 3.76 (m, 1H), 3.73 (ddd, J = 48, 7.7, 6.8 Hz, 2H), 3.33 (t, J = 1.7 Hz, 1H), 3.07 
(t, J = 7.7 Hz, 2H), 3.30 (s, 3H) 2.79 (t, J = 6.8 Hz, 2H), 2.30 – 2.27 (m, 1H), 2.14 – 2.10 (m, 1H), 1.90 – 
1.82 (m, 8H), 1.55 – 1.49 (m, 3H), 1.31 – 1.21 (m, 8H). 13C NMR (214 MHz, CD3OD): δ 162.2, 158.8, 
146.8, 137.5, 132.2, 128.4, 126.5, 121.0, 114.6, 74.9, 73.2, 70.4, 63.3, 62.3, 55.9, 55.8, 52.3, 49.4, 46.2, 
44.8, 42.1, 34.1, 31.2, 31.0, 30.4, 30.4, 30.3, 29.9, 28.2, 27.4, 25.8. HRMS: calculated for 




8-(BodipyGreen)-triazole)-octanoic acid (11)  
8-Azidooctanoic  acid 1027 (0.50  mmol,  93  mg) and BodipyGreen-
alkyne 1526 (0.50 mmol, 0.16 g, 1.0 eq.) were dissolved in DMF under 
argon atmosphere. After addition of copper(II)sulphate pentahydrate 
(100 μmol, 100 μL 1 M in H2O, 0.2 eq.) and sodium ascorbate (200 μmol, 200 μL 1 M in H2O, 0.4 eq.) 
the reaction mixture was heated to 80 °C and stirred overnight. The mixture was then evaporated in 
vacuo and purified by column chromatography (DCM → 2% MeOH in DCM) to yield BodipyGreen-
acid 11 as an orange  solid (0.24 g, 0.47 mmol, 94%). 1H NMR (400 MHz, MeOD): δ (ppm) 7.68 (d, J = 
8.4 Hz, 1H), 6.06 (s, 2H), 4.29 (t, J = 7.2 Hz, 2H), 2.84 –2.78 (m, 2H), 2.70 (t,  J = 6.8 Hz, 2H), 2.41 (s, 
6H), 2.26 (s, 6H), 2.26 – 2.21  (m, 2H), 1.86 – 1.77 (m, 4H), 1.56 – 1.49 (m, 4H), 1.40 – 1.17  (m, 6H). 
13C NMR (100 MHz, MeOD): δ (ppm) 177.5, 154.8, 147.8, 142.2, 136.4, 132.5, 122.6, 51.2, 32.0, 31.2, 
30.8, 29.9, 29.7, 28.9,  27.6, 27.2, 25.9, 25.8, 16.4, 14.5.  
 
ABP 4 
BodipyGreen-acid 11 (0.10 mmol, 51 mg) was preactivated with 
EEDQ (0.10 mmol, 25 mg, 1.0 eq.) in DMF (0.6 mL) under 
argon for 2 hours at room temperature.  Deprotected  aziridine 1 
(0.10 mmol) was dissolved in DMF (0.5 mL) under argon and 
cooled to 0 °C, after which 0.25 mL of the activated ester solution 
was added (50 μmol, 0.5 eq.) and the mixture was stirred at 0 °C for 30 min. Then another 0.5 eq. of 
the activated ester was added and the reaction mixture was stirred at 0 °C for another 60 min. After 
quenching with MeOH, the mixture was evaporated in vacuo, purified by HPLC under basic 
conditions using a gradient of 44 → 50% ACN in 25 mM aqueous NH4HCO3 in 12 min, and 
lyophilized to yield aziridine 4 as an orange powder (12 mg, 18 μmol, 18%). 1H NMR (600 MHz, 
MeOD): δ 7.69 (s, 1H), 6.11 (s, 2H), 4.35 (t, J = 7.0 Hz, 2H), 4.07 (dd, J = 8.6, 4.0 Hz, 1H), 3.8 – 3.84  
(m, 1H),  3.81 – 3.74  (m, 2H),  3.36 (dd, J = 1.7, 8.6 Hz, 1H),  3.04 – 3.00  (m, 2H), 2.96 (dd, J = 6.0, 
4.0 Hz, 1H), 2.78 (t, J = 12.6 Hz, 2H), 2.59 (d, J = 6.0 Hz, 1H), 2.54 – 2.42 (m, 2H), 2.44 (s, 6H), 2.38 (s, 
6H), 2.01 (td, J = 7.8, 7.3, 3.6 Hz, 1H), 1.96 – 1.83 (m, 4H), 1.69 – 1.63 (m, 2H), 1.61 – 1.55 (m, 2H), 
1.36 – 1.23 (m, 6H). 13C NMR (100 MHz, CDCl3): δ 188.6, 154.9, 148.5, 147.9, 142.2, 132.6, 123.4, 
122.6, 74.3, 74.2, 69.5, 62.8, 51.2, 44.5, 43.3, 39.4, 37.0, 32.2,  31.2,  30.8,  30.0,  29.6,  29.1,  27.4,  25.9,  





Cy5 OSu ester 1228 (3.10 g, 5.0 mmol) and propargylamine (0.35 mL, 5.5 
mmol) were dissolved in CH2Cl2 (25 mL). After addition of Et3N (6.0 
mmol, 0.84 mL), the reaction mixture was stirred for 2.5 h at room 
temperature. The reaction mixture was concentrated in vacuo and 
purification by column chromatography (1% MeOH in CH2Cl2 → 4% MeOH in CH2Cl2) gave Cy5-
alkyne 13 (690 mg, 1.24 mmol, 25%) as a dark-blue foam. 1H NMR (400 MHz, MeOD): δ 8.26 (t, J = 
13.1 Hz, 2H), 7.48 (d, J = 7.4 Hz, 2H), 7.44 – 7.35 (m, 2H), 7.29 (d, J = 7.9 Hz, 2H), 7.24 (t, J = 7.4 Hz, 
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2H), 6.71 (t, J = 12.4 Hz, 1H), 6.31 (t, J = 13.5 Hz, 2H), 4.12 (t, J = 7.4 Hz, 2H), 3.92 (d, J = 2.5 Hz, 2H), 
3.63 (s, 3H), 2.57 (t, J = 2.6 Hz, 1H), 2.23 (t, J = 7.3 Hz, 2H), 1.84 (dt, J = 14.9, 6.3 Hz, 2H), 1.75 – 1.66 
(m, 14H), 1.51 – 1.46 (m, 2H). 13C NMR (101 MHz, MeOD): δ 175.4, 175.2, 174.5, 155.4, 144.2, 143.5, 
142.6, 142.5, 129.7, 129.6, 126.8, 126.1, 123.4, 123.3, 112.0, 111.8, 104.4, 55.9, 50.5, 44.8, 36.4, 31.8, 
29.4, 28.2, 28.0, 27.9, 27.3, 26.4, 26.3. HRMS: calculated for [C35H42N3O]+ 520.33224, found 520.33172. 
 
ABP 5  
To a solution of 8-azidooctanoic acid27 (94 mg, 0.50 
mmol) in DMF (4 mL) was added Cy5-alkyne 13 (282 
mg, 0.50 mmol) at room temperature. After addition of 
copper(II)sulfate pentahydrate (500 μL, 1 M in H2O) and 
sodium ascorbate (700 μL, 1 M in H2O) the reaction 
mixture was heated up to 80 °C and stirred overnight. 
The reaction mixture was concentrated in vacuo, redissolved in CH2Cl2 and washed with HCl (0.1 M, 
3 x) and brine (1 x). The organic layer was dried over MgSO4 and concentrated in vacuo to obtain Cy5 
acid 14 (0.43 mmol, 0.32 g, 86%) which was used without further purification. LC/MS analysis: Rt 7.27 
min linear gradient 10% -> 90% B in 12.5 min, m/z 705.33 [M]+. HRMS: calculated for [C43H57N6O3]+ 
705.44867, found 705.44892. To a solution of crude Cy5 acid 14 (111 mg, 0.12 mmol) in DMF (0.8 
mL) was added EEDQ (30 mg, 0.12 mmol) and stirred for 2 h at room temperature to obtain a pre-
activated mixed anhydride solution. Aziridine 120 (17.4 mg, 0.1 mmol) was dissolved in DMF (0.4 mL) 
and pre-activated mixed anhydride solution (0.5 eq.) was added at 0 °C. After stirring for 30 min 
additional pre-activated mixed anhydride solution (0.5 eq.) was added. The reaction mixture was 
stirred for 30 min after which additional EEDQ (25 mg, 0.10 mmol) was added. After stirring 
overnight at 4 °C, the reaction mixture was quenched with MeOH at 0 °C and concentrated in vacuo. 
Purification by semi preparative reversed phase HPLC at neutral conditions (A: 50 mM NH4HCO3 in 
H2O, B: MeCN; linear gradient: 44% → 50% B in 12 min) gave compound 5 (4.39 mg, 4.88 μmol, 5%) 
as a blue powder. LC/MS analysis: Rt 6.13 min and 6.37 min, linear gradient 10% -> 90% B in 12.5 
min, m/z 862.40 [M]+. 1H NMR (850 MHz, MeOD): δ 8.24 (td, J = 13.2, 3.5 Hz, 2H), 7.84 (d, J = 4.7 
Hz, 1H), 7.49 (d, J = 7.3 Hz, 2H), 7.44 – 7.39 (m, 2H), 7.32 – 7.24 (m, 4H), 6.62 (t, J = 12.3 Hz, 1H), 
6.30 – 6.25 (m, 2H), 4.41 (d, J = 7.2 Hz, 2H), 4.38 – 4.34 (m, 2H), 4.11 – 4.06 (m, 3H), 3.87 – 3.84 (m, 
1H), 3.63 (s, 3H), 3.59 – 3.55 (m, 2H), 3.53 (dd, J = 10.7, 6.3 Hz, 1H), 3.44 (dd, J = 10.7, 6.0 Hz, 1H), 
3.36 (dd, J = 8.9, 1.9 Hz, 1H), 2.95 (dd, J = 6.0, 4.0 Hz, 1H), 2.60 (d, J = 6.0 Hz, 1H), 2.25 (t, J = 7.3 Hz, 
2H), 2.01 (td, J = 7.4, 3.8 Hz, 1H), 1.88 – 1.86 (m, 2H), 1.84 – 1.79 (m, 2H), 1.74 – 1.71 (m, 13H), 1.62 
– 1.55 (m, 2H), 1.48 – 1.45 (m, 2H), 1.36 – 1.27 (m, 6H). 13C NMR (214 MHz, MeOD): δ 187.2, 174.3, 
174.0, 173.2, 154.1, 154.0, 144.7, 142.8, 142.1, 141.2, 141.1, 128.3, 128.3, 125.2, 124.9, 124.8, 122.7, 
122.0, 121.8, 110.6, 110.4, 103.0, 102.8, 72.9, 71.7, 68.1, 64.2, 61.4, 61.4, 49.7, 43.3, 43.1, 41.8, 38.0, 35.0, 
34.2, 29.7, 28.7, 28.5, 28.2, 26.7, 26.5, 26.4, 25.9, 25.8, 24.9. HRMS: calculated for [C50H68N7O6]+ 
862.52256, found 862.52229. 
 
Materials of biological assays 




Enzyme activity assay 
To determine the apparent in vitro IC50 value, GLA was diluted in 150 mM Mcllvaine buffer (pH 4.6, 
supplemented with 0.1% (w/v) BSA and 0.1% (w/v) Triton X-100 (in case of ABP 5)) and pre-
incubated with a range of inhibitor dilutions. After 30 min at 37 oC, the substrate mix (100 μL, 1.0 
mg/mL  4-methylumbelliferyl-α-D-galactopyranoside in 150 mM McIlvaine pH 4.6 with 0.1% (w/v) 
BSA) was added. After 20 min of incubation at 37 oC, the reaction was quenched by adding an excess 
of NaOH-glycine buffer (pH 10.6 or 10.3 (in case of ABP 5)). The fluorescence of the formed 4-
methylumbelliferyl was measured with a fluorimeter LS55 (PerkinElmer) using λEX = 366 nm and λEM 
= 445 nm. To determine the influence of pH on the enzymatic activity, enzyme mixtures were firstly 
pre-incubated for 30 min on ice with McIlvaine buffers of pH 3−9 whereafter substrate was added, 
dissolved in Nanopure H2O. The influence of length of pre-incubation time on apparent IC50 was 
observed to determine the mode of binding of ABP 5.  The pre-incubation time of ABP 5 and rGLA 
was varied from 0 min (no pre-incubation) to 60 min whereafter the substrate mix was added. After 
incubation for 20 min at 37 oC, the reaction mixture was quenched and analyzed as described above. 
The in situ IC50 value was determined by incubating fibroblast cell lines, grown to confluency, with a 
range of inhibitor dilutions for 2 h. Hereafter, cells were washed three times with PBS and 
subsequently harvested by scraping in potassium phosphate buffer (25 mM K2HPO4-KH2PO4, pH 6.5, 
supplemented with 0.1% (v/v) Triton X-100 and protease inhibitor cocktail (Roche)). After 
determination of the protein concentration (BCA kit, Pierce), lysates were aliquoted and frozen at -80 
°C. The IC50 values of 2 and 3 were determined by replicating each assay twice in duplo in two 
separate cell lines. The IC50 values of 4 and 5 were measured in duplo. All IC50 values were corrected 
for background fluorescence (samples without enzyme), followed by normalization to the control 
sample (incubation without ABP). Curve-fitting via one phase exponential decay function was used to 
calculated the apparent IC50 values (Graphpad Prism 5.0 software (2, 3 and 4) and Graphpad Prism 6 
software (5)).21 
 
In vitro labeling and SDS-PAGE analysis of ABP 2 and ABP 3 
All pre-incubations and ABP labeling reactions occurred for 30 min at 37 °C, unless stated otherwise. 
The detection limit of was analyzed by labeling rGLA (10 pmol) with 10 000 – 0.01 nM ABP (2 and 3) 
for 30 min at 37 °C. The influence of pH on ABP labeling involved pre-incubation of the 
aforementioned enzyme at pH 3–10 for 30 min on ice, prior to addition of 1 mM ABP 2 and 3), 
dissolved in Nanopure H2O and incubation for 30 min at 37 °C. Assessment of ABP labeling kinetics 
involved precooling of rGLA (10 pmol) in 150 mM Mcllvaine buffer (pH 4.6, supplemented with 0.1% 
(w/v) BSA) on ice for 15 min, followed by addition of similarly cooled 10 pmol ABP solution in 
NanopureH2O. After mixing, ABP labeling was chased for 0–30 min, afterwhich labeling was stopped 
by denaturation. For ABPP, rGLA (10 pmol) or 100 mg total protein in lysate of human, wild-type 
GLA fibroblasts, was pre-incubated with 100 mm 8 (LWA481)20 or 9 (LWA468)21 or boiled for 4 min 
in 2% (w/v) SDS, prior to labeling with 1 mm ABP 2 or 3 (all dissolved in Nanopure H2O) for 30 min 
at 37 °C. Stability of the ABP–nucleophile adduct was analyzed by firstly labeling the various enzyme 
mixtures with the corresponding ABPs in the McIlvaine buffer after which the mixture was washed 
over Zeba spin desalting columns with 40K MWCO resin, according to the manufacturer’s 
instructions (Thermo Scientific). The eluted sample was separated, with 50% being snap-frozen in 
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liquid nitrogen and stored at -20 °C, whereas the remaining 50% was chased for 8 h, including hourly 
washing with the McIlvaine buffer, over a new Zeba column. Samples were denatured with 5 x 
Laemmli buffer (50% (v/v) 1M Tris-HCl, pH 6.8, 50% (v/v) 100% glycerol, 10% (w/v) DTT, 10% (w/v) 
SDS, 0.01% (w/v) bromophenol blue), boiled for 4 min at 100 °C, and separated by gel electrophoresis 
on 10% (w/v) SDS-PAGE gels running continuously at 90 V.21  
Wet slab-gels were then scanned for ABP-emitted fluorescence using a Typhoon TRIO variable mode 
imager (Amersham Biosciences) using λEX =532 nm and λEM =610 nm (band pass filter 30 nm) for the 
red fluorescent ABPs. 
 
Stability of ABP labeling of ABP 4 
Fabrazyme (5 nmol) in 150 mM McIlvaine buffer, pH 4.6, supplemented with 0.1% (w/v) BSA was 
labeled with 2.5 nmol ABP 2 or 4, solubilized in Nanopure H2O, during 1 h at 37 °C. Next, the 
mixture was washed over Zeba Spin Desalting Columns with 40K MWCO resin according to 
manufacturer's instructions (Thermo Scientific). After elution, half the sample was snap frozen in 
liquid nitrogen and stored at -20 °C. The remaining sample was chased and washed for 8 h by loading 
on a new Zeba column, thorough washing with 150 mM McIlvaine buffer, pH 4.6, and recollection 
(repeated every 2 h). Residual unlabeled α-galactosidase was post-labeled with 10 pmol ABP 4 (in case 
of pre-labeling with ABP 2) or with ABP 2 (in case of pre-labeling with ABP 4). Sample denaturation, 
SDS-PAGE electrophoresis and fluorescence detection was according to methods published earlier.29 
 
In vitro labeling and SDS-PAGE analysis of ABP 5 
Recombinant GLA was dissolved in 150 mM Mcllvaine buffer (pH 4.6) and 5 μL protein was mixed 
with 5 μL ABP 4 (20 mM, in H2O) at 37 oC. After incubation of 30 min, the proteins were denaturated 
by adding Laemmli buffer (2.5 μL, 50% (v/v) 1 M Tris-HCl, pH 6.8, 50% (v/v) glycerol, 10% (w/v) 
DTT, 10% (w/v) SDS and 0.01% (w/v) bromophenol blue). The reaction mixture was briefly vortexed 
and boiled for 4 min at 100 °C. The protein-ABP complex was loaded and separated by gel 
electrophoresis on 10% (w/v) SDS-PAGE, running at 90 V.21 The wet slab gel was scanned for 
fluorescence using the ChemiDoc imager (Bio-Rad) in the Cy5 channel (λEX = 647 nm; λEM = 695 nm; 
55 nm band pass filter). After fluorescence scanning, the SDS-PAGE gel was subjected to silver 
staining (Invitrogen Silverquest Silver Staining Kit; basic staining protocol) and scanned using the 




(1) Beenakker, T. J. M.; Kallemeijn, W. W.; Willems, L. I.; de Geus, M. A. R.; B. Gagestein; 
Codée, J. D. C.; van der Marel, G. A.; Aerts, J. M. F. G. and Overkleeft, H. S. contributed to 
the work described in this chapter. 
(2) Filoni, C.; Caciotti, A.; Carraresi, L.; Cavicchi, C.; Parini, R.; Antuzzi, D.; Zampetti, A.; 
Feriozzi, S.; Poisetti, P.; Garman, S. C.; Guerrini, R.; Zammarchi, E.; Donati, M. A.; 
Morrone, A. Biochim. Biophys. Acta 2010, 1802, 247. 
Chapter 2 
26 
(3) Shabbeer, J.; Yasuda, M.; Benson, S. D.; Desnick, R. J. Hum. Genomics 2006, 2, 297. 
(4) Sweeley, C. C.; Klionsky, B. J. Biol. Chem. 1963, 238, 3148. 
(5) Aerts, J. M.; Groener, J. E.; Kuiper, S.; Donker-Koopman, W. E.; Strijland, A.; Ottenhoff, 
R.; van Roomen, C.; Mirzaian, M.; Wijburg, F. A.; Linthorst, G. E.; Vedder, A. C.; 
Rombach, S. M.; Cox-Brinkman, J.; Somerharju, P.; Boot, R. G.; Hollak, C. E.; Brady, R. O.; 
Poorthuis, B. J. Proc. Natl. Acad. Sci. USA 2008, 105, 2812. 
(6) a) Auray-Blais, C.; Boutin, M.; Gagnon, R.; Dupont, F. O.; Lavoie, P.; Clarke, J. T. R. Anal. 
Chem. 2012, 84, 2745; b) Gold, H.; Mirzaian, M.; Dekker, N.; Ferraz, M. J.; Lugtenburg, J.; 
Codée, J. D. C.; van der Marel, G. A.; Overkleeft, H. S.; Linthorst, G. E.; Groener, J. E. M.; 
Aerts, J. M.; Poorthuis, B. J. H. M. Clin. Chem. 2013, 59, 547. 
(7) Schiffmann, R. Pharmacol. Ther. 2009, 122, 65. 
(8) Ferraz, M. J.; Kallemeijn, W. W.; Mirzaian, M.; Herrera Moro, D.; Marques, A.; Wisse, P.; 
Boot, R. G.; Willems, L. I.; Overkleeft, H. S.; Aerts, J. M. Biochim. Biophys. Acta 2013, 1841, 
811. 
(9) Tomasic, I. B.; Metcalf, M. C.; Guce, A. I.; Clark, N. E.; Garman, S. C. J. Biol. Chem. 2010, 
285, 21560. 
(10) Dean, K. J.; Sung, S. S.; Sweeley, C. C. Biochem. Biophys. Res. Commun. 1977, 77, 1411. 
(11) Chabas, A.; Duque, J.; Gort, L. J Inherit Metab Dis 2006, 30, 108. 
(12) Garman, S. C. Biocat. Biotransformation 2009, 24, 129. 
(13) Clark, N. E.; Garman, S. C. J. Mol. Biol. 2009, 393, 435. 
(14) Van Diggelen, O. P.; Schindler, D.; Kleijer, W. J.; Huijmans, J. M. G.; Galjaard, H.; Linden, 
H. U.; Peter-Katalinic, J.; Egge, H.; Dabrowski, U.; Cantz, M. The Lancet 1987, 330, 804. 
(15) Sakuraba, H.; Matsuzawa, F.; Aikawa, S.-I.; Doi, H.; Kotani, M.; Nakada, H.; Fukushige, T.; 
Kanzaki, T. J. Hum. Genet 2004, 49, 1. 
(16) Keulemans, J. L.; Reuser, A. J.; Kroos, M. A.; Willemsen, R.; Hermans, M. M. P.; van den 
Ouweland, A. M. W.; de Jong, J. G. N.; Wevers, R. A.; Renier, W. O.; Schindler, D.; Coll, M. 
J.; Chabas, A.; Sakuraba, H.; Suzuki, Y.; Van Diggelen, O. P. J. Med. Genet. 1996, 33, 458. 
(17) Garman, S. C.; Hannick, L.; Zhu, A.; Garboczi, D. N. Structure 2002, 10, 425. 
(18) Koshland, D. E. Biol. Rev. 1953, 28, 416. 
(19) Garman, S. C.; Garboczi, D. N. J. Mol. Biol. 2004, 337, 319. 
(20) Willems, L. I.; Beenakker, T. J. M.; Murray, B.; Gagestein, B.; van den Elst, H.; van Rijssel, 
E. R.; Codée, J. D. C.; Kallemeijn, W. W.; Aerts, J. M. F. G.; van der Marel, G. A.; 
Overkleeft, H. S. Eur. J. Org. Chem. 2014, 2014, 6044. 
(21) Willems, L. I.; Beenakker, T. J. M.; Murray, B.; Scheij, S.; Kallemeijn, W. W.; Boot, R. G.; 
Verhoek, M.; Donker-Koopman, W. E.; Ferraz, M. J.; van Rijssel, E. R.; Florea, B. I.; Codée, 
J. D. C.; van der Marel, G. A.; Aerts, J. M. F. G.; Overkleeft, H. S. J. Am. Chem. Soc. 2014, 
A new generation of fluorescent ABPs to target retaining α-galactosidases 
27 
136, 11622. 
(22) Willems, L. I.; Overkleeft, H. S.; van Kasteren, S. I. Bioconjugate Chem. 2014, 25, 1181. 
(23) Schmidinger, H.; Hermetter, A.; Birner-Gruenberger, R. Amino Acids 2006, 30, 333. 
(24) Fonović, M.; Bogyo, M. Expert Rev. Proteomics 2014, 5, 721. 
(25) The synthesis towards 1-azido-8-iodooctane is described in Chapter 3 of this Thesis. 
(26) Verdoes, M.; Hillaert, U.; Florea, B. I.; Sae-Heng, M.; Risseeuw, M. D. P.; Filippov, D. V.; 
van der Marel, G. A.; Overkleeft, H. S. Bioorg. Med. Chem. Lett. 2007, 17, 6169. 
(27) David, O.; Meester, W. J. N.; Bieräugel, H.; Schoemaker, H. E.; Hiemstra, H.; van 
Maarseveen, J. H. Angew. Chem. Int. Ed. 2003, 42, 4373. 
(28) Kvach, M. V.; Ustinov, A. V.; Stepanova, I. A.; Malakhov, A. D.; Skorobogatyi, M. V.; 
Shmanai, V. V.; Korshun, V. A. Eur. J. Org. Chem. 2008, 2008, 2107. 
(29) Kallemeijn, W. W.; Li, K.-Y.; Witte, M. D.; Marques, A. R. A.; Aten, J.; Scheij, S.; Jiang, J.; 
Willems, L. I.; Voorn-Brouwer, T. M.; van Roomen, C. P. A. A.; Ottenhoff, R.; Boot, R. G.; 
van den Elst, H.; Walvoort, M. T. C.; Florea, B. I.; Codée, J. D. C.; van der Marel, G. A.; 































xo-β-galactosidases catalyze the hydrolysis of terminal β-galactose residues in 
oligosaccharides, glycoproteins and glycosphingolipids. Two distinct β-
galactosidases are present in the human lysosome, namely, acid β-galactosidase (GLB1, 
EC 3.2.1.23, GH35) and galactosylceramidase (GALC, EC 3.2.1.46, GH59). Whereas 
both enzymes recognize β-galactopyranosides as substrate, they differ in their 
preference for the aglycon: GALC appears to have evolved to degrade 
galactosphingolipid substrates, whereas GLB1 takes on β-galactopyranosides featuring 
a carbohydrate aglycon.2 A selective readout for these enzymes in the context of 
complex biological mixtures would be interesting from a fundamental point of view but 





gangliosidosis3-5 and Morquio B syndrome.2,6,7 Although both lysosomal storage 
disorders (LSDs) are induced by mutations in the GLB1 gene, GM1-gangliosidosis is 
caused by accumulation of GM1 ganglioside in the central nervous system3-5,8,9, whereas 
Morquio B syndrome is characterized by storage of keratan sulfate.10 Krabbe disease in 
turn is a LSD caused by a deficiency in GALC. GALC catalyzes the hydrolysis of 
galactosylceramide and psychosine in the lysosome. In the brains of Krabbe affected 
individuals accumulation of psychosine is observed.11,12 Although the molecular 
mechanism is not yet fully elucidated, accumulation of psychosine is considered as the 
main cause of the pathogenic symptoms characteristic for Krabbe disease.13-15 
GLB1 and GALC hydrolyze their substrate β-galactopyranosides through a double-
displacement mechanism following principles originally outlined by Koshland.16 Upon 
binding of the substrate to the enzyme active site, the exocyclic oxygen bearing the 
aglycon is protonated by the general acid/base catalyst (Glu-18817 in the human GH35 
β-galactosidase or Glu-18218 in mice GH59 β-galactosidase on which structural studies 
demonstrating the mechanism of action were performed). Upon protonation and 
expulsion of the aglycon, the catalytic nucleophile (Glu-26817 in human GH35 β-
galactosidase or Glu-25818 in mice GH59 β-galactosidase) traps the emerging 
oxycarbenium ion, to yield in a formal SN2 displacement process a covalent enzyme-α-
galactopyranosyl adduct (Figure 3.1A). The covalent galactosyl-enzyme intermediate is 
subsequently hydrolyzed to release galactopyranose with an overall retention of 
configuration at the anomeric center. This mechanism, specifically the involvement of 
a covalent intermediate in GH35/GH59 galactosidase-mediated substrate processing, 
invites the design of activity-based probes (ABPs) following strategies that have been 
reported on in recent years (Figure 3.1B).19-22 
Figure 3.1 A) Double displacement mechanism of retaining β-galactosidases. B) Proposed mechanism 
of cyclophellitol aziridine based probes in β-galactosidases.  
 
Cyclophellitol, a natural product and retaining β-glucosidase inhibitor, has been 
modified for activity-based glycosidase profiling, by featuring a reporter moiety 
(fluorophore, biotin) at C6 (glucose numbering, C8 in cyclophellitol numbering).23 
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Cyclophellitol adopts a 4H3 conformation and thereby emulates the transiently formed 
oxycarbenium half-chair intermediate that also characterizes retaining β-glucosidase-
mediated substrate processing.24 The presence of a large, bulky group (the reporter 
moiety) at C6 induced a remarkable selectivity to the probes, which out of three cellular 
retaining β-glucosidases selected a single species, lysosomal glucosylceramidase 
(GBA1) as their single target. In a follow-up study and with the aim to develop to label, 
besides GBA1, also the two neutral, cytosolic retaining β-glucosidases, GBA2 and 
GBA3 (and, in intestines, the β-glucosidase activity in the enzyme complex, lactose-
phloritzin hydrolase), the reporter moiety was moved from C6 to the ring nitrogen of 
cyclophellitol aziridine. These studies disclosed that N-functionalized cyclophellitol 
aziridines are broad-spectrum activity-based probes for retaining β-glucosidases.25 
Recently Marques et al.26 reported that β-galactose-configured cyclophellitol with a 
reporter group at C6 is a selective probe for GALC. This situation resembles the one 
encountered previously with the C6-modified cyclophellitol probe.23 An obvious 
solution when aiming for profiling GALC and GLB1 in an ABPP fashion, thus both 
retaining β-galactosidases expressed in human cells, would be to prepare the 
corresponding β-galactopyranose-configured N-modified cyclophellitol aziridine 
probes. As is shown here, such β-galactopyranose-cyclophellitol aziridines bearing a 
reporter moiety at the aziridine nitrogen are indeed synthetically tractable, even though 
intermediates towards the final product are highly sensitive to hydrolysis. 
 
 
Figure 3.2 Structures of β-galactopyranose-cyclophellitol (1), intermediates 2 and 3 for bioorthogonal 
ligation, and ABPs (4 and 5) targeted in this study. 
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The free aziridine27 as well as azide 2 can be obtained in analytically pure form (Figure 
3.2), however ensuing copper(I)-catalyzed [2+3]-cycloaddition ‘click’ ligation to install 
a reporter moiety proved abortive. Altering the strategy to include inverse-electron 
demand Diels-Alder ligation between a norbornene and a tetrazine did yield the 
desired one-step broad-spectrum β-galactosidase probe, as is shown in the following. 
 
3.2 Results and discussion 
 
As the first research objective, a crystal of bacterial β-galactosidase of the carbohydrate 
family GH35 (CjGH35A) was soaked with β-galactose-configured cyclophellitol 
aziridine 7 (TB562)27 to confirm the mechanism-based design and covalent mode of 
action of this class of inhibitors towards GH35. This resulted in an enzyme-7 complex 
(Figure 3.3). The nucleophilic glutamate residue has reacted with compound 7 through 
nucleophilic addition at C1, which resulted in opening of the aziridine and 
concomitant conformation change of covalently bound substrate from a 4H3 half chair 
conformation to a 4C1 chair conformation. In addition, a fluorogenic substrate activity 
assay was performed in CjGH35A with compound 7. After 30 min of pre-incubation 
with varying concentrations of the inhibitor, the residual enzyme activity was measured 
using the fluorogenic 4-methylumbelliferyl β-D-galactopyranoside substrate. The 
apparent IC50 value of 21.55 ± 2.14 nM was obtained in this assay. These results 
underscore that cyclophellitol aziridine 7 is a suitable starting point for the design of 









Figure 3.3 Crystal structure of bacterial β-galactosidase of the carbohydrate family GH35 (CjGH35A) 
in complex with mechanism-based inhibitor 727. 
 
In initial studies on the use of cyclophellitol aziridine as a scaffold for ABP design, 
reporter moieties to the aziridine nitrogen were grafted through N-acylation.25,28-30 In a 
head-to-head comparative study (Chapter 2), N-alkyl aziridines featuring the same 
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carbohydrate-derived configuration were synthetically more tractable. In addition to 
this N-alkyl-cyclophellitol aziridines were equally potent in inhibiting retaining β-
glucosidases as their corresponding N-acyl counterparts.31 Based on these 
considerations, β-galactose-configured cyclophellitol aziridine 7, prepared as described 
previously27, was reacted with 8-azido-1-iodooctane 10 under basic conditions (Figure 
3.4A). In this way, analytically pure two-step ABP 2 was obtained in 25% yield. Cu(I)-
catalyzed azide/alkyne cycloaddition (CuAAC) with Cy5-alkyne32 however proved 
abortive, in that no homogeneous material was obtained after reversed phase HPLC. 
Instead, a number of unidentified products were obtained, and it may be that the 
aziridine moiety is unstable under the copper(I)-catalyzed click conditions, the work-



















Figure 3.4 A) Synthesis of precursor probe 2, reagents and conditions: a) Li, NH3, -60 °C, b) 10, 
K2CO3, DMF, 80 °C, overnight, 25%; c) NaN3, DMF, 80 °C, quant; d) PPh3, imidazole, I2, THF, -20 °C 
to rt, 15 min, 69%. B) Labeling of GALC in kidney and brain homogenates of wt and GALC-deficient 
mouse tissues (Galc KO) using copper(I)-catalyzed azide/alkyne cycloaddition (CuAAC). After 
incubation for 1 h with compound 2 (1 μM) at 37 °C, the mixture was diluted with a NaOAc buffer, 
incubated overnight at rt with BODIPY-alkyne 11 (1 μM), TBTA, CuSO4 and DTT and resolved by 































Efforts were next turned to two-step labeling to avoid purification of the one-step 
probe. This classical ABPP method was successful in labeling GBA1 in cell extracts 
using CuAAC.33 Following this protocol labeling of GALC in kidney and brain mice 
homogenates was attempted first. After incubation of the probe for 1 h in the 
homogenate, a fresh mixture of fluorophore 1134, CuSO4, 
tris(benzyltriazolylmethyl)amine (TBTA) and dithiothreitol (DTT) were added. The 
additive DTT was used to reduce CuII to active CuI and TBTA stabilizes the reactive 
CuI. After loading on gel a clear band in the fluorescent read-out of ABP 4 labeling 
GALC (~45 kDa35,36) was detected in the kidney lysate (Figure 3.4B). GALC-deficient 
lysates of a Twitcher mice were used as a control.37 
 
In another attempt to obtain a one-step β-galactosidase ABP, the inverse-electron-
demand Diels-Alder (IEDDA) ligation strategy was investigated to introduce the 
fluorophore at the final step of probe synthesis.38-40 For this purpose norbornene-
modified cyclophellitol aziridine 3 was synthesized and reacted with tetrazine-Cy5 22 
to obtain ABP 5 (Figure 3.2). The synthesis of norbornene-functionalized aziridine 
started with monotritylation of 1,6-hexanediol to give 13 (Scheme 3.1). Subsequent 
hydroxyl-halogen exchange of the primary alcohol with iodine followed by substitution 
with sodium azide afforded 15.41 Reduction of azide 15 using triphenylphosphine on 
beads gave amine 16. Norbornene-OSu ester 17 was obtained according to the 
literature procedure38 as a mixture of endo- and exo-isomers. This mixture was 
condensed with amine 16 resulting in a mixture of norbornene-trityl products 
(exo/endo, 1:2.3), which were easily separated by silica gel column chromatography. 
Deprotection of the major endo-product 19 under acidic conditions gave alcohol 20 in 
86% yield. Treatment of 20 with triphenylphosphine, iodine and imidazole at elevated 
temperatures in tetrahydrofuran afforded iodonorbornene 21.  
 























14, R = I
15, R = N3
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Reagents and conditions: a) 1,6-hexanediol, pyridine, CH2Cl2, rt, 90 min, 95%; b) imidazole, PPh3, I2, 
Et2O, CH3CN, rt, overnight, 80%; c) NaN3, DMF, 80 °C, overnight, quant; d) PPh3 on beads, H2O, 
THF, 48 h, quant; e) norbornene-OSu38, DIPEA, DCE, rt, overnight, 18 28%, 19 68%; f) p-
toluenesulfonic acid, CH2Cl2, MeOH, rt, overnight, 86%; g) PPh3, I2, imidazole, THF, reflux, 1.5 h, 
73%. 
 
Cyclophellitol aziridine 7 was then N-alkylated with iodonorbornene linker 21 using 
potassium carbonate as the base in DMF, yielding two-step ABP 3 in poor yield but 
useful quantities (Scheme 3.2). Subsequent ligation42 with Cy5 tetrazine 22 was 
successful and gave ABP 5 as mixture of isomers.  
 
Scheme 3.2 Synthesis of ABP 5 with a norbornene ligation handle. 
Reagents and conditions: a) 21, K2CO3, DMF, 75 °C, overnight, 12%. b) Cy5 tetrazine 22, MeOH, 
overnight, 87%.  
 
To determine the potency of inhibitors 1-3 (Figure 3.2), a fluorogenic substrate activity 
assay as described for CjGH35A was performed in human embryonic kidney 293 
(HEK293) cells overexpressing GALC and in human fibroblast lysates to determine the 
GLB1 activity. The apparent IC50 values are listed in Table 3.1. The obtained 
cyclophellitol aziridine inhibitors proved to be nanomolar inhibitors in these assays. 
 










Compound GLB1 GALC 
1 (LWA480)  21.743 39.143 
2 (TB422) 2.55 ± 0.47 11.96 ± 2.27 
3 (TB582) 57.84 ± 3.05 98.55 ± 20.84 
5 (TB652) 14.85 ± 0.98 61.02 ± 6.89 
7 (TB562) 2.55 ± 0.59 5.57 ± 0.36 
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In the next set of experiments ABP 5 probe was examined in an activity-based protein 
profiling setting in mouse kidney homogenates. GBA (58 - 66 kDa23), the lysosomal 
glucosylceramidase, has a similar mass as GLB1 (~64 kDa44). Therefore, lysates were 
pre-incubated with MDW93323, a known selective covalent GBA inhibitor. First, the 
pH-dependent activity of probe 5 was determined. As depicted in Figure 3.5A, ABP 5 
labels GLB1 and GALC (~45 kDa35,36) in an effective manner at pH 4.0 up to pH 6.0. 
With this result in hand, a concentration dependent labeling was performed at pH 4.5. 
As shown in Figure 3.5B, the probe labels both enzymes effectively at 1 μM 
concentration. Finally, the incubation time of the probe in the lysate was varied up to 
120 min without pre-incubation with MDW933 (Figure 3.5C). Labeling intensity of the 
proteins increases over time, supporting mechanism-based action of the probe.  
 
Figure 3.5 Activity-based protein profiling with probe 5 at various conditions in mouse kidney 
homogenates after blocking the GBA activity (A and B). A) pH-dependent labeling with 1 μM probe 5 
for 30 min. B) Concentration dependent labeling at pH 4.5 for 30 min. C) Incubation time dependent 




In conclusion, in this chapter the synthesis of cyclophellitol aziridine based ABPs for 
human lysosomal β-galactosidases is described. ABP 5 could be obtained even though 
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experiments, to be effective in labeling the human lysosomal β-galactosidases, GLB1 
and GALC. ABP 5 and differently functionalized ABPs (bearing, for instance, a biotin 
and potentially prepared through IEDDA as well) may be exploited to study the role of 
β-galactosidases in LSDs and the remarkable differences between GM1 gangliosidosis 




General: Chemicals were purchased from Acros, Sigma Aldrich, Biosolve, VWR, Fluka, Merck and 
Fisher Scientific and used as received unless stated otherwise. Dichloromethane (DCM), 
tetrahydrofuran (THF), N,N-dimethylformamide (DMF) and toluene were stored over flame-dried 4 
Å molecular sieves before use. Pyridine and triethylamine were stored on KOH pellets before use. 
Traces of water from reagents were removed by co-evaporation with toluene in reactions that require 
anhydrous conditions. All reactions were performed under an argon atmosphere unless stated 
otherwise. TLC analysis was conducted using Merck aluminum sheets (Silica gel 60 F254) with 
detection by UV absorption (254 nm), by spraying with a solution of (NH4)6Mo7O24·4H2O (25 g/L)  
and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid, a solution of KMnO4 (20 g/L) and K2CO3 (10 
g/L) in water or ninhydrin (0.75 g/L), followed by charring at ~150 ˚C. Size exclusion was performed 
on Sephadex LH-20 (eluent DCM/MeOH, 1:1). Column chromatography was performed using 
Screening Device b.v. Silica Gel (particle size of 40 – 63 μm, pore diameter of 60 Å) in the indicated 
solvents. For reversed-phase HPLC purifications a HPLC system equipped with a C18 semi-
preparative column (Gemini C18, 250x10 mm, 5 μm particle size, Phenomenex) was used. LC/MS 
analysis was performed on a Surveyor HPLC system (Thermo Finnigan) equipped with a C18 column 
(Gemini, 4.6 mm x 50 mm, 5 μm particle size, Phenomenex), coupled to a LCQ Adventage Max 
(Thermo Finnigan) ion-trap spectrometer (ESI+). The applied buffers were H2O, MeCN and 1% 
aqueous TFA. 1H NMR and 13C NMR spectra were recorded on a Brüker AV-400 (400 and 101 MHz 
respectively) spectrometer in the given solvent. Chemical shifts are given in ppm (δ) relative to the 
residual solvent peak or tetramethylsilane (0 ppm) as internal standard. Coupling constants are given 
in Hz. High-resolution mass spectrometry (HRMS) analysis was performed with a LTQ Orbitrap 
mass spectrometer (Thermo Finnigan), equipped with an electronspray ion source in positive mode 
(source voltage 3.5 kV, sheath gas flow 10 mL/min, capillary temperature 250 °C) with resolution R = 
60000 at m/z 400 (mass range m/z = 150–2000) and dioctyl phthalate (m/z = 391.28428) as a “lock 
mass”. The high-resolution mass spectrometer was calibrated prior to measurements with a 
calibration mixture (Thermo Finnigan). 
 
(1R,2S,3S,4S,5R,6R)-5-(hydroxymethyl)-7-azabicyclo[4.1.0]heptane-2,3,4-triol (7) 
NH3 gas was condensated at -60 °C and liquid NH3 was collected (± 5.0 ml). To the 
liquid NH3 was added lithium (35 mg) and the reaction mixture turned into a dark 
blue solution. The mixture was stirred until all the lithium was completely dissolved, 
after which a solution of benzylated aziridine 6 (70 mg, 0.20 mmol) in THF (3 ml) was added 
dropwise. After stirring for 45 min at -60 °C, the reaction mixture was quenched with MilliQ (2.0 ml). 
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The mixture was gradually warmed to rt and concentrated in vacuo. The crude product was dissolved 
in H2O and treated with Amberlite IR-120 NH4+ for 5 min. After filtration of the resin, the filtrate was 
concentrated in vacuo and retreated with Amberlite IR-120 NH4+ to obtain β-aziridine 7 (22.6 mg, 
0.13 mmol, 65%) as a white solid which was used without further purification. 1H NMR (400 MHz, 
D2O) δ 3.94 (d, J = 8.4 Hz, 1H), 3.84 – 3.80 (m, 3H), 3.40 (dd, J = 8.0, 0.8 Hz, 1H), 2.41 (s, 1H), 2.30 (d, 
J = 5.6 Hz, 1H), 2.17 (s, 1H). 13C NMR (101 MHz, D2O) δ 75.9, 70.3, 70.0, 61.1, 39.1, 34.3, 31.9. 
 
8-azidooctan-1-ol (9) 
To a solution of 8-chloro-1-octanol (1.68 mL, 10 mmol) in DMF (25 mL) was added 
sodium azide (5.50 g, 100 mmol). After stirring  overnight at 50 °C and an additional 4 h at 80 °C, the 
reaction mixture was concentrated in vacuo. The resulting crude product was dissolved in EtOAc (300 
mL) and washed with H2O (4 x 200 mL). The organic layer was dried over MgSO4 and concentrated in 
vacuo, resulting in azide alcohol 9 as a clear oil in quantitative yield (1.71 g, 10.0 mmol). 1H NMR (400 
MHz, CDCl3): δ (ppm) = 3.64 (t, J = 6.6 Hz, 2H), 3.26 (t, J = 6.9 Hz, 2H), 1.64 – 1.51 (m, 4H), 1.47 (s, 
1H), 1.44 – 1.28 (m, 8H). 13C NMR (101 MHz, CDCl3): δ (ppm) = 63.1, 51.6, 32.8, 29.4, 29.2, 28.9, 
26.8, 25.8. HRMS: calculated for [C8H18N3O]+ 172.14444, found 172.14419. 
 
1-azido-8-iodooctane (10) 
To a solution of 9 (1.71 g, 10.0 mmol) in THF (50 mL) was added triphenylphosphine (3.0 
g, 11.8 mmol) and imidazole (2.0 g, 29.4 mmol). The solution was cooled to - 20 °C and iodine (2.61 g, 
10.3 mmol) was added. After stirring the reaction mixture for 15 min at room temperature, the 
reaction was quenched with saturated NaHCO3 (30 mL) at 0 °C. The reaction mixture was extracted 
with Et2O (100 mL), dried over MgSO4 and concentrated in vacuo. Purification over silica gel column 
chromatography (pentane → 5% EtOAc in pentane) gave 10 (1.95 g, 6.9 mmol, 69%) as a clear oil. 1H 
NMR (400 MHz, CDCl3): δ (ppm) = 3.26 (t, J = 6.9 Hz, 2H), 3.19 (t, J = 7.0 Hz, 2H), 1.86 – 1.77 (m, 
2H), 1.66 – 1.54 (m, 2H), 1.46 – 1.27 (m, 8H). 13C NMR (101 MHz, CDCl3): δ (ppm) = 51.6, 33.6, 30.5, 




A mixture of cyclophellitol aziridine 7 (35 mg, 0.2 mmol), 10 (0.24 mmol, 67 
mg) and K2CO3 (119 mg, 0.86 mmol) in DMF (4 mL) was stirred at 80 °C. After 
stirring overnight the reaction mixture was concentrated in vacuo and purification over silica gel 
column chromatography (8% MeOH in DCM → 12% MeOH in DCM) gave azide-aziridine 
cyclophellitol 2 (21.5 mg, 65 μmol, 25%) as a white powder. 1H NMR (400 MHz, D2O): δ (ppm) = 3.93 
(d, J = 8.0 Hz, 1H), 3.81 – 3.75 (m, 3H), 3.34 (dd, J = 0.2 Hz, 2.0 Hz, 1H), 3.27 (t, J = 6.8 Hz, 2H), 2.53 
– 2.48 (m, 1H), 2.13 – 2.04 (m, 2H), 1.88 (d, J = 6.0 Hz, 1H), 1.85 (d, J = 6.0 Hz, 1H), 1.62 – 1.42 (m, 
4H), 1.40 – 1.22 (m, 8H). 13C NMR (101 MHz, D2O): δ (ppm) = 76.4, 70.7, 70.3, 61.0, 59.2, 51.2, 43.0, 
41.0, 39.5, 29.1, 29.0, 28.9, 28.5, 27.0, 26.4. HRMS: calculated for [C15H29N4O4]+ 329.21818, found 
329.21833.  
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6-(trityloxy)hexan-1-ol (13) 
To a solution of 1,6-hexanediol (11.8 g, 100 mmol) and pyridine (1.6 mL, 20 mmol) in 
DCM (100 mL) was added tritylchloride (2.78 g, 10 mmol) at room temperature. After vigorously 
stirring for 90 min, the solution was washed with brine (3x). The organic layer was dried with MgSO4, 
filtrated and concentrated in vacuo. Purification by column chromatography (30% EtOAc in pentane) 
gave tritylhexanol 13 (3.41 g, 9.47 mmol, 95%) as a white solid. Compound characteristics were 
conform with previously reported data.45,46 
 
(((6-iodohexyl)oxy)methanetriyl)tribenzene (14) 
Tritylhexanol 13 (3.35 g, 9.3 mmol) was dissolved in Et2O (35 mL) and CH3CN (11 mL). 
After addition of imidazole (1.90 g, 27.9 mmol) and triphenylphosphine (13.95 mmol, 3.66 g) the 
reaction mixture was cooled to 0 ºC and iodine (3.54 g, 13.95 mmol) was added in small portions. 
After stirring for 30 min, the reaction was allowed to warm to room temperature and stirred 
overnight. The reaction mixture was diluted with Et2O and the precipitated was filtered off. The 
filtrated was washed with Na2S2O3, dried with MgSO4, filtrated and concentrated in vacuo. 
Purification by column chromatography (pentane → 3% EtOAc in pentane) yielded title compound 14 




To solution of compound 14 (0.92 g, 2.0 mmol) in DMF (5 mL) was added NaN3 (1.30 g, 
20 mmol) and stirred at 80 ºC overnight. The reaction mixture was diluted with EtOAc and washed 
with H2O (4x). The organic layer was dried with MgSO4, filtrated and concentrated in vacuo to obtain 
the azide 15 (0.787 g, 2.0 mmol) as a clear oil, which was used without further purification. 1H NMR 
(400 MHz, CDCl3) δ 7.43 (d, J = 7.2 Hz, 6H), 7.32 – 7.16 (m, 9H), 3.21 (t, J = 7.0 Hz, 2H), 3.05 (t, J = 
6.5 Hz, 2H), 1.65 – 1.50 (m, 4H), 1.45 – 1.24 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 144.5, 128.8, 
127.8, 126.9, 86.4, 63.5, 51.5, 30.0, 28.9, 26.7, 26.0.  
 
6-(trityloxy)hexan-1-amine (16) 
To a solution of azide 15 (193 mg, 0.5 mmol) in THF (2.3 mL) and H2O (9 μL) was added 
PPh3 on beads (200 mg, 0.60 mmol, 3 mmol/g). After stirring for 48 h at room temperature, the 
reaction mixture was filtered and concentrated in vacuo. The crude product was co-evaporated with 
toluene (3x) to obtain amine 16 (186 mg, 0.517 mmol) as a clear oil which was used without further 
purification. 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 7.6 Hz, 6H), 7.31 – 7.18 (m, 9H), 3.05 (t, J = 6.6 
Hz, 2H), 2.63 (t, J = 7.0 Hz, 2H), 1.68 – 1.54 (m, 2H), 1.43 – 1.31 (m, 4H), 1.31 – 1.22 (m, 2H), 1.21 (s, 
1H). 13C NMR (101 MHz, CDCl3) δ 144.5, 128.7, 127.7, 126.9, 86.3, 63.6, 42.3, 33.8, 30.1, 26.8, 26.2. 
HRMS: Calculated for [C25H30NO]+ 360.23219, found 360.23228. 
 
(1R,2R,4R)-N-(6-(trityloxy)hexyl)bicyclo[2.2.1]hept-5-





To a solution of amine 16 (0.90 g, 2.52 mmol) in DCE (12.6 mL) was added norbornene-OSu 1738 
(0.61 g, 2.59 mmol; mixture of endo and exo, mostly endo) and DIPEA (1.07 mL) at room 
temperature. After stirring overnight the reaction mixture was concentrated in vacuo. Purification by 
column chromatography (20% EtOAc in pentane → 30% EtOAc in pentane) gave exo-product 18 
(0.34 g, 0.70 mmol, 28%) and endo-product 19 (0.82 g, 1.7 mmol, 68%) as a clear oil. Exo-product 18 
1H NMR (400 MHz, CDCl3) δ 7.47 – 7.40 (m, 6H), 7.30 – 7.20 (m, 9H), 6.13 (dd, J = 5.5, 3.0 Hz, 1H), 
6.08 (dd, J = 5.4, 3.2 Hz, 1H), 5.51 (s, 1H), 3.23 (d, J = 6.3 Hz, 1H), 3.20 (d, J = 6.5 Hz, 1H), 3.06 (d, J = 
6.3 Hz, 1H), 3.03 (d, J = 6.5 Hz, 1H), 2.90 – 2.87 (m, 2H), 1.96 – 1.86 (m, 2H), 1.72 (d, J = 8.3 Hz, 1H), 
1.66 – 1.57 (m, 2H), 1.52 – 1.44 (m, 2H), 1.41 – 1.34 (m, 2H), 1.33 – 1.31 (m, 1H), 1.31 – 1.25 (m, 3H). 
Exo-product 18 13C NMR (101 MHz, CDCl3) δ 175.6, 144.5, 138.3, 136.1, 128.8, 127.8, 126.9, 86.4, 
63.5, 47.3, 46.5, 44.8, 41.7, 39.7, 30.6, 30.0, 29.8, 26.9, 26.1. Exo-product 18: HRMS: Calculated for 
[C33H37NO2Na]+ 502.27165, found 502.27059. Endo-product 19  1H NMR (400 MHz, CDCl3) δ 7.51 – 
7.39 (m, 6H), 7.32 – 7.19 (m, 9H), 6.21 (dd, J = 5.6, 3.1 Hz, 1H), 5.95 (dd, J = 5.6, 2.8 Hz, 1H), 5.39 (s, 
1H), 3.17 (dd, J = 7.1, 2.6 Hz, 1H), 3.14 (dd, J = 7.2, 2.5 Hz, 1H), 3.10 (s, 1H), 3.04 (t, J = 6.6 Hz, 2H), 
2.89 (s, 1H), 2.85 – 2.80 (m, 1H), 1.94 – 1.87 (ddd, J = 11.9, 9.4, 3.8 Hz, 1H), 1.65 – 1.55 (m, 2H), 1.46 
– 1 .40 (m, 3H), 1.40 – 1.34 (m, 2H), 1.34 – 1.30 (m, 1H), 1.30 – 1.22 (m, 3H). Endo-product 19 13C 
NMR (101 MHz, CDCl3) δ 174.2, 144.5, 137.8, 132.4, 128.7, 127.8, 126.9, 86.4, 63.5, 50.1, 46.3, 44.9, 
42.8, 39.5, 30.0, 29.7, 26.9, 26.1. Endo-product 19 HRMS: Calculated for [C33H37NO2Na]+ 502.27165, 
found 502.27141.  
 
(1R,2R,4R)-N-(6-hydroxyhexyl)bicyclo[2.2.1]hept-5-ene-2-carboxamide (20) 
Compound 19 (0.815 g, 1.7 mmol) was dissolved in a mixture of DCM/MeOH (20 
mL, 1:1) and p-toluenesulfonic acid was added until pH 2. After stirring overnight 
at room temperature, the reaction mixture was neutralized with a saturated aqueous NaHCO3 
solution. The aqueous layer was extracted with EtOAc (3x) and the combined organic layers were 
washed with brine, dried with MgSO4, filtrated and concentrated in vacuo. Purification by column 
chromatography (5% Methanol in DCM → 8% Methanol in DCM) gave title compound 20 (0.349 g, 
1.47 mmol, 86%) as a clear yellow oil. 1H NMR (400 MHz, CDCl3) δ 6.22 (dd, J = 5.6, 3.1 Hz, 1H), 5.96 
(dd, J = 5.6, 2.8 Hz, 1H), 5.80 (s, 1H), 3.60 (t, J = 6.5 Hz, 1H), 3.23 – 3.15 (m, 2H), 3.13 (s, 1H), 2.91 (s, 
1H), 2.89 – 2.80 (m, 2H), 1.92 (ddd, J = 11.8, 9.4, 3.7 Hz, 1H), 1.59 – 1.51 (m, 2H), 1.50 – 1.41 (m, 3H), 
1.40 – 1.22 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 174.4, 137.7, 132.2, 62.3, 50.0, 46.2, 44.7, 42.7, 39.2, 
32.5, 29.8, 29.6, 26.5, 25.3. HRMS: Calculated for [C14H24NO2]+ 238.18016, found 238.18026. 
 
(1R,2R,4R)-N-(6-iodohexyl)bicyclo[2.2.1]hept-5-ene-2-carboxamide (21) 
To a solution of alcohol 20 (119 mg, 0.50 mmol) in THF (2.5 mL) was added PPh3 
(197 mg, 0.75 mmol) and imidazole (64 mg, 1.0 mmol). The reaction mixture was 
stirred and heated to reflux temperature. Carefully a solution of I2 (190 mg, 0.75 mmol) in THF (1.0 
mL) was added. After stirring for 1.5 h, the reaction mixture was concentrated, redissolved in EtOAc 
and washed with Na2S2O4. The organic layer was dried with MgSO4, filtrated and concentrated in 
vacuo. Purification by column chromatography (30% EtOAc in pentane) yielded title compound 21 
(126 mg, 0.361 mmol, 73%) as a clear yellow oil. 1H NMR (400 MHz, CDCl3) δ 6.24 (dd, J = 5.6, 3.1 
Hz, 1H), 5.97 (dd, J = 5.6, 2.8 Hz, 1H), 5.39 (s, 1H), 3.25 – 3.15 (m, 4H), 3.13 (s, 1H), 2.92 (s, 1H), 2.86 
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(dt, J = 9.2, 4.0 Hz, 1H), 1.94 (ddd, J = 11.9, 9.4, 3.8 Hz, 1H), 1.83 (t, J = 7.0 Hz, 1H), 1.80 (t, J =  7.0 
Hz, 1H), 1.54 – 1.36 (m, 5H), 1.35 – 1.27 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 174.2, 137.7, 132.2, 
50.0, 46.2, 44.7, 42.7, 39.2, 33.3, 30.1, 29.8, 29.5, 25.8, 7.2. HRMS: Calculated for [C14H23INO]+ 





A solution of norbornene 21 (83 mg, 0.24 mmol) in DMF (2 mL) was 
added to aziridine 7 (0.2 mmol). K2CO3 (119 mg, 0.86 mmol) was added 
to the reaction mixture followed by heating to 75 ºC. After stirring overnight, the reaction mixture 
was concentrated in vacuo. Purification by column chromatography (12% MeOH in DCM) followed 
by HPLC purification (A: 50 mM NH4HCO3 in H2O; B: MeCN; 20% → 26%, A in B) and lyophilisation 
resulted in compound 3 (24.3 μmol, 9.6 mg, 12%). LC/MS analysis: Rt 3.81 min (linear gradient 
10→90% B in 12.5 min), m/z 395.27 [M + H]+. 1H NMR (400 MHz, Deuterium Oxide) δ 6.23 (dd, J = 
5.6, 3.1 Hz, 1H), 5.90 (dd, J = 5.6, 2.8 Hz, 1H), 3.94 (d, J = 8.2 Hz, 1H), 3.79 (d, J = 7.4 Hz, 2H), 3.75 (s, 
1H), 3.33 (dd, J = 8.2, 2.2 Hz, 1H), 3.16 – 3.05 (m, 3H), 2.97 – 2.92 (m, 1H), 2.90 (s, 1H), 2.50 – 2.42 
(m, 1H), 2.18 – 2.04 (m, 2H), 2.02 (d, J = 6.1 Hz, 1H), 1.86 – 1.82 (m, 2H), 1.52 – 1.40 (m, 4H), 1.39 – 
1.22 (m, 7H). 13C NMR (101 MHz, D2O) δ 177.7, 138.4, 131.8, 76.2, 70.6, 70.4, 61.1, 58.4, 49.5, 46.4, 
44.1, 42.6, 42.5, 40.4, 39.2, 39.1, 29.5, 28.7, 28.3, 26.1, 25.7. HRMS: Calculated for [C21H35N2O5]+ 
395.25405, found 395.25336. 
 
ABP 5 
To a solution of norbornene 3 (0.94 mg, 2.38 
μmol) in MeOH (4 mL) was added Cy5 
tetrazine 22 (2.83 mg, 4.3 μmol). After shaking 
overnight, the reaction mixture was 
concentrated in vacuo and purified by HPLC 
under neutral conditions (A: 50 mM 
NH4HCO3 in H2O; B: MeCN; 49% ->52%, A in 
B) gave ABP 5 (2.12 mg, 2.07 μmol, 87%) as a mixture of regioisomers. HRMS: Calculated for 
[C62H80N7O6]+ 1018.61646, found 1018.61611. 
 
Crystal structure of CjGH35A complexed with TB562 (7) 
The gene for CjGH35A, cloned into a pET28a vector modified for Ligation Independent Cloning, was 
expressed, and the protein purified and crystallized as in Larsbrink et al.48, in 2.7 M sodium acetate pH 
7.2 (protein at 30 mg/ml, drop 1.2:1 μl over well).  A crystal was soaked in the presence of a speck of 
TB562 powder for 70 hours. The crystal was fished directly into liquid nitrogen without the need for 
additional cryoprotectant. Data were collected on beamline IO2 at the Diamond Light Source at 
wavelength 0.97950 Å, and were processed using DIALS49 and scaled with AIMLESS50 to 1.6 Å (Table 
2). The space group was P1 and the unit cell dimensions, 98.9, 115.8, 116.0 Å, and angles, 90.2, 90.2, 











performed using Phaser51, with the native structure, pdb entry 4d1i, as the model. The model was built 
manually in Coot52, followed by repeated cycles of REFMAC53 employing twin refinement using 
observed intensities. 
 
Table 2.  Data collection and refinement statistics. 
 
 CjGH35A in complex with TB562 (7) 
PDB code: 5JAW 
Data collection  
Space group P1 
Cell dimensions 
a, b, c (Å) 98.9, 115.8, 116.0 
α, β, γ (°) 90.2, 90.2, 90.4 
Resolution (Å) 81.99-1.6 (1.63-1.60)  
Rmerge 0.080 (0.588) 
Rpim 0.080 (0.588) 
CC(1/2) 0.979 (0.482) 
I /σI 6.0 (1.2) 
Completeness (%) 95.7 (94.1) 
Redundancy 1.8 (1.8) 
Refinement 
Resolution (Å) 1.60  
No. reflections 650665 
Rwork / Rfree 0.20/0.21 
No. atoms 
    Protein 33482 
    Ligand/ion 125 
    Water 1637 
B-factors (Å2) 
    Protein 25 
    Ligand/ion 20 
    Water 28 
R.m.s. deviations 
    Bond lengths (Å) 0.018 
    Bond angles (°) 1.927 
*Values in parentheses are for highest-resolution shell. 
 
Enzyme activity assays 
Mouse GALC shares 83% identity to the human GALC homologue and was used as GALC source.54 
Therefore, in human embryonic kidney 293 (HEK293) cells recombinant murine GALC was 
expressed. The produced protein which was secreted to the culture medium (DMEM high glucose, 
Gibco) was directly used in enzyme activity studies (5 μL volume was used). GLB1 from human 
fibroblast lysates (prepared in Kpi buffer (25 mM K2HPO4/KH2PO4, pH 6.5, 1% (v/v) Triton X-100, 
protease inhibitor cocktail (Roche, version 12)), 5.5 μg total protein was used). CjGH79 was prepared 
in KPi buffer (8.9 ng protein were used). The β-D-galactosidase activities were assayed at 37 °C with 1 
mM 4-methylumbelliferyl β-D-galactopyranoside as substrate in 150 mM McIlvaine buffer (pH 4.5) 
Activity-based protein profiling of lysosomal GH35 and GH59 β-galactosidases 
43 
with 0.2 M NaCl. To determine the apparent IC50 values, the enzymes were equilibrated in 12.5 μl  
McIlvaine buffer pH 4.5) and incubated with a range of inhibitor dilutions (12.5 μL) for 30 min at 37 
°C in triplicates in a flat-bottomed black 96-well plate (Greiner, medium binding). The mixtures were 
then incubated with 100 μl substrate. After 30 min at 37 °C, the reaction was quenched with 200 μl 1 
M NaOH-glycine (pH 10.3) and the 4-methylumbelliferyl fluorescence was measured with a 
fluorimeter LS-55 (PerkinElmer) using λex 366 nm and λem 445 nm. The data were corrected for 
background fluorescence (without enzyme), normalized to the untreated control condition (DMSO 
sample) and finally the residual activity was fitted with the X-Y scatter plot with the function 
[inhibitor] vs response—variable slope (four parameters) using the program Prism (Graphpad, 
version 7.0). 
 
Two-step labeling with BODIPY-alkyne 
The 2-step labeling using compound 2 and BODIPY-alkyne 11 was performed as previously described 
with slight alterations.33 Briefly, 1 μL of kidney or brain homogenate was incubated with 9 μL of 1.1 
μM compound 2 in McIlvaine buffer pH 4.3 (final concentration 1 μM) for 1 hr at 37 °C. Afterwards, 
the mixture was diluted with NaOAc buffer (30 μL, 50 mM pH 6.0, 0.1% SDS). A fresh mixture of 
TBTA (10 μL, 2 mM in DMF), CuSO4 (1 μL, 0.1 mM in H2O), DTT (0.5 μL, 0.1 mM in H2O) and 11 
(0.5 μL, 1 eq. compared to probe in ACN) was prepared, added to the enzyme solution, and the 
resulting mixture was incubated overnight at rt. The reaction was quenched by the addition of 4x 
sample buffer (15 μL) and loaded on a 7.5% SDS-PAGE gel. The wet slab gel was scanned for 
fluorescence using the Typhoon Variable Mode Imager (Amersham Biosciences, Piscataway, NJ, 
USA), using λex 488 nm and λem 520 nm (band pass 40). 
 
In vitro TB652 (5) labeling in mouse kidney homogenates 
Kidneys from wild type mice were homogenized in KPi buffer (25 mM K2HO4/KH2PO4, 0.1% (v/v) 
Triton X-100, protease inhibitor cocktail (Roche, version 12)) with 1 mm glass beads and a FastPrep-
24 homogenizer (MP Biomedicals). The basic labeling condition consists of equilibrating 25 μg total 
protein from the homogenate prepared in McIlvaine buffer (150 mM, various pH) in a total volume of 
10 μL, and ABP labeling in 1 step (5 μL of 3x concentrated ABP prepared in McIlvaine buffer) fashion. 
For labeling at varying pH, mouse tissue homogenates were equilibrated in McIlvaine buffer pH 3.0 – 
7.0 for 15 min at 37 °C, followed by incubating with 5 μM MDW93323 (end concentration; prepared in 
McIlvaine buffer pH 3.0 - 7.0) for 30 min at 37 °C to label all GBA, then 1 μM TB652 (prepared in 
McIlvaine buffer pH 3.0 -7.0) was added for 30 min at 37 °C. For labeling at varying ABP 
concentration, mouse kidney homogenates were equilibrated in McIlvaine buffer pH 4.5 for 5 min on 
ice, incubated with 5 μM MDW933 (end concentration; pH 4.5) for 30 min at 37 °C, and then with 
varying concentration of TB652 (end concentration = 10nM -10μM; pH 4.5) for 30 min at 37 °C. For 
labeling at varying incubation time, mouse kidney homogenates were prepared as above, and 
incubated directly with 1 μM TB652 (end concentration; pH 4.5) at 37 °C for 1 min to 2 h in absence 
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etaining exo-α-mannosidases are found in numerous organisms in nature. In 
humans, five different forms are present: MA2B1, MA2B2, MA2C1, MA2A1 and 
MA2A2, which are all part of the GH38 family. These glycosidases are capable of 
hydrolyzing α1-2, α1-3 or α1-6 linkages of high-, hybrid- or complex mannose N-
linked glycans.2 Diverse biological functions have been ascribed to these glycosidases. 
Some are involved in the biosynthesis assembly of N-linked glycans in the Golgi system 
(MA2A1 and MA2A2)3, whereas others are present in the lysosome (MA2B1, 
MA2B2)4,5 or in the cytosol (MA2C1)6,7 as part of the catabolic system.8 Retaining exo-
α-mannosidases have been associated with various pathologies. For instance, increased 
R 
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expression of lysosomal an α-mannosidases in larynx cancer cells was observed.9 α-
Mannosidosis, a lysosomal storage disorder10,11, results from mutations in the MAN2B1 
gen. Lack of hydrolysis results in swelling of lysosomes and loss of cellular functions.12 
The enzyme reaction itinerary of retaining exo-α-mannosidases takes place via a 
double-displacement mechanism, i.e. with retention of the configuration of the 
anomeric center. In general, the substrate proceeds according to the 0S2 → B2,5 → 1S5 → 
B2,5 → 0S2 catalytic itinerary (Figure 4.1).13,14 After the substrates adapts to a 0S2 skew boat 
conformation in the active site, an aspartic acid residue of the enzyme attacks the 
anomeric center and forms a covalent intermediate with the substrate after expulsion of 
the aglycon which is protonated by the acid/base residue. The glycosidic bond of the 
formed enzyme-substrate complex is then hydrolyzed, resulting in the enzyme and the 
α-mannose product. The catalytic nucleophile has been trapped with a fluorous 
substrate and analyzed by the group of Withers, who identified an aspartic acid as the 
catalytic nucleophile, which supports this mechanism.15,16 
 
Figure 4.1 Proposed mechanism of substrate hydrolysis by exo-α-mannosidases.13,14 
 
(+)-Cyclophellitol is a covalent inhibitor of retaining β-glucosidases.17,18 Several 
configurational isomers have been synthesized and resulted in selective and potent 
inhibitors of different glycosidases.19-21 Based on these precedents, in this chapter the 
synthesis of α-mannopyranose-configured cyclophellitol and cyclophellitol aziridine is 
described (Figure 4.2). Cyclophellitol aziridine 2 was used as a starting point in the 
synthesis of activity-based probes (ABPs) that specifically tag retaining exo-α-
mannosidases, which could help to elucidate the biological processes connected with 
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Figure 4.2 A) Structures of α-mannopyranose-configured cyclophellitol and cyclophellitol aziridine 
analogues examined in this study. B) Proposed mechanism of α-mannopyranose-configured 
cyclophellitol and α-mannopyranose-configured cyclophellitol aziridine (C) as mechanism-based α-
mannosidase inhibitors. 
 
4.2 Results and discussion 
 
The synthesis of α-mannose-configurated cyclophellitol 1 and α-mannose-configurated 
cyclophellitol aziridine 2 was previously described.23 However, a one-step synthesis of 
aziridine 10 was investigated24 with the aim to improve on this synthesis, which 
comprised mesylation of alcohols 8 and 9, followed by α-aziridine formation by 
treatment with LiAlH4, (Scheme 4.1). Staudinger reaction with compound 8 and 9 
using triphenylphosphine on beads gave aziridine 10 which was easily purified by 
filtration. Compared to the earlier described method (22%), the yield could be 
considerably improved in this manner (54%). Debenzylation using Birch reduction 
conditions gave aziridine 2.23 ABPs 4 - 6 were obtained by N-alkylation of aziridine 2 
with 1-azido-8-iodooctane followed by copper(I)-catalyzed [2+3]-cycloaddition ‘click’ 
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ligation with fluorophore 11 (see Chapter 2), 1225 or biotin-alkyne 1326. As described in 
Chapter 2, N-alkyl aziridines are more easily synthesized compared to N-acyl 
aziridines. However, in the case of GH29 α-fucosidases, the appropriately configured 
N-alkyl probes proved to considerable less effective than the corresponding N-acyl 
probes.27 Therefore and to be on the safe side, N-acyl probe 7 was synthesized as well. 
 
Scheme 4.1 Synthesis of α-mannopyranose-configured aziridine inhibitors and ABPs.  
Reagents and conditions: a) PPh3 polymer-bound on styrene-divinylbenzene copolymer, CH3CN, 
reflux, overnight, 54%; b) Li, THF, NH3 (l), - 60 °C, 75 min; c) 1-azido-8-iodooctane (see Chapter 3), 
K2CO3, DMF, 80 °C, overnight, 38% over 2 steps; d) 11 (see Chapter 2), 1225 or 1326, Cu.SO4·5H2O, 
sodium ascorbate, DMF, rt, 4 35%, 5 8.5%, 6 16%; e) 14 (see Chapter 2), EEDQ, DMF, 0 °C, 2.5 h, 8% 
over 2 steps. 
 
Inhibitory potency of α-mannopyranose-configured cyclophellitol 1 – 7. 
Having compounds 1 – 7 in hand, their inhibition potential was assessed towards 
GH38 jack bean (Canavalia ensiformis) α-mannosidase. The inhibitor was pre-
incubated for 30 min in varying concentrations after which the residual enzymatic 
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activity was measured using the fluorogenic substrate 4-methylumbelliferyl α-D-
mannoside. The resulting apparent IC50 values are listed in Table 4.1.  
 
Table 4.1 Apparent IC50 values of inhibitors 1 - 7 towards α-mannosidase from GH38 jack bean. 
 
 
The potency of α-mannosidase configurated cyclophellitol 1 is in agreement with 
previous published data.21 As observed in Table 4.1, the cyclophellitol aziridine isomers 
are in general more potent compared to the cyclophellitol isomer. The introduction of  
a lipophilic tail increases in general the potency even more. 
The next research object was to determine whether α-mannosidase configured 
cyclophellitols have an irreversible mode of binding – a prerequisite to allow their use 
in ABPP experiments. Therefore, Golgi α-mannosidase II from drosophila (GH38) was 
soaked with aziridine 2. Indeed, the catalytic nucleophile (Asp 20413) opened the 
aziridine moiety and a covalent enzyme-2 complex was formed. As depicted in Figure 
4.3, the cyclohexane adopts a skew boat (1S5) as expected according to the proposed 











Figure 4.3 Crystal structure of Golgi α-mannosidase II from drosophila (GH38) in complex with 
aziridine 2 (left). Proposed conformation of the substrate in GH38 retaining exo-α-mannosidases 
(right). 
Compound IC50 (μM) 
1 (TB440) 35.36 ± 6.7 
2 (TB450)   7.19 ± 0.1 
3 (TB481)   3.54 ± 0.5 
4 (TB482)   3.43 ± 0.7 
5 (TB521) 38.69 ± 4.5 
6 (TB484)   2.22 ± 0.2 
7 (TB480)   3.36 ± 1.3 
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Finally, ABPP was performed in commercial available GH38 jack bean α-mannosidase 
with compound 4 (Figure 4.4). The pH dependent labeling efficiency was investigated 
by treatment of 4 with the enzyme at various pH followed by analyzing the samples by 
SDS-PAGE and subsequently fluorescence scanning of the gels. Indeed, labeling of both 
subunits was observed (66 kDa and 44 kDa).28 The pH dependent labeling corresponds 














Figure 4.4 ABPP of GH38 jack bean α-mannosidase with 10 μM compound 4 at various pH at 37 °C. 
After incubation for 2 h, the samples were denatured, resolved by SDS-PAGE and scanned for Cy5 




In this chapter α-mannopyranose-configured cyclophellitol aziridine based inhibitors 
and probes  (4 – 7) were synthesized in order to specifically target retaining exo-α-
mannosidases. A fluorogenic substrate activity assay was performed to evaluate the 
inhibition potency of these probes, which revealed apparent IC50 values in the low 
micromolar range towards α-mannosidase from jack bean. Next, a covalent enzyme-
aziridine 2 complex was obtained, supporting the irreversible mode of binding of this 
class of compounds in GH38 glycosidases. Finally, ABPP with 4 in jack bean α-
mannosidase successfully labelled both subunits in a pH dependent fashion. These 
results set the stage for the synthesized probes (4 – 7) to perform additional ABPP 
experiments in vitro and in vivo and to use these ABPs as tools to further examine α-























General: Chemicals were purchased from Acros, Sigma Aldrich, Biosolve, VWR, Fluka, Merck and 
Fisher Scientific and used as received unless stated otherwise. Tetrahydrofuran (THF), N,N-
dimethylformamide (DMF) and toluene were stored over flame-dried 4 Å molecular sieves before use. 
Traces of water from reagents were removed by co-evaporation with toluene in reactions that require 
anhydrous conditions. All reactions were performed under an argon atmosphere unless stated 
otherwise. TLC analysis was conducted using Merck aluminum sheets (Silica gel 60 F254) with 
detection by UV absorption (254 nm), by spraying with a solution of (NH4)6Mo7O24·4H2O (25 g/L)  
and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid or a solution of KMnO4 (20 g/L) and K2CO3 
(10 g/L) in water, followed by charring at ~150 ˚C. Column chromatography was performed using 
Screening Device b.v. Silica Gel (particle size of 40 – 63 μm, pore diameter of 60 Å) in the indicated 
solvents. For reversed-phase HPLC purifications an Agilent Technologies 1200 series instrument 
equipped with a semi-preparative column (Gemini C18, 250 x 10 mm, 5 μm particle size, 
Phenomenex) was used. LC/MS analysis was performed on a Surveyor HPLC system (Thermo 
Finnigan) equipped with a C18 column (Gemini, 4.6 mm x 50 mm, 5 μm particle size, Phenomenex), 
coupled to a LCQ Adventage Max (Thermo Finnigan) ion-trap spectrometer (ESI+). The applied 
buffers were H2O, MeCN and 1% aqueous TFA. 1H NMR and 13C NMR spectra were recorded on a 
Brüker AV-400 (400 and 101 MHz respectively) or a Brüker DMX-600 (600 and 151 MHz 
respectively) spectrometer in the given solvent. Chemical shifts are given in ppm (δ) relative to the 
residual solvent peak or tetramethylsilane (0 ppm) as internal standard. Coupling constants are given 
in Hz. High-resolution mass spectrometry (HRMS) analysis was performed with a LTQ Orbitrap 
mass spectrometer (Thermo Finnigan), equipped with an electronspray ion source in positive mode 
(source voltage 3.5 kV, sheath gas flow 10 mL/min, capillary temperature 250 °C) with resolution R = 
60000 at m/z 400 (mass range m/z = 150 – 2000) and dioctyl phthalate (m/z = 391.28428) as a “lock 
mass”. The high-resolution mass spectrometer was calibrated prior to measurements with a 




To a mixture of 8 and 9 (0.193 g, 0.332 mol) in MeCN (3.3 mL) was added PPh3 
polymer-bound on styrene-divinylbenzene copolymer (0.188 g, 0.564 mmol, 3 
mmol/g). After stirring at reflux conditions overnight, the reaction mixture was concentrated in 
vacuo. Purification over silica gel column chromatography (1% MeOH in DCM) gave cyclophellitol 
aziridine 10 (95.6 mg, 0.178 mmol, 54%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.17 (m, 
20H), 4.93 (d, J = 12.3 Hz, 1H), 4.84 (d, J = 11.3 Hz, 1H), 4.76 – 4.57 (m, 3H), 4.55 – 4.34 (m, 3H), 4.21 
(t, J = 2.2 Hz, 1H), 3.80 – 3.65 (m, 2H), 3.61 (dd, J = 9.1, 4.0 Hz, 1H), 3.50 (t, J = 8.7 Hz, 1H), 2.42 (dd, 
J = 5.8, 2.3 Hz, 1H), 2.33 (d, J = 5.8 Hz, 1H), 2.30 – 2.22 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 139.2, 
139.0, 139.0, 138.5, 128.4, 128.4, 128.3, 128.1, 127.8, 127.7, 127.6, 127.5, 127.5, 80.8, 75.6, 75.2, 74.7, 
73.3, 73.0, 73.0, 70.9, 43.4, 34.5, 31.8. HRMS: calculated for [C35H38NO4]+ 536.27954, found 536.27923. 
 




Liquid NH3 (30 mL) was obtained by condensation of gas NH3 at -60 ºC. Lithium (140 
mg) was added and the mixture was stirred for 30 min, resulting in a dark blue 
solution. Aziridine 10 (149 mg, 278 mmol) was dissolved in THF (7 mL) and slowly added to the 
reaction mixture. After stirring for 75 min, the reaction was quenched with milliQ-H2O (4 mL). The 
solution was allowed to come to room temperature followed by concentrating in vacuo. The crude 
mixture was taken up in milliQ-H2O and neutralized with Amberlite IR H+. Product bound on the 
resin was washed with milliQ-H2O followed by elution with NH4OH (1M). The basic solution was 
concentrated in vacuo and dissolved again in milliQ-H2O. Addition of Amberlite-NH4+, followed by 
elution with milliQ-H2O and concentration in vacuo gave cyclophellitol aziridine 2 as a clear oil which 
was used without further purification. 1H NMR (400 MHz, D2O) δ 4.34 (s, 2H), 3.89 (dd, J = 11.1, 3.4 
Hz, 1H), 3.72 (dd, J = 10.9, 7.6 Hz, 1H), 3.51 – 3.42 (m, 2H), 2.50 (d, J = 5.5 Hz, 1H), 2.31 (d, J = 5.7 
Hz, 1H), 1.87 (s, 1H). 13C NMR (101 MHz, D2O) δ 70.5, 68.3, 66.5, 62.0, 45.0, 35.2, 31.0. 
 
(1S,2R,3S,4R,5R,6S)-7-(8-azidooctyl)-5-(hydroxymethyl)-7-
azabicyclo[4.1.0]heptane-2,3,4-triol (3, TB481) 
Cyclophellitol aziridine 2 (0.2 mmol), 1-azido-8-iodooctane (see 
Chapter 3, 0.24 mmol, 67 mg) and K2CO3 (118 mg, 0.86 mmol) in 
DMF (2 mL) was stirred at 80 °C. After stirring overnight the reaction 
mixture was concentrated in vacuo and purification over silica gel 
column chromatography (12% MeOH in DCM) gave azide-cyclophellitol aziridine 3 (25.2 mg, 76 
μmol, 38% over two steps) as a clear oil. 1H NMR (400 MHz, MeOD) δ 4.27 – 4.20 (m, 1H), 3.92 (dd, J 
= 10.6, 4.2 Hz, 1H), 3.62 (dd, J = 10.6, 8.4 Hz, 1H), 3.44 (dd, J = 10.2, 3.4 Hz, 4H), 3.38 (d, J = 9.2 Hz, 
1H), 3.30 (t, J = 3.4 Hz, 2H), 2.38 – 2.23 (m, 2H), 1.89 – 1.81 (m, 2H), 1.73 (d, J = 6.1 Hz, 1H), 1.66 – 
1.57 (m, 4H), 1.44 – 1.35 (m, 8H). 13C NMR (101 MHz, MeOD) δ 72.8, 69.7, 68.2, 63.9, 61.8, 52.4, 
47.0, 45.9, 41.7, 30.6, 30.2, 29.9, 28.3, 27.8. HRMS: calculated for [C15H29N4O4]+ 329.21833, found 
329.21822. 
 
General click procedure  
To a solution of aziridine-azide (1 equiv.) and desired alkyne (1 equiv.) in DMF (2.0 mL) were added 
copper(II)-sulfate pentahydrate (0.66 equiv., 1 M in H2O) and sodium ascorbate (0.76 equiv., 1 M in 
H2O). After stirring overnight at room temperature, the reaction mixture was concentrated in vacuo, 
purified with HPLC (linear gradient, A: 50 mM NH4HCO3 in H2O, B: MeCN, in 12 min) and 
lyophilized. 
 
ABP 4 (TB482) 
Azidirine-azide 3 (7.0 mg, 21 μmol) 
and Cy5-alkyne 11 (see Chapter 2, 
11.7 mg, 21 μmol) were treated 
according to General Click Procedure. 
Purification by HPLC (44% → 50%, A 
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in B) followed by lyophilizing gave ABP 4 (6.44 mg, 7.3 μmol, 35%) as a blue powder. 1H NMR (500 
MHz, MeOD) δ 8.29 – 8.21 (m, 2H), 7.84 (s, 1H), 7.50 (d, J = 7.2 Hz, 2H), 7.46 – 7.37 (m, 2H), 7.33 – 
7.23 (m, 4H), 6.62 (s, J = 12 Hz, 1H), 6.28 (d, J = 13.6 Hz, 2H), 4.41 (s, 2H), 4.37 (t, J = 7.0 Hz, 2H), 
4.22 – 4.16 (m, 1H), 4.09 (t, J = 7.4 Hz, 2H), 3.89 (dd, J = 10.6, 4.1 Hz, 1H), 3.63 (s, 3H), 3.59 (dd, J = 
10.6, 8.4 Hz, 1H), 3.40 (dd, J = 10.2, 3.5 Hz, 1H), 3.35 (t, J = 5.0 Hz, 1H), 2.30 – 2.19 (m, 4H), 1.90 (s, 
2H), 1.89 – 1.84 (m, 2H), 1.84 – 1.78 (m, 4H), 1.74 – 1.70 (m, 12H), 1.68 (d, J = 6.5 Hz, 1H), 1.55 – 
1.49 (m, 2H), 1.49 – 1.43 (m, 2H), 1.36 – 1.26 (m, 8H). 13C NMR (126 MHz, MeOD) δ 175.7, 175.4, 
174.6, 155.6, 146.2, 144.3, 143.5, 142.6, 142.5, 129.8, 129.7, 126.6, 126.3, 126.2, 124.1, 123.4, 123.3, 
112.0, 111.9, 104.4, 104.2, 72.8, 69.7, 68.2, 63.9, 61.8, 51.3, 50.6, 49.5, 49.3, 49.2, 49.0, 48.8, 48.7, 48.5, 
47.0, 45.9, 44.8, 41.7, 36.5, 35.6, 31.5, 31.3, 30.4, 29.9, 28.2, 28.1, 28.0, 27.8, 27.4, 27.3, 26.4. LC/MS 
analysis: Rt 6.10 min (linear gradient 10→90% B in 12.5 min), m/z 848.33 [M]+  HRMS: calculated for 
[C50H70N7O5]+ 848.54329, found 848.54294. 
 
ABP 5 (TB582) 
Azidirine-azide 3 (8.0 mg, 24 μmol) and Bodipy 
1225 (8.0 mg, 24 μmol) were treated according to 
General Click Procedure. Purification by HPLC 
(42% → 48%, A in B) followed by lyophilizing gave 
ABP 5 (1.34 mg, 2.05 μmol, 8.5%) as an orange 
powder. 1H NMR (600 MHz, MeOD) δ 7.74 (s, 1H), 6.12 (s, 2H), 4.35 (t, J = 6.9 Hz, 2H), 4.20 (dd, J = 
3.3, 1.9 Hz, 1H), 3.62 – 3.59 (m, 1H) 3.58 – 3.51 (m, 1H), 3.49 – 3.44 (m, 1H), 3.41 (dd, J = 10.2, 3.5 
Hz, 1H), , 3.07 – 3.00 (m, 2H), 2.79 (t, J = 7.2 Hz, 2H), 2.44 (s, 6H), 2.39 (s, 6H), 2.31 – 2.19 (m, 2H), 
1.95 – 1.79 (m, 6H), 1.70 – 1.63 (m, 3H), 1.55 – 1.49 (m, 2H), 1.35 – 1.26 (m, 8H). LC/MS analysis: Rt 
6.13 min (linear gradient 10→90% B in 12.5 min), m/z 657.00 [M + H]+. HRMS: calculated for 
[C34H52BF2N6O4]+ 657.41117, found 657.41122. 
 
ABP 6 (TB484) 
Azidirine-azide 3 (7.2 mg, 
22 μmol) and biotin 13 (9.1 
mg, 25 μmol) were treated 
according to General Click 
Procedure. Purification by 
HPLC (18% → 24%, A in B) followed by lyophilizing gave ABP 6 (2.6 mg, 3.6 μmol, 16%, purity > 
80%) as a white powder. LC/MS analysis: Rt 3.91 min (linear gradient 10→90% B in 12.5 min), m/z 
723.13 [M + H]+. 1H NMR (600 MHz, MeOD) δ 7.84 (s, 1H), 4.49 (dd, J = 7.8, 4.8 Hz, 1H), 4.42 (s, 
2H), 4.38 (t, J = 7.0 Hz, 2H), 4.30 (dd, J = 7.8, 4.5 Hz, 1H), 4.20 (dd, J = 3.2, 1.9 Hz, 1H), 3.90 (dd, J = 
10.7, 4.1 Hz, 1H), 3.70 – 3.66 (m, 1H), 3.58 – 3.55 (m, 3H), 3.53 (dd, J = 10.7, 6.3 Hz, 1H), 3.46 – 3.39 
(m, 1H), 3.37 – 3.34 (m, 1H), 3.21 (dd, J = 8.8, 5.0 Hz, 1H), 3.16 (td, J = 6.9, 2.2 Hz, 2H), 2.92 (dd, J = 
12.7, 5.0 Hz, 1H), 2.70 (d, J = 12.7 Hz, 1H), 2.33 – 2.28 (m, 1H), 2.25 – 2.17 (m, 5H), 1.89 (s, 2H), 1.86 
– 1.81 (m, 2H), 1.71 – 1.69 (m, 1H), 1.66 – 1.55 (m, 4H), 1.53 – 1.46 (m, 2H), 1.46 – 1.40 (m, 2H), 1.39 
– 1.26 (m, 9H).  HRMS: calculated for [C34H59N8O7S]+ 723.42219, found 723.42225. 
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ABP 7 (TB480) 
Cy5-acid 14 (see Chapter 2, 63 
mg, 85 μmol) was pre-
activated with EEDQ (21 mg, 
85 μmol) in DMF (2 mL) for 3 
h at room temperature. 
Deprotected aziridine 2 (0.10 
mmol) was dissolved in DMF 
(0.4 mL) and cooled to 0 °C, 
after which the activated ester solution (1.0 mL, 30 μmol, 0.5 equiv.) was added. After stirring at 0 °C 
for 30 min, another 0.5 equiv. of the activated ester was added. The reaction mixture was stirred for 
another 2 h at 0 °C before the reaction mixture was quenched with MeOH and concentration in 
vacuo. Purification by HPLC under neutral conditions with use of a gradient of 43 → 49% MeCN in 
H2O in 12 min followed by lyophilizing yielded ABP 7 (7.0 mg, 7.8 μmol, 8% over 2 steps) as a blue 
powder. 1H NMR (600 MHz, MeOD) δ 8.26 (t, J = 13.0 Hz, 2H), 7.82 (s, 1H), 7.51 (d, J = 7.4 Hz, 2H), 
7.49 – 7.42 (m, 2H), 7.34 – 7.25 (m, 4H), 6.64 (t, J = 12.5 Hz, 1H), 6.30 (d, J = 13.7 Hz, 2H), 4.42 (s, 
2H), 4.39 (t, J = 7.0 Hz, 2H), 4.31 – 4.27 (m, 1H), 4.11 (t, J = 7.5 Hz, 2H), 3.95 – 3.89 (m, 1H), 3.64 – 
3.62 (m, 4H), 3.50 – 3.42 (m, 2H), 2.89 (dd, J = 5.6, 2.1 Hz, 1H), 2.78 (d, J = 5.4 Hz, 1H), 2.49 – 2.34 
(m, 2H), 2.26 (t, J = 7.3 Hz, 2H), 2.07 – 1.94 (m, 3H), 1.90 – 1.87 (m, 2H), 1.85 – 1.82 (m, 2H), 1.74 (s, 
12H), 1.65 – 1.58 (m, 2H), 1.50 – 1.45 (m, 2H), 1.36 – 1.29 (m, 6H). 13C NMR (151 MHz, MeOD) δ 
187.9, 180.2, 175.7, 175.4, 174.6, 155.5, 155.4, 146.1, 144.2, 143.5, 142.6, 142.5, 129.7, 129.7, 126.6, 
126.3, 126.2, 124.1, 123.4, 123.2, 112.0, 111.8, 104.4, 104.2, 72.3, 69.1, 68.0, 63.3, 51.3, 50.5, 46.9, 44.7, 
42.6, 39.0, 37.2, 36.4, 35.5, 31.5, 31.2, 29.9, 29.6, 28.1, 27.9, 27.8, 27.3, 27.2, 26.4, 25.9. LC/MS analysis: 
Rt 6.44 min (linear gradient 10→90% B in 12.5 min), m/z 862.33 [M + H]+. HRMS: calculated for 
[C50H68N7O6]+ 862.52256, found 862.52240. 
 
Determination of the apparent IC50 values  
For the determination of apparent IC50  values of the inhibitors, α-mannosidase from Jack bean, 
(Canavalia ensiformis, Sigma Aldrich) 4 ng total protein was equilibrated in 12.5 μL McIlvaine buffer 
(150 mM, pH 4.5) for 5 min on ice. After which it was incubated with 12.5 μL inhibitor dilutions 
prepared in McIlvaine buffer for 30 min at 37 °C. After addition of 100 μL of 4-methylumbelliferyl-β-
D-mannopyranoside substrate mixture (10 mM 4-mu-α-D–mannopyranoside in McIlvaine buffer) 
and incubation for 30 min at 37 °C, the reaction was quenched by adding 200 μL 1M Glycine-NaOH 
(pH 10.3) to the reaction mixture. The 4-mu fluorescence was measured in 96-well plates using a LS55 
fluorometer (PerkinElmer) at λEx = 366 nm and λEm = 445 nm. Measured activity values were 
subtracted with background values, normalized against control values (no inhibitor), and plotted 
against the inhibitor concentrations. IC50 values were calculated with Prism 7.0 (Graphpad), using 
one-phase-exponential decay function. Standard deviations were obtained from 2 sets of calculated 
IC50 values, each derived from 3 technical repeats at each inhibitor concentrations. 
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Cloning and expression of dGMII 
A plasmid containing cDNA encoding for the dGMII gene was obtained with kind permission from 
Dr. Sean Sweeny (University of York).  From this plasmid, cDNA encoding for amino acids 76-1108 
of dGMII (to remove the N-terminal cytosolic, transmembrane, and stalk domains) was subcloned 
into the pOMNIBac vector (Geneva Biotech), behind a honeybee mellitin secretion peptide, 6xHis tag, 
and TEV cleavage site.   
Recombinant bacmid was produced using the Tn7 transposition method in DH10EMBacY (Geneva 
Biotech)30, and purified using the PureLink miniprep kit (Invitrogen) following standard protocols.  
V1 baculovirus was produced by transfection of bacmid into low passage adherent Sf21 cells 
(Invitrogen) using FuGENE HD transfection reagent (ProMega), at a ratio of 2 μg DNA to 4.5 μL 
FuGENE. V1  V2 virus amplification was carried out using suspension Sf21 cells, using the YFP 
marker present in EMBacY baculovirus to determine optimum amplification prior to harvesting 
(typically ~60% cells fluorescent). For expression, T. Ni cells (Invitrogen) were infected with V2 
baculovirus at a MOI>1, and infection followed using the EMBacY YFP marker to determine 
optimum timepoint for harvesting (typically 72 h, with > 80 % cells fluorescent). All insect cells used 
tested negative for mycoplasma contamination.  
 
Purification of dGMII 
Harvested High Five cultures were spun for 15 minutes at 200 g to remove cells and spun again at 
4000 g for 1 hour to remove insoluble cellular components. AEBSF (to a final concentration of 0.1 
mM) and DDT (to a final concentration of 1 mM) were added to the supernatant. Clarified 
supernatant was loaded on to 2 x 5mL HiTrap Blue HP columns (GE Healthcare) pre-equilibrated in 
blue agarose buffer A (20 mM HEPES pH 7.4, 100 mM NaCl, 1 mM DTT). Loaded columns were 
washed with 5 column volumes of blue agarose buffer A and eluted using a linear gradient of blue 
agarose buffer B (20 mM HEPES pH 7.4, 2 M NaCl, 1 mM DTT) over 20 column volumes. 
HiTrap Blue fractions containing dGMII (as determined by SDS-PAGE) were pooled and diluted 
approximately 5-fold in HisTrap buffer A (50 mM HEPES pH 8.0, 0.5 M NaCl, 30 mM Imidazole, 1 
mM DTT) and loaded on to a 1 mL HisTrap FF Crude column (GE Healthcare) The loaded histrap 
column was washed with 10 column volumes of HisTrap buffer A and dGMII eluted using a linear 
gradient of HisTrap buffer B (50 mM HEPES pH 8.0, 0.5 M NaCl, 0.5 M imidazole, 1 mM DTT) over 
20 column volumes, followed by 10 column volumes of 100 % Buffer B.  
HisTrap fractions containing dGMII were pooled and concentrated to less than 2 ml by centrifugation 
using VivaSpin 30,000 MW concentrator (GE Healthcare).  Pooled dGMII was rediluted to ~2 mL in 
1x AcTEV (Invitrogen) reaction buffer before addition of 5 μl AcTEV protease to remove the N-His-
TEV tag.  Digests were typically carried out overnight at ambient temperature, and reaction progress 
assessed by comparison to positive and negative controls using SDS-PAGE.  
Upon completion of the AcTEV digest, as indicated by SDS-PAGE, dGMII was purified using a S200 
16/600 size exclusion chromatography (SEC) column equilibrated in SEC buffer (50 mM HEPES pH 
7.4, 200 mM NaCl, 1 mM DTT), at 1 ml min-1. SEC fractions containing dGMII were pooled, 
concentrated to 10 mg ml-1 and stored in 20 μl aliquots at -80 °C.  
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3D Crystallography of dGMII 
Initial crystallization conditions were screened using JCSG+ HT-96, PACT premier HT-96 (both 
Molecular Dimensions), Index HT and PEG/Ion HT (both Hampton Research) commercial screens. 
Hits were optimized, scaled up to maxi 48-well plates and a dGMII seed stock generated from crystals 
grown in 0.1 M imidazole pH 7.0 and 10 % (w/v) PEG 3350 using the Seed Bead protocol (Hampton 
Research). The above screens were repeated with seeding using an Oryx8 (Douglas Instruments) and 
additional hits optimised further. Diffraction quality dGMII crystals were grown in maxi 48-well 
plates using sitting drop vapour diffusion in 0.1 M sodium succinate pH 7.0 and 10 % (w/v) PEG 
3350.  Crystals were cryoprotected using cryoprotectant solution (mother liquor supplemented with 
25% v/v ethylene glycol) prior to flash freezing in liquid N2 for data collection.   
Datasets were collected using beamline I04-1 at the Diamond Light Source, processed via with the 
xia2 pipeline31 of the CCP4 software suite, using XDS32 and Aimless33 for data processing.  Apo dGMII 
was solved by molecular replacement with PDB model 1HWW34 using MolRep35, followed by 
alternating rounds of manual model building and refinement using Coot and REFMAC5 
respectively36,37.  CCP4mg was used to produce figures of the crystal structure. 
For ligand complexes, dGMII crystals were soaked in solutions of TB450 (1 mM) or TB482 (1 mM) in 
dGMII cryoprotectant solution for ~3 hours before flash freezing in liquid N2 for data collection.  
Complexes were solved by molecular replacement with the apo dGMII structure, followed by rounds 
of manual model building and refinement using Coot and REFMAC5. Ligand coordinates were built 
using jLigand.38 Diagrams of dGMII-ligand complexes were generated using CCP4mg39. 
 
Labeling of jack bean α-mannosidase with TB482 (4) at varying pH 
Jack bean α-mannosidase (Sigma Aldrich, 1 pmol) was equilibrated in 10 μL McIlvaine buffer at 
varying pH (2.5 – 8.0) at 37 °C for 15 min. After incubation with 10 μM TB482 (4, end concentration; 
prepared in McIlvaine buffer at pH 2.5 – 8.0) at 37 °C for 2 h, the sample was denatured, resolved by 
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H2 exo-β-mannosidase is the lysosomal exoglycosidase responsible for the 
cleavage of the single β-mannoside linkage in the lysosomal degradation pathway 
of N-linked glycoproteins.2 Specifically, this glycosidase (EC 3.2.1.25), found in 
eukaryotes3 and bacteria4, hydrolyses the β-glycosidic linkage of the 
Man(β1→4)GlcNAc moiety. Therefore, a deficiency of this enzyme (MANBA gene) 
results in accumulation of Man(β1→4)GlcNAc glycans including sialylated versions 
thereof in various tissues. This causes β-mannosidosis, a lysosomal storage disorder, 




Chapter 5  
62 
GH2 exo-β-mannosidases are retaining glycosidases that catalyse the hydrolysis of their 
substrate via a double-displacement mechanism (Figure 1A). As depicted in Figure 1B, 
the proposed mechanism for exo-β-mannosidases proceeds via the 1S5 → B2,5 → 0S2 
catalytic itinerary. First, the conformation of the carbohydrate substrate changes into a 
1S5 skew boat and forms a Michaelis complex with the enzyme.8 The aglycon is 
protonated by the acid/base catalyst and subsequently expulsed. The emerging 
Figure 5.1 A) General retaining mechanism of exo-β-mannosidase. B) The proposed conformations 
of the catalytic itinerary of exo-β-mannosidase.9,22,23 Structure of cyclophellitol (C) and cyclophellitol 
aziridine (D) as mechanism-based β-glucosidase inhibitors. E) Structures of β-mannopyranose-
configured cyclophellitol and β-mannopyranose-configured cyclophellitol aziridine derivatives used 
























































































3 (TB429) R = N3
4 (TB434) R = Cy5
5 (TB520) R = Bodipy
6 (TB476) R = biotin
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oxycarbenium ion reacts with the catalytic nucleophile (Glu-5199) to form a covalent 
enzyme-β-mannopyranosyl adduct. Upon deprotonation of a water molecule and 
substitution of the anomeric carboxylate, the mannose is released from the enzyme.  
Based on this catalytic mechanism, cyclophellitol based β-mannosidase inhibitors can 
be designed. Cyclophellitol, isolated from mushroom Phellinus sp., proved to be a 
potent10, selective11 covalent inhibitor of almond β-glucosidase12,13, and in later studies 
to be an inhibitor of retaining β-glucosidases in general (Figure 1C).14 Cyclophellitol 
aziridine derivatives inhibit retaining β-glucosidases15 as well and can be modified to 
become viable β-glucosidase activity-based probes (ABPs) by functionalizing the 
aziridine moiety (Figure 1D).16 Various applications including selective fluorescent 
labeling and pull-down experiments have been performed to detect and monitor the 
specific enzymes of interest in vitro, in situ and in vivo.17,18 Based on these promising 
results configurational cyclophellitol aziridine analogues have been developed for ABP 
studies on several retaining glycosidase families.19-21 Interestingly, the configuration of 
the cyclophellitol warhead determines which glycosidase is targeted. Through 
obtaining β-mannopyranose-configured cyclophellitol based APBs, labeling and 
detecting of β-mannosidases would come within reach and would allow to investigate 
and monitor β-mannosidase activity in vitro, in situ and in vivo. In this chapter a 
straightforward synthesis of β-mannopyranose-configured cyclophellitol aziridine 
APBs (Figure 1E) and the biological validation of these probes in various biological 
tissues is presented. 
 
5.2 Results and discussion 
 
β-Mannopyranose-configured cyclophellitol aziridine 2 was obtained according to the 
efficient 13 steps synthesis described previously.24 N-alkylation with 1-azido-8-
iodooctane (see Chapter 3), resulted in chemical ligation handle 3 (Scheme 5.1). Azide-
alkyne Huisgen cycloaddition with fluorophore 7 (see Chapter 2), 825, or biotin 926, 
resulted in the corresponding ABPs 4 – 6.  
The configuration of cyclophellitol based inhibitors confers glycosidase selectivity in 
most examples studied.17,19-21 In order to determine the selectivity of the obtained 
compounds, biotin probe 6 was subjected to a mouse kidney homogenate. The pull-
down experiment was performed with streptavidin coated paramagnetic beads. The 
obtained proteins were subjected to trypsin digestion and the peptide fragments were 
analysed by LC-MS/MS and compared with the UniProt database by employing the 
Mascot search engine.20 In addition, control samples were generated by performing this 
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Scheme 5.1 Synthesis of β-mannopyranose-configured cyclophellitol aziridine inhibitors and ABPs. 
Reagents and conditions: a) 1-azido-8-iodooctane (see Chapter 3), K2CO3, DMF, 80 °C, overnight, 
64%; b) 7 (see Chapter 2), 825 or 926, Cu.SO4·5H2O, sodium ascorbate, 4 17%, 5 36% and 6 32%. 
 
protocol in lysate which was pre-incubated with ABP 4 prior to subjecting ABP 6 to the 
lysate or performing this protocol with DMSO only. After comparing with these 
control samples, 45 unique proteins were identified (See experimental Table S1). Of 
these proteins, MANBA, the exo-β-mannosidase present in mammalians was the single 
glycosidase identified.  
After having identified MANBA as the specific target of biotin probe 6 in mouse kidney 
homogenate, the potency of all compounds (1 – 6) was determined as inhibitors of the 
retaining β-mannosidase obtained from snail (Helix pomatia), which is commercially 
available. The inhibition potential was assessed at pH 4.2, according to literature 
procedure.27 The inhibitor was pre-incubated for 30 min with varying concentrations 
after which the residual enzymatic activity was measured using the fluorogenic 
substrate 4-methylumbelliferyl β-D-mannoside (4-mu β-man). However, up to 50 μM 
no inhibition was detected. The activity of glycosidases is pH dependent and therefore 
the potency of Cy5 tagged probe 4 was investigated at various pH by treatment of the 
enzyme at various pH followed by SDS-PAGE and fluorescence scanning of the gels 
(Figure 5.2A). The efficiency of MANBA labeling appeared maximal at pH 5.5 whereas 
it is negligible at pH 4.2. As a control, the activity of the enzyme at various pH was 
determined with the 4-mu β-man substrate and compared with the quantification of 
the fluorescence band in Figure 5.2A (Figure 5.2B). Although the enzyme activity 
pattern does not correspond with the inhibition potency pattern of compound 4 under 
strong acidic conditions, at pH 5.5 the enzyme is active and compound 4 is a potent 
inhibitor. Therefore, the apparent IC50 values of compounds 1 – 6 were reassessed at 
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pH 5.5 (Figure 5.2C). In this setting, N-alkylation of the cyclophellitol aziridine turned 
out to be low micromolair active probes (3 – 6). Finally, the labeling of MANBA with 
compound 4 at the optimal pH with various probe concentrations is depicted in Figure 
5.2D.  
Figure 5.2 A) ABPP of β-mannosidases from Helix p. with 10 μM compound 4 at various pH. After 
incubation for 1 h, the samples were resolved by SDS-PAGE and scanned for Cy5 fluorescence.  B) 
Quantification of the fluorescent read-out (A) compared with the hydrolysis of the fluorogenic 
substrate 4-methylumbelliferyl β-D-mannoside. C) Apparent IC50 values towards β-mannosidase from 
snail (Helix p.) of compounds 1 – 6 at pH 5.5. D) Labeling of β-mannosidases in Helix p. at various 
concentrations of compound 4 after incubation of 1 h at 37 °C and pH 5.5.  
 
The next pursued aim was activity-based protein profiling in lysates of kidney from 
mice with ABP 4. To this end, probe concentration dependent labeling was examined 
and from 1 μM of probe, labeling of MANBA (100.8 kDa) was observed (Figure 5.3A). 
Next, the pH dependent activity was examined, Figure 5.3B. Indeed, a similar pH 
tendency as towards β-mannosidases from Helix p. was obtained. Finally, the 
mechanism-based nature of the observed labeling was confirmed by an incubation time 
dependent experiment (Figure 5.3C). Labeling of MANBA is more intense after 
extended incubation time. This result indicates that ABP 4 binds in a covalent fashion 





























































Helix. p.  
β-man 
Chapter 5  
66 
Figure 5.3 Activity-based protein profiling with ABP 4 in mouse kidney homogenates. A) 
Concentration dependent labeling up to 10 μM probe for 1 h at pH 5.5. B) pH dependent labeling 
from pH 4.0 – 7.0 with 1 μM probe for 1 h. C) Incubation time dependent labeling at pH 5.5 with 1 
μM probe. Gels are 7.5% SDS-PAGE and scanned for Cy5 fluorescence. 
5.3 Conclusion 
In this chapter various β-mannopyranose-configured cyclophellitol aziridine based 
probes were synthesized in order to specifically target β-mannosidases. Biotin probe 6
successfully identified MANBA, a retaining exo-β-mannosidase, as the specific target. 
The pH optimum activity and labeling efficiency with ABP 4 was determined to be at 
pH 5.5 for β-mannosidase from Helix p. At this condition, ABPs 3 – 6 proved to be low 
micromolar inhibitors. Finally, in vitro activity-based protein profiling was performed 
with ABP 4 in homogenized mouse kidney resulting in effective labeling of MANBA in 
pH-dependent and incubation time dependent fashion. These ABPs can be employed 
for further ABPP and used as tools to examine β-mannosidosis. 
Experimental 
 
General: Chemicals were purchased from Acros, Sigma Aldrich, Biosolve, VWR, Fluka, Merck and 
Fisher Scientific and used as received unless stated otherwise. N,N-dimethylformamide (DMF) and 
toluene were stored over flame-dried 4 Å molecular sieves before use. Traces of water from reagents 
were removed by co-evaporation with toluene in reactions that require anhydrous conditions. All 
reactions were performed under an argon atmosphere. TLC analysis was conducted using Merck 
aluminum sheets (Silica gel 60 F254) with detection by UV absorption (254 nm), by spraying with a 
solution of (NH4)6Mo7O24·4H2O (25 g/L)  and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid or a 
solution of KMnO4 (20 g/L) and K2CO3 (10 g/L) in water, followed by charring at ~150 ˚C. Column 
chromatography was performed using Screening Device b.v. Silica Gel (particle size of 40 – 63 μm, 
pore diameter of 60 Å) in the indicated solvents. For reversed-phase HPLC purifications an Agilent 
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mm, 5 μm particle size, Phenomenex) was used. LC/MS analysis was performed on a Surveyor HPLC 
system (Thermo Finnigan) equipped with a C18 column (Gemini, 4.6 mm x 50 mm, 5 μm particle size, 
Phenomenex), coupled to a LCQ Adventage Max (Thermo Finnigan) ion-trap spectrometer (ESI+). 
The applied buffers were H2O, MeCN and 1% aqueous TFA. 1H NMR and 13C NMR spectra were 
recorded on a Brüker AV-400 (400 and 101 MHz respectively), a Brüker DMX-600 (600 and 151 MHz 
respectively) or a Bruker AV-850 (850 and 214 MHz respectively) spectrometer in the given solvent. 
Chemical shifts are given in ppm (δ) relative to the residual solvent peak of methanol-d. Coupling 
constants are given in Hz. High-resolution mass spectrometry (HRMS) analysis was performed with a 
LTQ Orbitrap mass spectrometer (Thermo Finnigan), equipped with an electronspray ion source in 
positive mode (source voltage 3.5 kV, sheath gas flow 10 mL/min, capillary temperature 250 °C) with 
resolution R = 60000 at m/z 400 (mass range m/z = 150 – 2000) and dioctyl phthalate (m/z = 
391.28428) as a “lock mass”. The high-resolution mass spectrometer was calibrated prior to 
measurements with a calibration mixture (Thermo Finnigan). 
 
General click procedure  
To a solution of aziridine-azide (1 equiv.) and desired alkyne (1 equiv.) in DMF (2.0 mL) were added 
copper(II)-sulfate pentahydrate (0.66 equiv., 1 M in H2O) and sodium ascorbate (0.76 equiv., 1 M in 
H2O). After stirring overnight at room temperature, the reaction mixture was concentrated in vacuo, 




azabicyclo[4.1.0]heptane-2,3,4-triol (3, TB429) 
Cyclophellitol aziridine 224 (0.4 mmol), 1-azido-8-iodooctane (see 
Chapter 3, 0.6 mmol, 168 mg) and K2CO3 (237 mg, 1.72 mmol) in 
DMF (4 mL) was stirred at 80 °C. After stirring overnight the reaction 
mixture was concentrated in vacuo and purification over silica gel column chromatography (6% 
MeOH in DCM → 8% MeOH in DCM) gave 3 (32.1 mg, 98 μmol, 64%) as a clear oil. 1H NMR (400 
MHz, MeOD) δ 4.14 (t, J = 3.8 Hz, 1H), 3.82 (dd, J = 10.2, 6.0 Hz, 1H), 3.70 (dd, J = 8.3, 11.7 Hz, 1H), 
3.51 (dd, J = 6.7, 4.7 Hz, 1H), 3.45 (dd, J = 6.6, 4.1 Hz, 1H), 3.28 (t, J = 6.8 Hz, 2H), 2.42 – 2.33 (m, 
1H), 2.23 – 2.13 (m, 1H), 2.10 – 2.05 (m, 2H), 2.05 – 1.96 (m, 1H), 1.58 (t, J = 6.9 Hz, 4H), 1.44 – 1.34 
(m, 8H). 13C NMR (101 MHz, MeOD) δ 103.8, 98.3, 93.8, 92.6, 89.6, 80.6, 73.0, 72.3, 71.3, 58.6, 58.6, 
58.4, 58.1, 56.5, 55.9. HRMS: calculated for [C15H29N4O4]+ 329.21833, found 329.21823. 
 
ABP 4 (TB434) 
Aziridine-azide 3 (13.1 mg, 
39.8 μmol) and Cy5-alkyne 7 
(see Chapter 2, 20 mg, 36 
μmol) were treated according 
to General Click Procedure. 
Purification by HPLC (40% → 
60%, A in B) followed by lyophilizing gave ABP 4 (5.3 mg, 6.0 μmol, 17%) as a blue powder. 1H NMR 
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(850 MHz, MeOD) δ 8.25 (dt, J = 3.6, 2.0 Hz, 2H), 7.85 (s, 1H), 7.49 (d, J = 7.4 Hz, 2H), 7.44 – 7.39 
(m, 2H), 7.32 – 7.24 (m, 4H), 6.62 (t, J = 12.4 Hz, 1H), 6.29 (d, 2.2 Hz, 1H), 6.27 (d, 2.2 Hz, 1H),  4.41 
(s, 2H), 4.37 (t, J = 7.1 Hz, 2H), 4.14 (t, J = 4.1 Hz, 1H), 4.10 (d, J = 7.5 Hz, 1H), 4.09 (d, J = 7.9 Hz, 
1H), 3.81 (dd, J = 10.2, 6.0 Hz, 1H), 3.68 (dd, J = 8.0, 9.1 Hz, 1H), 3.63 (s, 3H), 3.50 (dd, J = 6.5, 4.7 Hz, 
1H), 3.45 (dd, J = 6.6, 4.2 Hz, 1H), 2.37 – 2.32 (m, 1H), 2.25 (t, J = 7.3 Hz, 2H), 2.18 – 2.13 (m, 1H), 
2.08 – 2.02 (m, 2H), 2.01 – 1.98 (m, 1H), 1.87 – 1.85 (m, 2H), 1.82 – 1.79 (m, 2H), 1.79 – 1.70 (m, 
14H), 1.58 – 1.52 (m, 2H), 1.49 – 1.42 (m, 2H), 1.35 – 1.28 (m, 8H). 13C NMR (214 MHz, MeOD) δ 
175.7, 175.4, 174.6, 155.6, 155.5, 144.2, 143.5, 142.6, 142.5, 129.8, 129.7, 126.6, 126.3, 126.2, 123.4, 
123.2, 112.0, 111.9, 104.4, 104.2, 75.6, 70.1, 65.7, 64.4, 61.4, 51.3, 44.9, 44.8, 44.2, 43.2, 36.5, 35.6, 31.5, 
31.3, 30.3, 30.3, 29.9, 28.2, 28.1, 27.9, 27.8, 27.4, 27.3, 26.4. LC/MS analysis: Rt 6.18 min (linear 
gradient 10→90% B in 12.5 min), m/z 848.27 [M]+. HRMS: calculated for [C50H70N7O5]+ 848.54329, 
found 848.54278. 
 
ABP 5 (TB520) 
Aziridine-azide 3 (7.1 mg, 22 μmol) and Bodipy 
825(7.1 mg, 22 μmol) were treated according to 
General Click Procedure. Purification by HPLC 
(42% → 48%, A in B) followed by lyophilizing gave 
ABP 5 (5.13 mg, 7.82 μmol, 36%) as an orange 
powder. 1H NMR (600 MHz, MeOD) δ 7.74 (s, 1H), 6.11 (s, 2H), 4.35 (d, J = 7.2 Hz, 1H), 4.34 (d, J = 
6.6 Hz, 1H), 4.13 (t, J = 4.1 Hz, 1H), 3.81 (dd, J = 10.2, 6.0 Hz, 1H), 3.68 (dd, J = 10.2, 8.4, 1H), 3.50 
(dd, J = 6.7, 4.7 Hz, 1H), 3.47 – 3.42 (m, 1H), 3.35 (s, 3H), 3.32 – 3.28 (m, 2H), 3.04 – 2.97 (m, 2H), 
2.78 (d, J = 7.2 Hz, 1H), 2.77 (d, J = 7.2 Hz, 1H), 2.44 (s, 6H), 2.38 (s, 6H), 2.36 – 2.30 (m, 1H), 2.14 
(dt, J = 11.7, 7.1 Hz, 1H), 2.07 – 1.97 (m, 3H), 1.93 – 1.83 (m, 4H), 1.68 – 1.61 (m, 2H), 1.57 – 1.50 (m, 
2H), 1.36 – 1.24 (m, 8H). 13C NMR (151 MHz, MeOD) δ 154.9, 148.5, 147.9, 142.2, 132.6, 123.4, 122.6, 
75.6, 70.1, 65.7, 64.4, 61.4, 51.9, 49.9, 44.9, 44.1, 43.2, 32.2, 31.2, 30.8, 30.3, 30.3, 29.9, 29.1, 28.2, 27.3, 
25.9, 16.5, 14.4. LC/MS analysis: Rt 6.15 min (linear gradient 10→90% B in 12.5 min), m/z 657.07 [M + 
H]+. HRMS: calculated for [C34H52BF2N6O4]+ 657.41117, found 657.41122. 
 
ABP 6 (TB476) 
Azidirine-azide 3 (9.1 mg, 
28 μmol) and biotin 926(11.5 
mg, 28 μmol) were treated 
according to General Click 
Procedure. Purification by 
HPLC (18% → 24%, A in B) followed by lyophilizing gave ABP 6 (6.5 mg, 8.9 μmol, 32%) as a white 
powder. 1H NMR (500 MHz, MeOD) δ 7.84 (s, 1H), 4.49 (dd, J = 7.8, 4.9 Hz, 1H), 4.42 (s, 1H), 4.38 
(d, J = 7.6 Hz, 1H), 4.36 (d, J = 7.6 Hz, 1H), 4.30 (dd, J = 7.9, 4.4 Hz, 1H), 4.14 (t, J = 3.9 Hz, 1H), 3.81 
(dd, J = 10.2, 5.9 Hz, 1H), 3.69 (dd, J = 10.1, 8.8 Hz, 1H), 3.54 – 3.43 (m, 2H), 3.24 – 3.18 (m, 1H), 3.17 
– 1.12 (m, 2H), 2.92 (dd, J = 12.7, 5.0 Hz, 1H), 2.70 (d, J = 12.7 Hz, 1H),  2.39 – 2.32 (m, 1H), 2.26 – 
2.13 (m, 5H), 2.10 – 2.03 (m, 2H), 2.03 – 1.96 (m, 1H), 1.90 (s, 5H), 1.79 – 1.70 (m, 1H), 1.65 – 1.53 
(m, 6H) 1.52 – 148 (m, 2H), 1.43 – 1.39 (m, 2H), 1.36 – 1.25 (m, 9H). 13C NMR (126 MHz, MeOD) δ 
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176.0, 175.9, 146.2, 124.1, 75.6, 70.1, 65.7, 64.4, 63.4, 61.6, 61.4, 57.0, 51.3, 44.9, 44.1, 43.2, 41.0, 40.2, 
36.8, 36.7, 35.6, 31.2, 30.3, 30.3, 30.1, 29.9, 29.8, 29.5, 28.2, 27.5, 27.3, 26.9, 26.5. LC/MS analysis: Rt 
3.98 min (linear gradient 10→90% B in 12.5 min), m/z 723.20 [M + H]+. HRMS: calculated for 
[C34H59N8O7S]+ 723.42219, found 723.42220. 
 
Pull-down and LC/MS analysis with ABP 6 (TB476) 
4.0 mg total protein from mouse kidney homogenates were incubated with either DMSO, 10 μM 
biotin probe 6 (TB476), or 5 μM Cy5 probe 4 (TB434) followed by 10 μM 6, each step was taking 1 h 
at 37 °C in a total volume of 500 μL McIlvaine buffer pH 5.5 (750 mM citric acid/Na2HPO4). Samples 
were subsequently denatured with the addition of 125 μL 10% (w/v) SDS and boiling for 5 min at 100 
°C. From here on, samples were prepared for pull-down with streptavidin beads as published earlier.28 
After the pull-down procedure, half of the samples were treated by the trypsin digestion buffer (100 
mM Tris-HCl pH 7.8, 100 mM NaCl, 1 mM CaCl2, 2% (v/v) acetonitrile (ACN) and 10 ng/μL trypsin) 
and the bead suspension was incubated in a thermoshaker at 37 °C overnight. The supernatant 
containing the trypsin-digested peptides was desalted using stage tips, followed by evaporation and re-
dissolving in 75 μL sample solution (H2O/ACN/formic acid, 95/3/0.1, v/v/v). The beads containing 
active-site peptides were eluted with elution buffer (5% (v/v) formic acid, 25% (v/v) ACN, 70% (v/v) 
H2O, 10 μM biotin) for 30 min at 37 °C, after which the supernatant was desalted using stage tips and 
prepared for LC/MS analysis using the above mentioned procedures.  
For the LC/MS analysis, 1 μL of sample was injected with phase A (0.1 % (v/v) formic acid in 
ultrapure H2O) on a C18 column (Acquity UPLC M-Class 300 μm x 50 mm, packed with BEH C18 
material of 1.7 μm diameter and 300 Å pore size particles), eluted with a 50 min gradient of 10% to 
60% phase B (0.1 % (v/v) formic acid in ACN), followed by 10 min equilibration to 1% phase B at a 
flow of 0.4 μl/min, hyphenated with Electro-spray ionization (ESI) via Nano-spray source with ESI 
emitters (New Objectives) fused silica tubing 360 μm OD x 25 μm ID tapered to 5 ± 0.5 μm (5 nl/cm 
void volume) to a Synapt G2Si mass spectrometer (Waters) operating with Masslynx for acquisition 
and Ent3 software for polymer envelope signal deconvolution. The following settings in positive 
resolution mode were used: source temperature of 80 °C, capillary voltage 4.5 kV, nano flow gas of 
0.25 Bar, purge gas 250 L/h, trap gas flow 2.0 ml/min, cone gas 100 L/h, sampling cone 25V, source 
offset 25, trap CE 32V, scan time 3.0 sec, mass range 400-2400 m/z. Lock mass acquiring was done 
with a mixture of Leu Enk (556.2771) and Glu Fib (785.84265), lockspray voltage 3.5 kV, Glufib 
fragmentation was used as calibrant. The PLGS (Waters) program was used for data analysis, protein 
ID or extraction of mgf files for further Mascot (Matrix Science) search analysis. The identification 
results were exported as Excel file including protein accession numbers, mass of the protein, pI, PLGS 
score, and % coverage of the protein by amino acids identified by LC/MS.  
 
Comparing TB434 (4) labeling with enzymatic activity at varying pH 
For the enzymatic activity determination, 52 ng (0.55 pmole) β-mannosidase from Helix pomatia 
(Sigma) were equilibrated in 25 μL McIlvaine buffer at varying pH (3.0 – 8.0) at 37°C for 15 min, then 
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assayed with 4-mu-β-D-man substrate prepared at the respective pHs. All measurements were 
performed in triplicates. For the TB434 (4) labeling, 2.6  μg (27.5 pmole) of the same β-mannosidase 
were equilibrated in 10 μL McIlvaine buffer at varying pH (3.0 - 7.5) at 37 °C for 15 min, incubated 
with 10 μM TB434 (end concentration; prepared in McIlvaine buffer at pH 3.0 - 7.5) at 37 °C for 1 h, 
denatured and resolved by SDS-PAGE, scanned for cy5 fluorescence with a Typhoon FLA 9500 
imager (GE Healthcare), and fluorescent signals were quantified with the ImageQuant TL software 
(GE Healthcare). Both y values derived from activity measurement and the gel were normalized 
against the highest value in their respective experiment. 
The concentration dependent labeling of β-mannosidase from Helix pomatia with TB434 (4) was 
performed with varying probe concentrations (0 – 10 μM) for 1 h at 37 °C at pH 5.5. 
 
Enzyme activity assays 
The β-mannosidase activity was assayed at 37 °C by incubating 25 μL enzyme (with or without 
inhibitor pre-incubation) in a black 96-well plate (Greiner, medium binding) with 100 μL 2 mM 4-
methylumbelliferyl-β-D-mannopyranoside (4-mu-β-D-man) as substrate in 150 mM McIlvaine buffer 
(pH 4.2 or 5.5) for 30 min or 1 h, and stopping by adding 200 μL 1 M glycine-NaOH. Fluorescence 
was measured with a LS55 fluorometer (Perkin Elmer) using λEx = 366 nM and λEm = 445 nM.  
For the determination of apparent IC50 values from the inhibitors, 47 ng (0.5 pmol) β-mannosidase 
from Helix pomatia were equilibrated in 12.5 μL McIlvaine buffer (150 mM, pH 5.5) for 15 min at 37 
°C, then with 12.5 μL 2x ABP dilution (final [ABP] = 0.1 – 50 μM; diluted in McIlvaine buffer pH 5.5) 
for 2 h at 37 °C, followed by an 1 h incubation with the 4-mu-β-D-man substrate at 37 °C and pH 5.5. 
Apparent IC50 values for each inhibitor were calculated by fitting a non-linear [Inhibitor] vs response 
function (variable slope, four parameters, least squares fit, without constraint) to the measured values 
(in triplicates) at each inhibitor concentration, using Prism (GraphPad, version 7.0). 
 
In vitro ABPP with TB434 (4) in mouse kidney homogenates 
Kidneys from wild type mice were homogenized in KPi buffer (25 mM K2HO4/KH2PO4, 0.1% (v/v) 
Triton X-100, protease inhibitor cocktail (Roche, version 12)) with 1mm glass beads and a FastPrep-
24 homogenizer (MP Biomedicals). The basic labeling condition consists of equilibrating 25 μg total 
protein from the homogenate in McIlvaine buffer (150 mM, various pH) in a total volume of 10 μL, 
and ABP labeling with 5 μL of 3x concentrated ABP prepared in McIlvaine buffer. For concentration 
dependent labeling, mouse tissue homogenates were equilibrated in McIlvaine buffer pH 5.5 for 15 
min at 37 °C, followed by incubation with various probe concentrations up to 10 μM TB434 (end 
concentration, pH 5.5) at 37 °C for 1 h. For labeling at varying pH, mouse tissue homogenates were 
equilibrated in McIlvaine buffer pH 4.0 – 7.0 for 15 min at 37 °C, followed by incubating with 1 μM 
TB434 (prepared in McIlvaine buffer pH 4.0 -7.0) for 1 h at 37 °C. For labeling at varying incubation 
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time, mouse kidney homogenates were prepared as above, and incubated with 1 μM TB434 (end 
concentration; pH 5.5) at 37 °C for 2 min to 2 h. After incubation, samples were denatured with 3.75 
μL 5X Laemmli’s sample buffer at 98 °C for 5 min, resolved in 7.5% SDS-PAGE gels, and wet slab gels 
were scanned for Cy5 fluorescence by a Typhoon FLA 9500 imager (GE Healthcare). Coomassie stain 
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yclophellitol (1, Figure 6.1), isolated in 1990 from the mushroom Phellinus sp., is a 
potent mechanism-based inhibitor of retaining β-glucosidases.2 Cyclophellitol is a 
configurational analogue of β-glucopyranoses, but its conformational behaviour is 
different. Whereas β-glucopyranoses preferably adopt a 4C1 conformation, the epoxide 
annulation in 1 enforces a preferred 4H3 half-chair conformation onto the cyclitol 
moiety. A similar half-chair conformation is thought to occur during hydrolysis of β-
glucosidic linkages as effected by retaining β-glucosidases and for this reason 
cyclophellitol is thought to bind well within β-glucosidase active sites. After 
protonation of the epoxide oxygen by the acid-base catalyst residing within β-
glucosidase active sites and subsequent SN2 displacement by the active site nucleophile a 
covalent enzyme-inhibitor adduct emerges.3,4 This adduct is stable over time leading to 




















Figure 6.1 A) Cyclophellitol (1) and cyclophellitol aziridine (2) inhibit retaining β-glucosidases by 
initial binding in 4H3 conformation, followed by SN2 displacement of the (protonated) epoxide-oxygen 
or aziridine-nitrogen. B) Carba-cyclophellitols (3) are proposed to be competitive retaining β-
glucosidase inhibitors by mimicry of the 4H3 transition state. X = O or NH; R = alkyl or acyl. 
 
Following the discovery of cyclophellitol, a number of synthetic analogues were 
reported.5,6 Cyclophellitol aziridine (2), the cyclophellitol analogue in which the 
epoxide oxygen in cyclophellitol 1 is substituted by nitrogen, proved to inhibit β-
glucosidases covalently and irreversibly as well.7 The potency and specificity of 
cyclophellitol (1) and cyclophellitol aziridine (2), and their putative mode of action 
(entering the enzyme active site as a 4H3 half-chair transition state analogue followed by 
SN2 displacement of the epoxide/aziridine heteroatom) invited the question whether the 
corresponding carba analogue (3) (that is, substitution of the oxygen/nitrogen for a 
carbon atom) would yield viable retaining β-glucosidase inhibitors (Figure 6.1B). And, 
if so, whether such compounds would act as competitive inhibitors by transition state 
mimicry without – due to lack of a suitable leaving group – ensuing covalent bond 
formation. To test this hypothesis, a set of carba-cyclophellitols was designed (Figure 
6.2). Next to carba-cyclophellitols featuring a retaining β-glucopyranose configuration, 
analogues having an α-glucopyranose configuration, a β-galactopyranose configuration 
and an α-galactopyranose configuration were included in the synthetic targets, leading 
to the focused carba-cyclophellitol library 4-23 (Figure 6.2). In this chapter, the 
synthesis of these carba-cyclophellitols is presented. 
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Figure 6.2 Structures of the carba-cyclophellitols (4-23) that are subject of the studies presented in 
this chapter. 
 
6.2 Results and discussion 
 
The synthesis of compound 10, the most simple carba-cyclophellitol commenced with 
the preparation of key intermediate 24 following the procedure first described by the 
group of Madsen8 and optimized9 in more recent years (Scheme 6.1). Global 
benzylation of 24 was followed by a Simmons-Smith cyclopropanation6 to afford 
cyclopropane 26 in 46% yield as the single product. After palladium-catalyzed 
hydrogenolysis and subsequent acetylation, the acetylated intermediate was purified by 
silica gel column chromatography. Deacetylation under Zemplén conditions resulted in 
compound 10. After several protection group manipulations, compound 29 was 
obtained. Attempts to synthesize cyclopropane 30, an isomer of cyclopropane 10, from 
compound 29 following literature procedures (40%)6, however, turned out to be 
abortive, in that compound 30 could not be synthesized. 
As a next research objective, the discovery of a versatile intermediate as starting point 
to obtain various carba-cyclophellitol derivatives was undertaken. Ethyl diazoacetate 
(EDA)10,11 was employed as the cyclopropanylating agent for this purpose. When the 
conditions developed for cyclopropanation of glucals with Rh2(OAc)4 as catalyst12-14 
were applied to benzylated 25, trace amounts of the desired product were detected after 
TLC-MS analysis of the reaction mixture. Several other products with higher
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Scheme 6.1 Synthesis of cyclopropane 10. 
Reagents and conditions: a) BnBr, NaH, TBAI, DMF, 0 °C to rt, overnight, 94%; b) 1,2-
dimethoxyethane, boron trifluoride diethyl etherate, Et2Zn, CH2I2, CH2Cl2, rt, 3 h, 46%; c) (i) Pd/C, 
H2, MeOH, rt, overnight, (ii) Ac2O, pyridine, rt, 48 h, (iii) NaOMe, MeOH, rt, 2 h, 66% over three 
steps; d) TBS-Cl, imidazole, DMF, rt, 1 h; e) BnBr, NaH, TBAI, DMF, 0 °C to rt, overnight; f) TBAF, 
THF, rt, 2 h, 83% over 3 steps; g) 1,2-dimethoxyethane, Et2Zn, CH2I2, CH2Cl2, MeOH, rt, 5h. 
 
(compared to the desired product) molecular masses were detected (TLC-MS), which 
may be the result of Büchner-type ring expansion15,16, in which the benzyl ethers in 25 
may have reacted with EDA under the applied conditions.17,18 Furthermore, after 
adding the 3 eq. EDA over 6 h to the reaction mixture as is advocated in the literature, 
dimerization of EDA to ethyl maleate was observed to occur as a major event. The 
latter was circumvented by addition of less EDA (1.5 eq. EDA) over 6 h. A comparative 
study in which a number of transition metal catalysts were compared side-by-side was 
performed to further optimize the reaction conditions (Scheme 6.2) in terms of yield. 
Rh2(OAc)4, Cu(acac)2 and Pd(OAc)219, which are widely applied catalysts for EDA-
mediated cyclopropanation of various substrates20-22, were employed in this study.  
Palladium-based catalysts are, in general, optimal for addition to electron-poor alkenes 
whereas rhodium- and copper-based catalysts are more effective in catalyzing 
cyclopropanation of electron-rich olefins. The influence of the electron density of the 
alkene was studied by comparing peracetylated cyclohexene 31 and persilylated 
cyclohexene 32 (which were prepared by means of standard protective group 
manipulations from 24 – see Scheme 6.2) with perbenzylated cyclohexene 25. The 
combination of Cu(acac)2 as catalyst and tetra-O-benzyl-cyclohexene 25 came out as 
the optimal one based on TLC-MS analysis, even though, in contrast to compounds 31 
and 32, and as shown before, compound 25 can undergo Büchner-type reactions. With 
the aim to minimize such side reactions, which also occurred in Cu(acac)2/EDA-
mediated cyclopropanations, EDA is best added over time to a mixture of 25 and the 
copper(II) catalyst in ethyl acetate. Upon TLC-MS detection of Büchner adducts, the 
reaction was worked up by concentration, the desired product isolated, the side 
products removed and the remainder of starting material reused. In this manner and 
over three reaction cycles, compounds 33 and 34 can be obtained as a mixture (in a 
ratio of 2:1) in 35% yield. 
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Reaction conditions: a) (i) Li (s), NH3 (l), THF, -60 °C, 35 min, (ii) Ac2O, pyridine, rt, overnight, 79% 
over two steps; b) (i) NaOMe, MeOH, rt, overnight, (ii) TBS-Cl, imidazole, DMF, rt to reflux 
temperature, 7 days, 35%; c) To 0.1 mmol of substrate (25, 31, or 32) and 5 mol% of catalyst 
(Rh(OAc)2, Cu(acac)2 or Pd(OAc)2) in DCE (90 μL) at reflux temperature was added EDA (0.3 mmol) 
in DCE (300 μL) over 6 h. 
 
An alternative strategy is intramolecular cyclopropanation (Scheme 6.3). Alcohol 29 
was coupled with N-Boc-glycine to obtain 39. Treatment with TFA gave amine 40, 
which was subsequently subjected to diazotization to give 41. Based on the work of 
Corey23,24 internal cyclopropanation with Cu(N-tert-butylsalicylaldiminato)2 in toluene 
or Cu(acac)2 in EtOAc, was attempted. However, no product other than dimerisation 
could be detected (TLC) in this experiment. 
 
Scheme 6.3 An attempt to achieve intramolecular cyclopropanation. 
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Reagents and conditions: a) N-Boc-glycine, DIC, DMAP, rt, overnight, quant.; b) TFA, CH2Cl2, rt, 45 
min, quant.; c) NaNO2, monosodium citrate, CH2Br2, H2O, 0 °C, 1 h, 99%; d) Cu(acac)2 or Cu(N-tert-
butylsalicylaldiminato)2, toluene, EtOAc or DCE, reflux temperature; e) EtOH, H2SO4; f) KHMDS, 
THF, -78 °C. 
 
The versatility of carba-cyclophellitols 33 and 34 as starting materials for the synthesis 
of a number of functional analogues is demonstrated in Schemes 6.4 – 6.7. Separation 
of the stereoisomers 33 and 34 by silica gel column chromatography or HPLC was not 
successful. Crystallization of the mixture of compounds obtained after Cu(acac)2/EDA-
mediated cyclopropanation of 25 from ethanol, however, resulted in isolation of 
compound 33 as the sole isomer. Global debenzylation of 33 under standard palladium-
catalyzed hydrogenation conditions in EtOAc and AcOH resulted in compound 7 
(Scheme 6.4). Ester 33 was converted into ketone 45 and subsequently subjected to 
palladium-catalyzed hydrogenolysis in MeOH to obtain compound 8.  
 
Scheme 6.4 Synthesis of 7 and 8. 
Reagents and conditions: a) Pd(OH)2/C, H2, EtOAc, AcOH, rt, overnight, 97; b) N,O-
dimethylhydroxylamine hydrochloride, EtMgBr, THF, -5 °C to rt, overnight, 56%; c) Pd(OH)2/C, H2, 
MeOH, rt, overnight, 96%. 
 
After reduction of the mixture of esters 33 and 3425, alcohols 46 and 47 were obtained 
and successfully separated by column chromatography (Scheme 6.5). In the next steps, 
alcohol 47 was converted into compounds 4 and 5. Oxidation of alcohol 47 with 
aqueous sodium dichromate–sulphuric acid (Jones reagent) afforded acid 48. 
Esterification of acid 48 with ethanol gave ester 34, which was subjected to palladium-
catalyzed hydrogenolysis in EtOAc and AcOH to obtain compound 4 (81% yield). After 
conversion of ester 34 into ketone 49 and global debenzylation under standard 
palladium-catalyzed hydrogenation conditions in MeOH compound 5 was synthesized.  
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Scheme 6.5 Synthesis of 4 and 5.  
Reagents and conditions: a) DIBAL, THF, 30 min at 0 °C and then 1 h at rt, 46 (28%) and 47 (13%); 
b) Jones reagent, acetone, 0 °C, 3 h, 53%; c) EtOH, N,N’-diisopropylcarbodiimide, 4-
dimethylaminopyridine, toluene, rt, 4 h, 62%; d) Pd(OH)2/C, H2, EtOAc, AcOH, rt, overnight, 81%; e) 
N,O-dimethylhydroxylamine hydrochloride, EtMgBr, THF, -5 °C to rt, overnight, 45%; f) Pd(OH)2/C, 
H2, MeOH, rt, overnight, 58%.  
 
Alcohol 11 and ether 12 were synthesized from compound 46 (Scheme 6.6). Subjection 
of compound 46 to palladium-catalyzed hydrogenolysis in MeOH gave compound 11. 
Alkylation of compound 46 with bromoethane followed by global debenzylation 
afforded compound 12.  
 
Scheme 6.6 Synthesis of 11 and 12. 
Reagents and conditions: a) Pd(OH)2/C, H2, MeOH, rt, overnight, 11 (90%), 12 (94%); b) EtBr, NaH, 
TBAI, DMF, 0 °C to rt, 4 h, 59%. 
 
Next, the mixture of carba-cyclophellitols 33 and 34 was treated with LiOH and 
subsequently coupled to 1-azido-4-aminobutane linker 52, which was synthesized 
following the procedure of Ma et al (Scheme 6.7).26 Preparative HPLC allowed 
separation of 53 and 54. The thus purified compounds were treated with anhydrous 
BCl3 in dichloromethane to afford 6 and 9 in 99% and 88% yield. 
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Scheme 6.7 Synthesis of amide 6 and 9. 
Reagents and conditions: a) NaN3, DMF, H2O, 80 °C, overnight, 98%; b) PPh3, Et2O, EtOAc, 1 M 
HCl, 0 °C to rt, 20 h, 77%; c) (i) LiOH, THF, MeOH, H2O, rt, overnight, 82%; (ii) 52, HCTU, DIPEA, 
DCM, rt, overnight, 78%; d) BCl3, DCM, 9 (88%), 6 (99%). 
 
The galactopyranose-configured carba-cyclophellitol derivatives were synthesized in a 
similar fashion. Cyclohexene 55 was synthesized in large quantities as described by 
Willems27 based on the method of Llebaria.28 Simmons-Smith cyclopropanation of 
cyclohexene 55 afforded cyclopropane 566 in stereoselective fashion. In the next step, 
compound 56 was subjected to palladium-catalyzed hydrogenolysis to obtain target 
compound 21 (Scheme 6.8). The optimized conditions for EDA-mediated 
cyclopropanation of 25 as described before were applied on 55, yielding 57 and 58, 
which could, in contrast to the glucopyranose-configured isomer, be separated by silica 
gel column chromatography. Palladium-catalyzed hydrogenation in MeOH of 
compound 58 afforded compound 13. Compound 18 was obtained after palladium-
catalyzed hydrogenation of compound 57 in EtOAc with AcOH. 
 
Scheme 6.8 Synthesis of cyclopropane 21 and esters 13 and 18.  
Reagents and conditions: a) 1,2-dimethoxyethane, boron trifluoride diethyl etherate, Et2Zn, CH2I2, 
CH2Cl2, 84%; b) (i) Pd(OH)2/C, H2, MeOH, (99%); c) EDA, Cu(acac)2, EtOAc, 52 and 53 (3:1, 13%); 
d) Pd/C, MeOH, H2, overnight, 14%; e) Pd(OH)2, H2, EtOAc, AcOH, rt, overnight, 9%. 
 
A mixture of 57 and 58 was used as a starting point to synthesize various other 
galactopyranose-configured carba-cyclophellitols (Scheme 6.9). DIBAL-mediated 
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reduction of such a mixture provided alcohol 59 and alcohol 60 which were separated 
by silica gel column chromatography. Palladium-catalyzed hydrogenolysis of 
compound 59 resulted in compound 22. The free alcohol of 59 was alkylated with 
bromoethane to afford ether 61, which was subsequently debenzylated to obtain 
compound 23. Global debenzylation of alcohol 60 gave compound 16 in 87% yield. 
Treatment of alcohol 60 with ethylbromide, sodium hydride and tetrabutylammonium 
iodide gave compound 62. Debenzylation using palladium-catalyzed hydrogenolysis 
conditions afforded compound 17. The esters 57 and 58 were converted into the 
corresponding ketones 63 and 64 and subsequently separated by HPLC. Compound 63 
was deprotected by palladium-catalyzed hydrogenation to obtain compound 19. In a 
similar fashion compound 64 was converted into compound 14. Finally, a mixture of 57 
and 58 was treated with LiOH and coupled with 52.26 The obtained compounds 65 and 
66 were separated by HPLC. The benzyl protection groups of compound 65 were 
removed by 
 
Scheme 6.9 Synthesis of 14-17, 19, 20, 22 and 23. 
Reagents and conditions: a) DIBAL, CH2Cl2, 59 (40%) and 60 (36%); b) Pd/C, H2, MeOH, rt, 
overnight, 14 (88%), 16 (87%), 17 (quant.), 19 (80%),  22 (quant.), 23 (quant.); c) EtBr, NaH, TBAI, 
DMF, 0 °C to rt, 61 (80%) 62 (74%); d) N,O-dimethylhydroxylamine hydrochloride, EtMgBr, THF, -8 
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°C to rt, overnight, 63 (16%) and 64 (21%); e) (i) LiOH, THF, EtOH, H2O, rt, overnight; (ii) 52, 
HCTU, DIPEA, DCM, rt, overnight, 65 (24%) and 66 (18%); d) BCl3, DCM, 15 (70%), 20 (quant.). 
BCl3 to afford compound 20. Treatment of compound 66 with BCl3 afforded compound 
15. The configuration of the obtained carba-cyclophellitol products was determined by 
nuclear Overhauser effect spectroscopy (NOESY), Figure 6.3. Spatial couplings between 
H-1 and H-2 and between H-3 and H-7 were observed in compound 33. The observed 
spatial couplings in compound 34, a stereoisomer of 33, are between H-2 and H-7 and 













Cyclophellitols and cyclophellitol aziridines are potent, selective and covalent 
glycosidases inhibitors that act by mimicking the oxocarbenium ion transition state. 
Carba-cyclophellitol, an analogue of cyclophellitol and cyclophellitol aziridine, is 
expected to be a stable competitive inhibitor of glycosidases. In order to examine their 
inhibition properties, a set of 20 different carba-cyclophellitols is synthesized and 
described in this chapter. The described β-glucopyranose-configured carba-
cyclophellitols are further evaluated towards Thermotoga maritima TmGH1 in Chapter 




General: All chemicals were purchased from Acros, Sigma Aldrich, Biosolve, VWR, Fluka, Merck and 
Fisher Scientific and used as received unless stated otherwise. N,N-Dimethylformamide (DMF) and 
toluene were stored over flame-dried 4 Å molecular sieves before use. Traces of water from reagents 
were removed by co-evaporation with toluene in reactions that require anhydrous conditions. All 
reactions were performed under an argon atmosphere. TLC analysis was conducted using Merck 
aluminium sheets (Silica gel 60 F254) with detection by UV absorption (254 nm), by spraying with a 
solution of (NH4)6Mo7O24·4H2O (25 g/L)  and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid or a 
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solution of KMnO4 (20 g/L) and K2CO3 (10 g/L) in water, followed by charring at ~150 ˚C. Column 
chromatography was performed using Screening Device b.v. Silica Gel (particle size of 40 – 63 μm, 
pore diameter of 60 Å) in the indicated solvents. For reversed-phase HPLC purifications an Agilent 
Technologies 1200 series instrument equipped with a semiprep column (Gemini C18, 250 x 10 mm, 5 
μm particle size, Phenomenex) was used. LC/MS analysis was performed on a Surveyor HPLC system 
(Thermo Finnigan) equipped with a C18 column (Gemini, 4.6 mm x 50 mm, 5 μm particle size, 
Phenomenex), coupled to a LCQ Advantage Max (Thermo Finnigan) ion-trap spectrometer (ESI+). 
The applied buffers were H2O, MeCN and 1% aqueous TFA. 1H NMR and 13C NMR spectra were 
recorded on a Brüker AV-400 (400 and 101 MHz respectively), a Brüker DMX-600 (600 and 151 MHz 
respectively) or a Bruker AV-850 (850 and 214 MHz respectively) spectrometer in the given solvent. 
Chemical shifts are given in ppm (δ) relative to the residual solvent peak or to tetramethylsilane (0 
ppm) as internal standard. Coupling constants are given in Hz. High-resolution mass spectrometry 
(HRMS) analysis was performed with a LTQ Orbitrap mass spectrometer (Thermo Finnigan), 
equipped with an electronspray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10 
mL/min, capillary temperature 250 °C) with resolution R = 60000 at m/z 400 (mass range m/z = 150 – 
2000) and dioctyl phthalate (m/z = 391.28428) as a “lock mass”. The high-resolution mass 
spectrometer was calibrated prior to measurements with a calibration mixture (Thermo Finnigan). 
 
General procedure for global debenzylation. 
To a solution of the benzyl ether in MeOH was added a catalytic amount of 10% Pd on carbon or 
Pd(OH)2 on carbon. The reaction vessel was purged with hydrogen gas and the mixture was 
vigorously stirred overnight. After TLC analysis showed full conversion to a lower running spot, the 
palladium catalyst was filtered off over a pad of Celite followed by concentration in vacuo, which gave 
the corresponding product.  
 
((((1R,2R,3S,6R)-6-((benzyloxy)methyl)cyclohex-4-ene-1,2,3-triyl)tris(oxy))tris 
(methylene)) tribenzene (25) 
Diol 24 (2.21 g, 6.50 mmol) was dissolved in DMF (33 mL) at 0 °C. TBAI (22.0 mg, 60 
μmol, 0.01 eq.), BnBr (1.86 mL, 15.6 mmol, 2.4 eq.) and NaH (60% dispersion in mineral 
oil, 0.629 g, 15.7 mmol, 2.4 eq.) were added. After stirring overnight, additional BnBr (0.93 mL, 7.80 
mmol, 1.2 eq.) and NaH (60% dispersion in mineral oil, 0.315 g, 7.68 mmol, 1.0 eq.) were added at 0 
°C. After the mixture was stirred for 4 h, it was quenched with MeOH (2 mL) and concentrated in 
vacuo. The crude residue was redissolved in Et2O (100 mL) and washed with H2O (1 x 100 mL, 3 x 50 
mL). The aqueous layers were extracted with Et2O (50 mL) and the combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (3% 
EtOAc in pentane → 6% EtOAc in pentane) gave fully benzylated 25 as a yellow oil (3.17 g, 6.08 mmol, 
94%). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.56 – 7.00 (m, 20H), 5.83 – 5.56 (m, 2H), 4.98 – 4.86 (m, 
3H), 4.70 (s, 2H), 4.53 – 4.36 (m, 3H), 4.31 – 4.22 (m, 1H), 3.81 (dd, J = 10.1, 7.8 Hz, 1H), 3.67 (t, J = 
9.8 Hz, 1H), 3.52 (d, J = 4.4 Hz, 2H), 2.64 – 2.42 (m, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) 129.3, 
128.5, 128., 128.1, 128.0, 127.9, 127.8, 127.7, 127.0, 85.5, 81.0, 78.5, 75.5, 75.5, 73.2 72.2, 69.3, 44.5. 






To a solution of 1,2-dimethoxyethane (72 μL) in DCM (0.35 mL) was added boron 
trifluoride ethyl etherate (43 μL) and diethyl zinc (1 M in hexane, 0.7 mL, 0.7 mmol) at 
room temperature. After stirring for 5 min, diiodomethane (112 μL, 1.4 mmol) was added and the 
reaction mixture was stirred an additional 5 min. Compound 24 (36.3 mg, 70 μmol) was dissolved in 
DCM (0.85 mL) and added dropwise to the reaction mixture. After stirring for 3 h, the reaction 
mixture was quenched with a saturated aqueous NH4Cl solution and diluted with EtOAc. The 
aqueous layer was extracted with EtOAc (3x) and the combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (pentane → 8% 
EtOAc in pentane) gave cyclopropane 26 (17.3 mg, 32 μmol, 46%) as a yellow oil. 1H NMR (400 MHz, 
CDCl3): δ (ppm) 7.40 (d, J = 7.0 Hz, 2H), 7.37 – 7.27 (m, 16H), 7.18 – 7.12 (m, 2H), 4.89 – 4.75 (m, 
4H), 4.69 (d, J = 12 Hz, 1H), 4.55 – 4.36 (m, 3H), 4.14 – 4.04 (m, 1H), 3.59 (d, J = 4.2 Hz, 2H), 3.46 – 
3.24 (m, 2H), 1.93 – 1.85 (m, 1H), 1.44 – 1.34 (m, 1H), 1.17 – 1.07 (m, 1H). 0.82 – 0.74 (m, 1H), 0.40 – 
0.35 (m, 1H) 13C NMR (101 MHz, CDCl3): δ (ppm) 128.5, 128.5, 128.2, 128.1, 128.0, 127.8, 127.7, 
127.6, 84.4, 80.5, 79.5, 75.6, 75.3, 73.3, 71.4, 44.1, 16.2, 14.2, 10.4.  
 
(1S,2S,3R,4R,5R,6R)-5-(hydroxymethyl)bicyclo[4.1.0]heptane-2,3,4-triol (10) 
Compound 26 (760 mg, 1.4 mmol) was dissolved in MeOH (20 mL). The reaction 
mixture was purged with argon gas and 10% palladium on carbon (373 mg) was added. 
After the reaction vessel was purged with hydrogen gas and vigorously stirring 
overnight, the palladium catalyst was filtered off over a pad of Celite followed by concentration in 
vacuo. Purification by column chromatography (EtOAc → 30% MeOH in EtOAc) gave a crude 
product which was dissolved in pyridine (4.2 mL) and acetic anhydride (0.67 mL, 7.1 mmol) was 
added. After stirring for 2 days at room temperature, the reaction mixture was diluted with EtOAc (30 
mL) and washed with H2O (3x). The combined water layers were extracted with EtOAc (2x) and the 
combined organic layers were dried over MgSO4, filtered, concentrated in vacuo. Purification by 
column chromatography (pentane → 20% EtOAc in pentane) gave the corresponding acetylated 
product 10 (0.36 g, 1.0 mmol, 71%) as a clear oil. 1H NMR (400 MHz, CDCl3): δ (ppm) 5.39 (dd, J = 
8.7, 6.2 Hz, 1H), 5.00 – 4.84 (m, 2H), 4.18 – 4.05 (m, 2H), 2.19 – 2.13 (m, 1H), 2.09 (s, 3H), 2.06 (s, 
3H) 2.00 (s, 6H), 1.68 – 1.56 (m, 2H), 1.10  – 1.02 (m, 1H), 0.93 – 0.85 (m, 1H), 0.53 (q, J = 5.7 Hz, 
1H) 13C NMR (101 MHz, CDCl3): δ (ppm) 171.2, 170.8, 170.2, 169.9, 72.9, 71.6, 70.2, 64.6, 41.0, 21.2, 
21.0, 20.8, 20.8, 15.9, 13.6, 10.7. HRMS: calculated for [C16H22O8Na]+ 365.12069, found 365.12048. 
The acetylated product (25 mg, 73 μmol) was dissolved in MeOH (10 mL) and a catalytic amount of 
NaOMe was added. After TLC analysis showed full conversion to a lower running spot, the reaction 
mixture was neutralized with Amberlite-H+ IR-120, filtered and concentrated in vacuo to obtain 
compound 10 (12 mg, 68 μmol, 93%). 1H NMR (400 MHz, D2O): δ (ppm) 3.99 (dd, J = 8.8, 5.9 Hz, 
1H), 3.83 (dd, J = 10.9, 3.5 Hz, 1H), 3.70 (dd, J = 10.9, 6.3 Hz, 1H), 3.18 (t, J = 10.2 Hz, 1H), 3.09 (dd, J 
= 10.2, 8.9 Hz, 1H), 1.77 – 1.66 (m, 1H), 1.39 – 1.31 (m, 1H), 1.05 – 0.93 (m, 1H), 0.79 – 0.72 (m, 1H), 
0.29 (q, J = 5.4 Hz, 1H). 13C NMR (101 MHz, D2O): δ (ppm) 74.5, 72.1, 71.0, 63.1, 45.1, 17.6, 12.6, 9.2. 
HRMS: calculated for [C8H14O4Na]+ 197.07843, found 197.07845. 
 




Diol 24 (0.558 g, 1.64 mmol) was dissolved in DMF (8.2 mL), after which TBS-Cl (0.271 
g, 1.80 mmol, 1.1 eq.) and imidazole (0.279 g, 4.10 mmol, 2.5 eq.) were added. The 
reaction mixture was stirred at room temperature for 1 h and was then partitioned between Et2O (40 
mL) and H2O (40 mL). The organic layer was separated, washed with H2O (2x), dried over MgSO4, 
filtered and concentrated in vacuo to give crude title compound 27, which was continued without 




Crude compound 27 was dissolved in DMF (8.0 mL) at 0 °C, after which TBAI (catalytic 
amount), BnBr (0.23 mL, 1.97 mmol, 1.2 eq.) and NaH (60% dispersion in mineral oil, 
79.2 mg, 1.98 mmol, 1.21 eq.) were added. After stirring at room temperature overnight, the reaction 
mixture was concentrated in vacuo and partitioned between Et2O (25 mL) and H2O (25 mL). The 
organic layer was washed with H2O (3x) and the resulting aqueous layers were extracted with Et2O. 
The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo to give crude 
title compound 28 as a thick yellow oil, which was continued without further purification. HRMS: 
calculated for [C34H44O4SiNa]+ 567.29011, found 567.28989. 
 
((1R,4S,5R,6R)-4,5,6-tris(benzyloxy)cyclohex-2-en-1-yl)methanol (29) 
Crude compound 28 (0.893 g, 1.64 mmol) was dissolved in THF (8.2 mL), after which 
TBAF (1 M in THF, 9.8 mL, 9.8 mmol, 6.0 eq.) was added. After the mixture was stirred 
at room temperature for 2 h, it was quenched with 4 drops of H2O and concentrated in 
vacuo. Purification by column chromatography (30% EtOAc in pentane → 50% EtOAc in pentane) 
gave title compound 29 as a yellow oil (0.585 g, 1.36 mmol, 83% over 3 steps). 1H NMR (400 MHz, 
CDCl3): δ (ppm) 7.45 – 7.07 (m, 15H), 5.72 (dt, J = 10.0, 3.0 Hz, 1H), 5.53 (dt, J = 10.2, 2.6 Hz, 1H), 
5.03 – 4.84 (m, 3H), 4.74 – 4.57 (m, 3H), 4.28 – 4.17 (m, 1H), 3.83 (dd, J = 10.6, 7.4 Hz, 1H), 3.68 – 
3.50 (m, 3H), 2.46 (ddd, J = 14.3, 7.4, 3.7 Hz, 1H). 13C NMR (100 MHz, CDCl3: δ ppm) 138.8, 138.5, 
138.4, 128.6, 128.5, 128.5, 128.4, 128.3, 128.0, 128.0, 127.9, 127.7, 127.7, 85.2, 80.8, 78.7, 75.3, 75.2, 
72.1, 63.1, 45.8. HRMS: calculated for [C28H31O4]+ 431.22169, found 431.22174. 
 
(1R,2R,3S,6R)-6-(acetoxymethyl)cyclohex-4-ene-1,2,3-triyl triacetate (31) 
NH3 (20 mL) was condensed at -60 °C. Lithium (250 mg) was added and the reaction 
mixture was stirred until the lithium was completely dissolved. To this solution was 
added a solution of compound 24 (340 mg, 1.00 mmol) in THF (22.5 mL). The reaction 
mixture was stirred for 30 min at -60 °C and subsequently quenched with MeOH (10 mL). The 
solution was allowed to come to room temperature and stirred until all NH3 had evolved. The 
resulting crude was then dissolved in pyridine (6.0 mL) and acetic anhydride (5.0 mL) was added. 
After stirring overnight, additional acetic anhydride (9.0 mL) was added. The reaction mixture was 
partitioned between EtOAc (25 mL) and H2O (10 mL). The organic layer was washed with H2O (3x), 
dried over MgSO4 and concentrated in vacuo. The residue was taken up in pyridine (3.0 mL) and 
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Ac2O (2.0 mL). After stirring overnight at room temperature, the reaction mixture was partitioned 
between EtOAc (25 mL) and H2O (10 mL). The organic layer was washed with H2O (3x), dried over 
MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (10% EtOAc in 
pentane → 40% EtOAc in pentane) and coevaporation with toluene (to remove any residual pyridine) 
gave title compound 31 as a yellow oil (0.258 g, 0.786 mmol, 79% over 2 steps). 1H NMR (400 MHz, 
CDCl3): δ (ppm) 5.72 – 5.68 (m, 1H), 5.67 – 5.61 (m, 1H), 5.58 – 5.54 (m, 1H), 5.32 (dd, J = 10.6, 7.9 
Hz, 1H), 5.28 – 5.18 (m, 1H), 4.15 (dd, J = 11.3, 4.1 Hz, 1H), 4.02 (dd, J = 11.3, 5.1 Hz, 1H), 2.83 – 2.76 
(m, 1H), 2.03 (s, 12H). 13C NMR (100 MHz, CDCl3): δ (ppm) 170.9, 170.5, 170.3, 170.1, 128.5, 126.5, 





Compound 31 (69.5 mg, 0.434 mmol) was dissolved in MeOH (4.0 mL) and NaOMe 
(catalytic amount) was added. After stirring overnight, the reaction mixture was 
concentrated in vacuo and dissolved in DMF (3.1 mL). After addition of imidazole (0.708 g, 10.4 
mmol, 24 eq.) and a solution of TBS-Cl (0.864 g, 5.73 mmol, 13.2 eq.) in DMF (2.0 mL) the mixture 
was stirred at room temperature for 5 days and subsequently refluxed over 2 nights. The reaction 
mixture was partitioned between Et2O (10 mL) and H2O (10 mL). The organic layer was separated, 
washed with H2O (2x), dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (10% toluene in pentane) gave title compound 32 as a slightly yellow oil (94.0 mg, 
0.152 mmol, 35%). 1H NMR (400 MHz, CDCl3): δ (ppm) 5.74 (d, J = 3.6 Hz, 1H), 5.73 (d, J = 3.6 Hz, 
1H), 3.93 (d, J = 2.5 Hz, 1H), 3.90 (d, J = 2.0 Hz), 3.83 (d, J = 3.2 Hz, 1H), 3.61 (dd, J = 9.6, 8.0 Hz, 
1H), 3.52 (dd, J = 9.2, 7.2, 1H), 2.35 – 2.30 (m, 1H), 0.87 (s, 18H), 0.86 – 0.83 (m, 18H), 0.10 – 0.05 (m, 
18H), 0.01 (s, 3H), 0.00 (s, 3H). 13C NMR (100 MHz, CDCl3): δ (ppm) 127.3, 127.2, 76.0, 70.5, 69.2, 
65.4, 46.4, 26.3, 26.3, 26.2, 26.1, 18.6, 18.5, 18.2, -3.9, -4.1, -4.2, -4.5, -4.6, -5.0, -5.1. HRMS: calculated 




(33) and ethyl (1S,2S,3R,4R,5R,6S,7S)-2,3,4-tris(benzyloxy)-
5-((benzyloxy)methyl)bicyclo[4.1.0]heptane-7-carboxylate 
(34)  
EtOAc was dried over flame dried 4 Å molsieves overnight before use. To a solution of cyclic alkene 
25 (1.57 g, 3.01 mmol) in EtOAc (2.7 mL) in a 2-necked pear flask, was added Cu(acac)2 (79.0 mg, 
0.301 mmol, 0.1 eq.). The reaction mixture was stirred at 90 °C and a solution of ethyl diazoacetate (13 
wt% DCM, 4.52 mmol, 0.55 mL, 1.5 eq.) in EtOAc (9.0 mL) was added by syringe pump over 6 h. 
TLC-MS analysis indicated the presence of starting material, so an equal batch of ethyl diazoacetate 
diluted with EtOAc was added. After addition of a total of 6 eq. of ethyl diazoacetate, the formation of 
a product with m/z 715 [M + Na]+ was detected by TLC-MS analysis. The reaction was concentrated 
in vacuo and purification by column chromatography (3% EtOAc in pentane → 7% EtOAc in pentane) 
to give the desired product as a crude mixture of 2 isomers. In addition, recovered starting material 25 
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(0.433 g, 0.832 mmol, 28%) was obtained and was subjected to the same conditions as stated above. 
After addition of 4.5 eq. of ethyl diazoacetate, significant byproduct formation was observed by TLC-
MS analysis. After this cycle was repeated a second time a total crude mixture of α-ester 33 and β-ester 
34 (0.642 g, 1.06 mmol, 35%, 2:1, as a mixture of α/β) was obtained as a light yellow oil. Crystallization 
of the combined crude isomeric product mixture from ethanol gave 33 as a white solid (0.274 g, 0.452 
mmol, 15%) and a mixture of 33 and 34 as a light yellow oil (0.368 g, 0.606 mmol, 20%). 33 1H NMR 
(400 MHz, CDCl3): δ (ppm) 7.30 (m, 16H), 7.14 (m, 2H), 4.89 – 4.69 (m, 4H), 4.64 (d, J = 11.8 Hz, 
1H), 4.53 – 4.34 (m, 3H), 4.22 – 4.03 (m, 3H), 3.66 – 3.52 (m, 2H), 3.40 (t, J = 10.2 Hz, 1H), 3.25 (dd, J 
= 10.1, 8.3 Hz, 1H), 2.05 – 1.97 (m, 1H), 1.94 – 1.88 (m, 1H), 1.76 (ddd, J = 9.5, 4.7, 2.3 Hz, 1H), 1.67 
(t, J = 4.7 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ (ppm) 173.4, 139.0, 138.6, 
136.6, 138.3, 128.5, 128.5, 128.5, 128.4, 128.2, 128.0, 128.0, 127.8, 127.7, 127.6, 127.5, 84.1, 79.2, 78.5, 
75.7, 75.4, 73.3, 71.6, 70.2, 60.8, 43.1, 26.9, 25.0, 25.0, 14.4. HRMS: calculated for [C39H43O7]+ 
607.30542, found 607.30589.   
 
((1R,4S,5R,6R)-4,5,6-tris(benzyloxy)cyclohex-2-en-1-yl)methyl (tert-
butoxycarbonyl) glycinate (39) 
Compound 29 (51.9 mg, 0.120 mmol), N-Boc-glycine (31.5 mg, 0.18 mmol, 1.5 
eq.) and DMAP (catalytic amount) were dissolved in toluene (0.6 mL) and DIC 
(38 μL, 2 eq.) was subsequently added dropwise. After stirring overnight at room temperature, the 
reaction mixture was filtered over Celite, concentrated in vacuo and purified by column 
chromatography (8% EtOAc in pentane → 25% EtOAc in pentane) to give compound 39 as a yellow 
oil (69.4 mg, 0.120 mmol, quant.). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.42 – 7.21 (m, 15H), 5.72 
(dt, J = 10.2, 2.4 Hz, 1H), 5.58 – 5.46 (m, 1H), 5.04 – 4.49 (m, 6H), 4.28 (dd, J = 10.8, 3.2 Hz, 1H), 4.23 
(ddd, J = 7.7, 3.3, 1.9 Hz, 1H), 4.14 (dd, J = 10.9, 5.0 Hz, 1H), 3.80 (td, J = 13.3, 11.6, 7.5 Hz, 3H), 3.53 
(t, J = 9.8 Hz, 1H), 2.71 – 2.52 (m, 1H), 1.45 (d, J = 2.5 Hz, 9H). 13C NMR (75 MHz, CDCl3): δ (ppm) 
170.5, 138.9, 138.0, 128.6, 128.6, 128.5, 128.2, 128.0, 128.0, 127.9, 127.8, 127.5, 104.8, 101.9, 85.4, 80.8, 




To a solution of compound 39 (69.4 mg, 0.120 mmol) in DCM (0.3 mL) was 
added TFA (0.3 mL). After stirring for 45 min at room temperature, the reaction 
mixture was concentrated in vacuo to give compound 40 as a light yellow solid which was used 
without further purification (72.2 mg, 0.120 mmol, quant.). HRMS (as the free amine): calculated for 
[C30H34NO5]+ 488.24315, found 488.24285. Compound 40 (60.0 mg, 0.0990 mmol) was suspended in 
H2O (0.4 mL), after which monosodium citrate (31.7 mg, 0.149 mmol, 1.5 eq.) and CH2Br2 (0.5 mL) 
were added. The reaction was cooled to 0 °C and NaNO2 (8.19 mg, 0.119 mmol, 1.2 eq.) was added. 
After stirring at 0 °C for 1 h, the reaction mixture was warmed up to room temperature and the 
organic layer was removed by syringe. Additional CH2Br2 was added (0.5 mL) and after stirring for 10 
min the organic layer was removed again by syringe. The combined organic layers were combined 
and concentrated in vacuo to give compound 41 as a bright yellow oil (49 mg, 98.0 μmol, 99%). 1H 
NMR (400 MHz, CDCl3): δ (ppm) 7.45 – 7.16 (m, 15H), 5.73 (d, J = 10.2 Hz, 1H), 5.55 (d, J = 10.2 Hz, 
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1H), 4.96 (d, J = 10.8 Hz, 1H), 4.93 – 4.88 (m, 2H), 4.69 – 4.62 (m, 3H), 4.56 (d, J = 9.2 Hz, 1H), 4.33 
(dd, J = 10.8, 3.0 Hz, 1H), 4.23 – 4.18 (m, 2H), 3.82 (t, J = 8.4 Hz, 1H), 3.54 (t, J = 9.8 Hz, 1H), 2.61 (bs, 
1H). 13C NMR (100 MHz, CDCl3): δ (ppm) 138.9, 138.5, 138.4, 128.6, 128.6, 128.4, 128.1, 128.0, 127.9, 
127.8, 127.7, 85.3, 80.9, 77.9, 75.5, 74.4, 72.3, 63.9, 46.4, 43.6. 
 
Bis(N-tert-butylsalicylaldiminato)copper(II) 
Cu(OAc)2 (0.399 g, 2.00 mmol) was dissolved in H2O (5 mL) and a solution of 
salicylaldehyde (435 μL, 4.00 mmol, 2 eq.) in EtOH (2 mL) was added. After 
stirring for 1h at 55 °C, the precipitate was filtered off and subsequently 
suspended in EtOH (2 mL). After addition of tert-butylamine (525 μL, 5.00 
mmol, 2.25 eq.), the reaction mixture was refluxed for 1.5 h and concentrated in vacuo to give the title 




Benzylated 33 (72.9 mg, 0.120 mmol) was dissolved in EtOAc (1.25 mL) and 
AcOH (0.25 mL) was added. After addition of Pd(OH)2/C (catalytic amount) the 
reaction mixture was purged with H2. After stirring overnight at room temperature, the palladium 
catalyst was filtered off over a pad of Celite. Concentration in vacuo of the filtrate gave compound 7 as 
a brown thick oil (29.1 mg, 0.118 mmol, 97%). 1H NMR (400 MHz, CD3OD): δ (ppm) 4.12 (d, J = 7.2 
Hz, 1H), 4.09 (d, J = 7.2 Hz, 1H), 3.90 (dd, J = 8.7, 5.6 Hz, 1H), 3.83 (dd, J = 10.6, 3.9 Hz, 1H), 3.65 
(dd, J = 10.6, 6.6 Hz, 1H), 3.12 (t, J = 10.1 Hz, 1H), 3.04 – 2.94 (m, 1H), 1.94 – 1.85 (m, 1H), 1.78 – 
1.70 (m, 1H), 1.66 (t, J = 4.6 Hz, 1H), 1.61 (ddd, J = 9.1, 4.4, 1.6 Hz, 1H), 1.24 (t, J = 7.1 Hz, 3H). 13C 
NMR (100 MHz, MeOD): δ (ppm) 175.2, 76.2, 72.4, 72.0, 64.4, 61.8, 46.3, 30.4, 25.7, 25.0, 14.5. HRMS: 




Ester 33 (60.8 mg, 0.100 mmol) was added to Me(MeO)NH.HCl (12.2 mg, 0.125 
mmol, 1.25 eq.) in THF (0.5 mL). After addition of  EtMgBr (0.5 M in THF, 0.840 
mmol, 8.4 eq.) over 2 h at -5 – 0 °C, the reaction mixture was stirred overnight, quenched with 
aqueous HCl (3 M, 3 mL) and extracted with EtOAc (10 mL). The organic layer was dried, 
concentrated in vacuo and redissolved in THF (0.8 mL). After addition of EtMgBr (1 M in THF, 0.300 
mmol, 3 eq.) over 2 min at -20 °C, the reaction mixture was allowed to come to room temperature and 
was stirred for 75 min before quenching with aqueous HCl (3 M, 3 mL). The reaction mixture was 
extracted with EtOAc (10 mL) after which the organic layer was dried and concentrated in vacuo. 
Purification by column chromatography (6% EtOAc in pentane → 8% EtOAc in pentane) gave 
compound 45 as a white solid (32.8 mg, 55.6 μmol, 56%). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.39 – 
7.18 (m, 18H), 7.15 – 7.12 (m, 2H), 4.92 – 4.76 (m, 3H), 4.74 – 4.57 (m, 2H), 4.50 – 4.38 (m, 3H), 4.06 
(dd, J = 7.9, 5.8 Hz, 1H), 3.61 – 3.50 (m, 2H), 3.39 (t, J = 10.0 Hz, 1H), 3.34 – 3.24 (m, 1H), 2.58 (dd, J 
= 14.4, 7.6 Hz, 2H), 2.09 – 2.00 (m, 1H), 1.98 (t, J = 4.5 Hz, 1H), 1.95 – 1.89 (m, 1H), 1.86 – 1.78 (m, 
1H), 1.08 (t, J = 7.3 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ (ppm) 209.6, 139.1, 138.7, 138.6, 138.4, 
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128.6, 128.5, 128.5, 128.2, 128.0, 127.9, 127.8, 127.7, 84.3, 79.4, 78.7, 75.7, 75.5, 73.5, 71.6, 70.4, 43.5, 




Compound 45 (32.8 mg, 55.6 μmol) was treated according to General procedure for 
global debenzylation with Pd(OH)2/C to obtain title compound 8 as a clear oil (12.3 
mg, 53.4 μmol, 96%).  1H NMR (400 MHz, D2O): δ (ppm) 4.04 (dd, J = 8.6, 5.5 Hz, 1H), 3.84 (dd, J = 
11.0, 3.6 Hz, 1H), 3.72 (dd, J = 11.0, 6.2 Hz, 1H), 3.37 – 3.09 (m, 2H), 2.72 (dd, J = 7.2, 14.8 Hz, 2H), 
2.25 (t, J = 4.5 Hz, 1H), 2.11 – 1.98 (m, 1H), 1.90 – 1.83 (m, 1H), 1.68 – 1.61 (m, 1H), 1.04 (t, J = 7.3 
Hz, 3H). 13C NMR (100 MHz, D2O): δ (ppm) 216.1, 74.4, 70.7, 70.4, 62.5, 44.3, 36.6, 32.1, 31.9, 26.8, 






A crude mixture of 33 and 34 (0.142 g, 0.234 mmol) was dissolved in THF (1 mL) at 0 °C, after which 
DIBAL (1 M in hexanes, 2.1 mL, 2.1 mmol, 9.0 eq.) was added dropwise. After the mixture was stirred 
for 30 min at 0 °C followed by 1 h at room temperature, the reaction was quenched with EtOAc. The 
mixture was concentrated in vacuo and the residue was partitioned between EtOAc (20 mL) and 1 M 
aqueous HCl (20 mL). The aqueous layer was extracted with EtOAc (20 mL) and the combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (20% EtOAc in pentane →  25% EtOAc in pentane) gave title compounds 46 (36.6 
mg, 64.8 μmol, 28%) and 47 (17.1 mg, 30.2 μmol, 13%) as white solids. 46 1H NMR (400 MHz, 
CDCl3): δ (ppm) 7.46 – 7.20 (m, 18H), 7.19 – 7.11 (m, 2H), 4.96 – 4.64 (m, 5H), 4.55 – 4.29 (m, 3H), 
4.06 (dd, J = 7.9, 6.2 Hz, 1H), 3.59 (d, J = 4.1 Hz, 1H), 3.51 (dd, J = 11.2, 6.3 Hz, 1H), 3.40 – 3.18 (m, 
3H), 1.93 – 1.89 (m, 1H), 1.30 – 1.20 (m, 1H), 1.12 – 1.03 (m, 2H). 13C NMR (100 MHz, CDCl3): δ 
(ppm) 139.2, 139.1, 138.8, 138.5, 128.6, 128.5, 128.5, 128.2, 128.1, 128.1, 128.0, 127.9, 127.8, 127.8, 
127.7, 84.8, 80.1, 79.3, 75.7, 75.4, 73.4, 71.7, 70.9, 66.5, 43.6, 26.4, 22.0, 19.8. HRMS: calculated for 
[C37H41O6]+ 565.29485, found 565.29462. 47 1H NMR (400 MHz, CDCl3): δ (ppm) 7.63 – 6.95 (m, 
20H), 4.95 – 4.60 (m, 5H), 4.53 – 4.31 (m, 3H), 3.75 – 3.62 (m, 3H), 3.58 – 3.42 (m, 2H), 3.07 – 2.99 
(m, 2H), 2.41 – 2.30 (m, 1H, H-5), 1.14 (dd, J = 8.2, 4.7 Hz, 1H), 1.02 (dd, J = 8.9, 4.8 Hz, 1H), 0.97 – 
0.78 (m, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) 139.0, 138.6, 138.5, 138.2, 128.7, 128.6, 128.6, 
128.5, 128.3, 128.2, 128.1, 128.1, 128.0, 127.9, 127.9, 127.7, 127.7, 86.4, 82.3, 75.5, 75.3, 73.5, 72.5, 71.4, 




((benzyloxy)methyl)bicyclo[4.1.0]heptane-7-carboxylic acid (48) 
Chromic acid stock solution (1.0 M) was prepared (Caution: Chromic acid is 
corrosive, toxic and carcinogenic). Concentrated H2SO4 (2.25 mL, 40.5 mmol) is 
taken up in H2O (12.5 mL). To this solution was added CrO3 (2.50 g, 25.0 mmol) and the resulting 
bright red solution was stirred until all solids were completely dissolved. The solution was then 
diluted with H2O to a total volume of 25 mL. Compound 47 (261 mg, 0.462 mmol) was dissolved in 
acetone (9.2 mL) and cooled to 0 oC, after which the chromic acid stock solution (0.92 mL, 0.920 
mmol, 2 eq.) was added. After stirring for 3 h, the reaction mixture was diluted with EtOAc (150 mL) 
and washed with aqueous HCl (3 M, 2 x 150 mL) and brine (150 mL). The organic layer was dried 
over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (15% EtOAc 
in pentane → 35% EtOAc in pentane) gave carboxylic acid 48 as a white solid (141 mg, 0.244 mmol, 
53%). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.44 – 7.10 (m, 20H), 4.90 – 4.71 (m, 4H), 4.69 – 4.57 (m, 
1H), 4.54 – 4.34 (m, 3H), 3.75 (d, J = 8.1 Hz, 1H), 3.65 (dd, J = 8.9, 2.7 Hz, 1H), 3.60 – 3.51 (m, 2H), 
3.11 (t, J = 10.2 Hz, 1H), 2.45 – 2.33 (m, 1H), 2.03 – 1.98 (m, 1H), 1.80 (dd, J = 9.5, 4.5 Hz, 1H), 1.60 
(t, J = 4.6 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) 179.4, 138.9, 138.6, 138.5, 138.1, 128.7, 
128.6, 128.6, 128.5, 128.5, 128.2, 128.2, 128.1, 128.0, 127.9, 127.7, 85.8, 81.3, 76.2, 75.5, 75.4, 73.3, 72.5, 




To a solution of carboxylic acid 48 (141 mg, 0.244 mmol) in toluene (1.2 mL) was 
added ethanol (66 μL, 0.488 mmol, 2 eq.) and DMAP (catalytic amount). After 
DIC (75 μL, 0.484 mmol, 2.0 eq.) was added dropwise, the reaction mixture was stirred for 4 h at 
room temperature. The reaction mixture was filtered over Celite, concentrated in vacuo and 
purification by column chromatography (7% EtOAc in pentane → 10% EtOAc in pentane) gave title 
compound 34 as a white solid (91.4 mg, 0.151 mmol, 62%). 1H NMR (400 MHz, CDCl3: δ (ppm) 7.44 
– 7.14 (m, 20H), 4.89 – 4.72 (m, 4H), 4.64 (d, J = 11.6 Hz, 1H), 4.52 – 4.36 (m, 3H), 4.15 (d, J = 7.2 Hz, 
1H), 4.12 (d, J = 7.2), 3.75 (d, J = 7.8 Hz, 1H), 3.65 (dd, J = 8.9, 2.7 Hz, 1H), 3.61 - 3.48 (m, 2H), 3.14 
(t, J = 10.2 Hz, 1H), 2.45 – 2.29 (m, 1H), 1.96 - 1.84 (m, 1H), 1.74 (dd, J = 9.3, 4.5 Hz, 1H), 1.61 (t, J = 
4.7 Hz, 1H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ (ppm) 173.5, 138.9, 138.7, 138.6, 
138.2, 128.6, 128.5, 128.5, 128.4, 128.2, 128.1, 128.0, 128.0, 127.9, 127.8, 127.8, 127.7, 127.6, 127.5, 85.9, 
81.5, 76.3, 75.4, 75.4, 73.3, 72.4, 70.4, 60.8, 40.6, 26.4, 24.9, 22.2, 14.4. HRMS: calculated for 




Benzylated 34 (20.9 mg, 34.4 μmol) was dissolved in mixture of EtOAc (0.4 mL) 
and AcOH (0.1 mL). After addition of Pd(OH)2/C (catalytic amount), the reaction 
mixture was brought under H2 atmosphere. After stirring overnight, the palladium catalyst was 
filtered off over a pad of Celite. The filtrate was concentrated in vacuo and purification by column 
chromatography (10% MeOH in EtOAc) gave compound 4 as a clear oil (6.90 mg, 28.0 μmol, 81%). 
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1H NMR (400 MHz, D2O): δ (ppm) 4.22 - 4.09 (m, 2H), 3.94 (dd, J = 11.0, 3.9 Hz, 1H), 3.69 (d, J = 8.6 
Hz, 1H), 3.61 (dd, J = 11.0, 8.2 Hz, 1H), 3.30 (dd, J = 10.2, 8.7 Hz, 1H), 3.01 (t, J = 10.3 Hz, 1H), 2.20 – 
2.16 (m, 1H), 2.00 – 1.89 (m, 1H), 1.68 – 1.61 (m, 2H), 1.26 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, 
D2O): δ (ppm) 175.8, 77.3, 72.3, 68.1, 62.7, 62.1, 41.8, 27.4, 25.2, 21.7, 13.3. HRMS: calculated for 




Ethyl ester 34 (60.8 mg, 0.100 mmol) was added to Me(MeO)NH.HCl (12.2 mg, 
0.125 mmol, 1.25 eq.) in THF (0.5 mL). Subsequently, EtMgBr (0.5 M in THF, 
0.840 mmol, 8.4 eq.) was added over 2 h at -5 to 0 °C. After stirring overnight, the reaction mixture 
was quenched with aqueous HCl (3 M, 3 mL). The reaction mixture was extracted with EtOAc (10 
mL), after which the organic layer was dried and concentrated in vacuo. Purification by column 
chromatography (15% EtOAc in pentane) gave compound 49 as a white solid (29.4 mg, 47.9 μmol, 
48%). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.42 – 7.14 (m, 20H), 4.95 – 4.69 (m, 4H), 4.60 (d, J = 11.5 
Hz, 1H), 4.52 – 4.30 (m, 3H), 3.72 (d, J = 7.8 Hz, 1H), 3.69 – 3.46 (m, 3H), 3.26 (t, J = 10.2 Hz, 1H), 
2.38 (dd, J = 8.7, 7.4 Hz, 2H), 2.36 – 2.29 (m, 1H), 1.89 (t, J = 4.7 Hz, 1H), 1.84 – 1.82 (m, 1H), 1.82 – 
1.79 (m, 1H), 1.00 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ (ppm) 209.7, 139.0, 138.7, 138.6, 
138.2, 128.6, 128.6, 128.5, 128.5, 128.2, 128.2, 128.1, 127.9, 127.9, 127.8, 127.8, 127.7, 127.6, 86.1, 81.6, 
76.3, 75.4, 73.4, 72.2, 70.3, 40.7, 37.0, 29.8, 29.3, 26.4, 8.0. HRMS: calculated for [C39H42O5Na]+ 




Compound 49 (29.4 mg, 49.8 μmol) was treated according to General procedure for 
global debenzylation with Pd(OH)2/C to obtain title compound 5 as a clear oil (6.70 
mg, 29.1 μmol, 58%). 1H NMR (400 MHz, D2O): δ (ppm) 3.92 (dd, J = 11.2, 4.0 Hz, 1H), 3.89 (dd, J = 
0.8 Hz, 8.6 Hz, 1H), 3.60 (dd, J = 10.8, 8.2 Hz, 1H), 3.28 (dd, J = 10.1, 8.6 Hz, 1H), 3.05 (t, J = 10.0 Hz, 
1H), 2.69 (dd, J = 14.6, 7.4 Hz, 2H), 2.21 – 2.15 (m, 1H), 2.13 (t, J = 4.2 Hz, 1H), 1.93 (ddd, J = 9.7, 5.0, 
5.0, 1H), 1.67 (dd, J = 9.1, 4.3 Hz, 1H), 1.03 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, D2O): δ (ppm) 
216.2, 77.3, 72.4, 68.2, 62.7, 42.1, 36.6, 30.1, 29.2, 28.4, 7.4. HRMS: calculated for [C11H19O5]+ 




Compound 46 (25.6 mg, 45.1 μmol) was treated according to General procedure 
for global debenzylation with Pd(OH)2/C to obtain title compound 11 as a clear oil 
(8.30 mg, 40.6 μmol, 90%). 1H NMR (400 MHz, D2O): δ (ppm) 4.03 (dd, J = 8.7, 6.0 
Hz, 1H), 3.90 (dd, J = 10.9, 3.5 Hz, 1H), 3.78 (dd, J = 10.9, 6.1 Hz, 1H), 3.62 (dd, J = 11.6, 6.1 Hz, 1H), 
3.33 (dd, J = 11.5, 7.7 Hz, 1H), 3.25 (t, J = 10.1 Hz, 1H), 3.21 – 3.11 (m, 1H), 1.86 – 1.77 (m, 1H), 1.35 
(dt, J = 9.0, 5.5 Hz, 1H), 1.13 (dt, J = 11.3, 5.3 Hz, 1H), 1.05 – 0.97 (m, 1H). 13C NMR (100 MHz, D2O): 
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Compound 46 (18.0 mg, 32.0 μmol), TBAI (catalytic amount) and NaH (60%, 
2.55 mg, 2.0 eq.) were dissolved in DMF (0.3 mL) at 0 °C. After stirring for 5 min 
EtBr (21 μL, 0.287 mmol, 9.0 eq.) was added and the reaction mixture was allowed to stir at room 
temperature for 4 h. The reaction mixture was partitioned between H2O (10 mL) and EtOAc (10 mL) 
and the organic layer was washed with H2O (2x) and all the aqueous layers were extracted with EtOAc 
(1x). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (10% EtOAc in pentane → 20% EtOAc in pentane) gave title 
compound 47 as a clear oil (11.1 mg, 18.7 μmol, 59%). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.48 1 
7.11 (m, 20H), 4.91 – 4.72 (m, 4H), 4.66 (d, J = 11.7 Hz, 1H), 4.55 – 4.36 (m, 3H), 4.07 (dd, J = 8.0, 6.2 
Hz, 1H), 3.66 – 3.60 (m, 2H), 3.56 – 3.42 (m, 2H), 3.42 – 3.32 (m, 2H), 3.32 – 3.22 (m, 2H), 1.89 (dd, J 
= 6.6, 3.5 Hz, 1H), 1.34 – 1.28 (m, 1H), 1.17 (t, J = 7.0 Hz, 3H), 1.12 – 1.04 (m, 2H). 13C NMR (101 
MHz, CDCl3): δ (ppm) 139.3, 139.2, 138.9, 138.6, 128.6, 128.5, 128.5, 128.2, 128.2, 128.1, 128.0, 127.9, 
127.8, 127.7, 127.6, 127.1, 84.9, 80.2, 79.3, 75.7, 75.3, 74.1, 73.3, 71.1, 70.9, 65.8, 43.6, 23.5, 21.6, 20.4, 




Compound 47 (11.1 mg, 18.7 μmol) was treated according to General procedure 
for global debenzylation with Pd(OH)2/C to obtain title compound 12 as a clear oil 
oil (4.1 mg, 17.7 μmol, 94%). 1H NMR (400 MHz, D2O): δ (ppm) 4.00 (dd, J = 8.8, 
6.0 Hz, 1H), 3.87 (dd, J = 10.9, 3.5 Hz, 1H), 3.75 (dd, J = 10.9, 6.0 Hz, 1H), 3.65 – 3.55 (m, 3H), 3.24 – 
3.16 (m, 2H), 3.16 – 3.10 (m, 1H) 1.83 – 1.72 (m, 1H), 1.36 – 1.30(m, 1H), 1.20 (t, J = 7.1 Hz, 3H), 1.13 
– 1.05 (m, 1H), 1.08 – 0.95 (m, 1H). 13C NMR (100 MHz, D2O): δ (ppm) 79.3, 78.2, 75.8, 75.3, 70.5, 
67.3, 49.0, 27.6, 26.6, 23.4, 18.5. HRMS: calculated for [C11H21O6]+ 233.13835, found 233.13843. 
 
1,4-diazidobutane (51) 
To a solution of 1,4-dibromobutane (2.38 mL, 20.0 mmol) in DMF (20 mL) was 
added a solution of NaN3 (2.73 g, 42.0 mmol, 2.1 eq.) in H2O (10 mL). After stirring overnight at 80 
°C, the reaction mixture was cooled down to room temperature and diluted with brine (40 mL) and 
hexanes (40 mL). The organic layer was separated and the aqueous layer was extracted with hexane (2 
x 40 mL). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo to 




1,4-Diazidobutane (2.72 g, 19.4 mmol) 51 was dissolved in mixture of Et2O (12 mL), 
EtOAc (12 mL) and aqueous HCl (1 M, 40 mL). Triphenylphosphine (5.09 g, 19.4 mmol, 1.00 eq.) was 
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added portion wise over 1 h at 0 °C. The aqueous layer was separated and then washed with Et2O (2 x 
40 mL). The pH of the aqueous layer was adjusted to pH 13 with aqueous NaOH (2 M). After 
extraction with DCM (3 x 60 mL), the combined organic layers were dried over MgSO4, filtered and 
concentrated in vacuo to give title compound as a clear oil 52 (1.70 g, 14.9 mmol, 77%). Analytical 





carboxamide (53) and (1S,2S,3R,4R,5R,6S,7S)-
N-(4-azidobutyl)-2,3,4-tris(benzyloxy)-5-((benzyloxy)methyl)bicyclo[4.1.0]heptane-7-
carboxamide (54)  
To a mixture of 33 and 34 (0.142 g, 0.234 mmol) in THF (8 mL), was added MeOH (2 mL), H2O (1 
mL) and LiOH (22.4 mg, 0.94 mmol, 4 eq.). After stirring overnight at room temperature, 1 M 
aqueous HCl solution was used to acidify the reaction mixture to pH 2. The reaction mixture was 
diluted with EtOAc (20 mL) and washed with brine (10 mL). The aqueous layer was extracted with 
EtOAc (10 mL) and the combined organic layers were dried over MgSO4, filtered and concentrated in 
vacuo. Purification by column chromatography (30% EtOAc in pentane) gave the carboxylic acid 
derivatives as a mixture of alpha- and beta-isomers (119 mg, 0.206 mmol, 82%) as a clear oil. The 
carboxylic acid derivatives (0.346 g, 0.600 mmol) were dissolved in DCM (6.0 mL) and 4-azidobutan-
1-amine 52 (82.2 mg, 0.720 mmol, 1.2 eq.) was added. After addition of DIPEA (364 μL, 2.10 mmol, 
3.5 eq.) and HCTU (298 mg, 0.720 mmol, 1.2 eq.), the reaction mixture was stirred overnight at room 
temperature. The reaction mixture was concentrated in vacuo, dissolved in EtOAc (40 mL) and 
subsequently washed with aqueous HCl (1 M, 2 x 40 mL), saturated aqueous NaHCO3 (40 mL) and 
brine (2 x 40 mL), dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (30% EtOAc in pentane) gave the desired product as alpha- and beta-isomers (0.341 
g, 0.505 mmol, 78%) as a white solid, which were separated by HPLC purification (C18, linear 
gradient: 50-90% B in A, solutions used A: H2O, B: acetonitrile, 0.5% TFA, 15 min). 53 1H NMR (400 
MHz, CDCl3): δ (ppm) 7.38 – 7.10 (m, 20H), 5.66 (t, J = 5.8 Hz, 1H), 4.90 – 4.69 (m, 4H), 4.61 (d, J = 
11.6 Hz, 1H), 4.53 – 4.32 (m, 3H), 4.10 (dd, J = 8.2, 5.9 Hz, 1H), 3.59 (qd, J = 8.8, 3.8 Hz, 2H), 3.42 (t, J 
= 10.1 Hz, 1H), 3.30 (t, J = 6.1 Hz, 4H), 3.26 – 3.20 (m, 1H), 2.04 (dt, J = 10.0, 5.2 Hz, 1H), 1.94 – 1.85 
(m, 1H), 1.82 (ddd, J = 9.2, 4.4, 2.2 Hz, 1H), 1.65 – 1.57 (m, 4H), 1.35 (t, J = 4.5 Hz, 1H). 13C NMR 
(100 MHz, CDCl3): δ (ppm) 172.1, 139.1, 138.6, 128.6, 128.6, 128.6, 128.5, 128.3, 128.1, 128.0, 127.9, 
127.9, 127.7, 84.4, 79.4, 78.8, 75.7, 75.5, 73.5, 71.6, 70.5, 51.3, 43.4, 39.4, 27.3, 27.1, 26.5, 25.7, 23.8. 
HRMS: calculated for [C41H47N4O5]+ 675.35410, found 675.35411. 54 1H NMR (400 MHz, CDCl3): δ 
(ppm) 7.45 – 7.12 (m, 20H), 5.22 (t, J = 5.8 Hz, 1H), 4.87 (d, J = 12.3 Hz, 2H), 4.83 – 4.74 (m, 2H), 
4.60 (d, J = 11.5 Hz, 1H), 4.50 (d, J = 11.0 Hz, 1H), 4.37 (d, J = 2.4 Hz, 2H), 3.83 (dd, J = 9.1, 3.6 Hz, 
1H), 3.75 (d, J = 7.6 Hz, 1H), 3.66 – 3.52 (m, 2H), 3.34 (t, J = 10.2 Hz, 1H), 3.23 (t, J = 6.7 Hz, 2H), 
3.19 – 3.10 (m, 1H), 3.10 – 3.00 (m, 1H), 2.29 – 2.24 (m, 1H), 1.79 (dd, J = 9. 1, 4.8 Hz, 1H), 1.70 – 
1.63 (m, 1H), 1.55 – 1.44 (m, 2H), 1.43 – 1.30 (m, 3H). 13C NMR (100 MHz, CDCl3): δ (ppm) 172.1, 
139.0, 139.0, 138.7, 138.3, 128.7, 128.6, 128.5, 128.3, 128.1, 128.1, 127.9, 127.9, 127.8, 127.7, 127.4, 86.3, 
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81.6, 75.9, 75.4, 75.4, 73.2, 71.9, 70.3, 51.2, 40.5, 39.2, 27.1, 26.3  25.2, 24.5, 21.5. HRMS: calculated for 




To a cooled (-78 °C) solution of benzylated 53 (12.7 mg, 18.8 μmol) in DCM 
(0.2 mL) was added slowly BCl3 (1 M in DCM, 0.400 mL, 0.40 mmol, 20 eq.). 
After stirring for 5 h at -78 °C, the reaction was quenched with MeOH (5 mL) and allowed to warm to 
room temperature overnight. Concentration in vacuo, co-evaporation with toluene (3x) and 
purification by column chromatography (20% MeOH in DCM) gave compound 9 as a white solid 
(5.20 mg, 16.5 μmol, 88%). 1H NMR (400 MHz, MeOD): δ (ppm) 3.81 (dd, J = 8.7, 5.7 Hz, 1H), 3.72 
(dd, J = 10.6, 3.9 Hz, 1H), 3.55 (dd, J = 10.5, 6.5 Hz, 1H), 3.34 – 3.30 (m, 2H), 3.09 (t, J = 6.6 Hz, 2H), 
3.03 (t, J = 10.1 Hz, 1H), 2.97 – 2.85 (m, 1H), 1.85 – 1.80 (m, 1H), 1.74 – 1.70 (m, 1H), 1.63 – 1.54 (m, 
5H), 1.53 – 1.49 (m, 1H). ). 13C NMR (100 MHz, MeOD): δ (ppm) 174.8, 76.5, 72.6, 72.2, 64.7, 52.2, 





To a cooled (-78 °C) solution of benzylated 54 (12.7 mg, 18.8 μmol) in DCM 
(0.2 mL) was added slowly BCl3 (1 M in DCM, 0.400 mL, 0.40 mmol, 20 eq.). 
After stirring for 3 h at -78 °C, additional BCl3 (1 M in DCM, 0.400 mL, 0.376 mmol, 20 eq.) was 
added. After stirring overnight at -20 °C, the reaction was quenched with MeOH (5 mL) and allowed 
to warm to room temperature. Concentration in vacuo, co-evaporation with MeOH (3 x) and 
purification by column chromatography (20% MeOH in DCM) gave compound 6 as a slightly yellow 
solid (5.9 mg, 18.6 μmol, 99%). 1H NMR (400 MHz, MeOD): δ (ppm) 3.80 (d, J = 6.3 Hz, 1H), 3.53 – 
3.44 (m, 2H), 3.17 – 3.01 (m, 3H), 2.83 (t, J = 9.7 Hz, 1H), 2.07 – 1.90 (m, 1H), 1.76 – 1.61 (m, 1H), 
1.54 – 1.44 (m, 4H), 1.44 – 1.38 (m, 1H), 1.34 – 1.28 (m, 1H). 13C NMR (100 MHz, MeOD): δ (ppm) 
79.6, 74.5, 70.7, 65.1, 52.3, 43.8, 40.2, 27.9, 27.9, 27.5, 25.0, 24.5. HRMS: calculated for [C13H22N4O5]+ 




To a solution of DCM (0.5 mL) and 1,2-dimethoxyethane (100 μL) was added 
consecutively boron trifluoride ethyl etherate (62 μL) and diethylzinc (1 M in hexane, 
1.0 mL, 1.0 mmol) at room temperature. After stirring for 5 min, diiodomethane (161 μL, 2.0 mmol) 
was added and the reaction mixture was stirred for additional 5 min. Compound 55 (52.0 mg, 0.100 
mmol) was dissolved in DCM (1.0 mL) and added dropwise to the reaction mixture. After stirring 
overnight, the reaction mixture was quenched with a saturated aqueous NH4Cl solution and diluted 
with EtOAc. The aqueous layer was extracted with EtOAc (3x) and the combined organic layers were 
washed with brine, dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (pentane → 8% EtOAc in pentane) gave benzylated cyclopropane 56 (45.1 mg, 84.3 
Synthesis of carba-cyclophellitols: a new class of cyclophellitol derivatives 
97 
μmol, 84%) as a clear oil. 1H NMR (400 MHz, CDCl3): δ (ppm) 7.47 – 7.21 (m, 20H), 4.86 (dd, J = 
27.0, 11.7 Hz, 2H), 4.76 – 4.62 (m, 3H), 4.58 (d, J = 11.7 Hz, 1H), 4.47 (d, J = 4.4 Hz, 2H), 4.39 (dd, J = 
8.4, 6.6 Hz, 1H), 3.90 (s, 1H), 3.66 – 3.52 (m, 2H), 3.19 (dd, J = 8.4, 1.1 Hz, 1H), 1.90 – 1.85 (m, 1H), 
1.55 – 1.40 (m, 1H), 0.84 – 0.69 (m, 2H), 0.30 (q, J = 5.2 Hz, 1H). 13C NMR (101 MHz, CDCl3): δ 
(ppm) 139.4, 139.4, 139.2, 138.4, 128.5, 128.4, 128.4, 128.3, 128.1, 128.0, 127.9, 127.8, 127.5, 127.5, 
127.4, 83.3, 76.8, 76.3, 74.0, 73.3, 72.8, 71.3, 42.4, 16.3, 14.0, 11.5. HRMS: calculated for [C36H39O4]+ 
557.26623, found 557.26551. 
 
(1S,2S,3R,4S,5R,6R)-5-(hydroxymethyl)bicyclo[4.1.0]heptane-2,3,4-triol (21) 
Compound 56 (40.0 mg, 74.8 μmol) was treated according to General procedure for 
global debenzylation with Pd(OH)2/C to obtain title compound 21 as a clear oil (13.0 
mg, 74.7 μmol, 99%). 1H NMR (400 MHz, D2O): δ (ppm) 4.20 (dd, J = 9.0, 6.6 Hz, 1H), 
3.80 (s, 1H), 3.76 – 3.62 (m, 2H), 3.17 (dd, J = 9.1, 1.7 Hz, 1H), 1.83 – 1.78 (m, 1H), 1.42 – 1.32 (m, 
1H), 0.82 – 0.75 (m, 2H), 0.25 – 0.18 (m, 1H). 13C NMR (101 MHz, D2O): δ (ppm) 73.6, 71.8, 69.4, 








A 2-necked pear flask was charged with cyclic alkene 55 (0.52 g, 1.0 mmol), Cu(acac)2 (26 mg, 0.1 
mol, 0.1 eq.) and EtOAc (2.2 mL, dried over activated 4 Å molsieves overnight). After stirring under 
reflux at 90 °C a solution of ethyl diazoacetate (13 wt% DCM, 1.5 mmol, 0.18 mL, 1.5 eq.) in EtOAc 
(3.1 mL) was added by syringe pump over 6 h. The reaction was concentrated in vacuo and 
purification by column chromatography (50 cv of 5% EtOAc in pentane) gave the desired products 57 
(65 mg, 0.107 μmol, 10%), 58 (23 mg, 0.038 μmol, 3.5%) and crude recovered starting material 55 
(~80%). 57 1H NMR (400 MHz, CDCl3): δ (ppm) 7.34 – 7.23 (m, 20H), 4.88 (d, J = 11.6 Hz, 1H), 4.81 
– 4.60 (m, 4H), 4.56 (d, J = 11.6 Hz, 1H), 4.50 – 4.40 (m, 2H), 4.37 (dd, J = 8.2, 6.4 Hz, 1H), 4.14 – 4.08 
(m, 2H), 3.91 (s, 1H), 3.64 (t, J = 9.0 Hz, 1H), 3.56 (dd, J = 8.6, 6.3 Hz, 1H), 3.15 (d, J = 8.2 Hz, 1H), 
2.13 – 2. 04 (m, 1H), 1.99 – 1.93 (m, 1H), 1.62 – 1.58 (m, 1H), 1.40 – 1.34 (m, 1H), 1.28 – 1.25 (m, 
3H). 13C NMR (101 MHz, CDCl3): δ (ppm) 173.5, 139.2, 139.0, 139.0, 138.2, 128.6, 128.4, 128.3, 128.0, 
128.0, 127.9, 127.6, 127.5, 82.9, 76.2, 75.7, 74.1, 73.4, 73.0, 71.6, 70.5, 60.7, 41.4, 27.1, 26.0, 24.5, 14.4. 
HRMS: calculated for [C39H43O6]+ 607.30542, found 607.30560. 58 1H NMR (400 MHz, CDCl3): δ 
(ppm) 7.40 – 7.24 (m, 20H), 4.87 (d, J = 11.6 Hz, 1H) 4.78 – 4.65 (m, 4H), 4.53 – 4.40 (m, 3H), 4.14 – 
4.08 (m, 2H), 4.08 – 4.02 (m, 1H), 4.00 (d, J = 8.8 Hz, 1H), 3.66 – 3.58 (m, 1H), 3.57 –  3.51 (m, 1H), 
3.47 (dd, J = 8.8, 1.7 Hz, 1H), 2.47 – 2.38 (m, 1H), 2.09 (t, J = 4.6 Hz, 1H), 1.72 (dd, J = 9.4, 4.4 Hz, 
1H), 1.59 – 1.52 (m, 1H), 1.22 (s, 3H). 13C NMR (101 MHz, CDCl3): δ (ppm) 174.0, 139.2, 138.9, 
138.6, 138.3, 128.6, 128.5, 128.4, 128.3, 128.0, 127.8, 127.8, 127.7, 127.6, 127.6, 127.6, 127.4, 84.3, 77.7, 
74.9, 74.8, 73.4, 72.9, 72.7, 70.4, 60.7, 38.4, 26.1, 23.1, 22.6, 14.4. HRMS: calculated for [C39H43O6]+ 





Ester 58 (20 mg, 33 μmol) was treated according to the General procedure for 
global debenzylation with 10% Pd on carbon. Purification by column 
chromatography (acetone → 1% MeOH in acetone) gave β-debenzylated ester 13 (1.1 mg, 4.5 μmol, 
14%) as a clear oil. 1H NMR (400 MHz, D2O): δ (ppm) 4.17 – 4.07 (m, 2H), 4.01 – 3.97 (m, 1H), 3.88 
(d, J = 9.1 Hz, 1H), 3.78 – 3.65 (m, 2H), 3.43 (dd, J = 9.0, 2.3 Hz, 1H), 2.38 – 2.30 (m, 1H), 2.02 (t, J = 
4.7 Hz, 1H), 1.74 – 1.67 (m, 1H), 1.66 – 1.60 (m, 1H), 1.24 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, 
D2O): δ (ppm) 176.5, 75.5, 69.0, 68.7, 62.0, 61.9, 38.6, 27.7, 23.3, 22.7, 13.3. HRMS: calculated for 





Benzylated ester 57 (115 mg, 190 μmol) was dissolved in EtOAc (2 mL) and AcOH 
(0.4 mL) was added. The reaction mixture was purged with argon gas and 
Pd(OH)2/C (20 mg) was added. After the reaction vessel was purged with hydrogen gas and 
vigorously stirring overnight, the palladium catalyst was filtered off over a pad of Celite followed by 
concentration in vacuo. Purification by column chromatography (acetone → 2% MeOH in acetone) 
gave compound 18 (4.2 mg, 17.0 μmol, 9%) as a clear oil. 1H NMR (400 MHz, D2O): δ (ppm) 4.25 (dd, 
J = 9.1, 6.3 Hz, 1H), 4.17 – 4.10 (m, 2H), 3.86 (s, 1H), 3.78 – 3.66 (m, 2H), 3.22 (dd, J = 9.1, 1.8 Hz, 
1H), 2.09 – 2.02 (m, 1H), 2.01 – 1.93 (m, 1H), 1.70 (t, J = 4.6 Hz, 1H), 1.47 – 1.40 (m, 1H), 1.24 (t, J = 
7.2 Hz, 3H). 13C NMR (101 MHz, D2O): δ (ppm) 175.7, 73.3, 71.1, 67.7, 62.2, 62.0, 42.2, 28.8, 25.5, 







A mixture of 57 and 58 (0.254 g, 0.420 mmol) was dissolved in DCM (2.1 mL) at 0 °C, after which 
DIBAL (1 M in hexanes, 1.05 mmol, 2.5 eq.) was added dropwise. After the mixture was stirred for 1 h 
at 0 °C the reaction was quenched with EtOAc, diluted with DCM and washed with 1 M aqueous HCl. 
The layers were separated and the aqueous layer was extracted three times with DCM. The combined 
organic layers were washed with saturated aqueous NaHCO3 and brine, dried over MgSO4, filtered 
and concentrated in vacuo. Purification by column chromatography (pentane → 30% EtOAc in 
pentane) yielded compound 59 94.5 mg, 0.167 mmol, 40%) and compound 60 (85.7 mg, 0.152 mmol, 
36%) as yellow oils. 59 1H NMR (400 MHz, CDCl3): δ (ppm) 7.42 – 7.21 (m, 20H), 4.88 (d, J = 11.6 
Hz, 1H), 4.78 (d, J = 11.6 Hz, 1H), 4.73 – 4.64 (m, 3H), 4.57 (d, 11.6 Hz, 1H), 4.52 – 4.40 (m, 2H), 4.35 
(t, J = 8.0 Hz, 1H), 3.89 (s, 1H), 3.65 – 3.51 (m, 2H), 3.44 (dd, J = 11.2, 6.7 Hz, 1H), 3.35 (dd, J = 11.2, 
6.8 Hz, 1H), 3.17 (d, J = 8.3 Hz, 1H), 1.93 – 1.79 (m, 1H), 1.36 – 1.30 (m, 1H) 1.07 – 0.99 (m, 1H), 0.72 
– 0.63 (m, 1H). 13C NMR (101 MHz, CDCl3):  δ (ppm) 139.3, 139.3, 139.0, 138.3, 128.5, 128.5, 128.4, 
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128.3, 128.1, 128.0, 127.9, 127.8, 127.6, 127.5, 127.5, 83.6, 76.9, 76.1, 74.0, 73.3, 72.9, 71.7, 71.1, 66.6, 
41.8, 27.4, 22.1, 19.5. HRMS: calculated for [C37H41O5]+ 565.29485, found 565.29480. 60 1H NMR (400 
MHz, CDCl3): δ (ppm) 7.41 – 7.20 (m, 20H), 4.85 (d, J = 11.6 Hz, 1H), 4.78 – 4.67 (m, 4H), 4.53 – 4.41 
(m, 3H), 4.01 – 3.92 (m, 2H), 3.64 – 3.52 (m, 2H), 3.50 – 3.41 (m, 2H), 3.16 (dd, J = 11.1, 7.7 Hz, 1H), 
2.47 – 2.38 (m, 1H), 1.51 – 1.48 (m, 1H), 1.01 – 0.95 (m, 1H), 0.86 – 0.79 (m, 1H). 13C NMR (101 
MHz, CDCl3): δ (ppm) 139.3, 139.1, 139.0, 138.4, 128.6, 128.5, 128.4, 128.3, 128.0, 127.9, 127.8, 127.7, 
127.6, 127.6, 127.5, 127.4, 84.4, 78.2, 75.4, 74.7, 73.5, 72.8, 72.8, 71.0, 67.0, 37.9, 23.2, 21.5, 18.3. 




Alcohol 59 (30.0 mg, 53 μmol) was treated according to General procedure for 
global debenzylation with 10% Pd on carbon to obtain the title compound 22 (10.9 
mg, 53 μmol, quant.) as a clear oil. 1H NMR (400 MHz, D2O): δ (ppm) 4.20 (dd, J = 9.1, 6.6 Hz, 1H), 
3.85 – 3.82 (m, 1H), 3.78 – 3.66 (m, 2H), 3.58 (dd, J = 11.6, 6.1 Hz, 1H), 3.27 (dd, J = 11.6, 7.8 Hz, 1H), 
3.20 (dd, J = 9.1, 1.8 Hz, 1H), 1.90 – 1.82 (m, 1H), 1.36 – 1.29 (m, 1H), 1.05 – 0.97 (m, 1H), 0.77 – 0.70 
(m, 1H). 13C NMR (101 MHz, D2O): δ (ppm) 74.0, 71.6, 68.6, 65.3, 62.7, 42.7, 25.8, 23.2, 18.3. HRMS: 




To a solution of alcohol 59 (33.9 mg, 60.0 μmol) and TBAI (10 mg) in DMF (0.8 
mL) was added NaH (60% dispersion in mineral oil, 19.2 mg, 0.480 mmol 8 eq.) 
at 0 °C. After stirring the reaction mixture for 5 min, EtBr (20 μL, 0.36 mmol, 6 eq.) was added and 
the reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched 
with H2O (3 mL) and diluted with EtOAc (20 mL). The organic layer was separated and washed with 
saturated aqueous NaHCO3, H2O (3x) and brine. The combined aqueous layers were extracted with 
EtOAc and the combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (pentane → 20% EtOAc in pentane) gave ether 61 as a yellow 
oil (28.5 mg, 48.1 μmol, 80%).  1H NMR (400 MHz, CDCl3): δ (ppm) 7.43 – 7.21 (m, 20H), 4.88 (d, J = 
11.6 Hz, 1H), 4.83 (d, J = 11.6 Hz, 1H), 4.77 – 4.61 (m, 3H), 4.58 (d, J = 11.7 Hz, 1H), 4.52 – 4.40 (m, 
2H), 4.39 – 4.33 (m, 1H), 3.90 (s, 1H), 3.68 – 3.53 (m, 2H), 3.52 – 3.37 (m, 2H), 3.35 – 3.22 (m, 2H), 
3.18 (d, J = 8.3 Hz, 1H), 1.97 – 1.87 (m, 1H), 1.41 – 1.35 (m, 1H), 1.15 (t, J = 7.0 Hz, 3H), 1.04 (p, J = 
6.2 Hz, 1H), 0.70 – 0.64 (m, 1H). 13C NMR (101 MHz, CDCl3): δ (ppm) 139.5, 139.4, 139.2, 138.4, 
128.5, 128.4, 128.3, 128.3, 128.1, 127.9, 127.8, 127.5, 127.5, 127.4, 83.6, 76.9, 76.2, 74.2, 74.0, 73.3, 72.9, 





Ether 61 (20 mg, 34 μmol) was treated according to General procedure for global 
debenzylation with 10% Pd on carbon to obtain the title compound 23 (8.0 mg, 35 
Chapter 6 
100 
μmol, quant.) as a clear oil. 1H NMR (400 MHz, D2O): δ (ppm) 4.22 – 4.18 (dd, J = 6.4, 9.2 Hz, 1H), 
3.83 (s, 1H), 3.75 – 3.67 (m, 2H), 3.63 – 3.51 (m, 3H), 3.23 – 3.13 (m, 2H), 1.91 – 1.83 (m, 1H), 1.38 – 
1.28 (m, 1H), 1.17 (t, J = 7.1 Hz, 3H), 1.05 – 0.96 (m, 1H), 0.80 – 0.73 (m, 1H). 13C NMR (101 MHz, 
D2O): δ (ppm) 73.9, 73.8, 71.5, 68.6, 66.1, 62.6, 42.6, 23.3, 23.2, 18.7, 14.1. HRMS: calculated for 




Alcohol 60 (35 mg, 62 μmol) was treated according to General procedure for 
global debenzylation with 10% Pd on carbon to obtain the title compound 16 (11.2 
mg, 54 μmol, 87%) as a clear oil. 1H NMR (400 MHz, D2O): δ (ppm) 4.01 – 3.95 (m, 1H), 3.83 (d, J = 8 
Hz 1H), 3.78 – 3.64 (m, 2H), 3.41 – 3.31 (m, 3H), 2.29 – 2.20 (m, 1H), 1.31 – 1.21 (m, 1H), 1.02 – 0.92 
(m, 1H), 0.92 – 0.84 (m, 1H). 13C NMR (101 MHz, D2O): δ (ppm) 76.0, 69.6, 69.5, 65.6, 62.4, 38.8, 




To a solution of alcohol 60 (38.0 mg, 67.3 μmol) and a catalytic amount of TBAI 
in DMF (0.8 mL) was added NaH (60% dispersion in mineral oil, 21.4 mg, 0.536 
mmol 8 eq.) at 0 °C. After stirring the reaction mixture for 5 min, EtBr (50 μL, 0.66 mmol, 10 eq.) was 
added and the reaction mixture was stirred overnight. The reaction mixture was quenched with H2O 
(3 mL) and diluted with EtOAc (20 mL). The organic layer was separated and washed with saturated 
aqueous NaHCO3, H2O (3x) and brine. The combined aqueous layers were extracted with EtOAc and 
the combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. Purification 
by column chromatography (pentane → 20% EtOAc in pentane) gave ether 62 as a yellow oil (29.6 mg, 
50.0 μmol, 74%). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.40 – 7.22 (m, 20H), 4.87 (d, J = 11.6 Hz, 1H), 
4.80 – 4.67 (m, 4H), 4.49 – 4.44 (m, 3H), 4.03 (dd, J = 3.8, 1.7 Hz, 1H), 3.99 (d, J = 8.7 Hz, 1H), 3.68 – 
3.61 (m, 1H), 3.59 – 3.50 (m, 1H), 3.47 – 3.40 (m, 3H), 3.20 (d, J = 6.8 Hz, 2H), 2.40 – 2.37 (m, 1H), 
1.51 – 1.43 (m, 1H), 1.17 (t, J = 7.0 Hz, 3H), 0.99 (dd, J = 8.9, 4.4 Hz, 1H), 0.85 – 0.77 (m, 1H). 13C 
NMR (101 MHz, CDCl3): δ (ppm) 139.5, 139.2, 139.0, 138.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 
128.1, 127.9, 127.9, 127.7, 127.6, 127.5, 127.5, 127.5, 127.4, 127.3, 84.8, 78.3, 75.4, 74.8, 74.4, 73.5, 72.7, 





Ether 62 (23.0 mg, 39 μmol) was treated according to General procedure for global 
debenzylation with 10% Pd on carbon to obtain the title compound 17 (9.0 mg, 39 
μmol, quant.) as a clear oil. 1H NMR (400 MHz, D2O): δ (ppm) 4.02 – 3.95 (m, 
1H), 3.84 (d, J = 8.9 Hz, 1H), 3.75 – 3.67 (m, 2H), 3.62 – 3.52 (m, 2H), 3.42 – 3.33 (m, 2H), 3.29 – 3.22 
(m, 1H), 2.31 – 2.21 (m, 1H), 1.32 – 1.26 (m, 1H), 1.18 (t, J = 7.1 Hz, 3H), 1.02 – 0.96 (m, 1H), 0.93 – 
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0.86 (m, 1H). 13C NMR (101 MHz, D2O): δ (ppm) 75.9, 74.2, 69.5, 69.4, 65.9, 62.3, 38.9, 22.3, 20.1, 




one (63) and (1S,2S,3R,4S,5R,6S,7S)-1-(2,3,4-
tris(benzyloxy)-5-((benzyloxy)methyl)bicyclo[4.1.0]heptan-
7-yl)propan-1-one (64) 
To a mixture of 57 and 58 (126 mg, 0.207 mmol) in THF (2.7 mL) was added Me(MeO)NH.HCl (26.3 
mg, 0.270 mmol, 1.3 eq.) at -8 oC. Subsequently, EtMgBr (1 M in THF, 1.7 mL, 1.7 mmol, 8.4 eq.) was 
added over 2 h. After the mixture had stirred overnight, it was quenched with NaOH (0.5 M). The 
reaction mixture was extracted with EtOAc (10 mL), after which the organic layer was washed with 
aqueous HCl (3 M). The organic layer was dried over MgSO4, filtered, concentrated in vacuo and co-
evaporated with toluene (3x). The residue was dissolved in THF (1 mL) and EtMgBr (1 M in THF, 
0.60 mmol, 3 eq.) was added over 2 min at -20 oC. After the reaction was allowed to come to room 
temperature and stirred for 3 h, the reaction was quenched with a saturated aqueous NH4Cl solution. 
After extraction with EtOAc (10 mL), the organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography (8% EtOAc in pentane → 10% EtOAc 
in pentane) followed by purification by HPLC (C18, linear gradient: 50-90% B in A, solutions used A: 
H2O, B: acetonitrile, 0.1% TFA, 15 min) gave compound 63 (19.4 mg, 32.8 μmol, 16%) and 
compound 64 (25.2 mg, 42.6 μmol, 21%). 63 1H NMR (400 MHz, CDCl3): δ (ppm) 7.39 – 7.22 (m, 20 
H), 4.88 (d, J = 11.6 Hz, 1H), 4.76 – 4.52 (m, 5H), 4.44 (d, J = 3.1 Hz, 2H), 4.35 (dd, J = 8.3, 6.3 Hz, 
1H), 3.92 (s, 1H), 3.63 (t, J = 9.0 Hz, 1H), 3.57  – 3.50 (m, 1H), 3.19 (d, J = 7.6 Hz, 1H), 2.56 (d, J = 8.0 
Hz, 1H), 2.52 (d, J = 8.0 Hz, 1H), 2.14 – 2.07 (m, 1H), 1.98 – 1.87 (m, 2H), 1.48 – 1.39 (m, 1H), 1.06 (t, 
J = 7.3 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ (ppm) 209.8, 139.2, 139.0, 138.9, 138.2, 128.6, 128.5, 
128.4, 128.3, 128.0, 127.9, 127.9, 127.9, 127.7, 127.5, 127.5, 83.2, 76.5, 75.6, 74.1, 73.5, 72.9, 71.6, 70.6, 
41.7, 37.1, 33.7, 29.9, 26.6, 8.1. HRMS: calculated for [C39H43O5]+ 591.31050, found 591.31043. 64 1H 
NMR (400 MHz, CDCl3): δ (ppm) 7.39 – 7.22 (m, 20H), 4.90 (d, J = 11.6 Hz, 1H), 4.80 – 4.60 (m, 4H), 
4.53 – 4.38 (m, 3H), 4.07 – 4.01 (m, 1H), 3.96 (d, J = 8.7 Hz, 1H), 3.58 (t, J = 8.8 Hz, 1H), 3.54 – 3.44 
(m, 2H), 2.50 – 2.39 (m, 3H), 1.78 (dd, J = 9.2, 4.4 Hz, 1H), 1.60 – 1.5 (m, 1H), 1.03 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ (ppm) 210.4, 139.4, 138.9, 138.5, 138.3, 128.6, 128.5, 128.4, 128.4, 
128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 84.2, 77.9, 75.1, 74.9, 73.5, 72.9, 72.5, 70.4, 38.5, 37.1, 




Ethyl ketone 63 (14.8 mg, 25 μmol) was treated according to General procedure 
for global debenzylation with 10% Pd on carbon to obtain the title compound 19 
(4.6 mg, 20 μmol, 80%) as a white solid. 1H NMR (400 MHz, D2O): δ (ppm) 4.26 
(dd, J = 9.0, 6.1 Hz, 1H), 3.89 (s, 1H), 3.81 – 3.65 (m, 2H), 3.29 (dd, J = 9.1, 1.6 Hz, 1H), 2.74 (d, J = 8.0 
Hz, 1H), 2.70 (d, J = 8.0 Hz, 1H), 2.18 (t, J = 4.6 Hz, 1H), 2.11 – 2.04 (m, 1H), 2.03 – 1.96 (m, 1H), 1.50 
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– 1.42 (m, 1H), 1.04 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, D2O): δ (ppm) 216.2, 73.4, 71.1, 68.0, 




Ethyl ketone 64 (12.0 mg, 20 μmol) was treated according to General procedure 
for global debenzylation with 10% Pd on carbon to obtain the title compound 14 
(4.0 mg, 18 μmol, 88%) as a white solid. 1H NMR (400 MHz, D2O): δ (ppm) 3.93 (t, J = 2.8 Hz, 1H), 
3.81 (d, J = 9.2 Hz, 1H), 3.72 – 3.55 (m, 2H), 3.36 (dd, J = 9.0, 2.3 Hz, 1H), 2.64 – 2.54 (m, 2H), 2.37 (t, 
J = 4.6 Hz, 1H), 2.30 – 2.21 (m, 1H), 1.66 – 1.56 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, 
D2O): δ (ppm) 217.1, 75.4, 69.0, 68.8, 62.0, 38.8, 36.5, 30.4, 26.6, 7.6. HRMS: calculated for [C11H19O5]+ 







To a mixture of 57 and 58 (0.260 g, 0.428 mmol) in THF (16 mL), EtOH (4 mL), H2O (3 mL) and 
MeOH (0.5 mL), was added LiOH (150 mg, 6.3 mmol, 14.7 eq.). After the mixture was stirred 
overnight at room temperature, 1 M aqueous HCl solution was used to acidify to pH 1, and the 
reaction mixture was partitioned between EtOAc (125 mL) and brine (30 mL). The aqueous layer was 
extracted with EtOAc (50 mL) and the combined organic layers were dried over MgSO4, filtered and 
concentrated in vacuo, resulting in a yellow oil. The crude acid was used without further purification. 
HRMS: calculated for [C37H39O6]+ 579.27412, found 579.27384. The crude acid was dissolved in DCM 
(7.6 mL) to this were added 4-azidobutan-1-amine 52 (52 mg, 0.456 mmol, 1.1 eq.), N,N-
diisopropylethylamine (230 μL, 1.33 mmol, 3.1 eq.) and HCTU (188 mg, 0.456 mmol, 1.1 eq.). After 
stirring overnight at room temperature, the reaction mixture was concentrated in vacuo, redissolved 
in EtOAc (40 mL), washed with 1 M aqueous HCl and saturated aqueous NaHCO3, dried over 
MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (pentane → 30% 
EtOAc in pentane) followed by purification by HPLC (C18, linear gradient: 70-90% B in A, , solutions 
used A: H2O, B: acetonitrile, 0.1% TFA, 15 min) afforded compound 65 (68.9 mg, 0.102 mmol, 24%) 
and compound 66 (51.0 mg, 75.6 μmol, 18%) as white solids. 65 1H NMR (400 MHz, CDCl3): δ (ppm) 
7.39 – 7.21 (m, 20H), 5.70 – 5.63 (m, 1H), 4.88 (d, J = 11.6 Hz, 1H), 4.75 – 4.55 (m, 5H), 4.44 (d, J = 
2.7 Hz, 2H), 4.39 (dd, J = 8.3, 6.5 Hz, 1H), 3.93 (s, 1H), 3.66 (t, J = 8Hz, 1H), 3.58 – 3.54 (m, 1H), 3.31 
–3.22 (m, 4H), 3.13 (d, J = 8.4 Hz, 1H), 2.15 – 2.05 (m, 1H), 1.93 – 1.85 (m, 1H), 1.64 – 1.48 (m, 4H), 
1.45 – 1.36 (m, 1H), 1.31 – 1.23 (m, 1H). 13C NMR (101 MHz, CDCl3): δ (ppm) 172.1, 139.2, 138.9, 
138.8, 138.2, 128.5, 128.4, 128.4, 128.3, 128.1, 127.9, 127.9, 127.7, 127.5, 127.5, 83.1, 76.4, 75.5, 74.1, 
73.5, 72.7, 71.5, 70.6, 51.1, 41.6, 39.2, 28.1, 27.2, 26.3, 26.0, 23.0. HRMS: calculated for [C41H47N4O5]+ 
675.35410, found 675.35401. 66 1H NMR (400 MHz, CDCl3): δ (ppm) 7.40 – 7.24 (m, 20H), 5.56 (t, J 
= 5.6 Hz, 1H), 4.86 (d, J = 11.2 Hz, 1H), 4.81 – 4.61 (m, 4H), 4.54 – 4.42 (m, 3H), 4.06 – 4.05 (m, 1H), 
3.96 (d, J = 14.8 Hz, 1H), 3.60 (t, J = 9.0 Hz, 1H), 3.56 – 3.52 (m, 1H), 3.49 (dd, J = 8.7, 1.6 Hz, 1H), 
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3.31 – 3.16 (m, 4H), 2.51 – 2.42 (m, 1H), 1.77 – 1.72 (m, 2H), 1.60 – 1.51 (m, 5H). 13C NMR (101 
MHz, CDCl3): δ (ppm) 172.8, 139.4, 138.9, 138.6, 138.3, 128.5, 128.4, 128.4, 128.4, 128.0, 128.0, 127.9, 
127.9, 127.8, 127.8, 127.6, 127.5, 84.3, 77.7, 75.2, 75.1, 73.4, 72.9, 72.2, 70.3, 51.1, 39.3, 38.1, 27.1, 26.3, 




To a solution of benzylated 65 (62.5 mg, 93 μmol) in DCM (0.46 mL) was added 
slowly BCl3 (1 M in DCM, 1.9 mL, 1.9 mmol, 20 eq.) at -78 °C. After stirring for 4 h 
at -78 °C, the reaction mixture was quenched with MeOH (3 mL). concentrated in 
vacuo and co-evaporated with toluene (3x). Purification by column chromatography (EtOAc → 20% 
MeOH in EtOAc) gave title compound 20 (29.0 mg, 93 μmol, quant.) as a white solid. 1H NMR (400 
MHz, D2O): δ (ppm) 4.25 (dd, J = 9.1, 6.3 Hz, 1H), 3.85 (s, 1H), 3.77 – 3.65 (m, 2H), 3.33 (t, J = 6.2 
Hz, 2H), 3.28 – 3.14 (m, 3H), 1.97 – 1.87 (m, 2H), 1.66 – 1.52 (m, 5H), 1.31 – 1.25 (m, 1H). 13C NMR 
(101 MHz, D2O): δ (ppm) 174.6, 73.5, 71.1, 67.8, 62.3, 50.8, 42.2, 39.1, 27.0, 27.0, 25.8, 25.4, 21.8. 




To a solution of benzylated 66 (45.0 mg, 66 μmol) in DCM (0.50 mL) was added 
slowly BCl3 (1 M in DCM, 1.5 mL, 1.5 mmol, 23 eq.). After stirring for 4 h at -78 
°C, the reaction mixture was quenched with MeOH (3 mL). concentrated in vacuo 
and co-evaporated with toluene (3x). Purification by column chromatography (EtOAc → 20% MeOH 
in EtOAc) gave title compound 15 (14.6 mg, 46.4 μmol, 70%) as a white solid. 1H NMR (400 MHz, D-
2O): δ (ppm) 3.98 (t, J = 4.0 Hz, 1H), 3.84 (d, J = 9.0 Hz, 1H), 3.74 – 3.62 (m, 2H), 3.41 (dd, J = 9.0, 2.3 
Hz, 1H), 3.31 (t, J = 6.4 Hz, 2H), 3.18 (t, J = 6.3 Hz, 2H), 2.34 – 2.25 (m, 1H), 1.91 (t, J = 4.7 Hz, 1H), 
1.64 – 1.43 (m, 6H). 13C NMR (101 MHz, D2O): δ (ppm) 175.3, 75.5, 69.0, 68.9, 61.9, 50.7, 38.9, 38.5, 
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he diverse conformational pathways of glycosidases2,3 (for example Figure 7.1A) 
coupled to their phenomenal transition-state stabilization4 offers a powerful route 
to selective enzyme inhibition. One of the main goals of the field, very rarely achieved, 
is to design and apply conformationally-restricted inhibitors in order to provide both 
potency and specificity; conformationally-biased inhibitors that target specific classes of 
glycoside hydrolase (GH) would be of considerable use as cellular and mechanistic 
probes and potential as starting points for therapeutic compounds. Cyclophellitol (1) 
satisfy the criterion as a potential conformational analogue of the oxocarbenium ion 
transition-state during β-glucosidase-mediated hydrolysis of a β-glucosidic linkage. 





covalent enzyme-substrate adduct (Figure 7.1B). In a similar fashion cyclophellitol 
aziridine (2) is a potent covalent inhibitor. Carba-cyclophellitols (compounds in which 
the epoxide- or aziridine moiety in 1 or 2, respectively, is substituted with a 
cyclopropane moiety), are cyclophellitol analogues that, while harboring the 
conformational properties, would be inert towards nucleophiles. Indeed, mimicking the 
transition-state conformation of the oxocarbenium ion of β-glucosidases by carba-
cyclophellitol would result in a new class of potential competitive β-glucosidase 























Figure 7.1 A) Mechanistic itinerary of retaining β-glucosidases. B) Structure of cyclophellitol (1) and 
cyclophellitol aziridine (2) adopting a 4H3 conformation and its proposed mechanism of binding. C) 
Structure of carba-cyclophellitol (3) adopting a 4H3 conformation, positioned in the active site. X = O, 
NH; R = acyl. 
 
Bicyclic cyclopropyl glucosidase inhibitors, with the bridge between the “C6” and “O5” 

















































































1, X = O
2, X = NH
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configuration by Bennet and co-workers (5) and found to be good α-glucosidase and 
galactosidase inhibitors, respectively (Figure 7.2).6 More recently, the activated form of 
compound 5 (6) have been used as a covalent inhibitor.7 In these cases the 
conformational restriction limits the accessible conformations to “off-pathway” 3H2 and 
2H3 half chairs7 (or perhaps their related 1,4 boats) recently elegantly revealed by X-ray 
crystallography.8 Further, Stick and Stubbs9 synthesized a bicyclic cyclopropyl inhibitor 
(7) with the bridge between the “anomeric” C1 carbon position and the “C2” atom with 
a millimolar Ki value. 
Figure 7.2 Potent bicyclic carbacycle based glucosidase- (45 and 79) and galactosidase inhibitors (56 
and 67).  
 
The carba-cyclophellitol derivatives (8 – 10, Figure 7.3) could be by virtue of the 
advantage of their conformational restriction between the “O5” and “anomeric” C1 
carbon positions a potent inhibitor in which the conformational restraint is a 
glycosidase reaction coordinate relevant 4H3. In this chapter, carba-cyclophellitols (8 – 
10) were examined towards Thermotoga maritima TmGH1, a classical model β-
glucosidase, human lysosomal retaining β-glucosidase, GBA1 (deficiency of which is 
causative of the human lysosomal storage disorder, Gaucher disease) and human 
lysosomal α-glucosidase, GAA (deficient in the human glycogen storage disease, Pompe 
 
Figure 7.3 Structures of carba-cyclophellitol 8 – 10, DNJ (11), AMP-DNM (12, MZ-21) and 
KY17010,11 (13) used in this study.  
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disease). After analyzing carba-cyclophellitols by 1H NMR analysis, quantum 
mechanical analysis and DFT calculations, carba-cyclophellitol 10 was soaked in 
TmGH1 to elucidate the conformation binding mode in the active site. 
 
7.2 Results and discussion 
 
The synthesis of carba-cyclophellitols, including β-glucopyranose configured 8 – 10, is 
described in Chapter 6. After having carba-cyclopropane 8-10 in hand, their inhibition 
potency was studied in comparison with deoxynojirimycin (DNJ), a known competitive 
TmGH1 inhibitor and AMP-DNM (MZ-21), a known human retaining β-glucosidase 
inhibitor.13 Initial binding constant (Ki) values were determined on TmGH1 by 
monitoring the UV-absorbance of p-nitrophenolate from p-nitrophenyl β-D-
glucopyranoside using the Lineweaver–Burk method. Carba-cyclophellitol 8 and 9 
showed micromolar inhibition, consistent with our design strategy and similar to that 
displayed by the charged species DNJ, whereas 10 proved to be a strong reversible 
binding TmGH1 inhibitor with a Ki value of 8.2 nM, much more potent than DNJ14 and 
AMP-DNM  (low micromolar) (Table 7.1 and Figure 7.4). We then explored the activity 
of compound 10 in human lysosomal retaining β-glucosidase, GBA1 which resulted 
into an apparent IC50 of around 100 μM. No apparent inhibition of the human 
lysosomal α-glucosidase, GAA was observed at final concentrations of 10 up to 150 
μM. Thus, although less potent for GBA1 than for the bacterial enzyme tested, 
compound 10 appears to have selectivity for the human lysosomal β-glucosidase over 
the human lysosomal α-glucosidase, which is opposite of the selectivity observed for 
DNJ (Table 7.1). 
 
Table 7.1 Apparent IC50 values and inhibitory constants (Ki) for in vitro inhibition of α- and β-
glucosidase activity by compounds 8-10, DNJ (11) and AMP-DNM (12). 
 
Compound Ki[a] apparent IC50  
TmGH1[b] GBA1[c] GAA[c] 
8 (DW172) 22.3 μM >150 μM > 150 μM 
9 (DW174) 88.9 μM  >150 μM > 150 μM 
10 (DW082) 8.20 nM 99 ± 1.9 μM > 150 μM 
11 (DNJ) 2.50 μM[d] 109 ± 1.0 μM[e] 1.5 μM[g] 
12 (AMP-DNM) 4.97 μM 156 ± 16 nM[f] 0.4 μM[g] 
aKm TmGH1 = 0.24 mM. bThe assay was performed with p-NPG as substrate. cThe assay was 
performed with 2,4-DNPG as substrate. cValues in agreement with literature. dKi DNJ = 3.8 μM in 
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Figure 7.4 A) Lineweaver-Burk plots of β-glucosidase TmGH1 in the presence of inhibitors 10 (50 
nM), 11 (5 μM) and 12 (10 μM). B) Lineweaver-Burk plots of β-glucosidase TmGH1in the presence of 
inhibitor 10 at different concentrations (10, 20, 30 and 55 nM). C) Secondary plot for inhibitor 10. 
 
Inspired by the low μM to nM inhibition of TmGH1 by the carba-cyclopropanes, we 
sought to determine whether the cyclopropyl moiety indeed biased the conformation to 
4H3. The conformational free energy landscape (FEL) for generic cycloproyl (3, R = H) 
was calculated by ab initio metadynamics, and the Cremer-Pople puckering coordinates 
θ and ϕ were used as collective variables, yielding a Mercator representation for the FEL 
(as used previously for diverse glycosidase inhibitors14-16), Figure 7.5A. Compound 3 
clearly favors the 4H3 conformation in vacuo, with the flipped 3H4 form in another local 
energy minimum. Subsequent to FEL calculation, the experimental J values are 
compared of several (cyclohexane) ring protons of compound 9 with their calculated 
counterparts, in which calculations were performed on compound 9 in the 4H3 
conformation (Table 7.1). Both sets of values are in good agreement, which underscores 
the notion that compound 9, and by extension also the other compounds subject of this 
chapter (whose proton NMR of 10 give broadened signals due to the amide present) do 
indeed adopt the 4H3 conformation in solution (Table 7.2, Figure 7.6). 
A) 
10 (50 nM) 
11 (5 uM) 





Lineweaver-Burk plots B) 
10 (55 nM) 
10 (30 nM) 
10 (20 nM) 












Figure 7.5 A) A mercator representation for the computed free energy landscape (FEL) of cyclopropyl 
(3, R = H) (θ and ϕ are given in degrees). B) Crystal structure of TmGH1 in complex with unreacted 
KY170 (13). C) Crystal structure of TmGH1 in complex with carba-cyclophellitol 10, showing the 
carba-cyclophellitol-CO-NH group. Electron density maps for both B and C are maximum likelihood 
/ σA weighted 2Fobs-Fcalc syntheses contoured at 1.4σ. D) Overlay of (B) in ice blue and (C) in coral. 
 
Structural dissection of the inhibitory action of 10, and the conceptual link through to 
cyclophellitol 1, was achieved first by rapid soaking (as opposed to pre-incubation as 
used previously to trap the covalent adduct17) of crystals of TmGH1 with cyclophellitol 
derivative KY17010,11 (13). Serendipitously, this indeed afforded the unreacted 
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Table 7.2 The experimental (8 and 9) and calculated coupling constants of carba-cyclophellitols (14 - 





Coupling constants were determined by 1H NMR experiments (exp.) or obtained from DFT 







Figure 7.6 Optimized conformation of carba-cyclophellitol 14. 
 
cyclophellitol KY170 in 4H3 conformation, with the nucleophile poised to attack, Figure 
7.5B, confirming our hypothesis that (unreacted) cyclophellitols adopt a transition 
state-like 4H3 conformation. In order to dissect similar mimicry by carba-cyclopropane 
10, and confirm the FEL calculated by ab initio metadynamics, TmGH1 crystals were 
soaked with carba-cyclophellitol 10 and the subsequently obtained structure was 
analyzed and solved with X-ray crystallography. The obtained electron density pattern 
clearly demonstrates the presence of carba-cyclophellitol 10 in the active site in 4H3 
Coupling J exp. 8 J exp. 9 J calc. 14 J calc. 15 J calc. 16  
H1-H6 n.d. 9.1 9.0 8.7 7.9 
H1-H2 n.d. 0.8 0.5 0.6 0.5 
H2-H3 8.6 8.6 6.9 6.7 6.6 
H3-H4 10.3 10.1 8.0 8.1 8.1 
H4-H5 10.3 9.7 8.8 8.4 8.4 
H5-H6 n.d. 5.0 5.0 5.1 5.2 
H5-H8a 8.2 8.2 9.0 8.0 8.1 
H5-H8b 3.9 4.0 3.3 2.3 2.4 
H1-H7a n.d. 4.3 3.6 3.8 4.5 
H6-H7a n.d. 4.6 4.0 4.1 5.0 
H1-H7b     8.6 
H6-H7b     8.2 
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conformation (Figure 7.5C; the butyl azide moiety is highly mobile and differently 
disordered in the structure and not shown for clarity).  
Overlay of cyclophellitol derivative KY170 with carba-cyclophellitol 10 (Figure 7.5D) 
shows almost perfect coincidence of atomic positions, showing that, as suggested by the 
FEL, 10 is a permanent mimic of cyclophellitol posted in the active site prior to 
nucleophilic attack.  
The improved binding of 10, relative to 8 and 9 presumably stems from desolvation 
caused by the alkyl-azido “tail” sitting in the aglycone site. One of the design advantages 
of the carba-cyclopropanes is that any pendent R groups are disposed pseudo-axial to 
the sugar ring, consistent with the distortions seen during catalysis which presumably 
adds to their augmentation of binding. The 3-D structure with 10 confirms this and 
shows a lateral, anti-trajectory interaction of the catalytic amino acid Glu166 with the 
pseudo-axially disposed amide of 10. There are 4 molecules of TmGH1 in the 
crystallographically-observed asymmetric unit. While they all show the R group axial, 
they all show different degrees of disorder of this alkyl region itself. In one molecule, 
there is essentially no electron density for the tail, while in two molecules the chain 
passes through the aglycon region (that is flanked by Val169, Trp168 and Trp324) 
making nonspecific interactions with this region. In the fourth molecule of the AU, the 
alkyl azido chain appears to follow two separate routes along each hydrophobic flank of 




Carba-cyclophellitols are potent β-glucosidase inhibitors (Ki of 8.2 nM for the most 
potent derivative with an N-(4-azidobutyl)carboxamide moiety (10) towards TmGH1 
β-glucosidase). NMR analysis, ab initio metadynamics simulation of the 
conformational free energy landscape and DFT calculations indicated that carba-
cyclophellitols favors the relevant 4H3 conformation of the glycosidase reaction 
coordinate. 3-D structural analysis and comparison with unreacted epoxides show that 
compound 10 indeed bind in 4H3 conformation suggesting that conformational strain 
induced through a cyclopropyl unit may add to the armory of tight binding inhibitor 
designs. Given the large number of glycosidase inhibitors in medical use, including 
those being developed as pharmacological chaperones and as diagnostic tools, the 
harnessing of appropriate conformation restraint, coupled to correct stereochemistry, 
should add greatly to the enzymological, cellular, and, ultimately, therapeutic toolbox. 
 




Determination of the conformation of carba-cyclophellitol 
The calculated 1H NMR coupling constants were obtained by first finding the lowest energy 
conformation of carba-cyclophellitol 14, 15 or 16, for which a library of  gas  phase  conformations  
was  generated  using  conformer  distribution option  included  in  Spartan  0418  program,  
employing  Semiemperical/RM1. All  conformers  were  further  optimized  by  Gaussion  0319  at  
DFT/B3LYP  6-311++G(d,p),   their   zero-point   energies   were   calculated   and   the   energies 
corrected  for  solvent  by  another  optimization  step  employing  a  Polarizable Continuum Model 
set for water. The energies of these conformers, corrected for  their  zero-point  energies,  were  
compared  and  of  the lowest  energy conformer (Figure 7.6)  an  NMR  calculation  was  performed  




TmGH1 construct pET-28a-TmGH1-His6 was cloned, expressed and purified as described by Zechel 
et al.13 
 
Enzyme activity assays and IC50 measurements 
Enzyme preparations of recombinant human GBA1 (Cerezyme) and recombinant human GAA 
(Myozyme) used for IC50 measurements were obtained from Genzyme, USA.  
The activity of β-D-glucosidase GBA1 was assayed at 37 °C by monitoring the UV-absorbance of 2,4-
dinitrophenolate released from 2,4-dinitrophenyl β-D-glucopyranoside. To determine the apparent 
IC50 values, 2.6 μM of enzyme in 150 mM McIlvaine buffer pH 5.2 with 0.2% Taurocholate (w/v), 
0.1% Triton X-100 (v/v) and 0.1% Bovine Serum albumin (BSA) (w/v) was pre-incubated with a range 
of inhibitor dilutions (with 1% DMSO) for 15 min at 37 °C. The reaction was started by adding 5 μL 
of this enzyme-inhibitor mixture to 95 μL of 2,4-dinitrophenyl β-D-glucopyranoside substrate (200 
μM) in 150 mM McIlvaine buffer (pH 5.2) 0.2% Taurocholate (w/v), 0.1% Triton X-100 (v/v), 0.1% 
Bovine Serum albumin (BSA) (w/v).  
The activity of β-D-glucosidase GAA was assayed at 37 °C by monitoring the UV-absorbance of 2,4-
dinitrophenolate released from 2,4-dinitrophenyl α-D-glucopyranoside. To determine the apparent 
IC50 values, 8.9 μM of enzyme in 150 mM McIlvaine buffer pH 4.8 with 0.1% BSA (w/v) was pre-
incubated with a range of inhibitor dilutions (with 1% DMSO) for 15 min at 37 °C. The reaction was 
started by adding 5 μL of this enzyme-inhibitor mixture to 95 μL of 2,4-dinitrophenyl α-D-
glucopyranoside substrate (200 μM) in 150 mM McIlvaine buffer (pH 4.8) with 0.1% BSA (w/v).  
The release of 2,4-dinitrophenolate was monitored via absorbance at 400 nm every 2s for 60 s to 
determine the hydrolysis rate. All IC50 values were determined in triplicate. The data were normalized 
to the untreated control condition and finally the residual activity was calculated through equation 1, 
plotted against the log[I] and curve-fitted with one-phase exponential decay function (GraphPad 
Prism 5.0).  
 




The kinetics studies of reversible inhibitors in TmGH1 were performed by monitoring the UV-
absorbance of p-nitrophenolate released from p-nitrophenyl-β-D-glucopyranoside. TmGH1 at 3.7 μM 
in 50 mM phosphate buffer (pH 6.8) was pre-incubated with a range of inhibitor dilutions for 15 min 
at 25 °C. The reaction was then started by adding 5 μL of this enzyme-inhibitor mixture to 95 μL of p-
nitrophenyl β-D-glucopyranoside substrate (from 0.2 to 1 mM) in 50 mM phosphate buffer (pH 6.8). 
Following the onset inhibition (one minute incubation), the release of p-nitrophenolate was 
monitored via absorbance at 400 nm every 2s for 60 s to determine the hydrolysis rate. The Ki values 
of reversible inhibition were determined by taking the slopes from each Lineweaver-Burk plots and 
plotting them vs the inhibitor concentration (Figure 7.4). After fitting the data into a straight line by 
linear regression, the [I]-intercept gave the desired -Ki value. The Km of TmGH1 was determined from 
the value of the horizontal axis intercept (-1/Km). 
 
TmGH1 crystallization, data collection and structure refinement methods 
Crystals were grown using the Sitting Drop vapour diffusion method, with TmGH1 at 12.5 mg/ml, 
mixed in a volume ratio 0.6:0.1:0.4 protein: seed: well solution in the drop, over a well comprised of 
0.2 M K/Na tartrate, 0.1 M bis-tris propane pH 7.4, 20% polyethylene glycol  (PEG) 3350. The seed 
stock was prepared using crystals grown over  0.2 M Na malonate, 0.1 M bis-tris propane pH 6.6, 26% 
PEG 3350, which were vortexed with approximately 50 μl well solution, in an Eppendorf tube 
containing a polystyrene bead, for 1.5 min. A crystal was soaked with a speck of solid powder of 
KY170 (13) for an hour, and then harvested into liquid nitrogen with a nylon CryoLoopTM  via a 
cryoprotectant solution containing 0.2 M K/Na tartrate, 0.1 M bis-tris propane pH 7.4, 20% PEG 
3350, 25% (v/v) ethylene glycol.  X-ray diffraction data were collected at the European Synchrotron 
Radiation Facility beamline id 23-2, and the space group was P212121, with approximate unit cell 
dimensions a = 94.8 Å, b = 94.9 Å, c =112.9 Å, α = β = γ = 90°. The data were processed using 
iMOSFLM20, and scaled using AIMLESS21 to a resolution of 2.1 Å. 
Further crystals were grown using a similar method, with TmGH1 in a ratio of  0.5:0.1:0.6 protein:  
seed: well solution, over a well containing 11% PEG 4000, 0.1 M imidazole pH 7.0, 0.1 M Ca acetate, 
0.1 M trimethylamine N-oxide (TMAO), and with a seed bead stock prepared as above using crystals 
grown over 15% PEG 4000, 0.1 M imidazole pH 7.0, 0.22 M Ca acetate. The crystals were soaked with 
2.5 mM 10 in 11% PEG 4000, 0.1 M imidazole pH 7.0, 0.1 M Ca acetate, 0.1 M TMAO, for 4 hours, 
and harvested into liquid nitrogen with a nylon CryoLoopTM  via a cryoprotectant solution containing 
11% PEG 4000, 0.1 M imidazole pH 7.0, 0.2 M calcium acetate, 25% ethylene glycol. X-ray data were 
collected at the Diamond Light Source beamline IO2, and processed with DIALS22, and scaled with 
AIMLESS  to a resolution of 2.0 Å. The space group was P1 and the approximate unit cell dimensions, 
a = 71.6 Å , b = 76.7 Å, c = 95.3 Å, α = 72.3°, β = 86.4°, γ = 85.5°.  
Both structures were solved using programs from the CCP4 suite23. The native TmGH1 structure PDB 
entry 1OD013 was used as the model for molecular replacement using PHASER24. The structures were 
refined with cycles of maximum-likelihood refinement  using  REFMAC25, interspersed with manual 
rebuilding with Coot26. 
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In order to obtain the free energy landscape of carba-cyclophellitol (3, R = H), quantum mechanical 
calculations were performed using Density Functional Theory-based molecular dynamics (MD), 
according to the Car-Parrinello method.27 All systems were enclosed in an isolated cubic box of  12.0 
 10 13 
Data collection   
Space group P1 P212121 
Cell dimensions   
a, b, c (Å) 71.6, 76.7, 95.3 94.8, 94.8, 112.9 
α, β, γ (°) 72.3, 86.4, 85.6 90.0, 90.0, 90.0 




Rsym or Rmerge 9.7 (51.7) 10.5 (96.6) 
I / σI 5.2 (1.4) 12.8 (2.3) 
Completeness (%) 97.3 (95.4) 100.0 (100.0) 
Redundancy 2.7 (2.5) 7.4 (7.5) 
   
Refinement   
No. reflections 109393 60171 
Rwork / Rfree 0.24/0.31 0.18/0.24 
No. atoms   
    Protein 14155 7175 
    Ligand/ion 222 53 
    Water 403 263 
B-factors   
    Protein 31.8 37.0 
    Ligand/ion 34.0 38.7 
    Water 29.8 36.15 
R.m.s deviations   
    Bond lengths (Å) 0.018 0.016 
    Bond angles (°) 1.879 1.729 
Ramachandran plot  
residues 
  
In most favorable  
regions (%) 
96.2 97.7 
In allowed regions (%) 3.2 1.7 
PDB code 5N6S 5N6T 
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Å x 12.0 Å x 12.0 Å, using a fictitious electron mass of 700 au and a time step of 0.12 fs. The Kohn-
Sham orbitals were expanded in a plane wave (PW) basis set with a kinetic energy cutoff of 70 Ry. Ab 
initio pseudopotentials generated within the Troullier-Martins scheme were employed.28 The Perdew, 
Burke and Ernzerhoff generalized gradient-corrected approximation (PBE)29 was selected in view of 
its good performance in previous work on isolated sugars,14 glycosidases30 and glycosyltransferases.31 
The metadynamics algorithm32,33 was used to explore the conformational free energy landscape of the 
system, taking as collective variables θ and φ of the puckering coordinates of Cremer and Pople.34 
Initially, the height of the Gaussian terms was set at 0.6 kcal·mol-1 and a new Gaussian-like potential 
was added every 250 MD steps. Once the whole free energy space was explored, the height of the 
Gaussian terms was reduced to the half (0.3 kcal·mol-1) and a new Gaussian-like potential was added 
every 500 MD steps. The width of the Gaussian terms was set to 0.10 Å. The simulation was stopped 
according to the invariance of the energy differences between wells, which was further confirmed by a 
time-independent free energy estimator (Figure 7.7).35 The phase space was fully explored in less than 
60 ps and the simulation was further extended up to 180 ps. The errors in the energy minima, taken as 
















Figure 7.7 Error surface for carba-cyclophellitol. Plot calculated according to the time-independent 
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he enzymatic formation of glycosidic linkages is achieved by glycosyltransferases 
(GTs). At the end of their lifetime, glycosidic linkages within oligosaccharides and 
glycoconjugates (combined termed glycans) are hydrolysed by glycosidases (GHs), and 
thus GTs and GHs combined control glycan levels and diversity within cells and 
organisms. Just as is the case with GH inhibitors, GT inhibitors are widely sought after 
with the aim to exert control over glycan metabolism. Indeed, numerous potent and 
selective GH inhibitors have been discovered in the past decades, and some are in 
clinical use.2,3 However, and despite the therapeutic potential of GT inhibitors, potent 





Retaining galactosyltransferases (GalT) catalyse the transfer of galactose from UDP-α-
D-galactose (donor) to an acceptor molecule such as proteins, (oligo)saccharides and 
lipids (Figure 8.1). A double displacement mechanism is suggested for 
galactosyltransferases of the GT6 family, including α3GalT (E.C. 2.4.1.87), α-1,3-N-
acetylgalactosaminyltransferase (GTA, E.C. 2.4.1.40) and α-1,3-galactosyltransferase 
(GTB, E.C. 2.4.1.37).6 In this (putative) mechanism (Figure 8.1A), a covalent enzyme-
donor intermediate is formed via an oxocarbenium ion-like transition state. An 
incoming nucleophile (the acceptor-OH to be glycosylated) would then release the 
enzyme-bound galactoside to yield the galactosylated product with concomitant 
reforming of the enzyme active site.  
An alternative mechanism (Figure 8.1B), is suggested for lipopolysaccharyl-α-1,4- 
galactosyltransferase C (LgtC, GT8 family).7 In this SNi-like mechanism, a front-side  
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attack of the acceptor on the anomeric position of the donor takes place, while the 
leaving group departs simultaneously from the same face resulting in the formation of 
the product with retention of configuration. This mechanism, implies an 
oxocarbenium ion-like transition state or a potentially short-lived oxocarbenium ion 
intermediate.  
Finally, inverting galactosyltransferases, such as β-1,4-galactosyltransferase T1 (β4Gal-
T1), employ a SN2 nucleophilic attack of the acceptor at the anomeric center (Figure 
8.1). Indeed, the oxocarbenium-like transition state is formed as well in this 
mechanism, followed by expulsion of the UDP-moiety, resulting in product formation 
with inverted configuration at the anomeric center.8 
 
The promising results of carba-cyclophellitol derivatives as described in Chapter 6 and 
7 wherein the oxocarbenium ion-like transition state was mimicked by carba-
cyclophellitols, which employs a 4H3 conformation, served as a source of inspiration for 
the here-described research. Known α-galactosidase inhibitors, such as 1-deoxy-
galactosnojirimycin (DGJ, with an IC50 value of 4.7 nM for lysosomal α-galactosidase 
A9), do not inhibit galactosyltransferases, such as α3GalT.10 On the other hand, uridine 
diphosphate (UDP, 1) is a relatively potent α3GalT inhibitor with an IC50 of 13 μM 
(Figure 8.2A).10 Based on these considerations, compound 3 (AB209) was designed as a 
potential inhibitor of galactosyltransferases (Figure 8.2B). Furthermore, compound 4 
(AB209) was synthesized, based on 2 which is a moderatelty potent α3GalT inhibitor 
(IC50 value of 320 μM).11 In compound 2, an O-sulfamoyl amide bond was introduced 













Figure 8.2 A) Galactosyltransferase inhibitors described in the literature.10,11 B) Potential 
galactosyltransferase inhibitors that are the subject of the research described in this chapter. 
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In the second part of this chapter the synthesis of glucose-configured isomer 5 is 
described (Figure 8.3). Glucopyranose-configured carba-cyclophellitol derivatives are 
described in Chapter 6 and were used as a starting point to obtain this potential 







Figure 8.3 Structure of compound 5. 
 
8.2 Results and discussion 
 
The synthesis of compound 3 was inspired by the phosphoramidite-based sugar 
nucleotide synthesis as described by Gold and co-workers.12 α-Galactopyranose-
configurated carba-cyclophellitol 6 was synthesized as described in Chapter 6. Once a 
phosphodiester bond is formed however, all protective groups in the penultimate 
intermediate are ideally removed in a single (basic) step. Protection group 
manipulations were therefore executed to transform 6 into a suitable substrate (10) in 
which all alcohols barring the one intended for phosphorylation are masked as the 
acetate (Scheme 8.1). Briefly, the primary alcohol of compound 6 was reacted with 3,4-
dihydro-2H-pyran (DHP) and catalytic para-toluenesulfonic acid followed by removal 
of the benzyl ethers in the resulting THP ether 7 under Birch reduction conditions to 
give compound 8. Global acetylation and acid catalyzed THP deprotection afforded key 
intermediate 10. 
 
Scheme 8.1 Synthesis of alcohol 10. 
 
 
Reagents and conditions: a) 3,4-dihydro-2H-pyran, pTsOH, CH2Cl2, rt, 30 min, 79%; b) Li, NH3 (l), -
60 °C, 1 h; c) Ac2O, 4-dimethylaminopyridine, pyridine, rt, overnight, 88% over 2 steps; d) pTsOH, 
MeOH, rt, 1 h, 85%. 
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The obtained alcohol 10 was then coupled with uridine phosphoramidite 1113 (Scheme 
8.2). After 30 min, the phosphite moiety was oxidized with tert-butylhydroperoxide 
giving phosphate diester 13. In the following three-step-procedure all protecting 
groups were removed. Treatment with DBU resulted in the removal of the 2-cyanoethyl 
group and partial deacetylation was observed by LC/MS analysis. Next, aqueous 
ammonia was added to the reaction mixture. However, after stirring overnight the 
deacetylation process was not completed as determined by LC/MS analysis. Therefore, 
the reaction mixture was concentrated in vacuo and stirred overnight in 
Et3N/H2O/MeOH, providing the target compound. The crude product mixture was 
purified by size-exclusion chromatography followed by HPLC purification. Finally, 
treatment with Dionex sodium exchange resin provided compound 3 as the sodium 
salt in 22% yield. 
 
Scheme 8.2 Synthesis of compound 3. 
Reagents and conditions: a) DCI, acetonitrile, rt, 30 min; b) tBuOOH, rt, 30 min; c) DBU, rt, 1h; d) 
aqueous NH3, rt, 24 h; e) i) Et3N/H2O/MeOH (1:1:3), rt, overnight; ii) size-exclusion, HPLC 
purification, Dionex sodium exchange, 22% over 6 steps.  
 
In order to prepare compound 4, the UDP mimic had to be synthesized first (Scheme 
8.3). The synthesis of O-sulfamoylamide 16 was accomplished according to the 
literature procedure.14 Iodine-catalyzed acetalization of uridine 14 and acetone gave 
2’,3’-isopropylidene-uridine 15. Installment of the sulfamoyl functionality to give 16 
was accomplished by first generation of sulfamoyl chloride from chlorosulfamoyl 
isocyanate and formic acid followed by addition to the reaction mixture of compound 
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15. Purification of O-sulfamoylamide 16 however turned out to be troublesome. An 
alternative strategy comprises the protection of the uracil-nitrogen as the Boc derivative 
(15 to 17). O-sulfamoylation and ensuing purification now proceeded uneventfully 
yielding compound 18, which was used in the following steps instead of 16. 
 















Reagents and conditions: a) I2, acetone, rt, overnight, 83%; b) formic acid, chlorosulfamoyl 
isocyanate, NaH, THF, overnight, 0 °C to rt, 79%; c) i)TBDMS-Cl, N,N-dimethylpyridin-4-amine, 
pyridine, overnight,  88%; ii) Et3N, N,N-dimethylpyridin-4-amine, di-tert-butyl dicarbonate, CH2Cl2, 
rt, overnight, quantitative; iii) tetra-n-butylammoniumfluoride (TBAF), THF, 0 °C to rt, 40 min, 81%; 
d)  formic acid, chlorosulfamoyl isocyanate, pyridine, 0 °C to reflux, overnight, 30%; 
 
α-Galactopyranose-configured carba-cyclophellitol 19 was synthesized in sufficient 
quantities following the procedure described in Chapter 6. Treatment with lithium 
hydroxide in a mixture of THF, MeOH and H2O resulted in acid 20 (Scheme 8.4). 
Acylation of 20 using oxalyl chloride in toluene gave acid chloride 21. After having acid 
chloride 21 and O-sulfamoylamide 18 available, the key step in the sequence was 
investigated. Coupling of acid chloride 21 with O-sulfamoylamide 18 resulted in 
compound 22, which was purified by size-exclusion chromatography followed by silica 
gel column chromatography. In contrast to cyclophellitol and cyclophellitol aziridine15-
17, carba-cyclophellitol derivatives are stable towards acidic conditions. Therefore, the 
isopropylidene and tert-butyloxycarbonyl protecting groups of 22 could be successfully 
removed by treatment with TFA and H2O in CH2Cl2. The remaining benzyl groups 
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were removed under the agency of BCl3 as the Lewis acid. Purification by HPLC 
provided compound 4 in 69% yield. 
 
Scheme 8.4 Synthesis of compound 4. 
Reagents and conditions: a) LiOH, THF/MeOH/H2O (8:2:1), rt, overnight, 86%; b) oxalyl chloride, 
toluene, 40 °C, overnight c) 18, N,N-diisopropylethylamine, CH2Cl2, rt, 3 h, 60% over 2 steps; d) 
TFA/H2O (9:1), CH2Cl2, 0 °C to rt, 4.5 h, 81%; e) BCl3, CH2Cl2, -78 °C to 0 °C, 4.5 h, 69%. 
 
The synthesis of α-glucopyranose-configured carba-cyclophellitol 5 (Scheme 8.5), was 
based on the strategy as described above towards α-galactopyranose-configured 
analogue 4. The synthesis of compound 5 requires access to sufficient quantities of acid 
chloride 29. Cyclopropanation of cyclohexene 24 yielded ethyl ester 25 as an α/β-
mixture (see also Chapter 6). Crystallization in ethanol resulted in obtaining a pure 
fraction of α-ethyl ester 25. Hydrolysis by LiOH resulted in carboxylic acid 27. In order 
to obtain larger quantities of carboxylic acid 26, ethyl ester 25 as an α/β-mixture was 
first reduced with di-isobutyl aluminum hydride after which alcohol 27 was isolated by 
column chromatography (Chapter 6). Alcohol 27 was oxidized to carboxylic acid 26 
using Jones oxidation conditions. Having large quantities of carboxylic acid 26 
available, the synthesis was continued as described for compound 4. Briefly, acylation 
of acid 26 using oxalyl chloride afforded compound 28, which was coupled with 
previously synthesized uridine sulfamoyl amide 16 to obtain compound 29 as the 
DIPEA salt. Finally, global deprotection by treatment with BCl3, followed by quenching 
with MeOH gave compound 5, which was purified by precipitation in chloroform, 




Scheme 8.5 Synthesis of compound 5.  
 
Reagents and conditions: a) LiOH, THF/MeOH/H2O (6.5:1.5:1), rt, 5 h, 91%; b) Jones reagent, 
acetone, 0 °C, 70 min, 75%; c) oxalyl chloride, toluene, 40 °C, 4 h; d) 16, N,N-diisopropylethylamine, 
CH2Cl2, rt, overnight, 70% over 2 steps; e) i) BCl3, CH2Cl2, 0 °C, 3 h; ii) MeOH, 30 min, 54% over 2 
steps. 
 
The potency of the synthesised UDP-glucose and UDP-galactose mimetics to inhibit 
GH activities was established next (Table 8.1). Compound 4 turned out to be a potent 
human lysosomal α-galactosidase (α-GalA) inhibitor, with considerable less potency 
towards human lysosomal β-galactosidase (GALC). As can be seen from Table 8.1, no 
inhibition was observed for any of the α-glucosidases (GAA, GANAB) or β-
glucosidases (GBA1, GBA2) tested for compound 5 (ML128). Furthermore, 5 failed to 
inhibit glucosylceramide synthase (GCS), a glucosyltransferase. Inhibition assays to 
assess the potential of the compounds to target other transferases, including the α-
galactosyl transferases for which the galactose-configured compounds were designed, 
could not be performed in the timeframe of the PhD research described here, though 
compounds have been shared with interested groups who may shed light on their GT 
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Table 8.1 Apparent IC50 values of compounds 3 – 5 towards glycosidases and glucosyltranferase (μM). 
 
Compound α-galactosidase β-galactosidase  GlucT α-glucosidase β-glucosidase 
α-GalA GALC  GCS GAA GANAB GBA1 GBA2 
3 (AB209) >500 >500  -- -- -- -- -- 
4 (AB180) 18.84 ± 1.33 180.27 ± 4.52  -- -- -- -- -- 




In this chapter the versatility of carba-cyclophellitol as analogues of the oxocarbenium 
ion-like transition state is demonstrated by synthesizing potential inhibitors (3 and 4) 
towards galactosyltransferases. In the (near) future, their GT specific inhibition potency 
will be examined. Furthermore, compound 4 turned out to be a potent carba-
cyclophellitol-based α-galactosidase inhibitor. In a similar fashion compound 5 
(ML128) was successfully synthesized. However, inhibition towards GCS or various 




General methods: All chemicals were purchased from Acros, Sigma Aldrich, Biosolve, VWR, Fluka, 
Merck and Fisher Scientific and used as received unless stated otherwise. Dichloromethane (DCM), 
tetrahydrofuran (THF) and toluene were stored over flame-dried 4 Å molecular sieves before use. 
Pyridine and triethylamine were stored on KOH pellets before use. Traces of water from reagents 
were removed by co-evaporation with toluene in reactions that require anhydrous conditions. All 
reactions were performed under an argon atmosphere unless stated otherwise. TLC analysis was 
conducted using Merck aluminium sheets (Silica gel 60 F254) with detection by UV absorption (254 
nm), by spraying with a solution of (NH4)6Mo7O24·4H2O (25 g/L)  and (NH4)4Ce(SO4)4·2H2O (10 g/L) 
in 10% sulfuric acid, a solution of KMnO4 (20 g/L) and K2CO3 (10 g/L) in water or ninhydrin (0.75 
g/L), followed by charring at ~150 ˚C. Size exclusion was performed on Sephadex LH-20 (eluent 
DCM/MeOH, 1:1). Column chromatography was performed using Screening Device b.v. Silica Gel 
(particle size of 40 – 63 μm, pore diameter of 60 Å) in the indicated solvents. For reversed-phase 
HPLC purifications a HPLC system equipped with a C18 semiprep column (Gemini C18, 250x10 mm, 
5 μm particle size, Phenomenex) was used. LC/MS analysis was performed on a Surveyor HPLC 
system (Thermo Finnigan) equipped with a C18 column (Gemini, 4.6 mm x 50 mm, 5 μm particle 
size, Phenomenex), coupled to a LCQ Adventage Max (Thermo Finnigan) ion-trap spectrometer 
(ESI+). The applied buffers were H2O, MeCN and 1% aqueous TFA. 31P NMR, 1H NMR and 13C 
NMR spectra were recorded on a Brüker AV-400 (161.7, 400 and 101 MHz respectively) spectrometer 
in the given solvent. Chemical shifts are given in ppm (δ) relative to the residual solvent peak or 
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tetramethylsilane (0 ppm) as internal standard. Coupling constants are given in Hz. High-resolution 
mass spectrometry (HRMS) analysis was performed with a LTQ Orbitrap mass spectrometer (Thermo 
Finnigan), equipped with an electronspray ion source in positive mode (source voltage 3.5 kV, sheath 
gas flow 10 mL/min, capillary temperature 250 °C) with resolution R = 60000 at m/z 400 (mass range 
m/z = 150–2000) and dioctyl phthalate (m/z = 391.28428) as a “lock mass”. The high-resolution mass 





 Alcohol 6 (see Chapter 6, 708 mg, 1.25 mmol) was dissolved in DCM (15 mL) 
and 3,4-dihydropyran (170 μL, 1.9 mmol, 1.5 eq.) and a catalytic amount of 
pTsOH were added. After stirring for 30 min at room temperature, the reaction mixture was 
quenched with saturated aqueous NaHCO3, extracted with DCM, dried with Na2SO4, filtered and 
concentrated in vacuo. Purification by column chromatography (5% EtOAc in pentane → 20% EtOAc 
in pentane) gave a diastereomeric mixture of compound 7 (0.64 g, 0.99 mmol, 79%) as a clear oil. 1H 
NMR (400 MHz, CDCl3): δ (ppm) 7.51 – 7.19 (m, 20H, CHarom-Bn), 5.01 – 4.81 (m, 2H, CH2-Bn), 4.79 
– 4.54 (m, 5H, CH2-Bn, OCHO-THP), 4.38 (t, J = 7.4 Hz, 1H, H-2), 3.96 – 3.87 (m, 1H, H-4), 3.84 – 
3.78 (m, 1H, CH2O), 3.70 – 3.53 (m, 2H, H-8), 3.50 – 3.35 (m, 2H, CH2O, OCH2C-THP), 3.28 (dd, J = 
10.6, 6.6 Hz, 1H, OCH2C-THP) 3.20 (d, J = 8.2 Hz, 1H, H-3), 1.94 (m, 1H, H-5), 1.85 – 1.40 (m, 7H, 
H-1, 3 x CCH2C-THP), 1.08 (m, 1H, H-7), 0.78 – 0.63 (m, 1H, H-6). 13C NMR (101 MHz, CDCl3): δ 
(ppm) 139.3, 139.3, 139.3, 139.3, 139.1, 139.1, 138.3, 138.3 (Cq-Bn),, 128.4, 128.3, 128.2, 127.9, 127.8, 
127.8, 127.7, 127.6, 127.4, 127.4, 127.3, 127.2 (CHarom-Bn), 98.2, 97.3 (OCHO-THP), 83.5 (C-3), 76.7, 
76.7 (C-2), 76.0, 76.0 (C-4), 73.9, 73.9, 73.2, 73.1, 72.8, 72.7, 71.0, 70.9 CH2-Bn), 70.8, 70.8 (C-8), 70.5 
(OCH2C-THP), 62.0, 61.9 (CH2O), 41.6 (C-5), 30.7, 30.6, 25.5 (CCH2C-THP), 24.3, 24.1 (C-7), 21.8, 
21.5 (C-1), 19.8 (C-6), 19.4, 19.3 (CCH2C-THP), 19.2 (C-6). HRMS: calculated for [C42H48O6Na]+ 
671.33431, found 671.33379. 
 
(1R,2S,3R,4S,5R,6R,7R)-5-(acetoxymethyl)-7-(((tetrahydro-2H-pyran-2-
yl)oxy)methyl)bicyclo[4.1.0]heptane-2,3,4-triyl triacetate (9) 
 NH3 (50 mL) was condensed in a three necked flask at -60 °C after which solid 
lithium (0.25 g) was added resulting in a blue solution. After addition of a 
solution of 7 (0.34 g, 0.52 mmol) in THF (4 mL), the reaction mixture was stirred for 1 h before 
cautiously quenching with MilliQ (5 mL). The reaction mixture was gradually allowed to warm to 
room temperature and concentrated in vacuo to afford debenzylated product 8. The crude product 44 
was redissolved in pyridine (15 mL) and acetic anhydride (10 mL) and a catalytic amount of DMAP 
were added. After stirring overnight at room temperature, the reaction was quenched with H2O. The 
solution was extracted with EtOAc, washed with H2O (3x), dried with MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography (10% EtOAc in pentane → 50% 
EtOAc in pentane) gave a diastereomeric mixture of peracetylated 9 (210 mg, 0.46 mmol, 88% over 
two steps) as a pale oil. 1H NMR (400 MHz, CDCl3): δ (ppm) 5.41 (dd, J = 9.2, 6.8 Hz, 1H, H-2), 5.32 
(s, 1H, H-4), 4.65 – 4.57 (m, 2H, H-3, OCHO-THP), 4.14 – 4.05 (m, 2H, H-8), 3.85 – 3.75 (m, 1H, 
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OCH2C-THP), 3.56 (dd, J = 10.7, 6.6 Hz, 0.5H, H-9), 3.50 – 3.47 (m, 1H, OCH2C-THP), 3.40 (dd, J = 
6.3, 2.7 Hz, 1H, H-9), 3.26 (dd, J = 10.7, 6.6 Hz, 0.5H, H-9), 2.35 – 2.31 (m, 1H, H-5), 2.09 (d, J = 15.6 
Hz, 6H, CH3-Ac), 2.02 (d, J = 7.6 Hz, 6H, CH3-Ac), 1.80 – 1.54 (m, 7H, H-1, 3 x CCH2C-THP), 1.19 – 
1.15 (m, 1H, H-7), 0.79 (dd, J = 13.3, 5.5 Hz, 1H, H-6). 13C NMR (101 MHz, CDCl3): δ (ppm) 170.7, 
170.7, 170.7, 170.4, 170.2 (C=O-Ac), 98.3, 97.4 (OCHO-THP), 72.2 (C-3), 69.7 (C-2), 69.6, 69.1 (C-9), 
69.1 (C-4), 62.9, 62.9 (C-8), 62.0, 61.5 (OCH2C-THP), 38.2, 38.1 (C-5), 30.5, 30.4, 25.4, 25.3 (CCH2C-
THP), 24.4, 24.2 (C-7), 21.1, 21.0 (C-1), 20.8, 20.7, 20.7,20.7 (CH3-Ac), 19.3, 19.0 (CCH2C-THP), 18.2, 
17.9 (C-6). HRMS: calculated for [C22H32O10Na]+ 479.18877, found 479.18854. 
 
(1R,2S,3R,4S,5R,6R,7R)-5-(acetoxymethyl)-7-
(hydroxymethyl)bicyclo[4.1.0]heptane-2,3,4-triyl triacetate (10) 
 A solution of compound 9 (150 mg, 0.33 mmol) in MeOH (10 mL) was acidified 
to pH 2 with p-TsOH. After stirring for 1 h at room temperature, the reaction 
mixture was quenched with saturated aqueous NaHCO3 and extracted with DCM (3x). The combined 
organic layers were washed with brine, dried with MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (50% DCM in pentane → 10% MeOH in DCM) gave alcohol 
10(104 mg, 0.28 mmol, 85%) as a white solid. 1H NMR (400 MHz, CDCl3): δ (ppm) 5.39 (dd, J = 9.2, 
6.8 Hz, 1H, H-2), 5.31 (s, 1H, H-4), 4.64 (dd, J = 9.3, 1.6 Hz, 1H, H-3), 4.11 (d, J = 8.1 Hz, 2H, H-8), 
3.49 (dd, J = 11.4, 6.4 Hz, 1H, CH2), 3.42 (dd, J = 11.4, 6.4 Hz, 1H, CH2), 2.36 – 2.25 (m, 1H, H-5), 
2.09 (d, J = 15.6 Hz, 6H, CH3-Ac), 2.02 (d, J = 7.6 Hz, 6H, CH3-Ac), 1.67 (dt, J = 8.8, 6.5 Hz, 1H, H-1), 
1.16 (t, J = 5.5 Hz, 1H, H-7), 0.78 (ddd, J = 8.2, 4.7, 2.6 Hz, 1H, H-6). 13C NMR (101 MHz, CDCl3): δ 
(ppm) 171.2, 170.9, 170.6, 170.3 (C=O-Ac), 72.3 (C-3), 69.9 (C-2), 69.1 (C-4), 65.1 (CH2O), 62.9 (C-
8), 38.2 (C-5), 27.0 (C-7), 21.2 (C-1), 20.8, 20.8, 20.8, 20.7 (CH3-Ac), 17.9 (C-6). HRMS: calculated for 






sodium salt (3) 
 To a solution of phosphoramidite 1113 (52 mg, 0.09 mmol) in 
ACN (2 mL) was added a solution of alcohol 10 (43 mg, 0.11 mmol, 1.2 eq.) in ACN (3 mL). After 
stirring for 30 min at room temperature tBuOOH (5.5 M in decane, 70 μL, 0.40 mmol, 4.4 eq.) was 
added. After stirring for additional 30 min, DBU (75 μL, 0.50 mmol, 5.6 eq.) was added and the 
reaction mixture was stirred for 1 h before addition of aqueous NH3 (30-35%, 0.50 mL). After stirring 
overnight additional aqueous NH3 (30-35%, 0.50 mL) was added and stirred for 6 h. The reaction 
mixture was concentrated in vacuo and redissolved in MeOH (3 mL), H2O (1 mL) and Et3N (1 mL) in 
order to complete the deacetylation. After stirring overnight, the mixture was concentrated in vacuo 
and purified by size-exclusion chromatography (DCM/MeOH, 1:1) followed by HPLC purification 
(C18 column, linear gradient: A → 10% A in B, A = 100 mM NH4OAc in H2O, B = ACN, 15 min). 
Next, the purified product was dissolved in water and flushed through a tube of Dionex sodium 
exchange resin. Lyophilization afforded compound 3 (10 mg, 0.02 mmol, 22%) as a white solid. 31P 
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NMR (161.7 MHz, D2O): δ (ppm) 0.64. 1H NMR (400 MHz, D2O): δ (ppm) 7.91 (d, J = 8.1 Hz, 1H, H-
6), 5.97 – 5.92 (m, 1H, H-1’ and H-5), 4.38 – 4.31 (m, 2H, H-2’ and H-3’), 4.25 (s, 1H, H-4’), 4.22 – 
4.06 (m, 3H, H-5’, H-2’’), 3,83 (s, 1H, H-4’’), 3.80 – 3.66 (m, 4H, H-8’’, H-9’’), 3.20 (d, J = 9.1 Hz, 1H, 
H-3’’), 1.90 – 1.85 (m, 1H, H-5’’), 1.43 – 1.39 (m, 1H, H-1’’), 1.16 – 1.12 (m, 1H, H-7’’), 0.81 – 0.77 (m, 
1H, H-6’’). 13C NMR (101 MHz, D2O): δ (ppm) 166.6 (C-4), 152.1 (C-2), 141.5 (C-6), 102.5 (C-5), 88.7 
(C-1’), 83.1 (C-4’), 74.0 (C-3’’), 73.7 (C-2’), 71.5 (C-4’’), 69.6 (C-3’), 69.4, 69.3 (C-9’’), 68.5 (C-2’’), 
64.4, 64.3 (C-5’’), 62.5 (C-8’’), 42.5 (C-5’’), 24.2, 24.1 (C-7’’), 23.5 (C-1’’), 18.2 (C-6’’). HRMS: 
calculated for [C18H28N2O13P]+ 511.13235, found 511.13220. 
 
2’,3’-O-Isopropylideneuridine (15)  
To a solution of uridine 14 (4.88 g, 20.0 mmol) in acetone (200 mL) was added 
iodine (0.50 g, 2.0 mmol, 0.1 eq.). After stirring overnight at room temperature, the 
reaction mixture was quenched with saturated aqueous Na2S2O3 (30 mL) and 
concentrated in vacuo. The crude product was redissolved in DCM, dried with 
MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (5% MeOH in DCM → 10% MeOH in DCM) gave compound 15 (4.72 g, 16.6 mmol, 
83%) as a white solid. 1H NMR (400 MHz, MeOD): δ (ppm) 7.83 (d, J = 8.0 Hz, 1H, H-6), 5.87 (d, J = 
2.8 Hz, 1H, H-1’), 5.68 (d, J = 8.0 Hz, 1H, H-5), 4.91 - 4.82 (m, 2H, H-2’ and H-3’), 4.21 (dd, J = 8.0, 
3.6 Hz, 1H, H-4’), 3.78 (dd, J = 11.9, 3.6 Hz, 1H, H-5a’), 3.71 (dd, J = 11.9, 4.5 Hz, 1H, H-5b’), 1.54 (s, 
3H, CH3), 1.35 (s, 3H, CH3). 13C NMR (101 MHz, MeOD): δ (ppm) 166.2 (C-4), 152.1 (C-2), 143.9 (C-
6), 115.1 (Cq), 102.6 (C-5), 94.1 (C-1’), 88.4 (C-4’), 85.8 (C-2’), 82.2 (C-3’), 63.1 (C-5’), 27.5, 25.5 
(CH3). HRMS: calculated for [C12H17N2O6]+ 285.10811, found 285.10818. 
 
Sulfamoyl chloride 
Formic acid (1 eq.) was added to chlorosulfamoyl isocyanate (1 eq.) and stirred at 0 °C. 
When the evolution of gas stopped, the reaction mixture was concentrated under reduced 
pressure at room temperature to afford sulfamoyl chloride as a clear oil, which was directly used 
without further purification.  
 
2’,3’-O-Isopropylidene-5’-O-sulfamoyluridine (16)  
2’,3’-O-isopropylideneuridine 15 (1.00 g, 3.51 mmol) was dissolved in THF (20 
mL) and cooled to 0 °C, before sodium hydride (60% dispersion in oil, 0.700 g, 
17.6 mmol, 5 eq.) was added. After stirring for 15 minutes, sulfamoyl chloride 
(7.0 mmol, 2 eq.) in THF (4 mL) was added. After stirring for 4 hours at 0 °C, 
the reaction mixture was allowed to come to room temperature and stirred for 
an additional 12 h. The reaction mixture was quenched with MeOH (5 mL) and saturated aqueous 
NH4Cl (5 mL), filtrated and concentrated under reduced pressure. Purification by silica column 
chromatography (30% acetone in chloroform → 40% acetone in chloroform) resulted in O-
sulfamoylamide 16 (1.0 g, 2.8 mmol, 79%) as a white foam. 1H NMR (400 MHz, MeOD): δ (ppm) 7.64 
(d, J = 8.1 Hz, 1H, H-2’’), 5.82 (s, 1H, H-1’), 5.72 (d, J = 8.0 Hz, 1H, H-1’’), 5.03 (d, J = 8.6 Hz, 1H, H-
2’), 4.88 (dd, J = 6.3, 3.6 Hz, 1H, H-3’), 4.41 – 4.36 (m, 1H, H-4’), 4.36 – 4.27 (m, 2H, H-5’), 1.54 (s, 
3H, CH3), 1.35 (s, 3H, CH3). 13C NMR (101 MHz, MeOD): δ (ppm) 166.2 (C=O), 152.2 (C=O), 144.3 
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(C-1’’), 115.4 (Cq), 102.8 (C-2’’), 95.1 (C-1’), 86.1 (C-4’), 85.4 (C-3’), 82.4 (C-2’), 70.0 (C-5’), 27.6, 25.5 
(CH3). HRMS: calculated for [C12H18N3O8S]+ 364.08091, found 364.08074. 
 
2’,3’-O-Isopropylidene-5’-O-tert-butyldimethylsilyluridine (30) 
To a solution of alcohol 15 (2.0 g, 7.0 mmol) in pyridine (50 mL) was added 
TBDMS-Cl (1.26 g, 8.4 mmol, 1.2 eq.) and a catalytic amount of 4-
dimethylaminopyridine. After stirring overnight at room temperature, 
additional TBDMS-Cl (0.63 g, 3.5 mmol, 0.5 eq.) was added follewed by 
stirring for 1.5 h before the reaction mixture was quenched with MeOH (5 
mL) and concentrated in vacuo. The crude product was redissolved in EtOAc and washed with 
saturated aqueous NaHCO3 and brine. The organic layer was dried with MgSO4, filtered, and 
concentrated in vacuo. Purification by column chromatography (20% EtOAc in pentane →  50% 
EtOAc in pentane) gave title compound 30 (2.46 g, 6.2 mmol, 88%) as a white foam. 1H NMR (400 
MHz, CDCl3): δ (ppm) 9.48 (s, 1H, NH) 7.71 (d, J = 8.1 Hz, 1H, H-6), 6.00 (d, J = 2.7 Hz, 1H, H-1’), 
5.71 (d, J = 8.1 Hz, 1H, H-5), 4.78 - 4.71 (m, 2H, H-2’ and H-3’), 4.35 – 4.30 (m, 1H, H-4’), 3.94 (dd, J 
= 11.5, 2.7 Hz, 1H, H-5a’), 3.82 (dd, J = 11.5, 3.0 Hz, 1H, H-5b’), 1.60 (s, 3H, CH3), 1.37 (s, 3H, CH3), 
0.92 (s, 9H, CH3), 0.10 (d, J = 2.6 Hz, 6H, CH3). 13C NMR (101 MHz, CDCl3): δ (ppm) 163.6 (C-4), 
150.3 (C-2), 140.7 (C-6), 114.2 (Cq), 102.3 (C-5), 92.0 (C-1’), 86.8 (C-4’), 85.5 (C-2’), 80.4 (C-3’), 63.5 
(C-5’), 27.4 (CH3), 25.9 (Cq), 25.5 (CH3), 18.4 (Cq), -5.3, -5.4 (CH3). HRMS: calculated for 




 Silyl-protected alcohol  30 (2.04 g, 5.1 mmol) was taken up in DCM (30 mL). 
Et3N (2.2 mL, 15.3 mmol, 3 eq.), 4-dimethylaminopyridine (300 mg, 2.5 
mmol, 0.5 eq.) and di-tert-butyl dicarbonate (2.22 g, 10.2 mmol, 2 eq.) were 
added to the solution. After stirring overnight at room temperature, the 
reaction mixture was concentrated in vacuo, and purified by column chromatography (5% EtOAc in 
pentane → 10% EtOAc in pentane) to yield title compound 31 (3.14 g, 5.1 mmol, quantitative) as a 
yellow oil. 1H NMR (400 MHz, CDCl3): δ (ppm) 7.71 (d, J = 8.2 Hz, 1H, H-6), 5.93 (d, J = 2.1 Hz, 1H, 
H-1’), 5.70 (d, J = 8.2 Hz, 1H, H-5), 4.75 (m, 2H, H-2’ and H-3’), 4.37 – 4.34 (m, 1H, H-4’), 3.92 (dd, J 
= 11.6, 2.3 Hz, 1H, H-5a’), 3.79 (dd, J = 11.6, 3.0 Hz, 1H, H-5b’), 1.60 (s, 9H, CH3), 1.58 (s, 3H, CH3), 
1.36 (s, 3H, CH3), 0.90 (s, 9H, CH3), 0.09 (d, J = 3.2 Hz, 6H, CH3). 13C NMR (101 MHz, CDCl3): δ 
(ppm) 160.5 (C-4), 148.4 (C-2), 147.6 (C=O-Boc) 139.8 (C-6), 114.0 (Cq), 101.7 (C-5), 92.8 (C-1’), 
87.1 (C-4’), 86.8 (Cq), 85.6 (C-2’), 80.4 (C-3’), 63.4 (C-5’), 27.5 (CH3), 27.3 (CH3), 25.9 (Cq), 25.4 
(CH3), 18.4 (Cq), -5.4, -5.5 (CH3). 
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2’,3’-O-Isopropylidene -3-N-tert-butyloxycarbonyluridine (17) 
To a solution of Boc-protected uridine 31 (2.29 g, 4.6 mmol) in THF (50 mL) was 
added TBAF (6.9 mL, 6.9 mmol, 1.5 eq., 1 M in THF) at 0 °C. After stirring for 10 
min, the reaction mixture was allowed to warm to room temperature and stirred 
for additional 30 min before the reaction mixture was partitioned between H2O 
(50 mL) and EtOAc (150 mL). The aqueous layer was separated and extracted 
with EtOAc (3x).  The combined organic layers were washed with brine, dried with MgSO4, filtered 
and concentrated in vacuo. Purification by column chromatography (20% EtOAc in pentane → 50% 
EtOAc in pentane) afforded compound 17 (1.43 g, 3.7 mmol, 81%) as a white foam. 1H NMR (400 
MHz, CDCl3): δ (ppm) 7.72 (d, J = 8.2 Hz, 1H, H-6), 5.82 (d, J = 1.8 Hz, 1H, H-1’), 5.73 (d, J = 8.2 Hz, 
1H, H-5), 4.87 (m, 2H, H-2’ and H-3’), 4.34 – 4.31 (m, 1H, H-4’), 3.88 (dd, J = 11.9, 2.4 Hz, 1H, H-5a’), 
3.77 (dd, J = 11.9, 2.4 Hz, 1H, H-5b’), 1.59 (s, 9H, CH3), 1.56 (s, 3H, CH3), 1.35 (s, 3H, CH3). 13C NMR 
(101 MHz, CDCl3): δ (ppm)160.6 (C-4), 148.4 (C-2), 147.5 (C=O-Boc) 141.3 (C-6), 113.9 (Cq), 101.4 
(C-5), 93.8 (C-1’), 87.0 (C-4’), 86.8 (Cq), 84.5 (C-2’), 80.4 (C-3’), 62.2 (C-5’), 27.3, 27.0, 25.1 (CH3). 




 To a solution of alcohol 17 (552 mg, 1.4 mmol) in DCM (15 mL) was added 
pyridine (0.3 mL) and sulfamoyl chloride (345 mg, 3.0 mmol, 2.1 eq.). After 
the reaction mixture was refluxed overnight, the reaction mixture was 
concentrated in vacuo and purified by column chromatography (20% EtOAc 
in pentane → 50% EtOAc in pentane) to yield O-sulfamoylamide 18 (194 mg, 0.42 mmol, 30%) as a 
white solid. 1H NMR (400 MHz, CDCl3): δ (ppm) 7.40 (d, J = 8.2 Hz, 1H, H-6), 5.80 (d, J = 8.2 Hz, 1H, 
H-5), 5.75 (d, J = 1.8 Hz, 1H, H-1’), 5.00 (dd, 1H, H-2’), 4.87 (dd, 1H, H-3’), 4.43 – 4.40 (m, 1H, H-4’), 
4.38 – 4.35 (m, 1H, H-5’), 1.59 (s, 9H, CH3), 1.56 (s, 3H, CH3), 1.35 (s, 3H, CH3). 13C NMR (101 MHz, 
CDCl3): δ (ppm) 160.7 (C-4), 148.5 (C-2), 147.8 (C=O-Boc) 141.7 (C-6), 114.8 (Cq), 102.3 (C-5), 94.8 
(C-1’), 87.6 (C-4’), 84.7 (Cq), 84.3 (C-2’), 80.6 (C-3’), 69.5 (C-5’), 27.5, 27.1, 25.3 (CH3). HRMS: 
calculated for [C12H18N3O8S]+ 364.08091, found 364.08088. 
 
(1R,2S,3R,4S,5R,6R,7R)-2,3,4-tris(benzyloxy)-5-
((benzyloxy)methyl)bicyclo[4.1.0]heptane-7-carboxylic acid (20) 
Ester 19 (see Chapter 6, 0.30 g, 0.49 mmol) was dissolved in THF/MeOH/H2O 
(8:2:1, 25 mL) and LiOH (95 mg, 4 mmol, 8.0 eq.) was added. After stirring 
overnight at room temperature, the reaction mixture was acidified to pH 2 with aqueous HCl (1 M). 
The reaction mixture was diluted with H2O and extracted with EtOAc. The organic layer was dried 
with MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (20% EtOAc 
in pentane → 30% EtOAc in pentane) afforded carboxylic acid 20 (0.244 g, 0.42 mmol, 86%) as a clear 
oil. 1H NMR (400 MHz, CDCl3): δ (ppm) 7.41 – 7.20 (m, 20H, Harom), 4.87 (d, J = 11.6 Hz, 1H, 
CH2Bn), 4.77 – 4.61 (m, 4H, CH2Bn), 4.55 (d, J = 11.6 Hz, 1H, CH2Bn), 4.45 (s, 2H, CH2Bn), 4.41 – 
4.29 (m, 1H, H-2), 3.89 (s, 1H, H-4), 3.63 (t, J = 8.9, 1H, H-8), 3,55 (t, J = 7.5 Hz, 1H, H-8), 3.15 (d, J = 
8.2 Hz, 1H, H-3), 2.14 – 2.07 (m, H-1), 1.99 – 1.93 (m, 1H, H-5), 1.61 (t, J = 4.3 Hz, 1H, H-7), 1.40 – 
 Synthesis of potential glycosyltransferase inhibitors based on carba-cyclophellitol 
137 
1.36 (m, 1H, H-6). 13C NMR (100 MHz, CDCl3): δ (ppm) 179.4 (C=O), 139.1, 138.8, 138.1 (Cq), 128.6, 
128.4, 128.3, 128.0, 127.9, 127.9, 127.6, 127.5, 127.5 (CHarom), 82.7 (C-3), 76.0 (C-2), 75.6 (C-4), 74.1, 
73.4, 72.9, 71.8 (CH2Bn), 70.4 (C-8), 41.2 (C-5), 28.0 (C-1), 25.8 (C-7), 25.5 (C-6). HRMS: calculated 








 To a solution of carboxylic acid 20 (98 mg, 0.17 mmol) in toluene (5 mL) was added oxalyl chloride 
(0.15 mL, 1.7 mmol, 10 eq.). After stirring overnight at 40 °C, the reaction mixture was concentrated 
in vacuo followed by coevaporation with toluene (3x). The residu was redissolved in DCM (5 mL) and 
a solution of O-sulfamoylamide 18 (100 mg, 0.22 mmol, 1.3 eq.) in DCM (2 mL) and DIPEA (60 μL, 
0.34 mmol, 2 eq.) were added. After stirring for 3 h at room temperature, the reaction mixture was 
washed with an aqueous HCl solution (1 M), saturated aqueous NaHCO3 and brine. The organic layer 
was dried with Na2SO4, filtered and concentrated in vacuo. Purification by size exclusion 
chromatography (DCM/MeOH, 1:1) followed by silica column chromatography (20% EtOAc in 
pentane → 50% EtOAc in pentane) yielded compound 22 (100 mg, 98 μmol, 60%) as a white solid. 1H 
NMR (400 MHz, CDCl3): δ (ppm) 7.36 – 7.24 (m, 21H, H-6 and Harom), 5.79 (d, J = 1.8 Hz, 1H, H-1’), 
5.76 (d, J = 8.2 Hz, 1H, H-5), 4.88 – 4.43 (m, 12H, CH2Bn, , H-2’, H-3’ and H-5’), 4.39 – 4.33 (m, 2H, 
H-2’’ and H-4’), 3.93 (s, 1H, H-4’’),  3.64 – 3.54 (m, 2H, H-8’’), 3.13 (d, J = 8.5 Hz, 1H, H-3’’), 2.13 – 
2.09 (m, 1H, H-1’’), 2.02 – 1.97 (m, 1H, H-5’’), 1.66 – 1.61 (m, 1H, H-7’’), 1.58 (s, 9H, CH3), 1.55 (s, 
3H, CH3), 1.51 – 1.45 (m, 1H, H-6’’), 1.33 (s, 3H, CH3). 13C NMR (101 MHz, CDCl3): δ (ppm) 170.9 
(C-9’’), 160.5 (C-4), 148.6 (C-2), 147.7 (C=O-Boc) 140.8 (C-6), 138.9, 138.5, 138.1, 138.0, (Cq), 128.6, 
128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.6, 127.6, 127.5 (CHarom), 114.9 (Cq), 102.6 (C-5), 93.4 (C-
1’), 87.3 (Cq), 84.3 (C-2’), 83.9 (C-4’), 82.6 (C-3’’), 80.3 (C-3’), 76.2 (C-2’’), 75.1 (C-4’’), 74.2 (CH2Bn), 
73.4 (CH2Bn), 72.6 (C-5’), 72.5, 71.5 (CH2Bn), 70.4 (C-8’’), 45.9 (Cq) 41.0 (C-5’’), 28.6 (C-1’’), 27.5 








 To a cooled (0 °C) solution of compound 22 (100 mg, 98 μmol) 
in DCM (2 mL) was dropwise added a solution of TFA/H2O (9:1, 500 μL). After stirring for 4.5 h the 
reaction mixture was concentrated in vacuo followed by coevaporation with toluene (3x). Purification 
by column chromatography (50% EtOAc in pentane → EtOAc) afforded title compound 23 (70 mg, 79 
μmol, 81%) as a white solid. 1H NMR (400 MHz, MeOD): δ (ppm) 7.69 (d, J = 8.1 Hz, 1H, H-6), 7.39 – 
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7.17 (m, 20H, Harom), 5.89 (d, J = 3.9 Hz, 1H, H-1’), 5.72 (d, J = 8.1 Hz, 1H, H-5), 4.78 – 4.37 (m, 10H, 
CH2Bn and H-5’), 4.32 (dd, J = 8.3, 6.3 Hz, 1H, H-2’’), 4.21 – 4.10 (m, 3H, H-2’, H-3’ and H-4’), 3,90 
(s, 1H, H-4’’), 3.63 – 3.51 (m, 2H, H-8’’), 3.19 (d, J = 9.0 Hz, 1H, H-3’’), 2.17 – 2.09 (m, 1H, H-1’’), 
2.01 – 1.97 (m, 1H, H-5’’), 1.65 (t, J = 4.5 Hz, 1H, H-7’’), 1.50 – 1.42 (m, 1H, H-6’’). 13C NMR (101 
MHz, MeOD): δ (ppm) 173.5 (C-9’’), 166.0 (C-4), 152.3 (C-2), 142.3 (C-6), 140.2, 140.0, 139.9, 139.5 
(Cq), 129.5, 129.4, 129.4, 129.3, 129.1, 129.1, 129.1, 128.8, 128.7, 128.6, 128.5 (CHarom), 103.1 (C-5), 
90.5 (C-1’), 83.6 (C-3’’), 82.7 (C-4’), 76.9 (C-2’’), 76.7 (C-4’’), 75.2 (C-2’), 75.0, 74.2, 73.4, 72.7 
(CH2Bn), 71.9 (C-5’), 71.8 (C-8’’), 71.0 (C-3’), 42.2 (C-5’’), 29.3 (C-1’’), 28.4 (C-7’’), 26.7 (C-6’’). 







To a cooled (0 °C) solution of compound 23 (32 mg, 36 μmol) in 
DCM (2 mL) was dropwise added BCl3 (1 M in DCM, 300 μL, 0.30 mmol, 8 eq.). After stirring for 30 
min, the reaction mixture was allowed to warm to 0 °C. After stirring for additional 4 h, the reaction 
mixture was cooled to -78 °C and quenched with MeOH. The reaction mixture was concentrated in 
vacuo, redissolved in CHCl3 and stirred vigorously for 30 min before the suspension was filtered. The 
residue was taken up in methanol and concentrated in vacuo. Purification by HPLC (C18, linear 
gradient: 5 → 10% B in A, solutions used A: H2O, B: acetonitrile, 0.5% TFA, 15 min) afforded title 
compound 4 (13 mg, 25 μmol, 69%) as a white solid. 1H NMR (400 MHz, D2O): δ (ppm) 7.66 (d, J = 
8.1 Hz, 1H, H-6), 5.93 – 5.81 (m, 2H, H-1’ and H-5), 4.59 (dd, J = 11.4, 2.3 Hz, 1H, H-5’), 4.54 (dd, J = 
11.4, 3.4 Hz, 1H, H-5’), 4.31 – 4.27 (m, 2H, H-2’ and H-4’), 4.25 – 4.21 (m, 2H, H-2’’ and H-3’), 3.83 
(s, 1H, H-4’’), 3.74 – 3.51 (m, 2H, H-8’’), 3.20 (d, J = 9.1 Hz, 1H, H-3’’), 2.08 (ddd, J = 9.4, 6.1, 4.9 Hz, 
1H, H-1’’), 1.96 – 1.90 (m, 1H, H-5’’), 1.66 (t, J = 4.5 Hz, 1H, H-7’’), 1.45 – 1.40 (m, 1H, H-6’’). 13C 
NMR (101 MHz, D2O): δ (ppm) 173.9 (C-9’’), 166.1 (C-4), 151.6 (C-2), 141.6 (C-6), 102.4 (C-5), 89.3 
(C-1’), 80.9 (C-4’), 73.2 (C-3’’), 73.1 (C-2’), 70.9 (C-4’’), 70.7 (5’), 69.3 (C-3’), 67.4 (C-2’’), 62.1 (C-8’’), 
42.1 (C-5’’), 29.8 (C-1’’), 27.1 (C-7’’), 24.9 (C-6’’). HRMS: calculated for [C18H26N3O13S]+ 524.11808, 
found 524.11793.  
 
(1R,2S,3R,4R,5R,6R,7R)-2,3,4-tris(benzyloxy)-5-
((benzyloxy)methyl)bicyclo[4.1.0]heptane-7-carboxylic acid (26)  
Method A: To a solution of ester 25α (see Chapter 6, 0.202 g, 0.33 mmol) in 
THF/MeOH/H2O (6.5:1.5:1, 18 mL) was added LiOH (32 mg, 1.3 mmol, 4 eq.). 
After stirring for 5 h at room temperature, the reaction mixture was quenched with HCl (1 M) until 
pH 2. The reaction mixture was extracted with EtOAc (2x) and the combined organic layers where 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (10% 
EtOAc in pentane → 25% EtOAc in pentane) gave carboxylic acid 26 (0.173 g, 0.30 mmol, 91%) as a 
white oil.  
 Synthesis of potential glycosyltransferase inhibitors based on carba-cyclophellitol 
139 
Method B: Chromic acid stock solution (1.0 M) (Caution: Chromic acid is corrosive, toxic and 
carcinogenic): Concentrated H2SO4 (2.25 mL, 40.5 mmol) is taken up in H2O (12.5 mL). To this 
solution was added CrO3 (2.50 g, 25.0 mmol) and the resulting bright red solution was stirred until all 
solids were completely dissolved. The solution was then diluted with H2O to a total volume of 25 mL. 
Alcohol 27 (see Chapter 6, 0.116 g, 0.20 mmol) was dissolved in acetone (40 mL) and cooled to 0 °C, 
after which chromic acid stock solution (1M, 0.4 mL, 0.40 mmol, 2 eq.) was added. After stirring for 
70 min, the reaction mixture was diluted with EtOAc (150 mL) and washed with HCl (3 M, 2 x 100 
mL) and brine (100 mL). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (10% EtOAc in pentane → 25% EtOAc in pentane) resulted 
in carboxylic acid  26 (87 mg, 0.15 mmol, 75%) as a white solid. 1H NMR (400 MHz, CDCl3): δ (ppm) 
7.39 – 7.22 (m, 20H, Harom), 4.89 – 4.62 (m, 5H, CH2Bn), 4.43 (m, 3H, CH2Bn), 4.09 – 4.05 (m, 1H, H-
2), 3.61 (dd, J = 8.9, 4.5 Hz, 1H, H-8), 3.55 (dd, J = 8.9, 2.8 Hz, 1H, H-8), 3.40 (t, J = 10.2 Hz, 1H, H-4), 
3.29 – 3.22 (m, 1H, H-3), 2.06 – 2.05 (m, 1H, H-1), 1.99 – 1.90 (m, 1H, H-5), 1.84 – 1.80 (m, 1H, H-6), 
1.69 (t, J = 4.5 Hz, 1H, H-7). 13C NMR (101 MHz, CDCl3): δ (ppm)178.7 (C=O), 138.9, 138.5, 138.2, 
138.2 (Cq), 128.5, 128.5, 128.5, 128.5, 128.2, 128.0, 128.0, 128.0, 127.9, 127.8, 127.7 (CHarom), 84.0 (C-
3), 79.0 (C-2), 78.4 (C-4), 75.7, 75.4, 73.3, 71.7 (CH2Bn), 70.2 (C-8), 43.0 (C-5), 28.3 (C-1), 26.2 (C-9), 
24.7 (C-6). HRMS: calculated for [C37H38O6Na]+ 601.25606, found 601.25564. 
 





 Carboxylic acid 26 (74 mg, 0.12 mmol) was dissolved in toluene 
(6.0 mL) and oxalyl chloride (1 M in DCM, 0.24 mL, 0.24 mmol, 2.0 eq.) was added. The reaction 
mixture was stirred at 40 °C for 4 hours and concentrated in vacuo. The obtained acyl chloride was 
redissolved in DCM (7.0 mL) and O-sulfamoylamide 16 (0.100 g, 0.27 mmol, 2.3 eq.) and DIPEA (40 
μL, 0.24 mmol, 2 eq.) were added. After stirring overnight at room temperature, the reaction mixture 
was concentrated under reduced pressure and purified by size-exclusion column chromatography 
(DCM/MeOH, 1:1), resulting in product 29 (89 mg, 84 μmol, 70%) as a white wax. 1H NMR (400 
MHz, MeOD): δ (ppm) 7.75 (dd, J = 13.8, 7.7 Hz, 1H, H-6), 7.41 – 7.18 (m, 20H, Harom), 5.97 – 5.85 
(m, 1H, H-1’), 5.71 (d, J = 8.0 Hz, 1H, H-5), 4.89 – 4.86 (m, 1H, H-2’), 4.84 – 4.70 (m, 4H, H-3’, 
CH2Bn), 4.59 (d, J = 11.5 Hz, 1H, H-4’), 4.50 – 4.33 (m, 5H, CH2Bn), 4.31 – 4.23 (m, 2H, H-5’), 4.06 
(dd, J = 7.9, 5.9 Hz, 1H, H-2’’), 3.70 – 3.66 (m, 3H, Me-DIPEA), 3.58 – 3.57 (m, 2H, H-8’’), 3.35 – 3.27 
(m, 2H, H-4’’ and H-3’’), 3.21 – 3.15 (m, 2H, CH2-DIPEA) 2.09 – 2.02 (m, 1H, H-1’’), 1.95 (dd, J = 
12.9, 8.3 Hz, 1H, H-5’’), 1.74 (dd, J = 8.6, 5.3 Hz, 2H, H-7’’ and H-6’’), 1.56 – 1.47 (m, 3H. CH3), 1.39 – 
1.30 (m, 15H, CH3 and isopropyl DIPEA). 13C NMR (101 MHz, MeOD): δ (ppm) 166.1 (C=O), 162.7 
(C=O), 152.1 (C=O), 143.6 (C-2’’), 140.3, 140.0, 139.9, 139.6 (Cq), 129.4, 129.3, 129.3, 129.2, 129.2, 
129.1, 129.0, 129.0, 128.7, 128.5, 128.5 (CHarom), 115.2 (Cq), 103.2 (C-1’), 93.7 (C-1’’), 85.5 (C-2’), 85.4 
(C-4’), 85.1 (C-5), 82.3 (C-3), 80.4 (C-2), 79.9 (C-4), 76.3, 76.0, 74.1, 71.9 (CH2Bn), 71.4 (C-8), 70.1 
(C-5’), 55.8 (Me-DIPEA), 44.4 (C-5), 43.8 (CH2-DIPEA), 29.6 (C-7), 27.6 (C-1), 26.2 (CH3), 26.2 (C-








Compound 29 (86 mg, 81 μmol) was dissolved in DCM (10 mL) 
and cooled to 0 °C, before BCl3 (1 M in DCM, 1.11 mL, 1.11 mmol, 13.7 eq.) was added. After stirring 
for 3 h, the reaction mixture was quenched with MeOH. The reaction mixture was concentrated in 
vacuo, redissolved in CHCl3 and stirred vigorously for 30 min before the suspension was filtered. The 
residue was taken up in methanol and concentrated in vacuo. Purification by HPLC (C18, linear 
gradient: 5 → 10% B in A, solutions used A: H2O, B: acetonitrile, 0.5% TFA, 15 min) resulted into 
product 5 (23 mg, 43.5 μmol, 54%) as white solid. 1H NMR (400 MHz, MeOD): δ (ppm) 7.73 (t, J = 
10.0 Hz, 1H, H-6), 5.90 (d, J = 4.4 Hz, 1H, H-1’), 5.73 (dd, J = 19.7, 8.3 Hz, 1H, H-5), 4.55 – 4.47 (m, 
2H, H-5’), 4.20 (d, J = 4.1 Hz, 1H, H-4’), 4.18 – 4.11 (m, 2H, H-2’, H-3’), 3.98 – 3.90 (m, 1H, H-2’’), 
3.84 (dd, J = 10.5, 3.6 Hz, 1H, H-8’’), 3.70 – 3.59 (m, 1H, H-8’’), 3.14 (t, J = 10.1 Hz, 1H, H-4’’), 3.04 – 
2.95 (m, 1H, H-3’’), 2.03 – 1.97 (m, 1H, H-1’’), 1.80 – 1.65 (m, 3H, H-5’’, H-6’’, H-7’’). 13C NMR (101 
MHz, MeOD): δ (ppm) 172.8 (C=O), 152.6 (C=O), 142.4 (C-2’’), 103.1 (C- 1’’), 90.7 (C-1’), 82.8 (C-
4’), 76.2 (C-3), 75.0 (C-2’), 72.3 (C-2’), 72.1 (C-4), 71.7 (C- 2), 71.1 (C-3’), 64.2 (C-8), 46.2 (C-5), 31.3 
(C-1), 27.0 (C-6), 26.2 (C-7). HRMS: calculated for [C18H26N3O13S]+ 524.11808, found 524.11807. 
 
Materials of biological assays 
Recombinant human GBA1 (Cerezyme), recombinant human GAA (Myozyme) and recombinant 
human α-GalA (Fabrazyme) were obtained from Genzyme, USA. Bacterial GAA homologue 
CJAgd31B was kindly provided by professor Gideon Davies (University of York, UK). Cellular 
homogenates of a stable  human embryonic kidney 293 (HEK293) over-expressing GBA2 cell line18 
were pre-incubated for 30 min with an inhibitor of GBA1 (1 mM conduritol B epoxide (CBE)). 
Galactocerebrosidase (GALC) was obtained by expressing recombinant murine GALC in HEK293 
cells after which the secreted recombinant protein in the culture medium was directly used.19 
Fibroblasts of Pompe patients diagnosed on the basis of reduced GAA activity (obtained with consent 
from donors) were used for GANAB determinations. 
 
Enzyme activity assays, determination of the apparent IC50 values 
All activity assays were performed at 37 °C. To determine the apparent IC50 values, enzyme 
preparations were pre-incubated with a range of inhibitor concentrations for 30 min, where after the 
residual activity was measured by addition of the appropriated 4-methylumbelliferyl-based substrate 
mix. GBA1 residual activity was measured with 3.7 mM 4-methylumbeliferone(4-mu)-β-D-
glucopyranoside in 150 mM McIlvaine buffer, pH 5.2, supplemented with 0.2% Taurocholate (w/v), 
0.1% Triton X-100 (v/v), 0.1% Bovine Serum albumin (BSA) (w/v) for 30 min. GBA2 substrate mix 
consisted of 3.7 mM 4-mu-β-D-glucopyranoside in 150 mM McIlvaine, pH 5.8, 0.1% BSA (w/v) and 
was incubated for 1 h. α-GalA activity was determined with 2 mM 4-mu-α-D-galactopyranoside 
dissolved in 150 mM McIlvaine, pH 4.5, 0.1 % BSA (w/v) for 30 min. GAA substrate mix consisted of 
3 mM 4-mu-α-D-glucopyranoside pH 5.0, 0.1% BSA (w/v) for 1 h, GALC was assayed with 1.25 mM 
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4-mu-β-D-galactopyranoside in 150 mM McIlvaine pH 4.3 containing 0.2 M NaCl and 0.1% BSA 
(w/v) for 1h and GANAB with 3 mM 4-mu-α-D-glucopyranoside pH 7.0, 0.1% BSA (w/v) for 2 h. The 
bacterial enzyme activity of CJAgd31B was determined with 3 mM 4-mu-α-D-glucopyranoside in 50 
mM citrate buffer at the optimal pH 6.5, 0.1% BSA (w/v) for 1 h. After stopping the substrate reaction 
with an excess of 1 M NaOH-glycine (pH 10.3), liberated 4-mu fluorescence was measured with a 
fluorimeter LS55 (Perkin Elmer) using λEx 366 nm and λEm 445 nm. All IC50 values were determined in 
triplicate with Graphpad Prism 5 software.  
 
IC50 values for GCS were determined in situ with NBD-ceramide as substrate as previously 
described.20 Briefly, RAW 264.7 cells were grown to confluence in 6-well plates and pre-incubated for 
1 h with an inhibitor of GBA1 activity (300 μM CBE), followed by 1 h incubation at 37 °C with 1 nmol 
C6-NBD-ceramide (6-[N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) aminododecanoyl] 
sphingosine) and in the presence of a range of inhibitor concentrations. The cells were washed 3x with 
PBS and harvest by scraping. After lipid extraction21, the C6-NBD lipids were separated and detected 
by HPLC (λEx 470 nm and λEm 530 nm). IC50 values were determined in duplicate from the titration 
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alfunctioning of glycosidases causes various complex pathologies in man. 
Activity-Based Protein Profiling (ABPP) is a powerful technique to selectively 
analyze functional proteins in their physiological surroundings. Potent and selective 
activity-based glycosidase probes (ABPs) could help to understand the pathological 
processes connected with these enzymes. The first part of this Thesis describes the 
design, synthesis and application of a set of ABPs for retaining α-galactosidases, β-
galactosidases, α-mannosidases and β-mannosidases. The second part of this Thesis 
focuses on the design of functionalized bicycle [4.1.0] heptanes as potential competitive 
inhibitors of glycosidases (α-galactosidases, β-galactosidases, α-glucosidases and β-






Chapter 1 provides a brief overview of the basics of the ABPP technology. As well, 
information is provided on the reaction itineraries of retaining glycosidases, which are 
at the basis of the design of the covalent and competitive glycosidase inhibitors 
presented in this Thesis. Finally, the potencies of transition-state based inhibitors are 
described including therapeutic examples. Chapter 2 describes the development and 
validation of α-galactosidase selective probes that may be used to study the lysosomal 
storage disorders (LSDs), Fabry disease and Schindler disease. Both N-acylated- and N-
alkylated versions of α-galactose-configured cyclophellitol aziridines were examined on 
their capacity to inhibit and label, in an ABPP setting, retaining α-galactosidases. The 
N-acylated version is more prone to hydrolysis during purification and lyophilisation 
than its N-alkylated counterpart. However, this probe also proved the most effective in 
labeling retaining α-galactosidases. 
The synthesis and validation of a new β-galactosidase selective probe is presented in 
Chapter 3. Once the synthesis of the one-step ABP using the conventional method 
turned out to be abortive, a two-step bioorthogonal labeling approach was attempted. 
In this way, the human retaining β-galactosidase, GALC (lysosomal 
galactocerebrosidase) could be detected in kidney lysate by in-gel labeling. In a final 
attempt to obtain a one-step ABP, inverse-electron-demand Diels-Alder (IEDDA) 
ligation was successfully applied to obtain a potent one-step β-galactosidase probe for 
labeling of GLB1 and GALC in mouse kidney homogenates. This probe may in turn be 
used as tool to study GM1 gangliosidosis, Morquio B syndrome and Krabbe disease 
which are caused by mutations in GH35 and GH59 galactosidases, GBL1 and GALC, 
respectively. 
Looking forward to the sections on competitive inhibitors, Birch reduction of 
compound 11, which featured as an intermediate in the synthesis of galactose-
configured cyclophellitol, may yield cyclohexene 2 (Figure 9.1). Compound 2 may 
adopt the 4H3 conformation and thereby mimic the oxocarbenium ion transition-state 
of α-galactosidases (3) and β-galactosidases (4). Therefore, compound 2 may act as a 
potential reversible galactosidase inhibitor.  
 
The library of glycosidase ABPs is extended in Chapter 4 with the synthesis and 
validation of ABPs for retaining α-mannosidases. The reaction itinerary of α-
mannosidases is different from the previously described glycosidases, and a boat (B2,5) 
transition-state conformation is expected to emerge during substrate processing. A 
covalent enzyme-inhibitor complex was obtained after soaking of α-mannosidase 
configured cyclophellitol aziridine in GH38 Golgi α-mannosidase II from drosophila. 
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Figure 9.1 Cyclohexene 2 may adopt the 4H3 conformation and therefore conformationally mimic the 
oxocarbenium ion transition-state of α-galactosidases (3) and β-galactosidases (4). 
 
Herein, the cyclohexane has adopted the skew boat (1S5) conformation as expected 
from the reaction itinerary. The corresponding Cy5-functionalized ABP proved to label 
GH38 jack bean α-mannosidase in an activity-dependent fashion. Follow-up ABPP 
experiments in vitro and in vivo will reveal whether the α-mannosidases probes will be 
of use in diagnosing α-mannosidase connected diseases such as α-mannosidosis or 
larynx cancer, and the identification of therapeutics aimed at correcting these diseases.2 
The first part of this Thesis ends with the description, in Chapter 5, of a set of GH2 
exo-β-mannosidase selective ABPs. The β-mannopyranose-configured cyclophellitol 
aziridine based probes were validated in ABPP experiments with exo-β-mannosidases 
from Helix p. Furthermore, ABPP experiments in lysates of mice kidney resulted in 
labeling of MANBA, a GH2 β-mannosidase that is deficient in β-mannosidosis. 
 
Based on the results for mannosidases presented in this Thesis, it would be of interest 
to develop cyclophellitol-based ABPs (5 – 7, Figure 9.2) for other retaining 
exoglycosidases for which a boat transition-state conformation is expected as part of 
the reaction itinerary.3 In case of GH39 α-idurodinase, for example, such a 2,5B 
transition-state is expected to occur during substrate processing.4 α-Idurodinase 







Figure 9.2 Putative ABPs to target GH39 α-idurodinase (5), GH120 β-xylosidase (6) and GH78 α-




































I, caused by α-idurodinase deficiency.5 Another target could be GH120 β-xylosidase, 
found in Bifidobacterium adolescentis. Monitoring this enzyme with ABPs (6) could be 
of interest as this bacteria is present in the human gut.6 Finally, GH78 α-rhamnosidase 
is of industrial interest as this enzyme is used in the debittering of citrus juices.7-9 With 
ABPP using ABP 7 the enzyme activity could be monitored under various conditions.  
 
A putative synthesis of the α-L-rhamnopyranose-configured cyclophellitol aziridine 
based ABP 7 is depicted in Scheme 9.1. The synthetic strategy is based on the synthesis 
of cyclophellitol as described by Madsen and co-workers10, which has recently been  
 













Reagents and conditions: a) acetyl chloride, MeOH, 0 °C to rt; b) trityl chloride, pyridine, rt; c) BnBr, 
NaH, DMF, 0 °C to rt; d) pTsOH, DCM/MeOH (1:1), rt; e) i. PPh3, imidazole, THF, reflux; ii. I2, THF, 
reflux; f) Zn, THF/H2O (9:1), 50 °C, sonicate; g) ethyl 4-bromocrotonate, In (powder), La(OTf)3; h) 
Grubbs II, DCM, reflux; i) i. DIBAL, THF, 0 °C to rt; ii. NaBH4, EtOAc/H2O (2:1); j) pTsCl, Et3N, 
CH2Cl2; k) LiAlH4, THF, 0 C to rt; l) BnBr, NaH, DMF, 0 °C to rt; m) mCPBA, DCE, reflux; n) NaN3, 
LiClO4, MeCN, 80 °C; o) PPh3 polymer-bound on styrene-divinylbenzene copolymer, CH3CN, reflux, 
overnight; p) Li, THF, NH3 (l), - 60 °C; q) 1-azido-8-iodooctane, K2CO3, DMF, 80 °C, r) alkyne tags 
(see Chapter 4), Cu.SO4·5H2O, sodium ascorbate, DMF, rt. 
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optimized.11 Commencing with L-ribose12 (8) as starting material, aldehyde 9 may be 
obtained in 6 steps. Subsequently the stereoselective indium-catalyzed Barbier reaction 
with ethyl-4-bromocrotonate may be performed to obtain compound 10. The proposed 
stereoselective outcome of this reaction can be explained by the formed 6-membered 
transition state (Scheme 9.1). Grubbs II catalyzed ring closure metathesis of 10 
followed by reduction of the ethyl ester may give compound 11. Tosylation of the 
primary alcohol followed by treatment with lithium aluminium hydride13 may afford L-
rhamnopyranose-configured cyclohexene 12. After benzylation of 12, epoxidation with 
mCPBA may give the desired epoxide 13 and the diastereomeric isomer which may be 
separated by silica column chromatography. Treatment of epoxide 13 with sodium 
azide and lithium perchlorate14, followed by a Staudinger reaction using 
triphenylphosphine on beads may yield aziridine 14. After the Birch reduction, N-
alkylation with 1-azido-8-iodooctane and azide-alkyne Huisgen cycloaddition with a 
specific alkyne-tag (see Chapter 4), ABP 7 may be obtained. 
 
The galactopyranose-configured cyclophellitol (16) is an oxocarbenium ion transition-
state mimic (Scheme 9.2A and B). The introduction of a sulfate group, as in compound 
17, may result in a 4C1 conformational substrate mimic, which is susceptible to form a 
covalent enzyme-substrate adduct (Scheme 9.2C). The synthesis of this new class of 
cyclophellitols was explored starting from manno-configured cyclohexene 18 (Scheme 
9.2D). Ruthenium(III)-catalyzed syn-dihydroxylation15 of 18 proceeded in a 
stereoselective fashion and resulted into compound 19. After treatment with thionyl 
chloride and subsequent ruthenium catalyzed oxidation, cyclic sulfate 20 was obtained. 
Palladium-catalyzed hydrogenation gave target compound 21 (TB612). The 
conformation of TB612 may be confirmed by DFT calculations. No inhibition of 
TB612 in jack bean α-mannosidase was measured up to 50 μM. This result was 
expected, as the 4C1 conformation is not part of the reaction itinerary of α-
mannosidase. The herein described synthetic strategy could be extended to α-
galactopyranose-configured cyclophellitols. 
 
In Chapter 6 the synthesis is described of a focused library of carba-cyclophellitol 
based compounds with α-glucopyranose, β-glucopyranose, α-galactopyranose and β-
galactopyranose configuration. These are potential reversible inhibitors for glycosidases 
by mimicking the transition-state conformation of the oxocarbenium ion during the 
reaction itinerary. Alcohol 23 and ether 25 may be added to the described library 
(Scheme 9.3). Debenzylation of compound 22  using palladium-catalyzed 
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Scheme 9.2 Synthesis of cyclophellitol cyclosulfate 21.  
A) Proposed mechanisms of GH27 α-galactosidases. B) Galactopyranose-configured cyclophellitol 
(16) adopts a 4H3 conformation and mimics the oxocarbenium ion transition-state of GH27 α-
galactosidases. C) Compound 17 may adopt a 4C1 conformation and mimic the substrate 
conformation. Reagents and conditions: a) NaIO4, RuCl3.3H2O, H2O, EtOAc, MeCN, 0 °C, 1 h, 68%; 
b) i) SOCl2, Et3N, CH2Cl2, ii) NaIO4, RuCl3.3H2O, H2O, CCl4, MeCN, 0 °C, 1.5 h, 41% over 2 steps; c) 
10% Pd/C, H2, MeOH, 50%. 
 
hydrogenolysis conditions may give target compound 23. Alkylation (use of EtBr and a 
base) of alcohol 22, followed by palladium-catalyzed hydrogenolysis may afford 
compound 25. 
 
Scheme 9.3 The putative synthesis of β-glucopyranose-configured carba-cyclophellitol 23 and 25.  
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The β-glucopyranose-configured carba-cyclophellitols are biologically evaluated in 
Chapter 7 on their inhibitory potency of Thermotoga maritima TmGH1 β –glucosidase, 
GBA1 and GAA. Carba-cyclophellitols turned out to be selective β-glucosidase 
inhibitors. Futhermore, carba-cyclophellitol (26) with an N-(4-azidobutyl)carboxamide 
moiety is the most potent TmGH1 inhibitor (Ki of 8.2 nM, Figure 9.3). Next, the 
conformation of the carba-cyclophellitol derivatives were analysed by 1H NMR analysis, 
quantum mechanical analysis and DFT calculations, which all supported the 4H3 
conformation as the preferential conformation adopted by β-glucopyranose-configured 
carba-cyclophellitols. After soaking of carba-cyclophellitol DW082 in TmGH1, the 
obtained structure was analysed by X-ray crystallography, revealing that DW082 also 
shows up in 4H3 conformation when bound to the active site of this enzyme. As various 
glycosidase inhibitors are in clinical use or under examination as inhibitors, probes or 
pharmacological chaperones, the selectivity and tight binding properties of cyclopropyl 
sugars may be an attractive class for further investigation. Intestinal α-glucosidases, for 
example, is a target for treatment of diabetes mellitus type 2. Reversible inhibitors have 
been approved and are applied in the clinic.16 The α-glucopyranose-configured carba-
cyclophellitols, as described in Chapter 6, are designed as reversible α-glucosidase 
inhibitors and were examined as such. However, no inhibition up to 100 uM was 
observed using the 4-methylumbelliferyl-α-D-glucopyranoside as substrate in α-
glucosidases (GAA or GANAB). Similarly the α-galactopyranose-configured carba-
cyclophellitols were examined as potential α-galactosidase inhibitors and no inhibition 
up to 500 uM was observed using the 4-methylumbelliferyl-α-D-galactopyranoside as 
substrate and α-GalA as the glycosidase. The described β-galactopyranose-configured 
carba-cyclophellitols, however, do inhibit β-galactosidases in the micromolar range 
(Figure 9.3 and Table 9.1). 
Figure 9.3 The structures of DW082 (26) and β-galactopyranose configurated carba-cyclophellitols 




Table 9.1 The apparent IC50 values of compound 27 - 31 towards GALC and α-GalA in μM with 4-
methylumbelliferyl-α-D-galactopyranoside as substrate. 
 
Compound β-galactosidase (GALC) α-galactosidase (α-GalA) 
27 (TB304) >500  >500 
28 (TB405) 205.40 ± 10.95 >500 
29 (TB292) 39.91 ± 2.86 >500 
30 (TB283) 76.67 ± 0.89 >500 
31 (TB290) 349.53 ± 25.25 >500 
 
N-butyl-1-deoxynojirimycin (32, Zavesca, Figure 9.4) is an approved drug for the 
treatment of Gaucher disease in a substrate reduction therapy.17,18 This iminosugar is a 
potent (IC50 = 50 μM19) reversible inhibitor of glucosylceramide synthase (GCS), which 
significantly relieved the symptoms of Gaucher patients. Later, the more hydrophobic 
analogue, AMP-DNM (33) was reported to be a 100-fold more potent GCS inhibitor 
(IC50 = 0.2 μM19). Therefore, adamantane functionalized carba-cyclophellitol 34 
(TB648) was designed as a potential GCS inhibitor.  
Figure 9.4 The structures of potent (32 and 33) and potential (34) GCS inhibitors. 
  
The synthesis of TB648 is described in Scheme 9.4. Treatment of compound 35 
(Chapter 6) with diphenyl phosphoryl azide in the presence of triethylamine and tert-
butanol resulted into compound 36. Alkylation with 5-(adamant-1-yl-methoxy)-1-
bromopentane20, followed by global debenzylation and treatment with TFA gave target 
compound TB648 (34). The inhibition studies of TB648 towards GCS could not be 
performed in the timeframe of the here presented PhD research and will be performed 
in the near future. 
 
Zavesca and AMP-DNM are potential β-glucosidase inhibitors.20,21 The apparent IC50 
values were reassessed together with TB648 and extended to lysosomal α-glucosidase 
(GAA, Table 9.2). Zavesca and AMP-DNM inhibit GBA1 and GAA and more potently 
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Scheme 9.4 The synthesis of TB648 (34). 
Reagents and conditions: a) tBuOH, Et3N, diphenyl phosphoryl azide, 90 °C, overnight, 51%; b) 5-
(adamant-1-yl-methoxy)-1-bromopentane20, NaH, DMF, rt, 3 h, 81%; c) 10% Pd/C, H2, AcOH, 
MeOH, rt, 5 h; d) TFA, CH2Cl2, rt, 45 min, 80% over 2 steps.  
 
GBA2. TB648 turned out to be selective for GBA1 with potency in the nanomolar range 
(Table 9.2). Selective inhibitors of lysosomal glucocerebrosidase (GBA1) are pursued as 
they may be exploited in pharmacological chaperone therapy for Gaucher disease. 
Herein, the folding of the enzyme in the endoplasmic reticulum may be stabilized to 
restore the GBA1 activity.21 TB648 may therefore be exploited as a selective modulator 
of GBA1 in a clinical setting. 
 
Table 9.2 The apparent IC50 values of Zavesca (32), AMP-DNM (33) and TB648 (34) towards GBA1, 
GBA2 and GAA in μM. 
Compound 
Human β-glucosidases Human α-glucosidase 
GBA1 GBA2 GAA 
Zavesca (32) 604.40 ± 12.59 0.14 ± 0.01 39.37 ± 2.45 
AMP-DNM (33) 0.178 ± 0.003 0.0007 ± 0.0003 2.96 ± 0.07 
TB648 (34) 0.0111 ± 0.0008 47.91 ± 2.72 >1000 
 
The B2,5 transition-state is expected for mannosidases, unlike β-glucosidases or α-
galactosidases. This may explain the lower potency of mannopyranose-configured 
cyclophellitols towards mannosidases (Chapter 4 and Chapter 5) and therefore B2,5 
conformed compounds are interesting targets. The conformation of the bicyclic 
aziridine 38 was determined by J-coupling constant analysis and turned out to be 
predominantly B1,4 (Figure 9.5).22 This conformation resembles the conformation of 
oxocarbenium ion transition-state (39) present in the itinerary of α-mannosidases. This 
led to the design of bicyclic cyclopropyl 40 which may adopt a boat conformation as 
well. By altering of the hydroxyl conformations, a close mimic of 39 could be obtained 














Figure 9.5 Bicyclic aziridine 38 adopts predominantly the B1,4 conformation22 and therefore bicyclic 
cyclopropyl 40 is proposed to be a conformational mimic of the oxocarbenium ion transition-state of 
α-mannosidases. 
 
The putative synthesis of bicyclic cyclopropyl 40 is depicted in Scheme 9.5. 
Cyclopentene 4123 could be treated with HCl in a mixture of THF and H2O and 
subsequently benzylated to obtain compound 42. Cyclopropanation with EDA as 
described in Chapter 6 may give compound 43. Reduction of the ester followed by 
palladium-catalyzed hydrogenation may give target compound 40. 
 
Scheme 9.5 The putative synthesis of bicyclic cyclopropyl 40.  
Reagents and conditions: a) HCl, THF, MeOH; b) BnBr, NaH, DMF; c) EDA, Cu(acac)2, EtOAc; d) 
DIBAL, THF; e) Pd(OH)2/C, H2, MeOH. 
 
The substrate specificity of β-mannosidase over α-mannosidases is determined in part 
by the conformation of the aglycon. Bicyclic cyclopropyl 46 with the 2-hydroxyl group 
in axial position may result in a selective β-mannosidases inhibitor (Figure 9.6). The 
synthesis of this conformational analogue can be commenced with cyclopentene 47.24 
Global benzylation of compound 47, followed by cyclopropanation with EDA may give 
bicyclic cyclopropyl 49. After DIBAL-mediated reduction of 49 and palladium-
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Figure 9.6 Bicyclic cyclopropyl 46 is proposed to be a conformational mimic of the oxocarbenium ion 
transition-state of β-mannosidases (45). Reagents and conditions: a) BnBr, NaH, DMF; b) EDA, 
Cu(acac)2, EtOAc; c) DIBAL, THF; d) Pd(OH)2/C, H2, MeOH. 
 
The glycan metabolism is controlled by glycosidases together with glycosyltransferases 
(GTs). Potent GTs inhibitors, however, are scarce and often sought after as potential 
GT regulators. Based on the results of carba-cyclophellitols as analogues of the 
oxocarbenium ion-like transition-state, the synthesis of two potential carba-
cyclophellitol based galactosyltransferase (GalT) inhibitors (51 and 52, Figure 9.7) is 
described in Chapter 8. A O-sulfamoyl- (51) or a phosphate moiety (52) was 
introduced to mimic the substrate and enhance the potency towards GalTs.  
 
Figure 9.7 Potential carba-cyclophellitol based galactosyltransferase (GalT) inhibitors. 
 
Carba-cylophellitol UDP 57 may be an attractive target that could be obtained 
following the same synthetic strategy (Scheme 9.6A). After obtaining monophosphate 
55, the benzyl ethers may be removed with palladium-catalyzed hydrogenation. 
Coupling of phosphate 56 with phosphoramidite 58 using the previously described 
methodology could result into carba-cylophellitol UDP 57. As described by Wagner 
and co-workers, introduction of a formylthienyl moiety at position 5 of the uracil base 
of Gal-UDP resulted in an up to 10-fold lower Ki compared to the Km of the natural 
donor towards various galactosyltransferases.25 Therefore, Gal-UPD derivative 62 may 









































synthetic route towards compound 62 starts with 5-iodouridine-5’-
phosphoromorpholidate 60 which can be obtained from uridine (59) in 48% over three 
steps.25 Subsequently, tetrazole catalyzed coupling with carba-cyclophellitol 56, Suzuki 
coupling with (5-formyl-2-thienyl)boronic acid, deacetylation and treatment with 
Dionex sodium exchange resin may result in 5-(5-formylthien-2-yl) UDP carba-
cyclophellitol 62 as a sodium salt.  
 
Scheme 9.6 The putative synthesis compound 57 and compound 62. 
Reagents and conditions: a) tetrabenzyl pyrophosphate, LDA, THF, - 78 °C to rt, 2 h, 17%; b) i) H2, 
Pd/C 10%, MeOH, rt; ii) tertbutylammonium hydroxide (TBA-OH) 40% aqueous solution, 
lyophilisation; c) i) 5826, DCI, MeCN, rt; ii) tBuOOH, rt; ii) DBU, rt,; iii) Et3N/H2O/MeOH (1:1:3), rt; 
iv) size-exclusion, HPLC purification, Dionex sodium exchange; d) 56, tetrazole, DMF, rt; e) (5-
formyl-2-thienyl)boronic acid, Na2Cl4Pd, trisodium salt of triphenylphosphine-3,3’,3’’-trisulfonic acid 
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(TPPTS), Cs2CO3, H2O, 50 °C; f) Et3N/H2O/MeOH (1:3:1), rt, size-exclusion, HPLC purification, 
Dionex sodium exchange.  
 
To determine the potency of GalT inhibitors, the donor and acceptor substrate are 
required. The donor substrate of GTB, for example, is commercially available (UDP-α-
D-galactose as a disodium salt). A simplified acceptor substrate, α-L-Fucp-(1→2)-β-D-
Galp-O-(CH2)8N3 63 (Figure 9.8), can be synthesized (see experimental). Although this 






Figure 9.8 Structure of acceptor substrate 63. 
 
After having the donor and acceptor analogue 63 in hand a spectroscopic assay with a 
cascade of reactions, such as the commercial available Malachite green assay, can be 
performed to determine the inhibition potency of a potential inhibitor by a fluorescent 
output (Figure 9.9). In this assay, phosphatases will give inorganic phosphate (Pi) from 
the GTB produced UDP. After formation of Pi, a solution of ammonium molybdate in 
diluted sulfuric acid will be added followed by the addition of malachite green oxalate. 
Finally, the absorbance at 620 nm of the obtained malachite phosphomolybdate 
complex is proportional with the conversion of GTB.  
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Additionally compound 51 (AB180) and 52 (AB209) were examined towards 
galactosidases. AB180 turned out to be the first potent carba-cyclophellitol based α-
GalA inhibitor (Table 9.3).  
 
Table 9.3 The apparent IC50 values of 51 and 52 towards GALC and α-GalA in μM. 
Compound β-galactosidase (GALC) α-galactosidase (α-GalA) 
51 (AB180) 180.27 ± 4.52 18.84 ± 1.33 
52 (AB209) >500 >500 
 
In the second part of Chapter 8, compound ML128 (64) was synthesized and analysed 
towards glucosylceramide synthase (GCS) as well as towards α-glucosidases (GAA and 
GANAB) and β-glucosidases (GBA1 and GBA2). However, no inhibition was observed. 














Figure 9.10 A) Structures of compound 64 (ML128) and 65 (ML131). B) Synthesis of β-
glucopyranose-configurated carba-cyclophellitol 65 (ML131). Reagents and conditions: a) i) oxalyl 
chloride, toluene, 40 °C, 5 h; ii) 2’,3’-O-isopropylidene-5’-O-sulfamoyluridine, N,N-
diisopropylethylamine, CH2Cl2, rt, overnight, size-exclusion, 86%; b) i) BCl3, CH2Cl2, 0 °C, 3 h; ii) 
MeOH, HPLC purification, 20%. 
 
The inhibitory potency of ML131 65 was determined towards GBA1, GBA2, GAA and 
GANAB (all glycosidases) and GCS (a glycosyl transferase) in a similar fashion as for 
compound 64. ML131 turned out to be micromolar active towards GBA1 and GBA2 
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(Table 9.4), similar to the most potent carba-cyclophellitol analogue reported in 
Chapter 7, DW082. 
 
Table 9.4 Apparent IC50 values of compound 65 towards glucosyltranferase and glycosidases (μM). 
 
Compound β-glucosidase α-glucosidase GlucT 
 GBA1 GBA2 GAA GANAB GCS 





General methods: All chemicals were purchased from Acros, Sigma Aldrich, Biosolve, VWR, Fluka, 
Merck and Fisher Scientific and used as received unless stated otherwise. Dichloromethane (DCM), 
tetrahydrofuran (THF), N,N-dimethylformamide (DMF) and toluene were stored over flame-dried 4 
Å molecular sieves before use. Pyridine was stored on KOH pellets before use. Traces of water from 
reagents were removed by co-evaporation with toluene in reactions that require anhydrous 
conditions. All reactions were performed under an argon atmosphere unless stated otherwise. TLC 
analysis was conducted using Merck aluminium sheets (Silica gel 60 F254) with detection by UV 
absorption (254 nm), by spraying with a solution of (NH4)6Mo7O24·4H2O (25 g/L)  and 
(NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid, a solution of KMnO4 (20 g/L) and K2CO3 (10 
g/L) in water or ninhydrin (0.75 g/L), followed by charring at ~150 ˚C. Column chromatography was 
performed using Screening Device b.v. Silica Gel (particle size of 40 – 63 μm, pore diameter of 60 Å) 
in the indicated solvents. For reversed-phase HPLC purifications an Agilent Technologies 1200 series 
instrument equipped with a semiprep column (Gemini C18, 250 x 10 mm, 5 μm particle size, 
Phenomenex) was used. LC/MS analysis was performed on a Surveyor HPLC system (Thermo 
Finnigan) equipped with a C18 column (Gemini, 4.6 mm x 50 mm, 5 μm particle size, Phenomenex), 
coupled to a LCQ Adventage Max (Thermo Finnigan) ion-trap spectrometer (ESI+). The applied 
buffers were H2O (A) and MeCN with 1% aqueous TFA (B). Optical rotations were measured on a 
Propol automatic polarimeter. 31P NMR, 1H NMR and 13C NMR spectra were recorded on a Brüker 
AV-400 (161.7, 400 and 101 MHz respectively) spectrometer in the given solvent. Chemical shifts are 
given in ppm (δ) relative to the residual solvent peak or tetramethylsilane (0 ppm) as internal 
standard. Coupling constants are given in Hz. High-resolution mass spectrometry (HRMS) analysis 
was performed with a LTQ Orbitrap mass spectrometer (Thermo Finnigan), equipped with an 
electronspray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10 mL/min, 
capillary temperature 250 °C) with resolution R = 60000 at m/z 400 (mass range m/z = 150 – 2000) 
and dioctyl phthalate (m/z = 391.28428) as a “lock mass”. The high-resolution mass spectrometer was 






To a solution of cyclohexene 3 (1.04 g, 2.0 mmol) in EtOAc/ACN (1:1, 60 mL) was 
added a solution of sodium periodate (0.641 g, 3 mmol, 1.5 eq.) and catalytic amount 
of ruthenium(III) chloride trihydrate (36 mg, 0.14 mmol, 0.07 eq.) in H2O (16 mL) at 
0 °C. After vigorously stirring for 1 h, the reaction mixture was quenched with 10% aqueous Na2S2O3 
(15 mL) and diluted with saturated aqueous NaHCO3 and EtOAc. The aqueous layer was separated 
and extracted with EtOAc (3 x). The combined organic layers were washed with brine, dried over 
MgSO4 and concentrated in vacuo. Purification by column chromatography (30% EtOAc in pentane 
→ 40% EtOAc in pentane) gave diol 4 (0.746 g, 1.34 mmol, 68%) as a clear oil. 1H NMR (400 MHz, 
CDCl3) δ 7.40 – 7.24 (m, 18H), 7.22 – 7.17 (m, 2H), 4.89 (d, J = 11.0 Hz, 1H), 4.78 (d, J = 12.2 Hz, 1H), 
4.69 – 4.59 (m, 3H), 4.49 (s, 2H), 4.45 (d, J = 10.9 Hz, 1H), 4.06 – 3.91 (m, 5H), 3.64 (t, J = 9.3 Hz, 1H), 
3.56 (t, J = 9.0 Hz, 1H), 2.60 (s, 1H), 2.23 (qd, J = 9.4, 3.3 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
138.7, 138.5, 138.5, 137.4, 128.6, 128.4, 128.1, 128.0, 127.8, 127.7, 127.6, 81.2, 75.9, 75.7, 75.0, 73.6, 
73.3, 72.6, 71.9, 71.8, 71.8, 70.0, 42.7. HRMS: calculated for [C35H38O6]+ 555.27412, found 555.27433. 
 
(3aR,4S,5S,6R,7R,7aS)-4,5,6-tris(benzyloxy)-7-
((benzyloxy)methyl)hexahydrobenzo[d][1,3,2]dioxathiole 2,2-dioxide (5) 
Diol 4 (0.36 g, 0.65 mmol) was dissolved in CH2Cl2 (30 mL) and Et3N (0.33 mL, 2.4 
mmol, 3.7 eq.) was added at 0 °C. Next, thionyl chloride (0.15 mL, 2.1 mmol, 3.2 
eq.) was slowly added over 5 min. After stirring for 1 h, additional Et3N (90 μL, 0.65 mmol, 1 eq.) and 
thionyl chloride (45 μL, 0.65 mmol, 1 eq.) was added. The reaction mixture was stirred for an 
additional 30 min before quenching with cold H2O and dilution with cold Et2O. The layers were 
separated and the organic layer was washed with H2O (2 x), dried over MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography (3.5% EtOAc in pentane) gave the 
sulphite diastereomeric mixture (390 mg) as an orange oil. HRMS: calculated for [C35H37O7S]+ 
601.22545, found 601.22584. To a solution of the sulphite diastereomeric mixture (192 mg, 0.32 
mmol) in CCl4/MeCN (1:1, 24 mL) was added a solution of sodium periodate (0.137 g, 0.64 mmol, 2.0 
eq.) and a catalytic amount of ruthenium(III) chloride trihydrate (6 mg, 22 μmol, 0.07 eq.) in H2O (12 
mL) at 0 °C. After vigorously stirring for 1.5 h, the reaction mixture was diluted with Et2O and H2O. 
The organic layer was separated, washed with brine, dried over MgSO4 and concentrated in vacuo. 
Purification by column chromatography (8% EtOAc in pentane) gave title compound (81 mg, 0.131 
mmol, 41% over 2 steps) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.20 (m, 18H), 7.14 
(dd, J = 7.3, 2.2 Hz, 2H), 5.29 (dd, J = 11.2, 6.4 Hz, 1H), 5.20 (t, J = 6.2 Hz, 1H), 4.73 (dd, J = 19.8, 11.8 
Hz, 1H), 4.59 (d, J = 4.2 Hz, 2H), 4.59 – 4.51 (m, 1H), 4.43 (d, J = 11.7 Hz, 2H), 4.31 (d, J = 11.9 Hz, 
1H), 4.22 (d, J = 11.5 Hz, 1H), 4.11 (d, J = 1.6 Hz, 1H), 3.82 – 3.77 (m, 2H), 3.62 – 3.46 (m, 2H), 2.26 – 
2.16 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 138.0, 137.6, 137.5, 137.4, 128.7, 128.6, 128.5, 128.2, 
128.1, 128.0, 127.9, 127.7, 83.6, 80.0, 76.5, 74.2, 73.2, 72.9, 72.8, 72.6, 64.8, 42.5. HRMS: calculated for 
[C35H36O8SNa]+ 639.20231, found 639.20238. 
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(3aR,4S,5S,6R,7R,7aS)-4,5,6-trihydroxy-7-
(hydroxymethyl)hexahydrobenzo[d][1,3,2]dioxathiole 2,2-dioxide (6, TB612) 
Benzylated sulphate 5 (70 mg, 0.11 mmol) was dissolved in MeOH (10 mL). The 
reaction mixture was purged with nitrogen gas and 10% palladium on carbon (15 
mg) was added. After the reaction vessel was purged with hydrogen gas and vigorously stirring 
overnight, the palladium catalyst was filtered off followed by concentration in vacuo. Purification by 
column chromatography (10% MeOH in DCM → 20% MeOH in DCM) resulted compound 6 (14 mg, 
55 μmol, 50%) as a clear oil. 1H NMR (500 MHz, MeOD) δ 4.20 (d, J = 2.0 Hz, 1H), 4.15 (d, J = 5.2 Hz, 
1H), 4.08 (d, J = 5.3 Hz, 1H), 4.04 – 3.97 (m, 1H), 3.79 – 3.73 (m, 1H), 3.59 (dd, J = 10.6, 6.3 Hz, 1H), 







To a solution of carboxylic acid 35 (80 mg, 0.138 mmol) in tert-
butanol (4 mL) was added triethylamine (21 μL, 0.152 mmol, 1.1 
eq.) and diphenylphosphorylazide (33 μL, 0.152 mmol, 1.1 eq.). 
The reaction mixture was heated to 90 °C and stirred overnight. The solution was concentrated in 
vacuo, redissolved in EtOAc (15 mL) and washed with HCl (1 M) and saturated aqueous NaHCO3. 
The organic layer was dried over MgSO4 and concentrated in vacuo. Purification by column 
chromatography (10% EtOAc in pentane → 20% EtOAC in pentane) gave compound  36 (45 mg, 
0.069 mmol, 51%) as a white solid. HRMS: calculated for [C41H48NO6]+ 650.34761, found 650.34826. 
Compound 36 (9.1 mg, 14.1 μmol) was taken up in DMF (0.14 mL) and subsequently 5-(adamant-1-
yl-methoxy)-1-bromopentane (18 mg, 56 μmol, 4 eq.) and NaH (60% dispersion in mineral oil, 4.0 
mg, 0.10 mmol, 7 eq.) were added at room temeprature. After stirring for 3 h, the reaction mixture 
was diluted with Et2O and washed with aqueous HCl (0.1 M). The water layer was extracted with Et2O 
(3 x) and the combined organic layers were dried over MgSO4 and concentrated in vacuo. Purification 
by column chromatography (4% EtOAc in pentane → 8% EtOAc in pentane) gave title compound 37 
(10.1 mg, 11.4 μmol, 81%) as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 7.1 Hz, 2H), 7.37 – 
7.20 (m, 16H), 7.13 (dd, J = 6.7, 2.9 Hz, 2H), 4.88 (d, J = 11.0 Hz, 2H), 4.82 – 4.73 (m, 3H), 4.49 (d, J = 
2.5 Hz, 2H), 4.36 (d, J = 10.8 Hz, 1H), 3.88 (d, J = 8.0 Hz, 1H), 3.78 (dd, J = 8.7, 2.9 Hz, 1H), 3.66 (t, J = 
6.7 Hz, 1H), 3.54 (d, J = 7.8 Hz, 1H), 3.50 (d, J = 8.5 Hz, 1H), 3.30 (t, J = 6.5 Hz, 2H), 3.04 – 2.98 (m, 
1H), 2.93 (d, J = 2.5 Hz, 2H), 2.42 – 2.35 (m, 2H), 1.94 (s, 3H), 1.75 – 1.16 (m, 22H). HRMS: calculated 





(hydroxymethyl)bicyclo[4.1.0]heptane-2,3,4-triol (34, TB648) 
Compound 37 (9.5 mg, 10 μmol) was dissolved in MeOH (1 mL). A 
few drops of acetic acid (glacial) and 10% Pd on carbon (8 mg) 
were added and the reaction vessel was purged with hydrogen gas. 
After vigorously stirring for 5 h at room temperature, the solution 
was filtered and concentrated in vacuo. The residue was dissolved in CH2Cl2/trifluoroacetic acid (1.6 
mL, 1:1) and stirred for 45 min at room temperature. The reaction mixture was concentrated in vacuo 
an purification by HPLC purification (C18, linear gradient: 30-36% B in A, solutions used A: H2O, B: 
acetonitrile, 0.5% TFA) yielded adamantane 34 (3.4 mg, 8.1 μmol, 80%) as a clear oil. LC/MS analysis: 
Rt 5.6 min (linear gradient 10% → 90% B in 12.5 min, ). 1H NMR (850 MHz, MeOD) δ 4.62 (s, 1H), 
3.93 (dd, J = 10.5, 4.5 Hz, 1H), 3.61 (dd, J = 10.5, 7.9 Hz, 1H), 3.47 (dd, J = 8.4, 1.2 Hz, 1H), 3.39 (t, J = 
6.4 Hz, 2H), 3.09 (dd, J = 10.0, 8.5 Hz, 1H), 2.97 (s, 2H), 2.80 (t, J = 10.2 Hz, 1H), 2.69 (t, J = 7.6 Hz, 
2H), 2.03 – 1.98 (m, 1H), 1.94 (s, J = 7.9 Hz, 1H), 1.91 (d, J = 7.5 Hz, 1H), 1.77 (s, 1H), 1.75 (s, 1H), 
1.69 (s, 1H), 1.68 (s, 1H), 1.61 – 1.57 (m, 2H), 1.56 (s, 2H), 1.56 (s, 2H), 1.55 – 1.51 (m, 2H), 1.44 – 
1.38 (m, 2H), 1.37 – 1.30 (m, 2H), 1.22 (s, 2H), 1.06 (dd, J = 9.6, 1.0 Hz, 1H). 13C NMR (214 MHz, 
MeOD) δ 83.1, 79.4, 74.6, 72.5, 71.0, 64.9, 50.1, 49.3, 49.2, 49.1, 49.0, 48.9, 48.8, 48.7, 43.6, 40.8, 39.7, 




phosphoryl)oxy)methyl)bicycle[4.1.0]heptane-2,3,4-triyl triacetate (55) 
Alcohol 54 (142 mg, 0.38 mmol) was dissolved in THF (5 mL), cooled to -78 
°C and lithium diisopropylamide (2 M in THF, 0.21 mL, 0.42 mmol, 1.1 eq.) 
was added. After stirring for 5 min,  tetrabenzyl pyrophosphate (0.246 g, 0.46 mmol, 1.2 eq.) in THF 
(2 mL) was added. The reaction mixture was stirred for 3 h, before being quenched with saturated 
aqueous NaHCO3, extracted with  EtOAc and washed with brine. The aqueous layer was extracted 
once with EtOAc. The combined organic layers were dried over MgSO4, filtered and concentrated in 
vacuo. Purification by column chromatography (20% EtOAc in pentane → 50% EtOAc in pentane) 
gave compound 55 (42 mg, 66 μmol, 17%) as a white solid. 31P NMR (162 MHz, CDCl3): δ = -0.47. 1H 
NMR (400 MHz, CDCl3): δ 7.37 (s, 10H), 5.36 (dd, J = 9.2, 6.8 Hz, 1H), 5.26 (s, 1H), 5.08 – 4.98 (m, 
4H), 4.55 (dd, J = 9.3, 1.6 Hz, 1H), 4.10 – 3.94 (m, 2H), 3.85 – 3.67 (m, 2H), 2.16 – 2.13 (m, 1H), 2.10 – 
2.00 (m, 12H), 1.67 – 1.63 (m, 1H), 1.11 – 1.03 (m, 1H), 0.80 – 0.71 (m, 1H). 13C NMR (100 MHz, 
CDCl3): δ 171.0, 170.8, 170.6, 170.3, 135.9, 135.8, 128.8, 128.1, 72.1, 70.2, 70.2, 69.5, 69.4, 69.4, 69.2, 
69.0, 62.8, 38.0, 24.4, 24.3, 21.3, 21.2, 20.9, 20.9 20.8, 18.5. HRMS: Calculated for [C31H38O12P]+ 
633.20954, found 633.21000. 
 
Phenyl 3-O-benzyl-4,6-O-benzylidene-1-thio-β-D-galactopyranoside (68) 
To a solution of phenyl 4,6-O-benzylidene-1-thio-β-D-galactopyranoside29 (6.49 g, 
18.0 mmol) in toluene (45 mL) was added dibutyltinoxide (4.52 g, 18.2 mmol).30 
After reflux overnight in a Dean-Stark apparatus the reaction mixture was 
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concentrated in vacuo. The resulting mixture was redissolved in DMF (45 mL) and CsF (5.46 g, 36.0 
mmol) and BnBr  (3.21 mL, 27.0 mmol) were added. After stirring for 3 h at room temperature the 
reaction mixture was quenched with MeOH, filterated over celite and concentrated in vacuo. 
Purification by silica chromatography (5% EtOAc in toluene → 6% EtOAc in toluene) resulted in 
compound 68 (5.18 g, 11.5 mmol, 64%) as a white solid. [α]D20 = -8.0 (c = 0.1, CHCl3). 1H NMR (400 
MHz, CDCl3): δ = 7.71 – 7.64 (m, 2H), 7.47 – 7.11 (m, 13), 5.41 (s, 1H), 4.71 (d, J = 4.0 Hz, 2H), 4.50 
(d, J = 9.5 Hz, 1H), 4.34 (dd, J = 12.3, 1.3 Hz, 1H), 4.12 (d, J = 3.2 Hz, 1H), 4.00 – 3.89 (m, 2H), 3.49 
(dd, J = 9.3, 3.3 Hz, 1H), 3.41 (s, 1H), 2.47 (s, 1H). 13C NMR (101 MHz, CDCl3): δ = 138.0, 137.9, 
133.8, 130.7, 129.1, 129.0, 128.6, 128.2, 128.2, 128.0, 126.6, 101.2, 87.1, 80.3, 73.3, 71.7, 70.1, 69.5, 67.2. 




To a solution alcohol 68 (90 mg, 0.2 mmol) in pyridine (0.5 mL) was added benzoyl 
chloride (26 μL, 0.22 mmol). After stirring overnight at room temperature the 
reaction mixture was diluted with EtOAc, washed with H2O and brine. The organic layer was dried 
with MgSO4, filtered and concentrated in vacuo. Purification by silica chromatography (5% EtOAc in 
toluene) yielded in compound 69 (110 mg, 0.2 mmol, quant.) as a white solid. [α]D20 = -6.0 (c = 1.0, 
CHCl3). 1H NMR (400 MHz, CDCl3): δ = 8.12 (d, J = 7.6 Hz, 2H), 8.04 (d, J = 7.9 Hz, 2H), 7.59 – 7.09 
(m, 16H), 5.57 (t, J = 9.7 Hz, 1H), 5.48 (s, 1H), 4.80 (d, J = 9.8 Hz, 1H), 4.67 – 4.51 (m, 2H), 4.37 (d, J 
= 12.2 Hz, 1H), 4.24 (d, J = 3.1 Hz, 1H), 4.01 (d, J = 12.2 Hz, 1H), 3.76 (dd, J = 9.6, 3.2 Hz, 1H), 3.48 (s, 
1H). 13C NMR (101 MHz, CDCl3): δ = 172.1, 165.1, 137.7, 133.90, 133.8, 133.1, 131.7, 130.3, 130.3, 
130.0, 129.1, 128.8, 128.6, 128.5, 128.4, 128.2, 128.1, 127.8, 127.8, 126.7, 101.4, 85.5, 78.2, 73.2, 71.1, 




Compound 69 (124mg, 0.73 mmol) and 8-azidooctan-1-ol31 (443 mg, 0.8 mmol) 
were dissolved in CH2Cl2 (4 mL), after which activated molecular sieves (4 Å) 
were added. The reaction mixture was cooled to -45 °C and subsequently N-
iodosuccinimide (392 mg, 1.74 mmol) and TMSOTf (33 μL, 184 μmol) were added. After stirring for 
30 min at -40 °C the reaction mixture was quenched at 0 °C with Et3N (1 mL), diluted with CHCl3 and 
washed with NasS2O3 and H2O. The organic layer was dried with MgSO4, filtered and concentrated in 
vacuo. Purification by column chromatography (30% EtOAc in pentane →  50% EtOAc in pentane) 
gave compound 70 (380 mg, 618 μmol, 85%) as a clear yellow oil. 1H NMR (400 MHz, CDCl3): δ = 
8.04 (d, J = 7.1 Hz, 2H), 7.63 – 7.54 (m, 4H), 7.45 (t, J = 7.7 Hz, 2H), 7.40 – 7.32 (m, 3H), 7.28 – 7.14 
(m, 4H), 5.63 (dd, J = 10.0, 8.0 Hz, 1H), 5.52 (s, 1H), 4.69 (d, J = 12.9 Hz, 1H), 4.60 (d, J = 12.9 Hz, 
1H), 4.54 (d, J = 8.0 Hz, 1H), 4.37 – 4.29 (m, 1H), 4.24 (d, J = 3.4 Hz, 1H), 4.07 (dd, J = 12.3, 1.5 Hz, 
1H), 3.94 – 3.87 (m, 1H), 3.74 (dd, J = 10.1, 3.5 Hz, 1H), 3.48 – 3.37 (m, 2H), 3.16 (t, J = 7.0 Hz, 2H), 
1.47 – 1.39 (m, 3H), 1.21 – 1.00 (m, 9H). 13C NMR (101 MHz, CDCl3): δ = 165.2, 138.0, 137.8, 133.0, 
130.4, 129.9, 129.0, 128.4, 128.4, 128.2, 127.8, 126.6, 101.4, 101.3, 77.0, 73.2, 70.9, 70.9, 69.3, 69.3, 66.7, 
51.5, 29.4, 29.1, 29.0, 28.8, 26.6, 25.8. HRMS: calculated for [C35H42N3O7]+ 616.30173; found 616.30190 
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8-azidooctane 3-O-benzyl-4,6-O-benzylidene-β-D-galactopyranoside (71) 
To a solution of 70 (0.529 g, 0.859 mmol) in MeOH (29 mL) was added NaOMe 
(192 mg, 3.55 mmol) and stirred for 5 h at room temperature. After 
neutralization with Amberlite-H+ IR-200 the reaction mixture was filtered and 
concentrated in vacuo. Purification by silica chromatography (50% EtOAc in 
pentane) resulted in compound 71 (0.369 g, 0.72 mmol, 84%) as a white solid. [α]D20 = +21.6 (c = 1.0, 
CHCl3). 1H NMR (400 MHz, CDCl3): δ = 7.56 – 7.49 (m, 2H), 7.48 – 7.21 (m, 8H), 5.44 (s, 1H), 4.75 
(s, 2H), 4.32 – 4.24 (m, 2H), 4.11 (d, J = 3.4 Hz, 1H), 4.04 – 3.96 (m, 3H), 3.54 – 3.43 (m, 2H), 3.32 (s, 
1H), 3.23 (t, J = 6.9 Hz, 2H), 2.57 (s, 1H), 1.69 – 1.52 (m, 4H), 1.38 – 1.23 (m, 8H). 13C NMR (101 
MHz, CDCl3): δ = 138.2, 137.8, 128.9, 128.5, 128.1, 127.9, 126.4, 102.9, 101.1, 79.1, 73.2, 71.5, 70.1, 
69.7, 69.3, 66.6, 51.5, 29.5, 29.3, 29.1, 28.8, 26.6, 25.9. HRMS: calculated for [C28H38N3O6]+  512.27551; 




Compound 71 (0.316 g, 0.618 mmol) and 2-O-benzyl-3,4-O-pivaloyl-1-thio-α-L-
fucopyranoside32 (0.477 g, 0.928 mmol) were dissolved in CH2Cl2 (10.3 mL), 
after which activated molecular sieves (3 Å) and N-iodosuccinimide (0.333 g, 
1.48 mmol) were added. The reaction mixture was cooled to -45 °C and TMSOTf 
(11.2 μL, 62 μmol) was added. After stirring for 1 h at -40 °C the reaction mixture was warmed to -15 
°C, quenched with Et3N (3 mL) and washed with NasS2O3 and aqueous saturated NaHCO3. The 
organic layer was dried with MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (20% EtOAc in pentane) gave disaccharide 72 as a white solid (393 mg, 429 μmol, 
69%). [α]D20 = -36 (c = 0.4, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 7.53 (d, J = 6.3 Hz, 2H), 7.34 - 
7.14 (m, 11H), 7.07 – 7.01 (m, 2H), 5.64 (d, J = 3.4 Hz, 1H), 5.43 (s, 2H), 5.40 – 5.34 (m, 1H), 5.24 (d, J 
= 2.4 Hz, 1H), 4.77 – 4.73 (m, 2H), 4.60 (d, J = 12.4 Hz, 1H), 4.52 (d, J = 11.7 Hz, 1H), 4.46 (d, J = 7.8 
Hz, 1H), 4.40 (d, J = 12.4 Hz, 1H), 4.29 (d, J = 12.1 Hz, 1H), 4.22 – 4.13 (m, 2H), 4.02 (d, J = 11.8 Hz, 
1H), 3.97 – 3.90 (m, 1H), 3.85 – 3.74 (m, 2H), 3.46 – 3.39 (m, 1H), 3.35 (s, 1H), 3.23 (t, J = 7.0 Hz, 
2H), 1.36 – 1.30 (m, 4H), 1.36 – 1.30 (m, 8H), 1.14 (s, 9H), 1.13 (s, 9H), 1.04 (d, J = 6.4 Hz, 3H). 13C 
NMR (101 MHz, CDCl3): δ = 177.8, 177.4, 138.2, 137.8, 137.5, 128.8, 128.5, 128.4, 128.1, 128.0, 127.8, 
127.7, 127.6, 127.2, 126.2, 101.6, 100.6, 96.8, 81.3, 72.3, 72.3, 72.0, 71.5, 70.0, 71.4, 70.38, 69.7, 69.3, 
66.3, 64.7, 51.4, 39.0, 38.7, 29.6, 29.4, 29.1, 28.8, 27.3, 27.2, 26.7, 26.1, 15.8. HRMS: calculated for 




Disaccharide 72 (274 mg, 0.300 mmol) was dissolved in AcOH/H2O (6 mL, 4:1, 
v/v) and heated to 50 °C. After stirring overnight the reaction mixture was 
concentrated and co-evaporated with toluene (7x). Purification by silica 
chromatography (50% EtOAC in pentane) resulted in diol 73 (176 mg, 0.213 mmol, 71%) as a clear 
oil. [α]D20 = -60 (c = 1, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 7.38 – 7.23 (m, 5H), 7.23 – 7.13 (m, 
3H), 7.09 (dd, J = 7.2, 1.9 Hz, 2H), 5.58 (d, J = 3.5 Hz, 1H), 5.39 (dd, J = 10.8, 3.1 Hz, 1H), 5.26 (d, J = 
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2.4 Hz, 1H), 4.72 – 4.62 (m, 2H), 4.62 – 4.48 (m, 3H), 4.46 (d, J = 7.8 Hz, 1H), 4.04 – 3.87 (m, 4H), 
3.87 – 3.77 (m, 2H), 3.73 (dd, J = 9.3, 3.3 Hz, 1H), 3.52 – 3.46 (m, 2H), 3.26 (t, J = 7.0 Hz, 2H), 1.63 – 
1.53 (m, 4H), 1.38 – 1.26 (m, 8H), 1.18 (s, 9H), 1.15 (s, 9H), 1.04 (d, J = 6.5 Hz, 3H). 13C NMR (101 
MHz, CDCl3): δ = 177.4, 177.4, 137.5, 137.4, 128.7, 128.3, 128.0, 127.8, 127.7, 127.1, 101.8, 97.1, 82.8, 
73.8, 72.6, 72.4, 72.3, 71.4, 71.3, 70.2, 70.1, 66.3, 64.9, 62.5, 51.5, 39.0, 38.7, 29.7, 29.4, 29.1, 28.8, 27.2, 




Diol 73 (364 mg, 0.44 mmol) was dissolved in a mixture of THF/MeOH/H2O (44 
mL, 5:5:1, v/v/v). After addition of LiOH (197 mg, 8.23 mmol) was heated to 50 
°C and stirred for 48 h. The reaction mixture was concentrated in vacuo and co-
evaporated with toluene (3x). Purification by silica chromatography (100% EtOAC → 10% MeOH in 
EtOAc) resulted in compound 74 (267 mg, 0.40 mmol, 92%) as a clear oil. [α]D20 = -62.4 (c = 0.5, 
CHCl3). 1H NMR (400 MHz, CDCl3): δ = 7.35 – 7.22 (m, 8H), 7.14 (dd, J = 6.9, 2.6 Hz, 2H), 5.63 (d, J 
= 3.6 Hz, 1H), 4.75 (d, J = 11.6 Hz, 1H), 4.64 (d, J = 12.0 Hz, 1H), 4.55 – 4.48 (m, 2H), 4.45 (d, J = 7.8 
Hz, 1H), 4.27 (d, J = 12.0 Hz, 1H), 4.11 – 4.07 (m, 1H), 4.06 – 3.94 (m, 3H), 3.93 – 3.88 (m, 1H), 3.87 – 
3.82 (m, 1H), 3.79 – 3.75 (m, 1H), 3.73 (dd, J = 9.3, 3.3 Hz, 1H), 3.63 (dd, J = 9.9, 3.6 Hz, 1H), 3.55 – 
3.50 (m, 1H), 3.49 – 3.42 (m, 1H), 3.26 (t, J = 6.9 Hz, 2H), 2.50 (s, 1H), 2.36 (s, 1H), 2.22 (s, 1H), 1.62 
– 1.54 (m, 4H), 1.32 – 1.22 (m, 11H). 13C NMR (101 MHz, CDCl3): δ = 137.8, 137.4, 128.8, 128.6, 
128.1, 127.9, 127.1, 102.0, 96.2, 83.2, 75.7, 73.9, 72.3, 71.9, 69.5, 71.8, 71.1, 70.0, 66.2, 65.5, 62.5, 51.5, 
29.8, 29.5, 29.2, 28.9, 26.8, 26.2, 16.1. HRMS: calculated for [C34H49N3O10Na]+ 682.33102; found 
682.33054.  
 
8-aminooctane α-L-fucopyranosyl (1→2)-β-D-galactopyranoside (75) 
To a solution of compound 74 (59 mg, 89 μmol) in a mixture of 
THF/tBuOH/H2O (1:1:3, v/v/v, 2 mL) was added Pd(OH)2/C (100 mg). The 
reaction mixture was purged with H2 (g). After vigorous stirring overnight, the 
reaction mixture was filtered and concentrated in vacuo resulting in compound 
75 (60.5 mg, 67 μmol, 75%) a clear oil.  1H NMR (400 MHz, MeOD): δ = 5.22 (s, 1H), 4.34 – 4.23 (m, 
2H), 3.96 – 3.90 (m, 1H), 3.88 – 3.83 (m, 1H), 3.80 – 3.62 (m, 4H), 3.59 – 3.45 (m, 2H), 2.91 – 2.87 (m, 
2H), 1.66 (m, 4H), 1.45 – 1.30 (m, 8H), 1.21 (d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, MeOD): δ = 
103.6, 101.5, 79.0, 76.4, 75.6, 73.7, 71.7, 70.7, 70.6, 70.4, 67.8, 62.4, 49.6, 49.4, 49.2, 49.0, 48.8, 48.6, 
48.4, 40.8, 30.9, 30.2, 30.1, 28.5, 27.3, 27.1, 16.8. 
 
8-azidooctane α-L-fucopyranosyl (1→2)-β-D-galactopyranoside (63) 
Amine 75 (28.1 mg, 61.9 μmol) was dissolved in MeOH/H2O (2 mL, 1:1, v/v) and 
K2CO3 (25.6 mg, 0.186 mmol) and CuSO4.5H2O (1.2 mg) were added. After 
addition of imidazole-1-sulfonyl azide.HCl (20 mg, 0.93 mmol) the reaction was 
stirred overnight. The reaction mixture was concentrated in vacuo, co-
evapporated with toluene (3x) and redissolved in pyridine (6.2 mL). After addition of Ac2O (1.0 mL, 
10.6 mmol) the reaction mixture was stirred for 48 h. The reaction mixture was concentrated in vacuo 
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and purificated by silica chromatography (30% EtOAc in pentane). 1H NMR (400 MHz, CDCl3): δ = 
5.39 (d, J = 3.9 Hz, 1H), 5.34 – 5.26 (m, 3H), 5.06 – 4.93 (m, 2H), 4.60 (dd, J = 4.0, 13.0 Hz, 1H), 4.46 
(d, J = 7.8 Hz, 1H), 4.19 (dd, J = 11.2, 6.4 Hz, 1H), 4.10 (dd, J = 11.2, 7.1 Hz, 1H), 3.99 – 3.83 (m, 3H), 
3.57 – 3.48 (m, 1H), 3.27 (t, J = 7.0 Hz, 2H), 2.16 (s, 3H), 2.13 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.99 (s, 
3H), 1.98 (s, 3H), 1.67 – 1.55 (m, 4H), 1.42 – 1.31 (m, 8H), 1.12 (d, J = 6.5 Hz, 3H). 13C NMR (101 
MHz, CDCl3): δ = 170.8, 170.5, 101.7, 95.8, 77.5, 77.2, 76.8, 73.9, 71.78, 71.3, 70.5, 70.4, 68.4, 67.8, 
67.3, 64.7, 61.3, 51.6, 29.7, 29.4, 29.2, 28.9, 26.8, 26.1, 20.8, 20.8, 15.9. Next, the residue was dissolved 
in MeOH (4 mL) and NaOMe (catalytic amount) was added. After stirring for 30 min, the reaction 
mixture was neutralized with Amberlite-H+ IR-200, filtrated and concentrated in vacuo to obtain 
target compound 63 (8.3 mg, 17.3 μmol, 28% over three steps) as a white solid. 1H NMR (400 MHz, 
MeOD): δ = 5.20 (s, 1H), 4.34 – 4.26 (m, 2H), 3.91 (m, J = 9.4, 6.7 Hz, 1H), 3.82 (d, J = 2.4 Hz, 1H), 
3.78 – 3.70 (m, 4H), 3.70 – 3.63 (m, 3H), 3.57 – 3.47 (m, 2H), 3.28 (t, J = 8.0 Hz, 2H), 1.66 – 1.54 (m, 
4H), 1.43 – 1.31 (m, 8H), 1.19 (d, J = 6.6 Hz, 3H). 13C NMR (101 MHz, MeOD): δ = 103.6, 101.6, 79.0, 
76.5, 75.8, 73.8, 71.8, 70.7, 70.6, 70.4, 67.8, 62.4, 52.4, 49.6, 49.4, 49.2, 49.0, 48.8, 48.6, 48.4, 31.0, 30.5, 
30.3, 29.9, 27.8, 27.2, 16.8. HRMS: calculated for [C20H37N3O10Na]+ 502.23712; found 502.23683. 
 





To a solution of carboxylic acid 6633 (60 mg, 0.10 mmol) in 
toluene (6.0 mL) was added oxalyl chloride (1 M in DCM, 0.30 mL, 0.30 mmol, 3.0 eq.). After stirring 
for 5 at reflux conditions, the reaction mixture was concentrated in vacuo and redissolved in DCM 
(7.0 mL). 2’,3’-O-Isopropylidene-5’-O-sulfamoyluridine34 (0.100 g, 0.27 mmol, 2.3 eq.) and DIPEA (40 
μL, 0.24 mmol, 2.4 eq.) were added. After stirring overnight at room temperature, the reaction 
mixture was concentrated under reduced pressure and purified by size exclusion column 
chromatography (DCM/MeOH, 1:1), resulting in sulfonamide 67 (90 mg, 86 μmol, 86%) as a white 
wax. 1H NMR (400 MHz, MeOD): δ (ppm) 7.76 (d, J = 7.6 Hz, 1H), 7.38 – 7.17 (m, 20H), 5.94 – 5.88 
(m, 1H), 5.72 (d, J = 6.4 Hz, 1H), 4.87 (d, J = 1.9 Hz, 2H), 4.84 – 4.67 (m, 4H), 4.62 – 4.54 (m, 2H), 
4.52 – 4.43 (m, 2H), 4.41 – 4.35 (m, 1H), 4.30 – 4.23 (m, 2H), 3.74 (d, J = 5.8 Hz, 1H), 3.70 – 3.66 (m, 
3H), 3.67 – 3.64 (m, 1H) 3.54 – 3.42 (m, 2H), 3.21 – 3.14 (m, 2H), 3.10 (t, J = 10.1 Hz, 1H), 2.39 – 2.28 
(m, 1H), 1.94 (dd, J = 9.2, 4.7 Hz, 1H), 1.71 (dd, J = 9.1, 4.4 Hz, 1H), 1.61 (t, J = 4.6 Hz, 1H), 1.50 (d, J 
= 13.9 Hz, 3H), 1.32 (m, 15H). 13C NMR (101 MHz, MeOD): δ (ppm) 179.1, 166.0, 152.0, 143.7, 143.7, 
140.2, 139.9, 139.8, 139.6, 129.5, 129.5, 129.4, 129.3, 129.2, 129.1, 129.1, 128.9, 128.7, 128.7, 128.6, 
128.5, 128.5, 115.2, 103.2, 93.7, 87.0, 85.4, 85.3, 82.5, 82.4, 77.7, 76.0, 75.9, 74.2, 72.6, 71.8, 70.2, 55.8, 
43.8, 41.9, 27.5, 27.1, 26.5, 26.2, 25.6, 13.2. 







To a solution of sulfonamide 67 (89 mg, 84 μmol) in DCM (10 
mL) was drop-wise added BCl3 (1 M in DCM, 1.15 mL, 1.15 mmol, 13.7 eq.) at 0 °C. After stirring for 
3 h, the reaction mixture was quenched with MeOH and stirred for 30 min. The reaction mixture was 
concentrated in vacuo, redissolved in CHCl3 and stirred vigorously for 30 min before the suspension 
was filtered. The residue was taken up in methanol, concentrated in vacuo and purificated by HPLC 
(C18 column, linear gradient: 5 → 10% B in A, solutions used A: H2O, B: acetonitrile, 0.5% TFA, 15 
min) to obtain compound 65 (8.6 mg, 16 μmol, 20%) as a white solid. 1H NMR (400 MHz, CDCl3): δ 
7.73 (d, J = 8.2 Hz, 1H), 5.90 (d, J = 4.5 Hz, 1H), 5.75 (d, J = 8.1 Hz, 1H), 4.55 – 4.48 (m, 2H), 4.20 (dd, 
J = 4.9, 2.5 Hz, 1H), 4.13 (dd, J = 7.0, 4.7 Hz, 2H), 3.96 – 3.92 (m, 1H), 3.57 (d, J = 8.3 Hz, 1H), 3.19 
(dd, J = 10.0, 8.3 Hz, 1H), 2.89 (t, J = 10.1 Hz, 1H), 2.16 (s, 1H), 2.03 – 1.97 (m, 1H), 1.58 (s, 1H). 13C 
NMR (101 MHz, CDCl3): δ 172.8, 152.4, 142.4, 103.1, 90.7, 82.7, 79.3, 75.0, 74.0, 72.2, 71.0, 69.7, 64.2, 
43.7, 30.2, 28.0, 24.3. HRMS: calculated for [C18H26N3O13S]+ 524.11808, found 524.11799. 
 
Materials of biological assays 
Recombinant human GBA1 (Cerezyme), recombinant human GAA (Myozyme) and recombinant 
human α-Gal A (Fabrazyme) were obtained from Genzyme, USA. Cellular homogenates of a stable  
human embryonic kidney 293 (HEK293) over-expressing GBA2 cell line35 were pre-incubated for 30 
min with an inhibitor of GBA1 (1 mM conduritol B epoxide (CBE)). Galactocerebrosidase (GALC) 
was obtained by expressing recombinant murine GALC in HEK293 cells after which the secreted 
recombinant protein in the culture medium was directly used.36 Fibroblasts of Pompe patients 
diagnosed on the basis of reduced GAA activity (obtained with consent from donors) were used for 
GANAB determinations. 
 
Enzyme activity assays, determination of the apparent IC50 values 
All activity assays were performed at 37 °C. To determine the apparent IC50 values, enzyme 
preparations were pre-incubated with a range of inhibitor concentrations for 30 min, where after the 
residual activity was measured by addition of the appropriated 4-methylumbelliferyl-based substrate 
mix. GBA1 residual activity was measured with 3.7 mM 4-methylumbeliferone(4-mu)-β-D-
glucopyranoside in 150 mM McIlvaine buffer, pH 5.2, supplemented with 0.2% Taurocholate (w/v), 
0.1% Triton X-100 (v/v), 0.1% Bovine Serum albumin (BSA) (w/v) for 30 min. GBA2 substrate mix 
consisted of 3.7 mM 4-mu-β-D-glucopyranoside in 150 mM McIlvaine, pH 5.8, 0.1% BSA (w/v) and 
was incubated for 1 h. α-Gal A activity was determined with 2 mM 4-mu-α-D-galactopyranoside 
dissolved in 150 mM McIlvaine, pH 4.5, 0.1% BSA (w/v) for 30 min. GAA substrate mix consisted of 3 
mM 4-mu-α-D-glucopyranoside pH 5.0, 0.1% BSA (w/v) for 1 h, GALC was assayed with 1.25 mM 4-
mu-β-D-galactopyranoside in 150 mM McIlvaine pH 4.3 containing 0.2 M NaCl and 0.1% BSA (w/v) 
for 1h and GANAB with 3 mM 4-mu-α-D-glucopyranoside pH 7.0, 0.1% BSA (w/v) for 2 h. After 
stopping the substrate reaction with an excess of 1 M NaOH-glycine (pH 10.3), liberated 4-mu 
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fluorescence was measured with a fluorimeter LS55 (Perkin Elmer) using λEx 366 nm and λEm 445 nm. 
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lycosidases zijn enzymen die essentieel zijn in verschillende fundamentele 
biologische processen zoals de afbraak van koolhydraten (suikers), glycolipiden en 
glycoproteïnes.  Glycosidases zijn in staat om met grote efficiëntie glycosidische 
bindingen te hydrolyseren, dit terwijl zulke bindingen, bestaande uit acetalen, zeer 
stabiel zijn als ze zich in waterig milieu bevinden, zowel in zure of basische pH, en er 
geen glycosidases aanwezig zijn. Genetische aberraties in glycosidases zijn de oorzaak 
van verschillende complexe ziektes zoals lysosomale stapelingsziektes. Met behulp van 
een recent ontwikkelde techniek, genaamd ‘activity-based protein profiling’ (ABPP), 
kan de enzymatische activiteit van glycosidases in kaart worden gebracht. Hiervoor zijn 
de zogeheten ‘activity-based probes’ (ABPs) ontwikkeld. Deze ABPs zijn irreversibele 
remmers die een biotine of fluorescente groep bevatten. Na het incuberen van een 
biologische monster met een gebiotinyleerde ABP kunnen de gelabelde enzymen 
worden geïdentificeerd met behulp van massa spectrometrie. De daadwerkelijke 
activiteit van deze enzymen in de fysiologische omgeving kan worden gevisualiseerd en 
gekwantificeerd met behulp van fluorescente ABPs. 
 
Het onderzoek beschreven in dit proefschrift omvat de ontwikkeling en toepassingen 
van een set van selectieve ABPs voor verschillende ‘retaining’ glycosidases: α-
galactosidases, β-galactosidases, α-mannosidases en β-mannosidases. In het tweede deel 
van dit proefschrift wordt de ontwikkeling van een nieuwe klasse competitieve 
remmers gepresenteerd voor glycosidases en glycosyltransferases met mogelijke 
klinische toepassingen. Eerder beschreven overgangstoestand-gebaseerde remmers 
voor glycosidases zoals voor neuraminidases (oseltamivir/Tamiflu en 
zanamivir/Relenza) zijn succesvol gebleken en zijn geregistreerde geneesmiddelen. Alle 
beschreven ABPs en competitieve remmers in dit proefschrift zijn derivaten van 
cyclophellitol, een natuurstof en potente β-glucosidase remmer. 
 
In hoofdstuk 1 worden de principes van de ABPP techniek besproken die ten 
grondslag liggen aan het ontwerp van de verbindingen in het eerste deel van dit 




van verschillende glycosidases. Deze reactie routes dienen als basis voor het ontwerp 
van de ABPs en de competitieve remmers. Tenslotte wordt de potentie van 
overgangstoestand-gebaseerde remmers beschreven met onder andere voorbeelden die 
een therapeutisch toepassing hebben. 
Hoofdstuk 2 beschrijft de ontwikkeling van α-galactosidase selectieve ABPs die kunnen 
worden gebruikt om de ziekte van Fabry en de ziekte van Schindler te bestuderen. N-
acyl- en N-alkyl versies van de α-galactosidase selectieve ABPs zijn hierin vergeleken. 
Hoewel de N-geacyleerde versie vatbaarder is voor hydrolyse tijdens de zuivering en 
lyofilisatie heeft deze ABP de voorkeur vanwege de labelingsefficiëntie in de biologisch 
omgeving. 
De synthese en validatie van een β-galactosidase selectieve ABP is beschreven in 
hoofdstuk 3. Eerst is een kristalstructuur verkregen van CjGH35A galactosidase die het 
covalente werkingsmechanisme van de β-galactose-geconfigureerde cyclophellitol 
aziridines bevestigd. Vervolgens is met behulp van de Diels-Alder strategie een potente 
β-galactosidase ABP verkregen die GLB1 en GALC labelen in nieren van muizen. Deze 
ABP kan worden gebruikt als moleculair gereedschap om GM1 gangliosidose, het 
syndroom van Morquio type B of de ziekte van Krabbe te bestuderen die allen worden 
veroorzaakt door een mutatie in ofwel GLB1 of GALC. 
De bibliotheek van selectieve ABPs voor glycosidases is uitgebreid in hoofdstuk 4 met 
de synthese en validatie van ABPs voor α-mannosidases om de rol van deze enzymen in 
α-mannosidosis of strottenhoofd kanker te onderzoeken. De reactie route van α-
mannosidasen, waarin een boot (B2,5) overgangstoestand conformatie wordt verwacht, 
is verschillend van de eerder beschreven glycosidases. Desalniettemin is een covalente 
enzym-remmer complex verkregen na het doordrenken van de α-mannosidase 
geconfigureerde cyclophellitol aziridine in GH38 Golgi α-mannosidase II van een 
fruitvlieg. Zoals verwacht uit de reactie route heeft de cyclohexaan de zogenaamde 
‘skew-boat’ conformatie aangenomen. De ABP met een Cy5 label kan goed worden 
gebruikt voor het zichtbaar maken van GH38 α-mannosidases. 
Tenslotte vormen GH2 exo-β-mannosidase selectieve APBs het onderwerp van 
hoofdstuk 5. ABPP experimenten in lysaten van nieren afkomstig uit muizen 
resulteerde in het labelen van MANBA. Dit enzym is deficiënt in β-mannosidosis 
waardoor deze ABPs gebruikt kunnen worden als moleculair gereedschap om de 
pathologie te onderzoeken. 
In hoofdstuk 6 is de synthese van carba-cyclophellitol gebaseerde verbindingen 
beschreven in de α-glucopyranose, β-glucopyranose, α-galactopyranose en β-
galactopyranose configuratie. Deze verbindingen zijn potentiële reversibele glycosidase 
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remmers doordat ze de overgangstoestand conformatie van het oxocarbenium ion 
gedurende de reactie route nabootsen. 
Hoofdstuk 7 bevat een biologische evaluatie van de β-glucopyranose-geconfigureerde 
carba-cyclophellitol derivaten in Thermotoga maritima TmGH1, GBA1 (human 
lysosomale β-glucosidase) en GAA (humaan lysosomale α-glucosidase). Hieruit blijkt 
dat deze carba-cyclophellitol derivaten potente en selectieve β-glucosidase remmers 
zijn. DW082 is de meest potente TmGH1 remmer met een Ki van 8.2 nM. Vervolgens is 
de conformatie van de carba-cyclophellitol derivaten geanalyseerd met behulp van 1H 
NMR analyse, kwantum mechanische analyses en DFT berekeningen die de 4H3 
conformatie van carba-cyclophellitol ondersteunen. De verkregen structuur na het 
doordrenken van carba-cyclophellitol DW082 in TmGH1 bleek eveneens de 4H3 
conformatie te hebben aangenomen. Deze klasse cyclopropyl suikers zou daarom 
kunnen worden toegevoegd aan het arsenaal van motieven van sterk gebonden 
remmers. 
Hoofdstuk 8 beschrijft de synthese van carba-cyclophellitol gebaseerde remmers voor 
galactosyltransferases welke in de (nabije) toekomst onderzocht zullen worden. AB180 
bleek inmiddels de eerste potente carba-cyclophellitol gebaseerde α-galactosidase 
remmer te zijn. De glucosyl-analoog bleek geen potentie te hebben voor glycosidases of 
glucosylceramide synthase (GCS). 
Tenslotte wordt in hoofdstuk 9 een meer gedetailleerde samenvatting gegeven van het 
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